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iThesis Summary
Gastric cancer is one of  the leading causes of  cancer-related death worldwide. Since 
advanced gastric carcinoma often demonstrates marked architectural and cytological 
heterogeneity, chemotherapy or targeted agents are seldom effective across all gastric cancer 
patients. Therefore, there is an urgent need to develop effective biomarkers for identifying 
patients with highly invasive disease and plan individual treatment decisions for each gastric 
cancer patient. 
In this study, in Silico data analysis from TCGA was employed to discover miRNAs which 
had value in predicting patients’ outcome. Among them, miR-140-5p and -3p were chosen 
to confirm their expression pattern in two independent cohorts with and without 
neoadjuvant chemotherapy.
miR-140-5p, rather than miR-140-3p, was the dominant miRNA in both gastric tumours and 
adjacent normal tissues. Reduced expression of  miR-140-5p and -3p were found in most 
gastric tumours compared to matched normal tissues without chemotherapy through online 
data analysis and qPCR detection. Intestinal-type gastric cancer patients with lower 
expression of  miR-140-5p suffered worse survival. Gastric cancer patients treated with 5-
fluorouracil (5FU) based neoadjuvant treatment, both in online data and in independent 
cohort examination, showed increased expression of  miR-140-5p and -3p. Patients without 
upregulation of  neither miR-140-5p nor -3p exhibited the worst survival.
In this study, we explored a new potential target of  miR-140-5p, mouse double minute 2 
homolog (MDM2), which is the principle p53 antagonist in unstressed cells. We also provide 
evidence, via several functional assays, that enforced miR-140-5p expression inhibits 
malignant phenotypic characteristics, such as growth, spreading and attachment of  gastric 
cancer cells lines with wild-type p53. However enforced miR-140-5p expression increased 
the 5FU resistance in these cells, probably due to upregulated p21 and a relatively low 
proliferation rate. miR-140-5p expression may reflect the activity of  p53-dependent 
apoptosis when tumour cells are treated with 5FU. In this condition, elevated miR-140-5p 
correlated with higher BAX expression and indicated a highly activated cell apoptosis 
signaling. The results presented in this study collectively suggest that miR-140-5p and miR-
140-3p are involved in controlling the behavior of  gastric cancer cells, but their subtype-
ii
specific expression pattern may reflect distinct cell conditions or responses. Several molecular 
signaling pathways regulated by miR-140-5p or miR-140-3p that may be responsible for these 
changes. This study found that the expression of  miR-140-5p, in particular, could be used as 
a biomarker for identification of  gastric cancer patients with higher malignant potential and 
for selection of  gastric cancer patients who can benefit from the 5FU based treatment, and 
also may be used for monitoring patients’ chemotherapy response.
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General Introduction 
61.1 Gastric cancer
Gastric cancer is the fifth most common cancer worldwide and the third main cause of 
cancer-related death, accounting for 6.8% of new cancer cases and 13.7% of the total cancer 
deaths worldwide (Global cancer statistics from the World Health Organization (WHO) in
2012 (Ferlay et al. 2015). Whilst gastric cancer incidence and mortality decreased substantially 
over the last decades in most countries worldwide, there are differences in the trends and 
distribution in different areas (Ferro et al. 2014). As the early symptoms of gastric cancer are 
similar to those of many other conditions, such as gastritis, gastric polyps or gastrointestinal 
ulcers et al., early detection of gastric cancer mostly depends on opportunistic screening. 
Nearly half of patients diagnosed with stages T2-T4a (T category defined in the 7th American 
Joint Committee on Cancers (AJCC) TNM staging system as follows: T1a = mucosa, T1b = 
submucosa, T2 = muscolaris propria, T3 = subserosa, T4a = perforates the serosa, T4b = 
infiltration of adjacent structures (Marchet et al. 2011)) develop metastatic disease within two 
years. Clinical outcomes are poor in metastatic disease, with median survival being around 1 
year. For gastric cancer patients diagnosed at a surgically resectable stage, early radical 
gastrectomy with draining lymph node dissection remains the cornerstone of therapy of 
muscle-invasive disease. However, cancer-specific survival in patients with extra-gastric
extension or lymph node metastases after gastrectomy is relatively only around 25-48% (De 
Angelis et al. 2014; Ferro et al. 2014; Van Cutsem et al. 2016). In the United Kingdom over 
the last decade, gastric cancer incidence rates have decreased by more than a quarter while 
six in ten (4457/6740) gastric cancer patients die from this disease each year (Cancer 
Research UK 2016a). Approximately half of the world’s gastric cancer cases and deaths occur 
in China, roughly 1364 deaths per day (Zong et al. 2016).
Current treatment options for gastric cancer include surgical intervention, chemotherapy, 
and radiation therapy or a combination of these options. Surgery for gastric cancer although 
technically challenging, is still considered the only curative treatment currently. Optimal 
results are more likely to be achieved with the input of teams of experts from different 
disciplines through careful tumour staging which is crucial to ensure that appropriate 
interventions are selected (Coburn et al. 2018). Besides stage-based treatment determination, 
increased attention has been paid to the molecular classification of gastric cancer. Several 
histopathological characteristics have a significant prognostic impact on recurrence and 
7survival rates in gastric cancer and have shown great potential for improvement.
Conventional chemotherapy has been successful to some extent; the main drawbacks of 
chemotherapy are its poor bioavailability, high-dose requirements, adverse side effects, low 
therapeutic indices, development of multiple drug resistance, and non-specific targeting.
Targeted therapies, such as trastuzumab, an antibody against human epidermal growth factor 
receptor 2 (HER2, also known as ERBB2), the vascular endothelial growth factor receptor-
2 (VEGFR-2) antibody ramucirumab, and programmed cell death 1 (PD-1)/ programmed 
cell death ligand-1(PD-L1) antibody, also show promise. However, the remaining challenge 
is to find sufficient molecular markers for therapy selection and monitoring.
1.1.1 Epidemiology
According to incidence estimated in the GLOBOCAN 2012 (Torre et al. 2015; Ferlay J 2013), 
approximately 950 000 new cases are diagnosed annually, of whom 720 000 are expected to 
die (Ferlay et al. 2015). In 2015 (Fitzmaurice et al. 2017), there were 1.3 million (1.2-1.4 
million) incident cases of gastric cancer and 819 000 (95% uncertainty interval, UI: 795 000-
844 000) deaths worldwide (Figure 1.1).
Figure 1.1: Estimated age-standardized incidence rates of gastric cancer (ASR-World) 
in both sexes per 100,000, IARC GLOBOCAN 2012. Adapted from GLOBOCAN 2012. (Ferlay J 
2013; Torre et al. 2015) The highest rates occur in Eastern Asia, South America, and Eastern Europe.
Despite the decline rate, the absolute number of new cases per year is increasing, mainly due 
to aging in the world population. More than half of gastric cancer patients are over 60 years 
old and the median age at diagnosis is 70 years (Karimi et al. 2014). Furthermore, the trend 
toward declining incidence in young patients (younger than 50 years) has halted and replaced 
8by an upward trend in recent years (Correa 2011; Sonnenberg 2011). Gender, as well as age,
plays a crucial role in the incidence of gastric cancer. Age-standardized incidence rates are 
about twice as high in men as in women, ranging from 3.3 in Western Africa to 35.4 in 
Eastern Asia for men, and from 2.6 in Western Africa to 13.8 in Eastern Asia for women 
(Figure 1.2).
Figure 1.2: Cancer age-standardized incidence and mortality rates of gastric cancer
per 100,000 for in both sexes, GLOBOCAN 2012 estimates. Adapted from GLOBOCAN 2012(Torre 
et al. 2015; Ferlay J 2013).
Among males, incidence rates (cases/100,000) in Japan (Miyagi Prefecture, 66.7) and Korea 
(64.6) are twice as high as the next highest rates in Iran (Golestan Province, 30.4). Among 
females, incidence rates in Japan and Korea are 60% higher than the next highest rates in 
Ecuador and Costa Rica. It was estimated that 1 in 27 men and 1 in 68 women develop 
gastric cancer before age 79 years (Fitzmaurice et al. 2017). Moreover, globally, gastric cancer 
incidence shows remarkable international variation and distinct characteristics by two major 
9topographical subsites, true gastric adenocarcinomas (non-cardia gastric cancers), of which 
there were 691 000 new cases in 2012, and gastro-oesophageal-junction adenocarcinomas 
(cardia gastric cancers), of which there were 260 000 new cases in that year(Colquhoun et al. 
2015). As a result, the proportion of tumours located in the proximal two-thirds of the 
stomach now accounts for more than 40 percent of gastric in some reports (Borch et al. 
2000).
In Japan, the downward trend was particularly evident in young patients with non-cardia, 
sporadic, intestinal type of gastric cancer (Kaneko and Yoshimura 2001; Bertuccio et al. 2009). 
In China, the decline was less dramatic than other countries. Despite an overall decrease in 
gastric cancer incidence, an increase of non-cardia gastric cancer has been observed in the 
oldest and the youngest groups, and a less remarkable decline has been observed among 
women than in men (Jemal et al. 2006; J. Zhang et al. 2018). In the United States, the 
incidence rate for non-cardia gastric cancer declined among all race and age groups. People 
aged 65-74 are most frequently diagnosed, and the average age at diagnosis is 69 (National 
Cancer Institute 2018). About 6/10 patients diagnosed with gastric cancer each year are 65 
or older. However, in younger and middle-aged Caucasians (25 to 39 years) the incidence 
rate for non-cardia gastric cancer significantly increased between 1977 and 2007 (Camargo 
et al. 2011; Colquhoun et al. 2015; Anderson et al. 2010). Figure 1.3 depicts the global 
incidence rates of gastric cancer varied by gender; in particular, for cardiac gastric cancer, 
rates in men were three times the rates in women (Colquhoun et al. 2015).
Histologically, gastric cancer was classified into intestinal and diffuse types by Laurén (Lauren 
1965). These two biological entities are different with regard to epidemiology, aetiology, 
pathogenesis, and behavior (see Chapter 1.15). The intestinal type is more common in males, 
2:1 ratio worldwide. Diffuse-type cancers are equally distributed between males and females
(Jemal et al. 2011). There has been a worldwide decline in the incidence of the intestinal type 
in recent decades, which parallels the overall decline in the incidence of gastric cancer. By 
contrast, the decline in the diffuse type has been more gradual. Hence, the decrease in the 
intestinal type cancers may partly contribute to the shift from intestinal to diffuse type of
gastric cancers (Borch et al. 2000; Kampschoer et al. 1989; Sidoni et al. 1989).
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Figure 1.3: Global incidence estimates of cardia and non-cardia gastric cancer by 
region (A) and Estimated cardia and non-cardia gastric cancer age-standardized incidence rates 
(per 100 000) by region and sex (B). Source: Global patterns of cardia and non-cardia gastric cancer 
incidence in 2012 (Colquhoun et al. 2015).
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Figure 1.4: Cancers Ranked by Number of Deaths in Both Sexes, Global, by Region, by
Sociodemographic Index (SDI), and in the 50 Most Populous Countries, 2015. The highest rates occur in 
Eastern Asia, South America, and Eastern Europe (Global Burden of Disease Cancer et al. 2017).
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Mortality from gastric cancer has decreased in all countries over the last 50 years, for both 
men and women, although the rate of decline differs by region (Figure 1.4) (Amiri et al. 2011).
The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 
100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High 
mortality rates are also present in both sexes in Central and Eastern Europe and in Central 
and South America (Figure 1.2). Despite the decline in mortality, the 5-year survival rate has 
improved only by 11% (Figure 1.5) and is still poor in most countries (Collaborators 2016; 
Danaei et al. 2005; Fontham 2009). Five-year survival rates are as high as 64.6 % in Japan 
and 74.5% in South Korea (Matsuda et al. 2011). Well-developed, government-sponsored 
screening programmes for gastric cancer by barium photofluorography or endoscopy are 
available in these countries (Jung et al. 2017). The 5-year survival rate is 27.4% in China (M. 
Li et al. 2017) and 20% in the United Kingdom (Cancer Research UK 2016b).
Figure 1.5: Five-year survival rate by gastric cancer stage at diagnosis. Source: Cancer of 
the Stomach. Surveillance Research Program, Cancer Control, and Population Sciences (National Cancer 
Institute 2017). 
The comparisons of prognosis between women and men are controversial, and the 
difference is more likely to be tumour stage- and age-dependent (Matsuzaka et al. 2016; 
Maehara et al. 1992). Mortality rates for gastric cancer are highest in aged people (≥ 70 years)
(Liang et al. 2013). For all stages of gastric cancer, the relative 5-year survival is around 20% 
(Table 1.1) (Cancer Research UK 2016b). 
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Table 1.1: The 5-year survival rates by stage for gastric cancer treated with surgery. Source: 
Stomach Cancer. Survival by stage (Cancer Research UK 2016b) 
Stage1 5 year observed survival
Stage IA 80%
Stage IB 70%
Stage IIA 60%
Stage IIB 40%
Stage IIIA 25%
Stage IIIB 20%
Stage IIIC 10%
Stage IV 5% 
1 TNM classification according to the 6th AJCC staging system.
1.1.2 Risk factors and prevention
A person’s risk of  developing gastric cancer depends on multiple factors, including age, 
genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors)
(Figure 1.6). Gastric cancer represents a complex and heterogeneous disease. Studies of  
migrant populations point to the importance of  environmental factors in the aetiology of  
this disease (McCredie et al. 1999). 
Figure 1.6.: Summary of risk factors and independent prognostic factors in clinical use.
ECOG: The Eastern Cooperative Oncology Group, the ECOG Scale of  Performance Status is one such 
measurement. It describes a patient’s level of  functioning in terms of  their ability to care for themselves, 
daily activity, and physical ability (walking, working, etc.). WCC: the white blood cell count. Factors
highlighted in red font represent increased risk, factors highlighted in blue represent reduced risk.
Reactive oxygen species (ROS) is an essential factor in the pathogenesis of  gastric cancer
(Bhattacharyya et al. 2014). Low and moderate amounts of  ROS have beneficial effects on 
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several physiological processes including killing of  invading pathogens, wound healing, and 
tissue repair processes. Cancer treatment by chemotherapeutic agents and radiotherapy
depend largely on ROS generation to destroy malignant cells by inducing apoptosis. However, 
disproportionate generation of  ROS poses a serious problem to bodily homeostasis and 
causes oxidative tissue damage. Both environmental factors and specific genetic alterations 
are involved in the deregulation of  ROS-mediated gastric cancer (Figure 1.7). It has been
suggested that more than 90% of gastric cancer may be determined by environmental rather 
than genetic causes (Boland and Yurgelun 2017).
Figure 1.7: The induction of oxidative stress and its pathophysiological effects.
Oxidative stress damages internal organs by causing mucosal injury (Bhattacharyya et al. 2014).
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1.1.2.1 Infectious and non- infectious environmental risk factors
Helicobacter pylori (H. pylori) is the most important etiologic factor for gastric cancer
and is established as a class I carcinogen by the International Agency for Research on gastric 
cancer in 1994 (International Agency for Research on Cancer. 1994a; Fock et al. 2009). The 
presence of  geographic and familial clusters of  gastric cancer presented a conundrum until 
the most common cause of  this disease—chronic infection by H. pylori—was discovered by 
Marshall and Windsor (2005). It is estimated that 89% of  non-cardia gastric cancers, which 
accounts for 78% of  gastric cancer cases, are attributed to H. pylori infection (International 
Agency for Research on Cancer 1994b; De Martel et al. 2012). Non-cardia gastric cancer 
with a high serum anti-H. pylori IgG titre was significantly correlated with younger (median 
age, 55.0 years), a higher proportion of  female (45.0%), non-smokers (58.9%) and diffuse-
type gastric cancer (Gong et al. 2018). H. pylori infection, which infects approximately 50%
of  the world’s population, is a major factor in both the induction of  atrophic gastritis and
histological progression to gastric cancer (Fox and Wang 2007). Despite the high infection 
rate, most infected subjects develop no clinical symptoms or peptic ulceration and continue 
their life with superficial chronic gastritis (Figure 1.8). Approximately 17% of  infected 
subjects will develop peptic ulcers, and 1% will progress to gastric cancer (Salih 2009). A 
follow-up study of 1526 Japanese patients over a mean period of  7.8 years uncovered that
gastric cancer developed in 2.9% of  patients infected with H pylori but in none of  the
uninfected patients (Uemura et al. 2001; J. Kang et al. 2002).
H. pylori infection has been associated with an approximately six-fold increase in the risk of  
distal gastric adenocarcinomas compared to the cardic tumours, including both the intestinal 
and diffuse types. In terms of  histology, H. pylori infection may be linked more closely with 
intestinal-type gastric cancer because it was found in nearly 90% of  the noncancerous gastric 
mucosa in this setting, compared with less than one-third of  the diffuse-type cancers
(Parsonnet et al. 1991). A modest increase in fasting plasma glucose levels was found to be a 
risk factor for gastric cancer and that hyperglycaemia could be a possible cofactor increasing 
the risk posed by H. pylori infection (Yamagata et al. 2005).
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Figure 1.8: Natural history of H. pylori infection. The clinical course of H. pylori infection is 
highly variable depending on bacterial and host (genetic and immune) factors. Patients with increased acid 
secretion are more likely to have antral-predominant gastritis, which predisposes to duodenal ulcers. 
Patients with low acid secretion will more likely develop gastritis in the body of the stomach and are thus 
more likely to develop gastric ulcer, leading to gastric atrophy, intestinal metaplasia, dysplasia and, finally, 
in rare cases, gastric carcinoma. This sequence of events is more frequent in people of advanced age. 
Source: H. pylori infection and gastric cancer: state of the art (review) (Conteduca et al. 2013).
Long-term exposure to H. pylori promotes gastric carcinogenesis mainly through 2 
mechanisms: Firstly, H. pylori could cause chronic gastric inflammation which may progress 
to the precancerous changes of  atrophic gastritis and intestinal metaplasia. The risk of  gastric 
cancer increases in relation to the severity and extent of  those precancerous changes
(Naumann and Crabtree 2004); Secondly, chronic H. pylori infection can also contribute to 
gastric mucosal genetic instability by reducing gastric acid secretion (hypochlorhydria), which 
can promote the growth of  gastric microbiome that processes dietary components into
carcinogens (Amieva and Peek 2016; Machado et al. 2009). This risk can be even higher in 
patients with a higher intake of  salted foods (Peleteiro et al. 2011).
People who have had mucosa-associated lymphoid tissue (MALT) lymphoma also have an 
increased risk of  getting adenocarcinoma of  the stomach. This is probably because MALT
lymphoma of  the stomach is caused by infection with H. pylori bacteria (Sakai et al. 2003)
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(Figure 1.9). First-line eradication treatment of  H. pylori relies on proton pump inhibitors 
and the combination of  two antibiotics such as amoxicillin, clarithromycin, or metronidazole. 
If  the first therapy fails, then the proposed second-line treatment is bismuth salts, proton 
pump inhibitor, tetracycline, and metronidazole (Malfertheiner et al. 2007). H. pylori
eradication has been shown to yield 33%-47% reduction in gastric cancer incidence rate (Lee 
et al. 2016; Pan et al. 2016; Ford et al. 2014). However, more recently it has been reported 
that a considerable proportion of  these individuals continue to progress to gastric cancer 
even after the eradication of  H. pylori, it is thought that long-term proton pump inhibitors
may have an impact on the development of  gastric cancer as well (Cheung et al. 2018). The 
number of  gastric cancer cases that emerge after eradication has continued to increase. 
Moreover, whether H. pylori eradication enables recovery from atrophy and intestinal 
metaplasia, and eventually prevention for cancer development is not fully understood
(Poulsen et al. 2009; Uno et al. 2016; Song et al. 2017).
Figure 1.9: Multiple genetic and epigenetic alterations during gastric carcinogenesis 
and lymphomagenesis and the incidence rates in different types of gastrictumours. 
Source: H. pylori infection and gastric cancer: state of the art (review) (Conteduca et al. 2013).
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Epstein–Barr virus (EBV) is a human herpes virus which latently infects B lymphocytes in 
the majority of  adults. The causal role of  EBV in gastric carcinogenesis was suggested in 
1994 (Imai et al. 1994). Nowadays, 10% of  gastric carcinoma cases harbouring the clonal 
EBV genome were thought to be Epstein–Barr virus (EBV)-associated throughout the world
(Nishikawa et al. 2017). The presence of EBV is observed in 7%–20% of  gastric cancers, 
being slightly more frequent in diffuse-type gastric cancers (Ushijima and Sasako 2004). The 
highest EBV-positive rates were observed in the cardia and middle gastric cancer (Yamamoto 
et al. 1994). The association between EBV and carcinogenesis varies from 4% in China, 7.7% 
in France, 8.1% in Russia, 12.5% in Poland, to 17.9% in Germany (Takada 2000; Czopek et 
al. 2003). Early studies also demonstrated that EBV infection was absent in preneoplastic 
gastric lesions (intestinal metaplasia and dysplasia) but present in both intact stomach
carcinoma and gastric stump carcinoma suggesting that infection might be a late event in 
gastric carcinogenesis (Zur Hausen et al. 2004). Intriguingly, EBV is more prevalent in gastric 
remnant cancers (27.1%) than in an intact stomach. EBV has been shown to extend cell 
generations of  gastric epithelial cells in in vitro cell culture, but it cannot immortalize them
(Takada 2000). In addition, EBV in carcinoma biopsies indicates a monoclonal proliferation 
of  EBV-infected cells (Iizasa et al. 2012). However, the precise role of  EBV in the 
carcinogenic progress remains to be solved. Methylation of  the tumour suppressor genes,
such as p16, p73, and RUNX3 is a key abnormality in EBV associated gastric cancer (Kang 
et al. 2002; Nishikawa et al. 2017; Saito et al. 2013). Besides extreme DNA hypermethylation,
according to a novel classification system dividing gastric cancer established by The Cancer 
Genome Atlas (TCGA), EBV associated gastric cancer are characterized by recurrent 
PIK3CA mutations and amplification of  JAK2, PD-L1, and PD-L2 (Cancer Genome Atlas 
Research 2014). Mutation of p53 in gastric cancer was identified independently of  EBV 
infection (Szkaradkiewicz et al. 2006).
Increased age Two-thirds of  people who have gastric cancer are over age 65. Especially for 
intestinal-type gastric cancer, people aged 65-74 are the most frequently diagnosed 
population (the diffuse type occurs in all age groups with equal gender distribution) (Williams 
et al. 1988; Zali et al. 2011). Age was also found to be an independent prognostic factor in 
gastric cancer (Ma et al. 2018). Age-dependent accumulation of  DNA demethylation 
preceding diploidy loss accounted for a significant subset of  gastrointestinal cancers (Suzuki 
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et al. 2006). 
Dietary factors including diets, foods, individual nutrients, methods of  preparation, and 
habits of  consumption also have been proposed to protect against or increase the risk of
gastric carcinogenesis (Abnet et al. 2015). Healthy dietary habits, e.g. high intake of  fresh 
fruits and vegetables, Mediterranean diet, low-sodium diet, salt-preserved food, red and high 
cured meat, sensible alcohol drinking, and maintaining a proper weight might be associated 
with a decreased risk of  gastric cancer. An evaluation of  dose-response found similar levels 
of  association for fruits and vegetables: increase of  100 g of  intake/day of  fruit was 
associated with a significant decrease in risk of  gastric cancer (summary relative risk, 0.95), 
and vegetables had a comparable, but not statistically significant association with reduced 
risk (summary relative risk, 0.96) (Wang et al. 2014). In a large, prospective European study 
of  more than 450,000 people, those with higher fruit and vegetable intakes were less likely 
to develop any gastric cancer (hazard ratio [HR], 0.77; P for trend=0.02) (Gonzalez et al. 
2012). The associations were mainly significant for fresh fruit and diffuse-type gastric cancer 
(HR, 0.59; P for trend=0.03), for citrus and gastric cardia cancers (HR, 0.61; P for
trend=0.01), and for smokers and persons residing in Northern European countries
(Gonzalez et al. 2012). In addition to the quantity, the variety of  intake may be important. A 
prospective analysis of  a large European cohort containing 475 people who developed 
gastric or esophageal cancer revealed that increasing variety of  the types of  fruits and 
vegetables consumed, independent of  total consumption, was inversely associated with the 
risk of  esophageal squamous cell carcinoma, particularly among smokers (Jeurnink et al. 
2012). The mechanisms by which fruits and vegetables reduce cancer risk might involve their 
ability to prevent the development of  precancerous conditions, and probably, their high 
levels of  micronutrients (including b-carotene, vitamin C, vitamin E, folate and other 
antioxidants), which can decrease DNA damage by scavenging for oxygen radicals (Nomura 
et al. 2003; Abnet et al. 2015).
Smoking The causal relationship between tobacco smoking and gastric cancer had been 
controversial until 2002 (IARC. IARC monographs. Tobacco smoking and tobacco smoke.
Lyon: IARC, 2002) (Gonzalez et al. 2003). The positive correlation between smoking and the 
risk of  gastric cancer was further highlighted by a meta-analysis recently (Ferro et al. 2018a). 
Frequency, duration, and pack-years of  smoking were independently associated with risk of
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both gastric cardia adenocarcinoma and non-cardia adenocarcinoma (Steevens et al. 2010). 
Compared with never smokers, the multivariable-adjusted incidence rate ratio for current 
smokers was 1.60 for gastric cardia adenocarcinoma (Steevens et al. 2010). Targeting high-
risk smokers for serum pepsinogen screening was proposed to be a cost-effective strategy to 
reduce intestinal-type non-cardia gastric adenocarcinoma mortality (Yeh et al. 2016). 
Ethanol was thought to directly and dose-dependently impair the gastric mucosal barrier. 
Both acidification of  the mucosal cells and ethanol itself  induce the release of  inflammatory 
and vasoactive substances. Inflammation and vasoconstriction lead to ischemia and mucosal 
damage. However, an increased risk was only observed in case of  patients with chronic 
atrophic gastritis in Asian alcoholics, who are heterozygous for an inactive aldehyde 
dehydrogenase (ALDH2) genotype, which has a strong impact on carcinogenic acetaldehyde 
accumulation after drinking alcohol (Steevens et al. 2010; Testino 2011; Nemati et al. 2012; 
Ishioka et al. 2018; Choi et al. 2018). In achlorhydric atrophic gastritis, bacterial overgrowth 
results in the presence of  glucose in the formation of  minor concentrations of  endogenous 
ethanol and acetaldehyde in gastric juice. After administration of  a small amount of  alcohol,
intragastric acetaldehyde production increases 6.5-fold compared to healthy controls (Testino 
2011). For frequent alcohol drinkers (3 or more drinks per week) in US Hispanics, the risk 
may come from the risk of  weight gain (32% vs 26%) (Cokkinides et al. 2012). Meta-analyses 
of  the association between alcohol drinking and gastric cancer additionally indicated that 
individual participant data pooled analyses yielded more precise estimates for different levels 
of  exposure or cancer subtypes (Ferro et al. 2018b).
Obesity interacts with other mechanisms and results in earlier presentation or more 
complicate disease. High overall obesity (body mass index (BMI)) (highest (≥35 kg/m2) vs.
reference (18.5-<25 kg/m2) increased the hazard ratio of  gastric cardia adenocarcinoma to
3.67, 95% confidence interval, CI 2.00 to 6.71 (O'Doherty et al. 2012). Even in people having
no history of  reflux, central obesity (large waist circumferences) increased the risk of acid 
reflux and lengthening of  the cardiac mucosa (Robertson et al. 2013; Derakhshan et al. 2015), 
which was thought to be the cause of  the rapid rise in gastroesophageal junction tumours
(Quante et al. 2013). Obesity may enhance immature myeloid cell trafficking and TH17 
response which may result in accelerating H pylori-induced gastric carcinogenesis (Ericksen 
et al. 2014). A retrospective analysis of  1.79 million men and women from Israel suggested
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that adolescent obesity (the body mass index (BMI) ≥ 95th percentile of  the baseline) is also 
associated with an increased risk for non-cardiac gastric cancer (Levi et al. 2018). Leisure-
time physical activity has been proven to be associated with lower risk of gastric cardia cancer
(Moore et al. 2016; Keum et al. 2016). However, in patients undergoing curative gastric 
cancer surgery, those who were overweight or mildly-to-moderately obese (BMI 23 to 30 
kg/m2) preoperatively, had better overall survival (OS) and disease-specific survival (DSS) 
than normal-weight patients (Lee et al. 2018). Therefore, it is suggested that 
gastroenterologists are uniquely poised to participate in the multidisciplinary management 
of  obesity as physicians caring for people with obesity-related diseases, in addition to their 
expertise in nutrition and endoscopic interventions (Camilleri et al. 2017).
Others A number of  studies report that long-term use of  non-steroidal anti-inflammatory 
drugs (NSAID) such as aspirin is associated with a reduced risk of  gastric cancer in a dose-
dependent manner. However, such an impact may be more predominantly in intestinal gastric 
cancer (Lindblad et al. 2005; Wang et al. 2003; Dai and Wang 2006; Huang et al. 2017). The 
presumed mechanism of  chemoprevention is the inhibition of  cyclooxygenase (COX)-2. 
Aspirin exhibits an anti-cancerous effect through several inter-related mechanisms: 
prostaglandin synthesis and catabolism in epithelial cells, inhibition of  Wnt-β-catenin 
signaling, inactivation of  platelets, and the host immune response (Jackson et al. 2000). 
Previous partial gastrectomy is also a risk factor for gastric cancer even many years later
(Offerhaus et al. 1988; Sitarz et al. 2012). 
1.1.2.2 Genetic predisposition
Diet and infection with H. pylori are probably the prominent risk factors for gastric cancer, 
however, familial aggregation in a variable but significant proportion of cases suggests the 
importance of genetic predisposition (Caldas et al. 1999; Oliveira et al. 2015). About 10% of 
gastric cancer cases show familial clustering (Guilford et al. 1998; Zanghieri et al. 1990; La 
Vecchia et al. 1992). 1-3% of gastric cancers are linked to inherited gastric cancer
predisposition syndromes (Ang and Fock 2014). Earlier studies described a familial 
component only for diffuse gastric carcinoma, designated hereditary diffuse gastric cancer
(HDGC) (Lehtola 1978). Germline mutations in the epithelial cadherin (CDH1) gene 
associated HDGC is characterized by an increased risk for diffuse gastric cancer and lobular 
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breast cancer (Kaurah et al. 2007). Later research found that intestinal-type adenocarcinoma 
is the main histological subtype of  hereditary gastric cancers (Ang and Fock 2014). The 
definition of  family gastric cancer syndromes was extended to hereditary diffuse gastric 
cancer, familial intestinal gastric cancer and gastric cancer in other familial cancer syndromes, 
such as familial adenomatous polyposis (FAP) caused by defects in the adenomatous 
polyposis coli (APC) gene, Lynch syndrome, an autosomal dominant disease caused by 
germline mutations in DNA mismatch repair genes (mainly Hmsh2, Hmsh1, Hmsh6, Hpms1, 
Hpms2) as well as mutations in the EPCAM gene, which inactivates MSH2 via promoter 
hypermethylation (Galiatsatos et al. 2017). Li-Fraumeni syndrome (LFS) associated with 
germline mutations in the TP53 gene, and Peutz-Jeghers syndrome caused by mutations in 
STK11 (Van Lier et al. 2011) et al.
Other uncommon genetic reasons also include: polymorphisms in inflammatory genes (M. 
Li et al. 2013; Wen et al. 2014), the variant genotype of  folate intaking related enzymes 
MTHFR (Larsson et al. 2006), hypertrophic gastropathy (including Ménétrier’s disease)
(Tersmette et al. 1990) and even rare inherited cancer syndromes, such as phosphatase and 
tensin homolog (PTEN) hamartoma tumour (Cowden’s) syndrome (Ha et al. 2012). For 
unknown reasons, people with type A blood have a higher risk of  developing gastric cancer
(Aird et al. 1953).
1.1.2.3 Precursor lesions
Atrophic gastritis is characterized by the presence of  metaplastic epithelial changes. There 
are two main subtypes, autoimmune (AMAG) and environmental metaplastic atrophic 
gastritis (EMAG). AMAG is associated with T-cell mediated destruction of  the oxyntic 
mucosa and production of  autoantibodies directed against parietal cell antigens and intrinsic 
factor, resulting in progressive atrophy of  the glandular epithelium with loss of  parietal and 
chief  cells (Nguyen et al. 2013). The loss of  the normal exocrine glands of  the gastric mucosa 
causes hypochlorhydria and a resultant increase in gastric pH. Autoimmune gastritis is 
increasingly recognized as a contributing aetiology, with or without the presence of  H. pylori
(Coati et al. 2015). Populations with a high prevalence of  atrophic gastritis have a high 
prevalence of  gastric cancer, and vice versa. Unlike AMAG, mucosal changes in patients with 
EMAG affect both the body/fundus and the antrum in a multifocal distribution, but with 
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the heaviest involvement of  the antrum and a relatively preserved gastric acid production. 
Without the relative protective effect of  the accompanying hypochlorhydria, EMAG patients 
are more likely to develop gastric ulcer disease. It was estimated that atrophic gastritis and 
other conditions that cause gastric atrophy are associated with an increased risk of  both 
cardia and non-cardia gastric adenocarcinomas, the magnitude of  the risk ranges from 3 to 
18 times greater than an age-matched population. The crude incidence for cancer was 1.7% 
for atrophic gastritis during the observation period (Kato et al. 1992; Helicobacter and 
Cancer Collaborative 2001; De Vries et al. 2008; Cheung 2017).
Metaplasia is thought to be involved in the pathogenesis of  gastric cancer, particularly the 
intestinal type. The estimated odds ratio of  gastric cancer adjusted for age and sex, varied 
from 17.1, for those with baseline diagnoses of  superficial intestinal metaplasia (IM), to 29.3, 
for those with deep IM or mild dysplasia or IM with glandular atrophy and neck hyperplasia, 
to 104.2, for those with moderate or severe dysplasia, as compared with subjects with 
superficial gastritis or chronic atrophic gastritis at baseline (You et al. 1999). Most patients 
diagnosed with high-grade dysplasia of  the gastric mucosa either already have or will soon 
develop gastric cancer. In gastrectomy specimens for gastric cancer, 20-40% of  patients have 
associated dysplasia (Rugge et al. 1994). A report from Sweden which included 405,172 
patients with gastric biopsy samples taken for a non-malignant indication between 1979 and 
2011, found that the risk of  gastric cancer was significantly increased in the presence of  
intestinal metaplasia (hazard ratio [HR] 6.2, 95% CI 4.7-8.2) and dysplasia (HR 10.9, 95% CI 
7.7-15.4). It was estimated that approximately 1 in 39 patients with intestinal metaplasia and 
1 in 19 with dysplasia would develop gastric cancer within 20 years (Song et al. 2015).
Gastric polyps are typically found incidentally when upper gastrointestinal endoscopy is 
performed for an unrelated indication; only rarely do they cause symptoms or other clinical 
signs. Nevertheless, their discovery can be important since many polyps have malignant 
potential (Rugge et al. 2016).
Gastric ulcer with benign morphology increased the risk of  gastric cancer (incidence ratio 
1.8), and this association probably reflects common risk factors (e.g., mainly H. pylori 
infection) However, the risk were unchanged among patients with prepyloric ulcers, and 
decreased among those with benign duodenal ulcers (incidence ratio 0.6) (Ihre et al. 1964; 
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Rollag and Jacobsen 1984; Hansson et al. 1996; Sogaard et al. 2016). A 3.4-year follow-up 
study involving 1120 Japanese patients with peptic ulcer disease who had H. pylori eradication 
therapy revealed that gastric cancer developed only in patients with a gastric ulcer but not 
patients with duodenal ulcers. Patients who developed gastric cancer were significantly more 
likely to have persistent H. pylori infection (hazard ratio 3.4). Another follow-up study from 
the same group showed that, in patients with peptic ulcer disease, the risk of  gastric cancer 
was also significantly increased with a higher grade of  baseline gastric mucosal atrophy, and 
older age (Take et al. 2005; Take et al. 2007).
Besides the above factors, the interactions between host and environmental influences are 
also worth attention. The best strategy to reduce the mortality for gastric cancer is to 
schedule appropriate screening and surveillance programs. Currently, endoscopy is generally 
considered to be the most sensitive and specific diagnostic screening method for gastric 
cancer. However, mass screening for early detection of  gastric cancer is expensive, and the 
compliance of patients with endoscopy is poor, therefore, national screening programme are
only used in regions with high incidences, such as Japan, South Korea, and Singapore.
Endoscopic ultrasound is at present available in many centers and, although mainly used to 
stage previously diagnosed tumours, it might be helpful in identifying early diffuse-type
gastric carcinoma lesions. Future studies of  these and other methods of  examining the 
stomach in predisposed subjects are needed to draw conclusions on their use in diagnosing 
early gastric lesions. For now, in the surveillance of  those predisposed to gastric cancer 
development, clinicians are urged to undertake detailed endoscopic mucosal examination 
with multiple biopsies of  even the subtlest of  lesions. However, endoscopic surveillance 
should be performed once or twice a year in patients who are at higher risk of  gastric cancer
(history of  gastric cancer in the family, inherited cancer syndromes) (Kim et al. 2016). Several 
serum-based tumour markers including carbohydrate antigen (CA) 72-4, CA12-5 and 
pepsinogenI/II have been widely used in clinical practice for gastric cancer, 
carcinoembryonic antigen (CEA) and CA19-9 are the two most common markers for 
following gastric cancer patients with known disease. However, insufficient sensitivity (20%-
30%) and specificity of  these protein biomarkers limit their utility for early gastric cancer
detection. More prospective studies are needed to determine the use of  other biomarkers in 
the early detection of  gastric cancer.
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1.1.3 Anatomy, Histophysiology and Function of the Stomach
In humans, the stomach is a flattened J-shaped muscular organ located in the upper left part 
of  the abdomen. It extends from the left hypochondriac region into the epigastric region 
obliquely, starting at the esophagogastric junction (EGJ) and leading to the duodenum via 
the pylorus (Figure 1.10). 
Figure 1.10: Location of the stomach. Source: Anatomy of  Stomach, available at https://www. 
Earthslab.com/anatomy/stomach/
The stomach acts to blend ingested food with gastric secretions to create chyme, a semifluid 
substance. The stomach controls the speed of  delivery of  chyme into the small intestine to 
enable proper digestion and absorption. The gastric glands secret hydrochloric acid which 
kills bacteria ingested in food. Citadel’s Intrinsic Factor within the gastric juice helps in the 
absorption of  vitamin B12 in the small intestine. Thus, the stomach is first and foremost a 
principal site of  digestion. It is the first site of  protein break down by the stomach’s pepsin 
enzyme. The capacity of  the stomach is variable as the stomach is extremely distensible; At 
birth the capacity is only 30 mL, at puberty the capacity is 1000 mL and in adults the capacity 
is 1500 to 2000 mL. The stomach consists of  various parts that serve distinct functions. For 
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the purposes of  gross description, four main sections are identified in the stomach: cardia, 
fundus, corpus (or body), and antrum (pylorus) (Figure 1.10). The superomedial margin is 
termed the lesser curvature, and the inferolateral margin is termed the greater curvature.
Figure 1.11: The folds of the stomach wall (rugae) lining under the light microscope.
A. Haematoxylin and eosin staining show the structure of  the stomach lining under the light 
microscope. The numerous glands invaginate into the lamina propria. The mucosal layer appears with its 
columnar epithelial cells, narrow lamina propria, and pink-staining muscularis mucosa. The loose 
connective tissue of  the submucosa contains some blood vessels. Adopted from
http://medcell.med.yale.edu/ histology/gi_tract_lab/stomach.php. B. A diagram of the layers of  the 
stomach wall. Adopted from http://heritance.me/anatomy -of-stomach-wall. 
The wall of the stomach has four layers (see Figure 1.11), similar to most of  the alimentary 
canal. From inside outwards, these are mucosa, submucosa, muscularis propria, and 
subserosa (Mackintosh and Kreel 1977), but the muscularis and mucosa are modified for the 
special roles of  the stomach. Besides the usual circular and longitudinal layers of  smooth 
muscle, the muscularis external has an incomplete innermost layer of  smooth muscle fibres 
which run obliquely. This structure allows the stomach not only to mix, churn, and move 
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food along the tract, but also to pummel the food, physically breaking it down into smaller 
fragments and passing it through to the small intestine (Maintenance of  the body, Human 
Anatomy and Physiology, Tenth Edition, Pearson). The mucosa is the most internal layer, it
is relatively thick (1.5-2 mm), soft, and velvety. It comprises a single layer of  columnar 
epithelium composed of  mucous cells; they produce a cloudy, protective two-layer coat of  
alkaline mucus in which the surface layer consists of  viscous, insoluble mucus that traps a 
layer of  bicarbonate-rich fluid beneath it. 
There are three types of  glands in the stomach: glands in the cardiac region secrete mucous; 
glands in the fundus and body include mucous neck cells, which secrete mucus, 
parietal/oxyntic cells, which secrete hydrochloric acid and gastric intrinsic factor, and chief  
cells, which secrete pepsinogen; glands in the pyloric region secrete mucus. Endocrine cells 
in the pyloric mucosa produce the gastrin hormone which increases the secretion of  gastric 
juice. The oxyntic glands in the orad stomach make up 75% of  the total number of  glands. 
The remaining 25% are pyloric glands in the antrum and pylorus.
To protect itself  from chemical or physical trauma, the stomach mucosa produces a mucosal 
barrier, by a thick coating of  bicarbonate-rich mucus building up on the stomach wall. The 
epithelial cells of  the mucosa are joined together by tight junctions which prevent gastric 
juice from leaking into underlying tissues layers. Additionally, the damaged epithelial mucosal 
cells are shed and quickly replaced by division of  undifferentiated stem cells that reside where
the gastric pits join the gastric glands. The surface epithelial mucous cells are completely 
renewed every three to six days, but the more sheltered glandular cells deep within the gastric 
glands have a longer lifespan. Anything that breaches the gel-like mucosal barrier causes 
inflammation of  the stomach wall, a condition called gastritis. Persistent damage to the 
underlying tissues can promote peptic ulcers.
The next layer, the submucosa is where the nerve bundles locate. Moving outward there are 
three layers of  smooth muscle tissue that form the muscularis external which is responsible 
for the movements of  the stomach, from inner to outer, they are inner oblique layer, circular 
muscle layer, and longitudinal layer. Finally, the outermost layer is the serosa which encloses 
the stomach organ and is connected to the lining of  the abdominal cavity.
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Five arteries supply blood to the stomach. The left gastric artery arises directly from the 
celiac axis and supplies the cardiac region. The right gastric artery (which supplies the lesser 
curve) and the right gastroepiploic artery (which supplies the greater curve) arise from the 
hepatic artery. The left gastroepiploic and the short gastric arteries arise from the splenic 
artery and also supply the greater curvature. The sympathetic nerve supply to the stomach is 
derived from the celiac plexus via nerves that follow the gastric and gastroepiploic arteries. 
Branches also are received from the left and right phrenic nerves. The parasympathetic 
supply is the vagus nerve via the main anterior and posterior trunks which lie adjacent to the 
esophagogastric junction. 
Recent studies have disproved the former view that lymphatic channels are present at all 
levels of  the lamina propria. By using careful ultrastructural techniques, lymphatics have been 
demonstrated to be limited to the portion of  the lamina propria immediately superficial to 
the muscularis mucosae. From there, efferents penetrate the muscle and communicate with 
larger lymphatic channels running in the submucosa. This arrangement implies that an early 
gastric cancer may have lymphatic metastases, even though the primary tumour is entirely 
superficial to the muscularis mucosae.
The lymphatic trunks of  the stomach generally follow the main arteries and veins. Four areas 
of  drainage can be identified, each with its own group of  nodes. The largest area comprises 
the lower end of  the oesophagus and most of  the lesser curvature, which drains along the 
left gastric artery to the left gastric nodes. From the immediate region of  the pylorus, on the 
lesser curvature, drainage is to the right gastric and hepatic nodes. The proximal portion of  
the greater curvature drains to pancreatic splenic nodes in the hilum of  the spleen, and the 
distal portion of  the greater curvature drains to the right gastroepiploic nodes in the greater 
omentum and to pyloric nodes at the head of  the pancreas. Efferents from all four groups 
ultimately pass to celiac nodes around the main celiac axis (Human Anatomy and Physiology, 
Tenth Edition, Pearson). 
1.1.4 Classification of gastric cancer
Carcinomas of  the stomach are morphologically heterogeneous. This heterogeneity is 
reflected in the diversity of  histopathological classifications available which are based on 
different approaches, such as histological profile, degree of  differentiation, pattern of  growth, 
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and histogenesis. Several pathohistological classification systems proposed for the diagnosis 
of  gastric cancer based on macroscopic and/or microscopic feature. It is still controversial 
as to which classification system imparts the most reliable information, and therefore, the 
choice of  system is varied in clinical routine. (Surgical Pathology criteria, Stanford Medicine, 
Available at http://surgpathcriteria.stanford.edu/gitumours/ gastric-adenocarcinoma/). 
Clinically, TNM (tumour, node, metastases) staging is far more important for prediction of  
survival than any of  these classifications. 
1.1.4.1 Early and advanced gastric cancer
Early gastric cancer is defined as invasive cancer confined to mucosa and/or submucosa, 
with or without lymph node metastases, irrespective of  the tumour size (Hamilton R, 
Aatonen LA. Tumours of  Digestive System. Lyon: IARC; 2000:39-52). Most early gastric 
carcinomas are small, measuring 2 to 5 cm in size, and often located at lesser curvature near
the angularis. Some early gastric carcinomas can be multifocal, often indicative of  a worse 
prognosis. 10% of  early gastric cancer presents with lymph node metastases (Hu et al. 2012).
Early gastric carcinoma is divided into Type I for tumours with exophytic growth, Type II 
with superficial growth, Type III with excavating growth, and Type IV for infiltrating growth 
with lateral spreading (Figure 1.12) (Hu et al. 2012). Type II tumours are further divided into 
IIa (elevated), IIb (flat) and IIc (depressed), as proposed by the Japanese Endoscopic Society
(Japanese Gastric Cancer 2011). A Paris classification has endorsed three gross patterns for 
superficial neoplastic lesions in the gastrointestinal tract. Grossly and endoscopically, 
tumours are classified as Type 0-I for polypoid growth (which is subcategorized to 0-Ip for 
pedunculated growth and 0-Is for sessile growth), Type 0-II for nonpolypoid growth (which 
is subcategorized into Type 0-IIa for slightly elevated growth, Type 0-IIb for flat growth, and 
Type 0-IIc for slightly depressed growth), and Type 0-III for excavated growth. 
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Figure 1.12: Pathological types of early gastric cancer. A. Paris classification. B. Japanese 
classification.
Histologically, approximately 50-70% early gastric cancers are well differentiated, 10-30% are 
poorly differentiated (Green and O'Toole 1982; Q. Huang et al. 2015). Tubular and papillary 
architecture are the most common forms of  well-differentiated early gastric cancer (Hu et al. 
2012). The distinction between well-differentiated carcinoma and high-grade dysplasia or 
carcinoma-in-situ can be challenging when only mucosal tissue is available for histologic 
assessment (Hu et al. 2012). Intramucosal invasion may not be as easily confirmed as an 
invasive carcinoma into submucosa where stromal desmoplasia is usually evident (Hu et al. 
2012). The distinction between intramucosal carcinoma and carcinoma-in-situ or high-grade
dysplasia is important, as the intramucosal carcinoma of  stomach, unlike the intramucosal 
carcinoma in the colon, does metastasize (Hu et al. 2012). Generally, the useful histologic 
features of  intramucosal invasion are single tumour cell in the lamina propria and 
significantly fused neoplastic glands of  various sizes (Hu et al. 2012). Through adequate
tumour section and lymphadenectomy, the prognosis of  early gastric carcinoma can reach 
ever greater than 90% (Onodera et al. 2004; Suzuki et al. 2016). 
Advanced gastric cancer, defined as carcinoma with muscularis propria invasion or beyond, 
carries a much worse prognosis, with a 5 years survival rate at less than 60% (Hu et al. 2012). 
Gastric cancer patients classified as stages II-IV (the 7th AJCC cancer staging system)
demonstrated high recurrence rates ranging from 25%-40% in an adjuvant setting, with 
metastatic cases not amenable to re-resection (Cristescu et al. 2015). The distinction between 
early and advanced gastric carcinoma before resection is clinically important because it helps 
to decide if  a neoadjuvant (pre-operative) therapy, which has shown to improve disease-free 
survival (DFS) and OS, is warranted (Cunningham et al. 2006; Ychou et al. 2011). While the 
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macroscopic appearance is informative, the most accurate pre-operative staging information 
is generally obtained with endoscopic ultrasonography (EUS) and computerised tomography 
(CT) (Hwang et al. 2010). 
1.1.4.2 Borrmann’s classification
The appearance of advanced gastric carcinomas can be exophytic, ulcerated, infiltrative or 
combined (Hu et al. 2012). Endoscopic classification of  advanced gastric cancer is well 
known and was introduced by Borrmann in 1926 (Borrmann 1926) including 4 types: type I 
for polypoid growth, type II for fungating growth, type III for ulcerating growth, and type 
IV for diffusely infiltrating growth which is also referred to as linitis plastica-a signet ring cell 
carcinoma involving most of  gastric wall by infiltrating tumour cells. Histologically, advanced 
gastric carcinoma often demonstrates marked architectural and cytological heterogeneity, 
with several co-existing histologic growth patterns (Hu et al. 2012). 
1.1.4.3 Cardia gastric cancer and Non-cardia gastric cancer
Anatomically, gastric cancers are classified into true gastric (non-cardia) and gastro-
oesophageal-junction cancers (cardia). Due to their differences in incidence, geographical 
distribution, causes and clinical disease course, treatments for them also differ. The Siewert 
classification (Figure 1.13) based on the epicentre location of  tumour is widely used to 
category the gastro-oesophageal-junction cancers into three types (Siewert and Stein 1998). 
However, the biology difference between Siewert type II and type III gastric cancer is unclear.
The classification is also criticized by the non-specific definition of  gastro-oesophageal-
junction adenocarcinoma (Demicco et al. 2011). TNM classification introduced a more 
simplified categorization to aid correct anatomical classification, in which both the epicentre 
and the tumour extension margin (within or beyond the gastro-oesophageal junction) are 
included. 
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Figure 1.13: Schematic illustration of the modified Siewert’s classification. The distance
of  the center of  a tumour from anatomical cardia determines tumour type. Source: Oesophagogastric 
junction adenocarcinoma: which therapeutic approach (Mariette et al. 2011).
1.1.4.4 Laurén classification
Some national guidelines for the treatment of  gastric cancer refer to the Laurén or the WHO 
classifications regarding therapeutic decision-making (Okines et al. 2010), which underlines 
the importance of  a reliable classification system for gastric cancer. Currently, Laurén
(Lauren 1965) and WHO [FT Bosman, F Carneiro, RH Hruban, ND Thiese (Eds.), WHO 
classification of tumours of  the digestive system (4th ed.), IARC, Lyon (2010), pp. 44-58] 
schemes are the most commonly used (Table 1.2). 
Table 1.2: Laurén and WHO classification. Source: Pathohistological classification systems in gastric 
cancer: Diagnostic relevance and prognostic value (Berlth et al. 2014).
Laurén classification WHO classification
Intestinal type Papillary adenocarcinoma
Tubular adenocarcinoma
Mucinous adenocarcinoma
Diffuse type Signet-ring cell carcinoma and other poorly 
cohesive carcinomas
Indeterminate type Mixed carcinoma
Adenosquamous Carcinoma
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Squamous cell carcinoma
Hepatoid adenocarcinoma
Carcinoma with lymphoid stroma
Choriocarcinoma
Carcinosarcoma
Parietal cell carcinoma
Malignant rhabdoid tumour
Mucoepidermoid carcinoma
Paneth cell carcinoma
Undifferentiated carcinoma
Mixed adeno-neuroendocrine carcinoma
Endodermal sinus tumour
Embryonal carcinoma
Pure gastric yolk sac tumour
Oncocytic adenocarcinoma
According to the Laurén classification, gastric carcinomas are separated into intestinal and 
diffuse two main histological types presenting differences in not only in histomorphology
but also in clinical and epidemiological characteristics. Cohesiveness and glandular 
differentiated malignant epithelial cells infiltrating the stroma characterize intestinal 
carcinomas. Tumour cells may display varying degrees of  nuclear atypia and may present 
tubular, trabecular, papillary or tubular-papillary structures (Figure 1.14 A-C). According to 
cellular and architectural criteria, gastric adenocarcinomas are classified as well, moderately 
and poorly differentiated. A small percentage of  adenocarcinomas are mixed, presenting 
features of  both types. Cytologically, cells are large and display cytoplasmic as well as nuclear 
pleomorphism. In intestinal-type carcinoma, mitoses are frequently seen, as are 
polymorphous inflammatory infiltrates.
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Figure 1.14: Haematoxylin-eosin staining for Laurén classification of gastric cancer.
A-C, Intestinal-type. Three different tumours are shown with the formation of  irregular glands, tubules, 
and papillae. D, Mucinous adenocarcinoma, with small groups of tumour cells floating in pools of  mucin. 
E, F, Diffuse type. Two different tumours are shown composed of  non-cohesive individual cells 
infiltrating the stroma. Signet ring cell carcinoma (F) is formed by cells with abundant intracytoplasmic 
mucin and nuclei displaced to the periphery. This morphology is characteristic of  this tumour type. Source: 
Gastric cancer: Overview, available from http://colombiamedica.univalle. Edu.co/index.php/comedica
/article/view/1263/2150
In contrast, diffuse carcinomas are composed of  discohesive cells that infiltrate the stroma 
individually or in small groups (Figure 1.14 E-F). In some cases, the tumour may form solid 
masses, but even in these cases the cells appear to be loose, with little cohesiveness and do 
not form epithelial cords. Occasionally, tiny glandular lumens can be observed, formed by 
cells that have no polarity and are surrounded by a diffuse infiltration of  isolated tumour 
cells. Infiltration of  malignant cells with indistinct cytoplasm and pyknotic nuclei often 
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produces a connective tissue proliferation and a chronic, lymphocytic type of  inflammation. 
A variant of  the diffuse histological type is the signet ring cell adenocarcinoma. By definition, 
it must be predominantly composed (>50%) of  signet ring cells. These cells are characterized 
by abundant cytoplasmic mucin that displaces the nucleus to the periphery (Figure 1.14 F)
(Parsonnet et al. 1991).
Mucinous (colloid) adenocarcinomas may originate in adenocarcinomas of  either intestinal 
or diffuse types (Lauren 1965). They are rare histological subtype of  undifferentiated gastric 
carcinoma, accounting for approximately 2.6–6.6% of  all gastric cancer cases (Kunisaki et al. 
2006; Huszno et al. 2012). Mucinous gastric cancer exhibits a poorer prognosis compared to 
non-mucinous gastric cancer, partly due to a more frequent incidence of  advanced-stage 
disease at diagnosis (Isobe et al. 2015). These tumours are composed of  malignant epithelial 
cells floating loose or in small groups in large mucinous areas (Figure 1.14 D). In some cases, 
signet ring cells may be observed. By definition, the extracellular mucinous pools constitute 
at least 50% of  the tumour.
Despite its high clinical relevance, the prognosis value of  Laurén’s classification remained 
controversial (Goseki et al. 1992; Qiu et al. 2013). A recent systematic review and meta-
analysis which included 61,468 patients from 73 published studies, revealed that gastric 
cancer patients with diffuse-type histology have a worse prognosis than those with intestinal 
subgroup in all studies (HR 1.23; 95% CI, 1.17–1.29; P<0.0001). This applies to both loco-
regional confined (HR 1.21; 95% CI, 1.12–1.30; P<0.0001) and advanced disease (HR 1.25; 
95% CI, 1.046–1.50; p=0.014), in both Asiatic (HR 1.2; 95% CI, 1.14–1.27; P<0.0001) and 
Western patients (HR 1.3; 95% CI, 1.19–1.41; P<0.0001). Furthermore, both in those not 
exposed (HR 1.15; 95% CI, 1.07–1.24; P<0.0001) or exposed (HR 1.27; 95% CI, 1.17–1.37; 
P<0.0001) to (neo) adjuvant therapy. This provides important evidence for the use of  
classification systems for stratification purposes in future clinical trials (Petrelli et al. 2017).
Similarly, a study enrolling 3071 patients evaluating the prognostic significance of  Lauren’s 
classification in gastric cancer also showed with intestinal-type gastric cancer (57.7%) had a 
better 5-year OS than diffuse type (45.6%) and mixed type (43.4%, p < 0.001). Besides, 
gastric cancer patients with intestinal type were older (p < 0.001), male predominant 
(p < 0.001), smaller tumour size (p < 0.001), distal stomach predominant (p < 0.001), 
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relatively well differentiated (p < 0.001), less advanced Borrmann type (p < 0.001), less 
scirrhous type stromal reaction(p < 0.001), less infiltrating type of  Ming’s histology type
(refer to 1.1.4.6)(p < 0.001), less tumour invasion depth and less lymphovascular invasion 
(p < 0.001). Lauren’s classification is an independent prognostic factor in gastric cancer 
patients undergoing gastrectomy (Chen et al. 2016).
1.1.4.5 WHO classification
WHO classification includes not only adenocarcinoma of  the stomach but also all other 
types of  gastric tumours of  lower frequency (Table 1.2). The most common type of  gastric 
cancer is tubular adenocarcinoma, followed by papillary and mucinous types. Signet ring cell 
carcinoma accounts for approximately 10% of  gastric cancers and is defined by the presence 
of  signet ring cells in over 50% of  the tumour. Patients with papillary adenocarcinoma, 
mucinous adenocarcinoma were reported to experience unfavorable prognosis (Yasuda et al. 
2000; Zheng et al. 2010; Kawamura et al. 2001). The Japanese classification system further 
divides tubular adenocarcinoma into well-differentiated and moderately differentiated 
adenocarcinoma (Japanese Gastric Cancer Association 2011).
1.1.4.6 Goseki classification (microscopic) and Ming classification (microscopic)
Prognostic-related but less common classification systems were demonstrated to correlate
with the pre-existing classification systems. Goseki et al. grading system (Goseki et al. 1992),
based on tubular differentiation and mucin secretion, was described to divide gastric cancer 
into four groups, as presented in Table 1.3. Ming described the growth pattern of  the lesion 
and recognized two main growth patterns: the expanding growth pattern and the infiltrating 
growth pattern (Table 1.4) (Ming 1977).
Table 1.3: Goseki classification. Source: Pathohistological classification systems in gastric cancer: 
Diagnostic relevance and prognostic value (Berlth et al. 2014).
Type Tubules Intracytoplasmic Mucin
I Well-differentiated Poor
II Well-differentiated Rich
III Poorly differentiated Poor
IV Poorly differentiated Rich
37
Table 1.4: Ming classification. Source: (Surgical Pathology criteria, Stanford Medicine. (Available at
http://surgpathcriteria.stanford.edu/gitumours/gastric-adenocarcinoma/).
In conclusion, the histotype-based classification system for gastric cancers demonstrated a 
potential role as an effective tool for distinguishing patients in different clinical settings and 
with distinct outcomes. However, due to the limited advantages of  any one particular 
classification, there’s no international consensus for research purposes. The difficulty of  
assessing the prognosis of  gastric cancer using histological methods is widely accepted and 
this is also reflected in the essentially descriptive character of  presently used classifications. 
Several histotypes exhibited lower malignant potential have been identified, including 
lymphocyte-rich cancer, muconodular cancer, very-well-differentiated tubular cancer with an 
intestinal or gastric phenotype, and a low-grade subtype of  diffuse desmoplastic cancer. 
Other types of  gastric cancer with poor outcome have also been identified from poorly 
differentiated neuroendocrine carcinoma to anaplastic diffuse cancer or hepatoid, 
chorioncarcinomatous and adenosquamous carcinoma. The different behaviour of  these 
histotypes led to a development of  a histological grading system for prognostic evaluation, 
in which low-grade or grade 1 (G1) was defined as muconodular, well-differentiated tubular, 
diffuse desmoplastic and high lymphoid response (HLR); high-grade or grade 3 (G3) was
anaplastic and mucinous invasive and intermediate-grade or grade 2 (G2) was described as 
ordinary cohesive, diffuse and mucinous cancers. This grading system was highly predictive 
of  patient outcome when applied to a large tumour series (Solcia et al. 2009; Chiaravalli et al. 
2012). While for the evaluation of  grade 2 ordinary cancers, which form a very large, 
histologically heterogeneous group with a wide prognostic spectrum, carefully assessed stage,
other common histological parameters (invasive pattern, proliferative rate, structural or 
cytological atypia, tumour cell phenotype) or a variety of  promising molecular tools are 
crucial for appropriate clinical decisions (Chiaravalli et al. 2012).
Type Description
Expanding type Infiltrating cohesive cell aggregates
Infiltrating type
Diffuse permeative infiltration by single noncohesive 
cells or individual glands
Unclassified
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1.1.4.7 Molecular classification 
1.1.4.7.1 The classification system proposed by TCGA 
The latest results from gastric cancer molecular subtype studies indicate that it might be 
useful to integrate genomic and proteomic-based features of  gastric cancer into the 
classification systems to establish prognostic relevance (Berlth et al. 2014; Wong et al. 2014).
Several whole genome projects were carried out to develop a biologic classification scheme
helping guide patient therapy. TCGA research network published the results of  full genomic 
profiling of  295 primary gastric adenocarcinomas in 2014 (Cancer Genome Atlas Research 
2014), which ushered in an era of  precision medicine of  gastric cancer with strong genetic–
clinical association.
Through complex statistical analyses, four tumour subgroups were identified: positive for 
Epstein-Barr virus (EBV, 9%), microsatellite unstable tumours (MSI, 22%), genomically 
stable tumours (GS, 20%), and chromosomally instability tumours (CIN, 50%). Correlation 
with histological characteristics revealed enrichment of  the diffuse subtype in the 
genomically stable group (73%) (Figure 1.15). The frequency of  chromosomally unstable
tumours was increased in gastro-oesophageal-junction adenocarcinomas, and most tumours
positive for Epstein-Barr virus were located in the fundus or body of  the stomach. Finally,
tumours positive for this virus were mostly found in men (81%), but the predominance of  
microsatellite unstable tumours slightly favored women (56%) (Figure 1.16). 
EBV subtype Deregulated pathways and candidate drivers of  each distinct classes of  gastric 
cancer were identified underlining the possibility of customized treatment and determination
of  prognosis. EBV-positive tumours harbor a high CpG island methylator phenotype CIMP) 
and exhibit a strong predilection for PIK3CA mutations and ARID1A mutations. All EBV-
positive tumours assayed displayed CDKN2A (p16INK4A) promoter hypermethylation but 
lacked the MLH1 hypermethylation characteristic of (MSI-associated tumours in line with 
previous studies (Bernal et al. 2012). EBV-positive tumours also show amplification of  
immune stimuli related kinase JAK2, and immunosuppressant proteins: PD-L1 and PD-L2, 
suggesting that PD-L1/2 antagonists and JAK2 inhibitors be tested in this subgroup (Cancer 
Genome Atlas Research 2014).
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Figure 1.15: Differences in clinical and histological characteristics among subtypes.
A Flowchart outlines how tumours were classified into molecular subtypes. B, Epstein–Barr virus (EBV)-
positive (red), microsatellite instability (MSI, blue), genomically stable (GS, green) and chromosomal 
instability (CIN, light purple) and ordered by mutation rate. The plot of  patient age at initial diagnosis 
shows the median, 25th, and 75th percentile values (horizontal bar, bottom and top bounds of  the box), 
and the highest and lowest values within 1.5 times the interquartile range (top and bottom whiskers, 
respectively). GE, gastroesophageal. Source: Comprehensive molecular characterization of  gastric 
adenocarcinoma (Cancer Genome Atlas Research 2014).
MSI subtype tumours showed elevated mutation rates and hypermethylation (including 
hypermethylation at the MLH1 promoter). Mutations in the top ten significantly mutated 
genes, including TP53, KRAS, ARID1A, PIK3CA, ERBB3, PTEN, HLA-B, RNF43, B2M,
and NF1. B2M resulted in loss of  expression of  HLA class 1 complexes (Bernal et al. 2012), 
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suggesting an impair in reducing antigen presentation to the immune system (Cancer 
Genome Atlas Research 2014).
Figure 1.16: Key features of gastric cancer molecular subtypes. As proposed by TCGA. 
This schematic lists some of the salient features associated with each of the four molecular 
subtypes of gastric cancer. Distribution of molecular subtypes in tumours obtained from 
distinct regions of the stomach is represented by inset charts. Epstein–Barr virus (EBV)-
positive (red), microsatellite instability (MSI, blue), genomically stable (GS, green) and 
chromosomal instability (CIN, light purple) (Cancer Genome Atlas Research 2014).
CIN subtype Phosphorylation of  EGFR (Py1068) was significantly elevated in the CIN 
subtype, consistent with amplification of  EGFR within that subtype. Elevated expression of  
p53 was also consistent with frequent TP53 mutation and aneuploidy in the CIN subtype
(Cancer Genome Atlas Research 2014). Suppressed cytokines such as IL1B, IL2, IL3, IL21, 
IL27, and INFG were found in CIN suggesting that high copy-number alteration may play 
roles in cancer immunity by suppressing activation of  immune cells (Sohn et al. 2017).
GS subtype CDH1 somatic mutations (37% of  cases) and ras homolog family member A
(RHOA) mutations were almost exclusively enriched in the genome stable subtype. Analysis 
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of  base changes’ patterns within gastric cancer revealed elevated rates of  C to T transitions 
at CpG dinucleotides and A to C transversions at the 3′ adenine of  AA dinucleotides, 
especially at AAG trinucleotides. In agreement with a prior study, the A to C transversions 
were prominent in CIN, EBV and genome stable gastric cancers, not in MSI tumours (Dulak 
et al. 2013).
The clinical utility of  molecular classification has been reported recently. The EBV subtype 
was associated with the best prognosis, for both DFS (P=0.006 by the log-rank test) and OS. 
The genomically stable (GS) subtype was associated with the worst prognosis. Patients with 
the MSI and CIN subtypes had a moderate prognosis. Patients with the CIN subtype 
exhibited the greatest benefit from adjuvant chemotherapy (either single-agent 5-fluorouracil 
(5FU) or a combination of  5FU and cisplatin/oxaliplatin, doxorubicin, or paclitaxel), as 
evidenced by significantly increased DFS rates. The 3-year DFS rate was 58.7% for those 
who received chemotherapy, compared with 33.5% for those who did not. The hazard ratio 
(HR) for recurrence among those who received adjuvant chemotherapy was 0.39 (95% CI, 
0.16–0.94, p=0.03). However, no benefit from adjuvant chemotherapy was observed among 
patients with the GS subtype. Activated transcription regulator NUPR1 may be blamed for 
chemoresistance (Vincent et al. 2012; Chowdhury et al. 2009). Patients with the MSI subtype 
showed only moderate benefit from adjuvant chemotherapy. The benefit of  adjuvant 
chemotherapy could not be assessed for patients with the EBV subtype because all patients 
received chemotherapy (Sohn et al. 2017).
1.1.4.7.2 The classification system proposed by ACRG 
Similarly, the Asian Cancer Research Group (ACRG) (Cristescu et al. 2015) also proposed a 
four-subgroup classification system associated with distinct genomic alterations, disease 
progression, and prognosis across multiple gastric cancer cohorts, including microsatellite 
stable with epithelial-to-mesenchymal transition features (MSS/EMT), MSS with mutant 
type of  TP53 (MSS/TP53+), and MSS with wild-type TP53 (MSS/TP53–). 
MSI tumours (22.7%), with a parallel distribution ratio as the analysis from TCGA (22%), 
were hyper-mutated intestinal-subtype tumours (>60%) predominantly occurring in the 
antrum; diagnosed at clinical stage I/II (>50%). MSI tumours had the best prognosis; their 
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recurrence rate (22%) after surgical resection of  primary GC was the lowest among all 4 
subtypes.
MSS/EMT subtype The MSS/EMT (15.3%) and MSI distribution outliers exhibited a 
mutually exclusive pattern. MSS/EMT subtype occurred at a significantly younger age than 
did other subtypes. The majority (>80%) of  the subjects in this subtype were diagnosed with 
diffuse-type at stage III/IV. The MSS/EMT subtype also had the worst prognosis and the 
highest recurrence rate (63%), with recurrences located mostly in the peritoneal cavity. CDH1
mutations were highly prevalent (37%) in the TCGA Genome Stable (GS) subtype but were 
infrequent in the ACRG MSS/EMT subtype (2.8%).
For the remaining tumours, a two-gene (CDKN1A [also known as p21] and MDM2) p53-
activity signature was applied to reflect p53-activity. The signature shows a high score in
tumours with intact p53 activity (26.3%) and a low score in tumours with the p53 functional 
loss (35.7%). Further analysis revealed a significant association between the p53 activity 
signature and p53 mutation status. The MSS/p53− subtype showed the highest prevalence 
of  p53 mutations (60%), with recurrent focal amplifications in ERBB2, EGFR, Cyclin E1 
(CCNE1), Cyclin D1 (CCND1), MDM2 and MYC and a corresponding increased mRNA 
and protein levels of  EGFR and ERBB2; By contrast the MSS/p53+ subtype showed a 
relatively higher prevalence (compared to MSS/p53−) of  mutations in APC, ARID1A, 
KRAS, PIK3CA, and SMAD4. MSS/p53+tumours which were found to be correlated with
EBV infection and had the second-best prognosis, followed by MSS/p53-tumours. Whereas 
the p53 signature is associated with survival in the MSS non-EMT subtype, neither p53
mutation status nor tumour proliferation signature alone significantly predicts survival. A 
more recent project from Japan, employing ACRG classification to categorize patients with 
gastric cancer using p53 tumour-specific single nucleotide mutation, found that the patients 
were significantly younger in EMT. The undifferentiated type was significantly dominant in 
MSI. There was no statistically significant difference in tumour depth, lymph node metastasis, 
or tumour stage among the groups. Two-year cause-specific survival (CSS) rates were 95.5% 
in MSI, 49.9% in EMT, 65.5% in p53+, and 78.5% in p53- (P=0.048). Although the follow-
up period was insufficient, CSS was worse in p53+ than in p53-tumours (Ahn et al. 2017).
These two newly classification system delineated the molecular signatures associated with 
distinct clinical outcomes and potential therapeutic implications. Currently, the antitumour 
43
efficacy of  a molecularly targeted agent is tested in all gastric cancer types regardless of  
molecular subtypes both in preclinical and clinical trials. Molecular screening and therapeutic 
development according to gastric cancer molecular classifications may help to stratify 
patients. (Cancer Genome Atlas Research 2014).
1.1.5 Pathology of gastric cancer
The morphological heterogeneity of  gastric carcinomas is also reflected by the frequent 
occurrence of  two or more distinct components in individual cases (Caldas et al. 1999). The 
classical classification system Laurén’s criteria, introduced in 1965, and remains currently 
widely accepted and employed, since it constitutes a simple and robust classification 
approach (Lauren 1965). As discussed in the previous section, intestinal and diffuse gastric 
cancers exhibit a number of  distinct clinical and molecular characteristics, including 
histogenesis, cell differentiation, epidemiology, aetiology, carcinogenesis, biological 
behaviours, and prognosis.
Carcinogenesis of  intestinal gastric cancer
It is believed that a multistep cascade model for the development of  intestinal-type gastric 
adenocarcinoma consists of  a sequential precancerous process of  with the following well-
recognized steps progression from chronic superficial (non-atrophic) gastritis (chronic active 
inflammation), to chronic atrophic gastritis (gland loss) to intestinal metaplasia, followed by 
dysplasia and finally, gastric adenocarcinoma（Figure 1.17）(Lauren 1965; Correa 1992). It 
is generally recognized that the process starts during childhood, triggered by the infection 
with H. pylori, and advances slowly through the years, eventually leading in a few patients, 
after several decades, to invasive carcinoma (Correa and Piazuelo 2011). This chronic 
inflammation could induce higher levels of  inducible nitric oxide synthase and spermine 
oxidase, enzymes involved in nitrosative and oxidative stress that permanently alter the DNA 
molecules of  the gastric epithelial cells, such as p53 mutation and deficiency in mismatch 
repair genes. Another hypothesis postulates that host innate immune response such as bone 
marrow-derived cells contribute to the development of  gastric cancer in the Helicobacter-
infected gastric mucosa. Experiments in mice reconstituted with labeled bone marrow and 
infected with H. felis (the mouse-adapted Helicobacter species) demonstrated that bone 
marrow-derived cells travel to, and engraft in, gastric mucosa with chronic inflammation and 
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progress to adenocarcinoma (Peek et al. 2010). At the same time, the host genetic 
susceptibility cannot be ignored. Important advances include investigations of  
polymorphisms in genes associated with the immune response to H. pylori infection, mainly 
in IL-1B, IL1RN, TNF, and IL10. IL-1β is a proinflammatory cytokine and a potent inhibitor 
of  gastric acid secretion (El-Omar 2001). It has been hypothesized that profound 
suppression of  acid secretion promotes dissemination of  H. pylori proximally to the corpus, 
leading to a more extensive and severe gastritis that may favor the development of  atrophy 
and subsequently cancer (El-Omar 2001).
Figure 1.17: Haematoxylin-eosin staining for Correa’s precancerous cascade in gastric cancer. A,
Normal gastric mucosa. B, Non-atrophic chronic gastritis. The abundant inflammatory infiltrates in 
lamina propria with well-preserved glands observed in the deeper half  of  the mucosa. C, Multifocal 
atrophic gastritis without intestinal metaplasia. Marked loss of  glands, with a prominent inflammatory,
infiltrate and proliferation of  fibrous tissue in the lamina propria. D, Intestinal metaplasia, complete type. 
Goblet cells alternating with absorptive enterocytes that present well-developed brush border. E, Intestinal 
metaplasia, incomplete type. Goblet cells alternating with columnar cells that contain mucin droplets of  
variable sizes. F, Dysplasia. Epithelium with high-grade dysplasia (lower half  of  the photograph) 
occurring in a background of  incomplete metaplasia (observed in the foveolar superficial epithelium). 
(H&E; original magnification: A-C x100; D-F x200). Source: Gastric Cancer: Overview, available from 
http://colombiamedica.univalle.edu.co/index.php/comedica/article/view/1263/2150
Carcinogenesis of  diffuse gastric cancer
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Diffuse-type adenocarcinomas do not show gender predominance, tend to develop in 
younger subjects, have a poorer prognosis than the intestinal-type tumours, and are more 
frequently located in the proximal stomach than in the distal stomach. Although 
environmental factors seem to play a less important role than in the intestinal-type tumours, 
H. pylori infection is also associated with the development of  diffuse-type adenocarcinomas
(Gong et al. 2018; Kwak et al. 2014; Correa and Piazuelo 2012; Watanabe et al. 2012; 
Tatemichi et al. 2008; Parsonnet et al. 1991; Marshall and Warren 1984). H. pylori-induced 
inflammation activity has been shown to be well correlated with serum Hp-IgG or 
pepsinogen II levels (Biasco et al. 1993; Plebani et al. 1996; Tu et al. 2014; Hsu et al. 1997; 
Tatemichi et al. 2008). In a recent study, the proportion of  diffuse-type gastric cancers
increased with higher Hp-IgG titre groups only among the non-smokers, and more patients 
with intestinal-type gastric cancer had histories of  smoking than those with diffuse-type 
gastric cancer (Kwak et al. 2014). This could be partly explained by the hypothesis that 
intestinal-type gastric cancer is more likely related to environmental factors than diffuse-type 
gastric cancer (Chen et al. 2016). (Table 1.5)
Table 1.5: The comparison between the intestinal and diffuse type of gastric cancer.
Summarized from the review: Laurén classification and individualized chemotherapy in gastric cancer (Ma 
et al. 2016).
Characteristics
Laurén classification type
Intestinal gastric cancer Diffuse gastric cancer
Clinical commonly in elderly male patients commonly in younger female patients 
usually affects the gastric antrum usually affects the stomach body 
exhibits a longer course and better 
prognosis 
presents shorter duration and worse 
prognosis 
Pathological with exitence of adhesion lacking adhesion and infiltrate the stroma 
as single cells or small subgroups, leading 
to a population of non-cohesive, scattered
tumour cells
arranged in tubular or glandular 
formations 
Intracellular mucus may push the nucleus 
of the cell aside to form signet-ring cell 
carcinoma.
Associated with intestinal metaplasia without easily recognized precursor 
lesions
associated with lymphatic or 
vascular invasion
Peritoneal metastasis of diffuse gastric 
cancer
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lesions are scattered in distant 
positions
Epidemiological more prevalent in high-risk areas more prevalent in low-risk areas
Etiology and 
Pathogenesis
associated with environmental 
factors
presents a genetic etiology 
share common dietary and 
environmental risk factors
atrophic gastritis, intestinal
metaplasia
gastritis
involves DNA methylation (such as 
CDH1), histone modifications and 
chromosome recombination
(Yamamoto et al. 2011)
Genetic factors CTNNB1 (the gene encoding β-catenin) mutation 17-27%
K-ras mutation 0-18% in both histological types
Amplifications of the ERBB2
p53 mutations (36-43%) p53 mutations (0-21%)
Somatic mutations of E-cadherin (in 33-
50% sporadic diffuse-type gastric cancer)
Laurén’s classification has, nevertheless, several drawbacks. The first concerns the existence 
of  a fairly large group of tumours which do not fit within the two major types. This group 
of  “unclassified” or “indeterminate” gastric cancer includes undifferentiated (solid) 
carcinomas, as well as carcinomas exhibiting a dual pattern of  differentiation (mixed 
intestinal and diffuse). The solid carcinomas display a clinicopathological profile similar to 
that of  glandular (intestinal) carcinomas, thus supporting the assumption that they could be 
considered as a solid variant of  intestinal carcinoma. Another drawback to Laurén’s 
classification concerns the confusion linked to the term “intestinal”. This led to the proposal 
of  a modification of  Laurén’s classification which recognizes four main types of  gastric 
cancer: glandular, isolated cell type, solid, and mixed carcinoma (Caldas et al. 1999). The 
importance of  distinguishing two main histopathological types of  gastric cancer, one with a 
diffuse component (isolated cell and mixed types) and one without a diffuse component 
(glandular/intestinal and solid types), is highlighted by finding somatic E-cadherin mutations 
exclusively in the first group (Muta et al. 1996; Tamura et al. 1996; Machado et al. 1999).
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Features of  gastric mucosa at the periphery of  sporadic gastric carcinomas are in keeping 
with these two histogenetic pathways. Chronic atrophic gastritis and intestinal metaplasia are 
significantly more frequent at the periphery of  glandular (intestinal) carcinomas and there is 
a higher prevalence of  foveolar hyperplasia at the mucosa overlying or at the periphery of  
isolated cell type (diffuse) carcinomas (Carneiro et al. 1994).
Mixed stomach carcinomas, regardless of  displaying a predominantly intestinal (glandular), 
or a predominantly diffuse (isolated cell) pattern, do carry, in a multivariate analysis, a 
significantly worse prognosis than the main types of  Laurén’s classification (intestinal, diffuse 
and unclassified/solid types) (Carneiro et al. 1995).
1.1.6 Diagnosis and staging of gastric cancer
Diagnosing gastric cancer in its early stages is a difficult task. Symptoms do not appear until 
the lesion reaches late stages of  development and are generally non-specific (Caldas et al. 
1999). When the diagnosis of  gastric carcinoma is established, it is at an incurable advanced 
stage (stage III or IV) in over two-thirds of  cases in non-endemic regions. In endemic regions 
such as Japan, which use mass screening protocols, a higher rate of  diagnosis of  early-stage
gastric cancers has been observed for the past two decades (Yoshida and Saito 1996). Survival 
after early gastric cancer is much better than advanced lesions, so identifying these lesions at 
the earliest of  stages is imperative for optimal survival. There are several conditions/lesions
of  the stomach, such as chronic atrophic gastritis, intestinal metaplasia,
dysplasia/intraepithelial neoplasia, generally recognized as precancerous with varying 
degrees of  risk but, excluding dysplasia, routine interval surveillance examinations such as 
endoscopy are not routinely performed in these conditions (The American Society for 
Gastrointestinal Endoscopy 1988, Dinis-Ribeiro et al. 2012).  
The most common symptoms at diagnosis of  gastric cancer are anorexia, dyspepsia, weight 
loss, and abdominal pain. Patients with tumours at the gastro-oesophageal junction or 
proximal stomach may also present with dysphagia.
The diagnosis of  gastric cancer relies on endoscopy and biopsy. For locally advanced gastric 
cancer, EUS and CT of  the chest and abdomen are currently the primary means of  staging. 
Laparoscopy is used to exclude small-volume peritoneal metastatic disease. A meta-analysis 
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showed that the sensitivity and specificity of  EUS could discriminate between T1–T2 
(superficial) and T3–T4 (advanced) gastric carcinomas, with a sensitivity of  86% (95% CI 
81%-90%). The sensitivity values for diagnosis of  superficial tumours (T1a vs T1b) and
lymph node status (positive vs negative) were 87% (81%-92%) and 83% (79%-87%), 
respectively (Mocellin and Pasquali 2015).
EUS is useful in the preoperative diagnosis of  T stage for selecting limited treatments, such 
as laparoscopic proximal gastrectomy (LPG), which lacks the ability to palpate the tumour.
The tumour size may be underestimated if  tumours are located in the upper third of  the 
stomach and are more histologically diffuse, scirrhous, with infiltrative growth, and more 
frequent lymphatic and venous invasion. It is suggested that gastric cancer in the upper third 
of  the stomach with diffuse-type histology and >20 mm needs particular attention when 
considering the application of  LPG (Van Cutsem et al. 2016).
PET-CT (positron emission tomography [PET]) and MRI are not routinely used for staging 
in gastric cancer, although growing evidence suggests that PET-CT could improve staging 
through increased detection of  involved lymph nodes and metastatic disease. These tests, 
however, are not always informative, especially in patients with mucinous tumours, as they 
might under stage the disease (Van Cutsem et al. 2016; Altini et al. 2015; Waddell et al. 2014). 
A role for MRI also seems to be emerging, especially for the detection of  peritoneal 
metastases. Intraperitoneal metastases are common in people with gastric or gastro-
oesophageal-junction carcinomas and are difficult to diagnose with conventional imaging 
methods.
Laparoscopic staging, with or without peritoneal lavage for malignant cells, remains 
controversial, but expert groups recommend this approach in patients with potentially 
curable gastric or gastro-oesophageal-junction carcinomas (Waddell et al. 2014; Van Cutsem 
et al. 2008). Peritoneal lavage showing positive cytology, in the absence of  macroscopic 
peritoneal metastases, is associated with poor survival and is defined as metastatic disease
(Mezhir et al. 2011). Serosal infiltration is a strong indicator of  peritoneal carcinomatosis, 
which develops in up to 60% of  patients with gastric cancer (Nakamura et al. 1992).
The staging system most often used for gastric cancer is the AJCC TNM system, which is 
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based on tumour size (T), number of  lymph node involved (N), metastasis to distant sites
(M). TNM classification and the corresponding staging is crucial to ensure that appropriate 
interventions are selected, and for monitoring outcomes. According to guidelines from the 
American Cancer Society, pathologic stage (pStage, also called the surgical stage) is 
determined by examining tissue removed during an operation. If  surgery is not possible, the 
cancer will be given a clinical stage (cStage) instead, which is based on the results of  a physical 
exam, biopsy, and imaging tests. The clinical stage will be used to help plan treatment, but it 
may not predict the patient’s outlook as accurately as a pathologic stage, due to the difficulty 
in accurately staging tumour thickness and nodal status.
Staging and TNM classification of  gastric cancer according to the most recent American 
Joint Committee on Cancer (AJCC) system 8th edition of  the guidelines and staging manual 
is listed in Table 1.6 (Gastric cancer Stages, available at https://www.cancer.org/ 
cancer/stomach-cancer/detection-diagnosis-staging/staging.html). 
With the development of  neoadjuvant chemotherapy in gastric cancer (see details below), a 
new concept of  post neoadjuvant pathological stage (ypTNM or ypStage) is introduced. 
ypStage represents the combination of tumour status and its response to preoperative 
therapy; pStage does not incorporate tumour treatment response. This new ypStage system 
was created based on the National Cancer Database (NCDB), which included a relatively 
small number of  patients treated with preoperative therapy (<700) with a short median 
follow-up (23 months); therefore, additional studies from more cancer centers that utilize 
preoperative therapy are needed (Ikoma et al. 2018).
Table 1.6: Pathologic stage. It is determined by examining tissue removed during an operation. Source: 
Gastric cancer Stages, American Cancer Society, available at https://www.cancer.org /cancer/stomach-
cancer/detection-diagnosis-staging/staging.html. The T categories are described in the table below, except 
for TX: the main tumour cannot be assessed due to lack of  information. T0: No evidence of  a primary 
tumour. The N categories are described in the table below, except for NX: Regional lymph nodes cannot 
be assessed due to lack of  information. 
AJCC Stage Stage grouping Stage description
0 Tis N0 M0 There is high-grade dysplasia (very abnormal-looking cells) 
in the stomach lining OR there are cancer cells only in the 
top layer of  cells of  the mucosa (innermost layer of  the 
stomach) and have not grown into deeper layers of  tissue 
such as the lamina propria (Tis). This stage is also known 
as carcinoma in situ (Tis). It has not spread to nearby 
lymph nodes (N0) or distant sites (M0).
IA T1 N0 M0 The tumour has grown from the top layer of  cells of  the 
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mucosa into the next layers below such as the lamina 
propria, the muscularis mucosa, or submucosa (T1). It has 
not spread to nearby lymph nodes (N0) or to distant sites 
(M0).
IB T1 N1 M0 The cancer has grown from the top layer of  cells of  the 
mucosa into the next layers below such as the lamina 
propria, the muscularis mucosa, or submucosa (T1) AND 
it has spread to 1 to 2 nearby lymph nodes (N1). It has not 
spread to distant sites (M0).
T2 N0 M0 The cancer is growing into the muscularis propria layer 
(T2). It has not spread to nearby lymph nodes (N0) or to 
distant sites (M0).
IIA T1 N2 M0 The cancer has grown from the top layer of  cells of  the 
mucosa into the next layers below such as the lamina 
propria, the muscularis mucosa, or submucosa (T1) AND 
it has spread to 3 to 6 nearby lymph nodes (N2). It has not 
spread to distant sites (M0).
T2 N1 M0 The cancer is growing into the muscularis propria layer 
(T2) and it has spread to 1 to 2 nearby lymph nodes (N1) 
but not to distant sites (M0).
T3 N0 M0 The cancer is growing into the subserosa layer (T3). It has 
not spread to nearby lymph nodes (N0) or to distant sites 
(M0).
IIB T1 N3a M0 The cancer has grown from the top layer of  cells of  the 
mucosa into the next layers below such as the lamina 
propria, the muscularis mucosa, or submucosa (T1) and it 
has spread to 7 to 15 nearby lymph nodes (N3a). It has not 
spread to distant sites (M0).
T2 N2 M0 The cancer is growing into the muscularis propria layer 
(T2) and it has spread to 3 to 6 nearby lymph nodes (N2). 
It has not spread to distant sites (M0).
T3 N1 M0 The cancer is growing into the subserosa layer (T3) and it 
has spread to 1 to 2 nearby lymph nodes (N1) but not to 
distant sites (M0).
T4a N0 M0 The tumour has grown through the stomach wall into the 
serosa, but the cancer hasn’t grown into any of  the nearby 
organs or structures (T4a). It has not spread to nearby 
lymph nodes (N0) or to distant sites (M0).
IIIA T2 N3a M0 The cancer is growing into the muscularis propria layer 
(T2) AND it has spread to 7 to 15 nearby lymph nodes 
(N3a). It has not spread to distant sites (M0).
T3 N2 M0 The cancer is growing into the subserosa layer (T3) and it 
has spread to 3 to 6 nearby lymph nodes (N2). It has not 
spread to distant sites (M0).
T4a N1 M0 The cancer has grown through the stomach wall into the 
serosa, but it has not grown into any of  the nearby organs 
or structures (T4a). It has spread to 1 to 2 nearby lymph 
nodes (N1) but not to distant sites (M0).
T4a N2 M0 The cancer has grown through the stomach wall into the 
serosa, but it has not grown into any of  the nearby organs 
or structures (T4a). It has spread to 3 to 6 nearby lymph 
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nodes (N1) but not to distant sites (M0).
T4b N0 M0 The cancer has grown through the stomach wall and into 
nearby organs or structures (T4b). It has not spread to 
nearby lymph nodes (N0) or to distant sites (M0).
IIIB T1 N3b M0 The cancer has grown from the top layer of  cells of  the 
mucosa into the next layers below such as the lamina 
propria, the muscularis mucosa, or submucosa (T1) and it 
has spread to 16 or more nearby lymph nodes (N3b). It has 
not spread to distant sites (M0).
T2 N3b M0 The cancer is growing into the muscularis propria layer 
(T2) and it has spread to 16 or more nearby lymph nodes 
(N3b). It has not spread to distant sites (M0).
T3 N3a M0 The cancer is growing into the subserosa layer (T3) and it 
has spread to 7 to 15 nearby lymph nodes (N3a). It has not 
spread to distant sites (M0).
T4a N3a M0 The cancer has grown through the stomach wall into the 
serosa, but it has not grown into any of  the nearby organs 
or structures (T4a) and it has spread to 7 to 15 nearby 
lymph nodes (N3a). It has not spread to distant sites (M0).
T4b N1 M0 The cancer has grown through the stomach wall and into 
nearby organs or structures (T4b). It has spread to 1 to 2 
nearby lymph nodes (N1) but not to distant sites (M0).
T4b N2 M0 The cancer has grown through the stomach wall and into 
nearby organs or structures (T4b). It has spread to 3 to 6 
nearby lymph nodes (N1) but not to distant sites (M0).
IIIC T3 N3b M0 The cancer is growing into the subserosa layer (T3) and it 
has spread to 16 or more nearby lymph nodes (N3b). It has 
not spread to distant sites (M0).
T4a N3b M0 The cancer has grown through the stomach wall into the 
serosa, but it has not grown into any of  the nearby organs 
or structures (T4a) and it has spread to 16 or more nearby 
lymph nodes (N3b). It has not spread to distant sites (M0).
T4b N3a M0 The cancer has grown through the stomach wall and into 
nearby organs or structures (T4b) and it has spread to 7 to 
15 nearby lymph nodes (N3a). It has not spread to distant 
sites (M0).
T4b N3b M0 The cancer has grown through the stomach wall and into 
nearby organs or structures (T4b) and it has spread to 16 
or more nearby lymph nodes (N3b). It has not spread to 
distant sites (M0).
IV Any T Any N M1 The cancer can grow into any layers (Any T) and might or 
might not have spread to nearby lymph nodes (Any N). It 
has spread to distant organs such as the liver, lungs, brain, 
or the peritoneum (the lining of  the space around the 
digestive organs) (M1).
1.1.7 Treatment of gastric cancer
Treatment of  gastric cancer depends on the TNM classification and staging which reflect 
both the primary site of cancer started and its pattern of  growth and metastasis. Despite 
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invading the wall of  the stomach and nearby organs, the stomach has a very rich network of  
lymph vessels and nodes, and the biological factors determine that gastric cancers spread 
easily through the lymph vessels and nearby lymph nodes. As gastric cancer becomes more 
advanced, it can travel through the bloodstream and metastasize to organs such as the liver, 
lungs, and bones, which make it harder to treat.
1.1.7.1 Surgery
Adequate surgical resection is the only therapeutic option with an intention to cure for gastric 
cancer (Ikoma et al. 2018). Endoscopic resection might be suitable as an alternative to surgery 
for small well-differentiated early-stage tumours (T1a). The extent of  surgery is determined 
by tumour stage, diameter, location, and histological type. Adequate surgery in the stomach 
is defined as complete resection of  primary cancer with tumour-free surgical margins of  at 
least 4 cm and adequate lymphadenectomy (Van Cutsem et al. 2016). These requirements 
correspond to total gastrectomy for gastric cancers with signet-ring cells (linitis plastica), and 
those located in the upper third of  the stomach or with atrophic gastritis. Cancer in the lower 
two-thirds of  the stomach can often be treated with subtotal gastrectomy. At least 16 lymph 
nodes should be removed to enable adequate tumour staging and ensure optimum surgical 
resection (Van Cutsem et al. 2016). Although there is no worldwide consensus on the degree 
of  lymphadenectomy, the D2 lymphadenectomy (perigastric [D1] plus coeliac artery and its 
branches) is generally recommended if  the associated postoperative morbidity and mortality 
rates are acceptably low—for instance, in high-volume hospitals with experienced surgeons
(Songun et al. 2010; Van Cutsem et al. 2016). This approach, together with the improved 
methods for staging, increased use of  adjuvant and neoadjuvant therapies, and centralization
of  surgery has contributed to improved cure rates in various registries and studies, from 30% 
to up to 55% in the past decade. 
Transabdominal total gastrectomy is the standard surgical approach to treat patients with 
Siewert type II or III cancer of  the gastro-oesophageal junction. This procedure is extended 
with a transhiatal resection of  the distal esophagus and lymphadenectomy of  the lower 
mediastinum and the abdominal D2 nodal compartment. A thoracoabdominal approach in 
these patients can increase the risk of  morbidity without improving survival and, therefore, 
is not usually recommended to treat cardia (type II) or subcardia (type III) gastric cancers
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(Van Cutsem et al. 2016; Sasako et al. 2006).
Early gastric cancer is limited to the mucosa or submucosa (pathologically staged as T1 or 
lower), regardless of  nodal status. Even in early gastric cancer, use of  a multidisciplinary 
approach to determine the best therapeutic strategy (i.e., endoscopic or surgical resection) is 
mandatory because lymph-node metastases occur in up to 20% of  patients and correlate well 
with tumour penetration of  the stomach wall and large tumour diameter (Dinis-Ribeiro et al. 
2012; Wang et al. 2014). 
Endoscopic versus surgical management of  early gastric cancer has not been studied in 
randomized clinical trials, but surgical resection is viewed as the gold standard and is 
associated with 5-year recurrence-free survival of  up to 98% (Youn et al. 2010). For mucosal 
gastric carcinoma (T1a), endoscopic resection is deemed sufficient in all European guidelines 
because the incidence of  the lymph-node metastatic disease is very low. For patients with the 
early disease but suspected or histologically proven lymph-node metastasis, endoscopic 
resection should not be attempted, If  the histopathological findings confirm a submucosal 
carcinoma (T1b) after endoscopic resection, surgical resection that includes systematic 
lymphadenectomy is recommended, because lymph-node involvement is seen in up to 20% 
of  these patients. Endoscopic resection of  early gastric cancer should be done as a complete 
en-bloc resection to allow full histological assessment of  the lateral and basal margins (Van 
Cutsem et al. 2008; Moehler et al. 2015). Patients who have endoscopic resection should be 
monitored frequently by endoscopic surveillance.
Most patients with locally advanced gastric cancer, which invades the muscularis propria and 
beyond (pathologically staged as T2 or higher), present with metastases in lymph nodes, 
distant organs, or both. Locally advanced gastric cancer may need total resection of  involved 
structures. Prophylactic splenectomy is discouraged because it increases the risk of  operative 
morbidity and mortality without any survival benefit but might be necessary if  the spleen or 
its hilar lymph nodes are affected. Only patients without metastatic disease are potential 
candidates for surgical management with curative intent, although selected patients with 
peritoneal carcinomatosis or positive peritoneal cytology might benefit from aggressive 
surgery in expert centers (Sano et al. 2004). Cytoreductive surgery with hyperthermic 
intraperitoneal chemotherapy for prevention and treatment of  peritoneal carcinomatosis 
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from gastric cancer was reported to be associated with improved OS at 1, 2, and 3 years, but 
not at 5 years in a meta-analysis (Coccolini et al. 2014). However, better designed randomized
clinical trials with robust methods are needed to confirm the potential benefits of  this 
approach (Van Cutsem et al. 2016).
Minimally invasive surgery by laparoscopy has been gradually accepted in surgical oncology
over the past decade. Laparoscopic distal gastrectomy compared with open surgery was 
associated with similar lymph-node dissection and long-term survival and with reduced 
intraoperative blood loss, postoperative complications, analgesic consumption, and length of  
hospital stay (Zeng et al. 2012). Well-designed randomized clinical trials with robust methods, 
a precision evaluation of  preoperative stage and a comprehensive understanding of  the 
biological behavior of  gastric cancer may be required for better selection of  adequate patients 
who can benefit from laparoscopic gastrectomy.
1.1.7.2 Radiotherapy
Ionizing radiation (IR) introduces overwhelming genetic lesions in the DNA of  irradiated 
cells, causing cell death. Currently, adjuvant radio-chemotherapy is recommended in patients 
with loco-regionally advanced carcinoma of  the gastro-oesophageal junction (T2N1-3M0 or 
T3N0-3M0) (Zeng et al. 2012). For patients with ≥Stage IB gastric cancer who have 
undergone surgery without administration of  preoperative chemotherapy (e.g. due to 
understaging before the initial decision for upfront surgery), postoperative 
chemoradiotherapy (CRT) or adjuvant chemotherapy is recommended (Smyth et al. 2016). 
Although, radiotherapy is proven to be tolerated, improves the resectability of  the tumour, 
and does not increase the frequency of  surgical complications. Off-target effects remain a 
serious burden on patients receiving radiation therapy. The lungs are one of  the most 
sensitive organs to radiation, and chest radiation has a high chance of  leading to radiation-
induced lung injury. For unresectable gastric cancer, radiotherapy is justified in cases with 
anaemia, and/or in the cases with pyloric or cardiac obstruction (Sitarz et al. 2018). A recent 
meta-analysis demonstrated that more than two-thirds of  patients receiving palliative 
radiotherapy would have a clinical benefit. Low biological equivalent dose (<39Gy regimens) 
can be adequate for symptom palliation, such as diminishing bleeding and/or improving the 
food passage. Toxicity rates appear acceptable for patients treated with palliative radiotherapy 
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alone. The optimal dose fractionation regimen for symptom palliation remains unclear. The 
effect is usually short (3–6 months), but it is an easy therapeutic option. Prospective studies 
to determine the effects of  palliative gastric palliative radiotherapy on health-related quality 
of  life outcomes are still warranted (Tey et al. 2017).
1.1.7.3 Chemotherapy
No further treatment is usually needed after surgery for stage 0, or IA gastric cancer. 
However, for management of  locally advanced disease, especially for patients with T3, T4, 
or node-positive tumours, adjuvant and neoadjuvant therapies are recommended. There is
improved DFS and OS in patients who have undergone adequate complete surgical resection 
(R0) of  locally advanced gastric cancer by eradicating microscopic disease locoregionally and 
at a distance from the primary tumour (Lutz et al. 2012; Van Cutsem et al. 2011; Cunningham 
et al. 2006). 
Single-agent activity of  many classical drugs was tested in advanced gastric cancer before the 
1980s. Complete responses with single-agent therapy are uncommon, and partial responses 
ranged from 10-20%, followed by a short time period to disease progression (Table 1.7).
Table 1.7: Single-agent activity in advanced gastric cancer. Agents that have obtained more than
10% response rate. Source: Chemotherapy for gastric cancer (Sastre et al. 2006).
Agents Response rate (%)
Mitomycin C 30
Doxorubicin 17
Epirubicin 19
Cisplatin 19
BCNU 18
5FU 21
Etoposide (oral) 21
Hydroxyurea 19
UFT 27
Capecitabine 19
S-1 45
Paclitaxel 17-23
Docetaxel 17-29
CPT-11 18
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Chemotherapy regimens for gastric cancer have varied considerably since the 1980s. There 
were no analyses supporting the regular use of  adjuvant chemotherapy for gastric cancer 
until 1993. Combination regimens of  Platinum compounds, 5FU, taxanes or irinotecan were
developed to improve overall response rate and survival (Table 1.8).
Table 1.8: Combination therapy for advanced gastric cancer. FAM fluorouracil-doxorubicin-
mitomycin C, FAMTX methotrexate-leucovo-5FU-adriamycin, FEMTX adriamycin was substituted by 
its analogue 4-epi-doxorubicin, ELF 5FU-leucovorin -intravenous etoposide, modified-EFL oral 
etoposide, oral leucovorin and either 5FU continuous infusion or tegafur, ECF continuous 5FU infusion, 
cisplatin and epirubicin, PF cisplatin and 5FU, EAP cisplatin-etoposide-doxorubicin, FLEP 5FU 
modulated by folinic acid (FA)- epirubicin-cisplatin, ECC epirubicin-cisplatin-capecitabine, P-S-1 
cisplatin- S-1 (oral fluoropyrimidine derivative analogue), MCF mitomycin C, cisplatin and fluorouracil, 
DP docetaxel-cisplatin, DCF docetaxel-cisplatin-5FU, EOF epirubicin-oxaliplatin-5FU, ECX epirubicin-
cisplatin-capecitabine, EOX epirubicin-oxaliplatin-capecitabine
Response rate (%) Median survival (months)
5FU-based combinations
FAM 30-42 6-9 
FAMTX 33-63 6
ELF 53 11
Modified-ELF 16-42 6-9.5
Cisplatin-5FU CI synergism
PF 40 9-10
ECF 59-71 8.7
P-5FU 48-h CI 50 9.3
P-5FU 24-h CI 58 11
Cisplatin-based combinations
EAP 33-64 9
FLEP 35 8
FLEP-type 39 11
LV5FU2-P 27 13.3
Combinations including new drugs
P-CPT11 41-58 9-12
LOHP-CPT11 50 8.5
CPT11-bolus 5FU 22 7.6
CPT11- 5FU CI 20 7
P-Xeloda 54.8 10.1
ECC 59 9.6
P-S-1 73-74 12
TPFU/LV 50 11-14
DP 37-56 9-11
DCF 51 9.3
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It is now well recognized that combination chemotherapy regimens improve patient 
outcomes, but there is no accepted global standard regimen. In the daily clinical practice, 
several drugs such as fluorouracil, capecitabine, cisplatin, oxaliplatin docetaxel, epirubicin, 
paclitaxel, and irinotecan are major components of  conventional regimens. 5FU given as a 
continuous infusion in combination with cisplatin (FP) has consistently demonstrated 
superiority in terms of  response rate and time to disease progression, compared with 5FU
monotherapy and other combination regimens, although it has not shown a significant 
survival advantage in phase III clinical trial (Koizumi et al. 2008; Van Cutsem et al. 2006; Al-
Batran et al. 2008; Boku et al. 2009; Cunningham et al. 2008). A small but clinically relevant 
1-month mean average survival benefit of  combination chemotherapy was shown to be 
statistically significant (p=0.001) compared to monotherapy in a meta-analysis of  several 
clinical trials (Wagner et al. 2006). The combination of  cisplatin, 5FU +/- epirubicin is the 
mostly commonly recommended first-line treatment for advanced gastric cancer (Bittoni et 
al. 2015). There are some regional variations in chemotherapy regimens. In the UK, the most 
popular chemotherapy is epirubicin plus cisplatin plus 5FU or epirubicin plus oxaliplatin plus 
capecitabine (Cunningham et al. 2008). In Europe, the most commonly used regimen is 
docetaxel plus cisplatin plus 5FU (DCF) or 5FU, leucovorin, and oxaliplatin (FOLFOX) (Van 
Cutsem et al. 2006). Cisplatin plus 5FU or DCF is the commonest scenario in the United 
States, while in Eastern countries, two drugs combination S-1 plus cisplatin in Japan, or 
capecitabine and oxaliplatin in South Korea are the most commonly administered therapy
(Noh et al. 2014; Koizumi et al. 2008). The overall response rate for sequential treatment 
with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU 
(DOF) in a single-institution from Italy was 51.1 % (95 % CI 35.7-66.2 %) and 93.3 % of  
patients were progression-free 6 months after the onset of  chemotherapy. A similar response 
rate (61.7%) was shown in the TCOG 3211 Clinical Trial conducted in Taipei, where the 
median progression-free survival and OS were 8.6 and 11.0 months, respectively (M. H. Chen 
et al. 2016). A recent Cochrane meta-analysis (Wagner et al. 2017) confirmed that
chemotherapy improves gastric cancer patients’ survival (by approximately 6.7 months) and 
quality of  life in comparison to best supportive care alone. Furthermore, First-line 
combination chemotherapy improves survival (by one month) compared to single-agent 5FU.
People with locally advanced disease or age<65 might benefit from a three-drug regimen 
including 5FU, docetaxel, and oxaliplatin as compared to a two-drug combination of  5FU
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and oxaliplatin. However, the OS benefit from treatment with adjuvant chemotherapy is 
estimated to be approximately 4%, with the greatest benefit in patients with node-positive 
disease. A meta-analysis (GASTRIC [Global Advanced/Adjuvant Stomach Tumour
Research International Collaboration] Group 2013) from Global Advanced/Adjuvant 
Stomach Tumour Research International Collaboration in 2013 collected individual
treatment information from 4245 patients of  22 clinical trials and demonstrated the benefits 
of  the experimental treatments over their corresponding controls which hazard reductions 
of  13% for OS (HR = 0.87, P < 0.0001,) and 21% for PFS (HR = 0.79, P < 0.0001,).
Although these overall relative risk reductions translate into only modest absolute 
improvements in median OS and PFS, they nevertheless confirm the benefit of  
chemotherapy for advanced gastric cancer and justify further efforts at improving current 
regimens.
Given the relatively minor benefits of  adjuvant chemotherapy seen in these early analyses, 
the high rate of  local relapse continued to stimulate interest in adjunctive treatment 
modalities, resulting in two different but beneficial approaches. The first was postoperative 
chemoradiotherapy, which was tested in a US Southwest Oncology Group/Intergroup study 
(SWOG 9008/INT 0116, Figure 1.18A) (Macdonald et al. 2001), and the second was 
perioperative chemotherapy, tested in a UK Medical Research Council (MRC) randomized 
trial (the MRC Adjuvant Gastric Infusional Chemotherapy [MAGIC] trial, Figure 1.18B)
(Cunningham et al. 2006). These trials demonstrated clinically and statistically significant 
survival benefits that have changed practice with two different treatment options in 
resectable gastric cancer. As the patient populations studied were different, the results are 
not directly comparable, but they do suggest treatment options for patients at different points 
in their care.
Based on experience from adjuvant chemotherapy, most patients, currently receive
fluoropyrimidine- and platinum-based neoadjuvant therapy before initial surgery. This 
approach is preferred especially for patients with a high likelihood of  developing distant 
metastases (i.e., those with bulky T3/T4tumours, visible perigastric nodes by preoperative 
imaging studies, a linitis plastica appearance, or positive peritoneal cytology in the absence 
of  visible peritoneal disease). However, there are no randomized trials demonstrating better 
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outcomes from neoadjuvant therapy versus initial surgery followed by any form of  adjuvant 
therapy. Pragmatically there is a greater chance of  delivering therapy in the preoperative 
setting, and patients who are at high risk of  developing distant metastases may be spared the 
morbidity of  unnecessary gastrectomy if  evidence of  distant metastases emerges after 
chemotherapy. Currently, upfront surgery still remains an accepted approach, especially for 
patients with clinically staged, non-bulky, T2 or T3 tumours with no visible perigastric nodes. 
Clinical studies for choosing the best chemotherapy regimen are still ongoing (Cunningham 
et al. 2006; Al-Batran et al. 2016; Xiong et al. 2014; Ronellenfitsch et al. 2013). 
Figure 1.18: Designs of the Intergroup 0116 Trial and of the UK Medical Research 
Council’s MAGIC Trial. A. A trial of  postoperative chemoradiotherapy in stage IB-IV gastric cancer. 
5FU stands for fluorouracil; LV stands for leucovorin. B. A trial of  perioperative chemotherapy in patients 
with operable gastric cancer. ECF= epirubicin/cisplatin/fluorouracil; Source: Therapeutic Options in 
Gastric Cancer (Jackson et al. 2007).
The outlook for patients with metastatic gastric cancer is very poor, with median survival 
ranging from 4 months when treated only with best supportive care, to around 12 months 
when treated with combination cytotoxic chemotherapy. The most frequently used standard 
first-line chemotherapy regimen in metastatic gastric cancer is a combination of  a 
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fluoropyrimidine with a platinum, although triple regimens including docetaxel might be 
useful in otherwise healthy patients with a high tumour burden. Median survival does usually 
not exceed 1 year. In patients with good performance status and organ function, second-line 
treatment with agents that were not used in first-line treatments (i.e., taxanes or irinotecan) 
can lead to slight survival benefits (Ford et al. 2014; Kang et al. 2012; Bolke et al. 2008; Van 
Cutsem et al. 2006). 
Generally, treatment regimens selection, dosing, administration, and the management of  
related adverse events for gastric cancer can be a complex process that should be handled by 
an experienced healthcare team. Clinicians must choose and verify treatment options based 
on the individual patient. Drug dose modifications and supportive care interventions should 
be administered accordingly. The cancer treatment regimens in Appendix 6 includes both 
U.S. Food and Drug Administration-approved and unapproved indications/regimens. These 
regimens are provided only to supplement the latest treatment strategies. The guidelines are 
a work in progress that may be refined when new significant data becomes available. 
1.1.7.4 Target therapy
The pivotal ToGA trial was the first randomized, prospective, multicentre phase 3 trial to 
study the efficacy of  targeted therapy with first line trastuzumab (a monoclonal antibody 
against HER2) in patients with HER2-positive advanced gastric or gastro-oesophageal-
junction cancer (Bang et al. 2010). Up to 20% of  gastric tumours overexpress the HER2 
receptor, mostly because of  HER2 amplification. 584 patients were enrolled and received 
study treatment at least once. Median OS was 13.8 months (95% CI 12-16) in the 
trastuzumab group, compared with 11.1 months in the chemotherapy group (10–13) (hazard 
ratio 0·74; 95% CI 0·60-0·91; p=0·0046). The longest survival (median 16.0 months) was 
seen in patients with high HER2 protein overexpression and HER2 amplification. On the 
basis of  this study, trastuzumab in combination with cisplatin and a fluoropyrimidine has 
been approved for first-line treatment of  advanced HER2-positive gastric and gastro-
oesophageal-junction adenocarcinomas (Van Cutsem et al. 2015; Jorgensen 2010). 
Randomised trials have included assessments of  antibodies against EGFR (Waddell et al. 
2013; Lordick et al. 2013), and VEGFR2 (Wilke et al. 2014; Fuchs et al. 2014) in combination 
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with chemotherapy, but results have generally shown no or limited benefit, partly due to the 
inappropriate selection of  patients (Lordick et al. 2014; Tan et al. 2011). Several other 
biological targeted agents are being, or have been, investigated. Hepatocyte growth factor 
(HGF) and its receptor, the transmembrane tyrosine kinase cMET, as well as fibroblast 
growth factor receptor (FGFR) are among the candidate targets for new agents in advanced 
gastric cancer. Additionally, in view of  the new data from the Cancer Genome Atlas research 
network, PD-1 and PD-L1 may serve as emerging targets for treatment, and initial promising 
results have been reported with pembrolizumab.
There is increasing recognition that for gastric cancer and other malignancies, that besides 
the tumour stage, the intrinsic subtypes of  GC, based on distinct patterns of  expression, 
may influence patient survival and response to chemotherapy. Distinct patterns of  genomic 
alteration or protein expression may provide clues for management and improvement of  
patients’ clinical outcomes. 
1.1.8 Precision medicine for gastric cancer
Identifying specific signaling pathways in individual patients might improve treatment 
outcomes, for example, the use of  anti-human epidermal growth factor receptor-2 
monoclonal antibody, trastuzumab (Bang et al. 2010), anti-vascular endothelial growth factor 
receptor-2 monoclonal antibody, ramucirumab (Fuchs et al. 2014), and has shifted the 
previous histopathologic paradigm to incorporate new genetic and molecular features (Figure 
1.19). However, equally importantly, tailoring individualized cytotoxic therapy for the 
treatment of  gastric cancer is warranted (Ma et al. 2016). 
Figure 1.19: Timeline of selected major developments in gastric cancer (above arrow) 
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and related clinical trials (below arrow) in recent years. Source: Gastric Cancer in the Era of  
Precision Medicine. (Liu and Meltzer 2017)
1.1.8.1 Cytotoxic drugs sensitivity in gastric cancer according to Laurén
classification
Evidence of  different response to treatment between gastric cancer subtypes has been 
reported not only in patients with advanced disease but also in the adjuvant setting. In 
particular, in an updated analysis of  the INT-0116 study, evaluating post-operative chemo-
radiotherapy in patients with resected gastric cancer, it has been shown that the benefit of  
adjuvant treatment is minimal in patients with diffuse histology while is significant in all the 
other subsets (Smalley et al. 2012). Similar findings have been observed also in the ITACA-
S trial, a multicentre phase III trial comparing 5FU and leucovorin versus a sequential 
regimen including irinotecan and 5FU followed by cisplatin and docetaxel in the adjuvant 
treatment of  resected gastric cancer patients. In a subgroups analysis of  the trial, which could 
not demonstrate any benefit for the intensive treatment versus the fluorouracil monotherapy, 
the authors compared the outcome of  patients according to disease histopathologic and 
anatomic criteria-diffuse gastric cancer presented a worse outcome in terms of  OS compared 
to distal non-diffuse gastric cancer (HR=1.35; 95% CI 1.06–1.72, p=0.016) while no 
significant difference in terms of  prognosis was found between distal or proximal non-
diffuse gastric cancer. None of  the three subtypes showed a benefit for the experimental arm 
versus the 5FU arm.
It has been observed that the overall response rate to first-line chemotherapy (two drugs 
fluoropyrimidine-based chemotherapy regimen or three drugs regimen as first-line 
combination chemotherapy, including a platinum derivate, a fluoropyrimidine, and a third
drug) was 29.6%. The response rate for diffuse gastric cancer is about 20.4%, while in 
patients with proximal non-diffuse gastric cancer or distal non-diffuse gastric cancer, the 
response rate is higher, 46.1% and 34.3% respectively. Diffuse type gastric cancer patients 
also presented a shorter PFS compared to other subgroups with a median PFS of  4.2 months 
compared to 7.2 months for proximal non-diffuse gastric cancer patients and 5.9 months for 
distal non-diffuse gastric cancer patients. These differences translated into statistically 
significant differences in OS (Shah et al. 2011).
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Interestingly, in these studies, gastroesophageal tumours, usually considered more aggressive 
and presenting a worse prognosis compared to tumours arising from the rest of  the stomach
(Kattan et al. 2003; Sakaguchi et al. 1998), had a greater benefit from the treatment. A subset 
analysis of  a phase II trial evaluating bevacizumab with a modified DCF regimen (docetaxel, 
cisplatin, 5FU) in advanced gastric cancer patients diffused type of  gastric cancer was shown 
to have significantly worse PFS and OS compared to other subtypes. Diffuse tumours also 
presented the worse response rate with 38% compared to 56% of  distal/body diffuse gastric 
cancer and 85% of  proximal non-diffuse gastric cancer (Shah et al. 2011).
A subset analysis comparing the efficiency of  trastuzumab in intestinal and diffuse type 
gastric cancers showed that the addition of  trastuzumab to chemotherapy showed that
diffuse type gastric cancer patients with 2% HER2 amplification had no effect on survival 
with an HR for OS of  1.07 (0.56-2.05) versus an HR of  0.69 (0.54-0.88) for intestinal type 
gastric cancer patients with 21.5% HER2 amplification (Bang et al. 2010; Tanner et al. 2005).
A multicentre study with more than 1000 HER2 negative gastric cancers undergoing
chemotherapy containing 2-3 drugs, sought to evaluate whether Laurén type influences the 
efficacy of  various chemotherapies and on patient OS. The ORR was found decreased when 
tumours presenting a diffuse component. Anthracycline- or docetaxel-containing schedules 
increased ORR only in the intestinal type. The diffuse type displayed increased mortality with 
HR of  1.201 (95% CI, 1.054-1.368), Patients receiving chemotherapy with docetaxel had no 
increase in OS for the subset having a diffuse component but exhibited increased OS in the 
intestinal type: HR 0.65 (95% CI, 0.49-0.87). There was a similar significant difference for 
the PFS analysis. These results further proved the clinical application utility of  Laurén
classification in survival prediction and also to guide in chemotherapy selection (Jimenez 
Fonseca et al. 2017).
1.1.8.2 Chemotherapy-associated genes in gastric cancer
Innate and acquired chemoresistance is multi-factorial and involves multiple key molecules
and accounts for the majority of  relapse cases in cancer patients. Untailored treatment may 
result in side effects and great economic burden without actual benefit. 
Cell kinetic differences in normal and malignant tissues could significantly influence the 
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survival response of  mammalian cells to most anti-tumour agents (Meyn et al. 1980). This 
has been demonstrated by a quantitative assay for assessing the sensitivity of  resting normal 
bone marrow stem cells and rapidly dividing clonogenic AKR lymphoma cells to a variety 
of  cytotoxic agents. These agents are classified into 3 classes according to their activities
during certain phases of  the cell cycle and on resting cells. For Class I agents there was no 
difference in the toxicity exerted in rapidly proliferating or resting cells. Agents in this class 
(e.g. X-irradiation) were said to be non-specific. In Class II the agents were more toxic to 
proliferating cells than to the resting cells, with increasing doses killing a greater number of  
cells until a plateau was reached, after which there was no further increase in cell kill. This 
second class of  agents is called phase-specific because proliferating cells were killed during a 
specific part of  the cell cycle. Resting (G0) cells do not appear to be affected by these agents 
provided the exposure time is kept short (24 hours). For Class III agents, the survival curves 
were exponential, but there was a great variance between the slopes. For equivalent doses, 
some compounds exerted greater specificity against the tumour cells. These agents were 
termed cycle specific, since although they damaged both proliferating and resting cells, 
dividing cells were more sensitive than G0 cells and were killed throughout the cell cycle 
(Figure 1.20). 
Figure 1.20: Dose-survival curves for both normal hematopoietic and transplanted 
lymphoma colony forming units. Normal or tumour-bearing mice were given different doses of  
various agents and their femoral bone marrows were assayed 24 hours later for their content of  colony-
forming units. Source: The cell cycle and its significance for cancer treatment (Hill and Baserga 1975).
When mice were treated with short courses of  phase-specific or cycle-specific agents there 
was a much greater loss of  malignant as opposed to normal stem cells. Subsequent studies
65
have confirmed that prolonged exposure to cycle specific agents resulted in an increased 
sensitivity of  normal stem cells, whereas tumour cells appeared less sensitive as treatment 
continued. Similarly, if  mice were treated after the previous injury to the marrow when 
hematopoietic stem cells were proliferating to repair the damage, the specificity of  these 
agents for malignant cells was lost. Owing to these earlier studies relevant to the mode of  
action, indications, and scheduling of  cell cycle-specific and cell cycle-nonspecific drugs, 
information on cell and population kinetics of  cancer cells explain, in part, the limited 
effectiveness of  most available anticancer drugs. Also, the kinetic classification of  antitumour 
drugs is well-documented and aid the establishment of  principles for agents’ administration
in clinical practice (Hill and Baserga 1975). Conventional chemotherapeutic agents are falling 
into these two major classes (Table 1.9). A schematic summary of  cell cycle kinetics is 
presented in Figure 1.21. 
Table 1.9: Cell cycle effects of major classes of anti-cancer drugs. Source: https://
basicmedicalkey .com /cancer-chemotherapy/
Cell cycle-Specific (CSS) Agents Cell cycle-Nonspecific (CCNS) Agents
Antimetabolites (S phase) Alkylating agents
Capecitabine Altretamine
Cladribine Bendamustine
Clofarabine (ara-C) Busulfan
Fludarabine Carmustine
5FU Chlorambucil
Gemcitabine Cyclophosphamide
Methortrexate (MTX) Dacarbazine
Nelarabine Lomustine
Pralatrexate Mechlorethamine
6-Thioguanine (6-TG) Melphalan
Topoisomerase II inhibitor (G1-S phase) Temzolomide
Etoposide Thiotepa
Topoisomerase I inhibitor (G2-M phase) Antitumour antibiotics
Irinotecan Dactinomycin
Topotecan Mitomycin
Taxanes (M phase) Platinum analogues
Albumin-bound paclitaxel Carboplatin
Cabazitaxel Cisplatin
Docetaxel Oxaliplatin
Paclitaxel Anthracyclines
Vinca alkaloids (M phase) Daunorubicin
Vinblastine Doxorubicin
Vincristine Epirubin
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Vinorelbine Idarubicin
Antimicrotubule inhibitor (M phase) Mitoxantrone
Ixabepilone
Eribulin
Antitumour antibiotics (G2-M phase)
Bleomycin
Figure 1.21: The different phases of the cell cycle. The cell cycle includes four distinct phases: 
G1 (gap phase 1), S (DNA synthesis), G2 (gap phase 2), and M (mitosis). In the first phase (G1) the cell 
grows. When it has reached a certain size, it enters the phase of  DNA-synthesis (S) where the 
chromosomes are duplicated. During the next phase (G2) the cell prepares itself  for division. During 
mitosis (M) the chromosomes are separated and segregated to the daughter cells, which thereby get exactly 
the same chromosome set up. The cells are then back in G1 and the cell cycle is completed. G0 is the 
resting phase when the cell does not undergo division. Source: https://basicmedicalkey.com/cancer-
chemotherapy/
5FU is a remarkable drug that has been available in the past half-century and has become 
the mainstay of  chemotherapy for gastrointestinal cancer. 5FU is an analogue of  uracil with 
a fluorine atom at the C-5 position in place of  hydrogen (Wohlhueter et al. 1980). It rapidly 
enters cells using the same facilitated transport mechanism as uracil. 5FU has converted 
intracellularly to several active metabolites: fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). These 
active metabolites disrupt RNA synthesis and the action of  thymidylate synthase (TS). The 
rate-limiting enzyme in 5FU catabolism is dihydropyrimidine dehydrogenase (DPD), which 
converts 5FU to dihydrofluorouracil (DHFU). More than 80% of  administered 5FU is 
normally catabolized primarily in the liver, where DPD is abundantly expressed (Diasio and 
Harris 1989). TS catalyzes the reductive methylation of  deoxyuridine monophosphate 
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(dUMP) to deoxythymidine monophosphate (dTMP), with reduced 5,10-
methylenetetrahydrofolate (CH2THF) as the methyl donor. This reaction provides the sole 
de novo source of  thymidylate, which is necessary for DNA replication and repair. The 36-
kDa TS protein functions as a dimer, both subunits of  which contain a nucleotide-binding 
site and a binding site for CH2THF. The 5FU metabolite FdUMP binds to the nucleotide-
binding site of  TS, forming a stable ternary complex with the enzyme and CH2THF, thereby 
blocking binding of  the normal substrate dUMP and inhibiting dTMP synthesis (Rennert 
and Anker 1963; Sommer and Santi 1974). The exact molecular mechanisms that mediate 
events downstream of  TS inhibition have not been fully elucidated. Deoxynucleotide pool 
imbalances (in particular, the dATP/dTTP ratio) are thought to severely disrupt DNA 
synthesis and repair, resulting in lethal DNA damage (Yoshioka et al. 1987; Houghton et al. 
1995). In addition, TS inhibition results in the accumulation of  dUMP, which might 
subsequently lead to increased levels of  deoxyuridine triphosphate (dUTP). Both dUTP and 
the 5FU metabolite FdUTP can be misincorporated into DNA. Repair of  uracil and 5FU-
containing DNA by the nucleotide excision repair enzyme uracil-DNA-glycosylase (UDG) 
is futile in the presence of  high (F) dUTP/dTTP ratios and only results in further false-
nucleotide incorporation (Lindahl 1974). These futile cycles of  misincorporation, excision,
and repair eventually lead to DNA strand breaks and cell death. DNA damage due to dUTP
misincorporation is highly dependent on the levels of  the pyrophosphatase dUTPase, which 
limits the intracellular accumulation of  dUTP (Ladner 2001; Webley et al. 2000). 
The 5FU metabolite FUTP is extensively incorporated into RNA, disrupting normal RNA 
processing and function. Significant correlations between 5FU misincorporation into RNA 
and loss of  clonogenic potential have been shown in human colon and breast cancer cell 
lines (Glazer and Lloyd 1982; Kufe and Major 1981). A number of in vitro studies indicated
that 5FU misincorporation can potentially disrupt many aspects of  RNA processing, leading 
to profound effects on cellular metabolism and viability.
To inhibit DPD-mediated degradation of  5FU. The UFT (uracil/Ftorafur) formulation uses 
a 4:1 combination of  uracil with the 5FU pro-drug Ftorafur, which improves 5FU
bioavailability by saturating DPD with its natural substrate (Adjei 1999). On this basis, further 
optimization was made in a novel oral DPD inhibitory fluoropyrimidine S-1 containing
tegafur and two types of  enzyme inhibitors, 5-chloro-2,4-dihydroxypyridine and potassium 
68
oxonate in a molar ratio of  1:0.4:1 (Maehara 2003). Another approach has been to design 
5FU pro-drugs that avoid DPD-mediated degradation in the liver. Capecitabine is an oral 
fluoropyrimidine that is absorbed unchanged through the gastrointestinal wall and is 
converted to 5′-deoxy-5-fluorouridine (5′DFUR) in the liver by the sequential action of  
carboxylesterase and cytidine deaminase (Johnston and Kaye 2001). 5′DFUR is then 
converted to 5FU by thymidine phosphorylase (TP) and/or uridine phosphorylase (Cao et 
al. 2002; Miwa et al. 1998), both of  which have been reported to be significantly more active 
in tumour tissue than in normal tissue.
1.1.8.2.1 Metabolic related genes
Several studies have been set up to characterize the biological factors which correlate with 
response to 5FU-based chemotherapy in order to define those patients who are most likely 
to benefit of these drugs. Preclinical studies have demonstrated that TS expression is a key 
determinant of  5FU sensitivity. Gene amplification of  TS with consequent increases in TS 
mRNA and protein has been observed in cell lines which are resistant to 5FU and 
fluorodeoxyuridine (FUDR) (Copur et al. 1995; Cao et al. 2002). The TS gene promoter is 
polymorphic and usually has either two (TSER*2) or three (TSER*3) 28-base-pair tandem-
repeat sequences (Horie et al. 1995). Preliminary studies indicate that TSER*3/TSER*3 
homozygous patients are less likely to respond to 5FU-based chemotherapy than 
TSER*2/TSER*2 homozygous and TSER*2/TSER*3 heterozygous patients (Pullarkat et 
al. 2001; Marsh et al. 2001). Treatment with 5FU has been shown to acutely induce TS 
expression in both cell lines and tumours (Swain et al. 1989; Chu et al. 1993). The thymidylate 
synthase (TS) gene, which is induced at the G1–S transition in growth stimulated cells, 
encodes an enzyme that is essential for DNA replication and cell survival. A study by 
Kamoshida et al assessed the expression of  TS, DPD, and TP levels in different tumour
types, including intestinal-type and diffuse-type gastric adenocarcinoma. The authors found 
a high level of  expression of  TS, which may be associated with poor response to 5FU based 
chemotherapy, in diffuse GC while TS was not overexpressed in intestinal type gastric cancer
(Kamoshida et al. 2005).
1.1.8.2.2 Cancer stem cells and epithelial-to-mesenchymal transition
The cancer stem cell theory postulates that cancers harbour a subset of  cells which share 
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characteristics of  normal stem cells, with a capacity for self-renewal and differentiation
(Rocco et al. 2012). Numerous studies have demonstrated that purported cancer stem-like 
cells (CSC) are more resistant to chemotherapy than non-CSCs (Alison et al. 2012). Acquired 
resistance is driven, in part, by intratumoural heterogeneity, that is, the phenotypic diversity 
of  cancer cells co-inhabiting a single tumour mass. This concept, taken together with the 
identification of  the EMT programme as a critical regulator of  the CSC phenotype, offers 
an opportunity to investigate the nature of  intratumoural heterogeneity and a possible 
mechanistic basis for anticancer drug resistance. Accumulating evidence has indicated that 
conventional therapies often fail to eradicate carcinoma cells which have entered the CSC 
state via activation of  the EMT programme, thereby permitting CSC-mediated clinical 
relapse (Shibue and Weinberg 2017). Diffuse gastric cancer was demonstrated to be enriched 
in genome stable subtype in TCGA classification and in MSS-EMT subtype in ACRG 
classification. Certain relevant genes correlated to the EMT process may contribute to drug 
resistance in diffuse gastric cancers. 
Two studies in Nature Genetics further confirmed a ranging mutation from 14.3%- 25.3%
of RHOA in diffuse gastric cancers (Kakiuchi et al. 2014; Kumar et al. 2016). Higher activity
of  RhoA by its mutation in spheroids growth was proven in vitro and negatively correlated 
with 5FU and cisplatin efficiency in vivo. Inhibition of  RhoA could synergetically improve 
tumour suppression with cisplatin by more than 70%. 
BMI1, belonging to a polycomb group family, was found enriched in a CD44+ subgroup of  
gastric cancer cells and was identified as a CSC biomarker in many malignancies. High BMI1 
levels in gastric cancer cells increased resistance to 5FU, whereas BMI1 silencing enhanced 
5FU antitumour activity (Xu et al. 2015).
1.1.8.2.3 Cell cycle-related genes
As mentioned above, slowly proliferating or quiescent cells are more resistant to DNA 
damaging agent treatments such as 5FU acting in S phase of  the cell cycle to cause DNA 
damage. Cancer stem-like cells exhibit a low rate of  division and proliferation in their niche 
that helps them to avoid chemotherapy and radiation (Zou 2008). Usually, cells take a range 
of  actions to respond to the cytotoxic agents and involve a number of  downstream sensors, 
mediators, transducers and final effectors of  the DNA damage response. 
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If  a DNA lesion cannot be repaired quickly, apoptosis is initiated to eliminate the damaged 
cell before it can undergo malignant transformation. p53 plays a crucial role in double-strand 
break (DSB)-induced apoptosis. In response to DSBs, transcriptional activation of  
proapoptotic factors such as Fas cell surface death receptor (FAS), B cell 
leukaemia/lymphoma 2 (BCL2) associated X apoptosis regulator (BAX) and BCL2 binding 
component 3 (BBC3, also known as PUMA), and is induced by ataxia telangiectasia mutated
(ATM)/ cell cycle checkpoint kinase 2 (CHK2) and ataxia telangiectasia-mutated and RAD3-
like protein (ATR)/ checkpoint kinase 1 (CHK1), phosphorylating and stabilizing p53. 
CHK1 and CHK2 also stimulate the expression of  E2F1 and p73 to support the action of  
p53. This, in turn, transcribes BAX, PUMA, and phorbol-12-myristate-13-acetate-induced 
protein 1 (Pmaip1, also known as NOXA).  
In addition to cell apoptosis, p53 is also an important anticipator in the major pathway 
controlling the DNA damage-induced G1/S-phase checkpoint and triggering G1-phase 
arrest, i.e. the ATM/ATR-CHK2/CHK1-p53/MDM2-p21 pathway. DSBs and single-strand 
breaks activate ATM/CHK2 and ATR/CHK1, which mediates MDM2 phosphorylation and 
subsequent degradation through a self-catalytic mechanism, thereby stabilizing p53 
expression and inducing p21 expression, which inhibits the activity of  CCNE/CDK2 and 
CCND/CDK4/6 complexes. This signalling cascade leads to cell-cycle arrest at G1 phase. 
The cell-cycle arrest may also be induced via activation of  CHK1/CHK2 and inactivation 
of  the CDC25A phosphatase. It consequently inhibits expression of  the CCNE/CDK2 and 
cyclin A/CDK2 complexes and delays the cell cycle at the G1/S transition (Kastenhuber and 
Lowe 2017). 
Thus, one important mechanism leading to chemoresistance is the dysfunction or loss of  
p53-mediated apoptotic pathways typically triggered by DNA damage. For example, the loss 
of  the tumour suppressor protein p53 due to deregulated expression of  its regulators 
(MDM2 [de Rozieres et al. 2000]) leads to abnormal downstream targets such as p21, and 
growth arrest and DNA damage-inducible 45 (Gadd45) (Brady et al. 2011).
As the most frequently mutated gene in human tumours (Kandoth et al. 2013), p53 mutations 
were reported to induce resistance for a variety of  standard chemotherapies in previous 
studies. The primary alterations in p53 resulting from most tumour-associated mutations 
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could be only a single amino acid substitution in the 393-amino-acid protein, most of which 
are within the central DNA-binding domain and can be any amino acid in this region. There 
are a number of  hotspots, including R175, G245, R248, R249, R273, and R282. Besides the 
loss of tumour suppressor function and acquisition of  the ability to suppress the function 
of  the remaining wild-type p53 allele via a dominant-negative mechanism, p53 mutations can 
also demonstrate an abnormal gain of  function (GOF) to facilitate oncogenesis, metastasis 
and chemoresistance. This phenomenon has been widely demonstrated by many in vivo and 
in vitro experiments. The most compelling evidence of  mutant p53 (mutp53) GOF comes 
from mice engineered to harbour tumour-associated hot spot p53 mutations. Knock-in mice 
exhibited a broader tumour spectrum with a more invasive and metastatic phenotype than 
p53–/– or p53+/– mice (Donehower 2014). Major mechanisms of  mutp53-induced 
chemoresistance include enhanced drug efflux and metabolism, promoting cell survival, 
inhibiting apoptosis, upregulating DNA repair, suppressing autophagy, elevating 
microenvironmental resistance and inducing a stem-like phenotype. However, mutp53 has
also been identified as a good predictor of  chemoresistance in some clinical studies (Young 
et al. 2008; Perrone et al. 2010; Kandoth et al. 2013; Yamasaki et al. 2010; Dawson et al. 
2009).
The transcriptional activation function of  p53 is fundamental for both cell cycle arrest and
apoptosis pathways. The p53 protein consists of  two N-terminal transactivation domains 
followed by a conserved proline-rich domain, a central DNA binding domain, and a C 
terminus encoding its nuclear localization signals and an oligomerization domain needed for 
transcriptional activity. p53 contains two distinct transcriptional activation domains
(comprising residues 1–40 and 40–83, respectively). Different p53 transcriptional activation 
requirements, associated with different target gene expression programs, are important in the 
settings of  acute genotoxic stress and oncogenic stimuli. A functional assay using an allelic 
series of  p53 transactivation domain mutant knock-in mice suggested that p53 may trigger 
multiple sub-programs which cooperate to promote tumour suppression, in response to 
acute DNA damage or senescence, and by regulating actin dynamics or cell migration, and 
DNA repair (Brady et al. 2011). p53 responses to acute DNA damage in primary cells rely 
on an intact first transcriptional activation domain of  p53 as the L25Q; W26S mutations 
within this domain severely impair transactivation of  most classical p53 targets including p21, 
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NOXA, and PUMA, and abrogate activity in both DNA damage-induced G1 arrest and 
apoptosis(Brady et al. 2011). Consistent with the importance of  p53-mediated transcription 
in tumour suppression, the vast majority of  tumour-derived p53 mutations occur in the 
region encoding p53’s DNA binding domain. In normal cells, p53 protein is maintained at 
low levels by a series of  regulators including MDM2, which functions as a p53 ubiquitin 
ligase to facilitate its degradation. DNA damage and replication stress produced by 
deregulated oncogenes will activate p53 by promoting p53 phosphorylation, phosphorylation
or by inducing the ARF tumour suppressor to inhibit MDM2 (Xu and El-Gewely 2001).
Recently, advances in next-generation sequencing (NGS) technologies have defined the 
genomic landscape of  gastric cancer; studies of  miRNAs and long noncoding RNAs 
(lncRNAs), as well as novel preclinical models (such as patient-derived tumour xenografts 
(PDX) and patient-derived organoids), have largely filled the gap between cancer genetics 
and phenotype. These advances have made it possible to integrate traditional, genome-based 
and phenotype-based diagnostic and therapeutic methods with application to individual 
gastric cancer patients in the era of  precision medicine (Liu and Meltzer 2017).
1.2 microRNAs (miRNAs)
MicroRNAs, a class of  short RNAs; together with a variety of  long ncRNAs (lncRNAs), 
such as lincRNAs, antisense RNAs, pseudogenes, and circular RNAs (Figure 1.22) are
collectively known as the noncoding RNAs (ncRNAs). They constitute the majority of  the 
transcribed genome, of  which only 1–2% code for proteins (Djebali et al. 2012; Carninci et 
al. 2005), hinting that higher eukaryotes increased their complexity not by increasing the 
number of  genes but through more sophisticated regulation in which the ncRNAs are also 
involved. Interest in this field has seen numerous studies delineating the coding-independent 
functions of  this novel class of  RNAs, to decipher their roles and corresponding mechanism 
in biological processes in different diseases, including in cancer development (Chan and Tay 
2018). 
miRNAs regulate post-transcriptional gene expression and may be exported from cells via 
exosomes or in partnership with RNA-binding proteins. miRNAs in body fluids can act in a 
hormone-like manner and play important roles in disease initiation and progression. Hence, 
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miRNAs are promising candidates for biomarkers (Pacholewska et al. 2017).
Figure 1.22: Noncoding RNA Regulatory Networks in Cancer. Noncoding RNAs 
(ncRNAs) constitute the majority of the human transcribed genome. The different subclasses of 
ncRNAs include microRNAs, a class of short ncRNAs; and a variety of long ncRNAs (lncRNAs), 
such as lincRNAs, antisense RNAs, pseudogenes, and circular RNAs (circRNA). Many studies have 
demonstrated the involvement of these ncRNAs in competitive regulatory interactions, known as 
competing endogenous RNA (ceRNA) networks, whereby lncRNAs can act as microRNA decoys to 
modulate gene expression. These interactions are often interconnected, thus aberrant expression of 
any network component could derail the complex regulatory circuitry, culminating in cancer 
development and progression. (Chan and Tay 2018).
1.2.1 Discovery of miRNAs
Six decades ago, Francis Crick proposed the 'central dogma', asserting that genetic 
information travels from DNA through RNA towards protein synthesis (Crick 1970). Since 
then RNAs have been mainly characterized as intermediaries in the process of  protein 
production, principally as temporary copies of  genetic information (mRNA), components 
of  the ribosome (ribosomal RNAs [rRNAs]) or translators of  codon sequence (tRNAs). For 
many years, proteins represented the primary functional end product of  genetic information, 
though the genes that encode them account for less than 2% of  the genome. Twenty years 
ago, the first small temporal RNAs, lineage defective 4 (lin-4)4 and lethal 7 (let-7), were 
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discovered in Caenorhabditis elegans, demonstrating that some RNAs, despite lacking protein-
coding regions, are conserved functional molecules required for development. These two 
important findings demonstrated a new post-transcriptional gene regulation mechanism. 
Approximately seven years later, the importance of  miRNAs was realized when Ruvkun and 
Horvitz identified another miRNA in C. elegans (Reinhart et al. 2000). Later, small interfering 
RNA (siRNA) was described -another short-chain RNA involved in the process of  RNA 
interference and related phenomena in plants and animals. In 2001, three research groups 
from different countries all identified 21–22 nucleotide (nt) non-coding small RNA 
molecules in C. elegans, Drosophila and humans (Hutvagner et al. 2001). These single-
stranded small RNA molecules with spatial and temporal expression were different from the 
previously reported siRNA detected in the interference pathway (RNA interference; RNAi) 
and were subsequently named miRNA (Xu et al. 2013).
miRNAs, together with the transcribed ultra-conserved regions and circular RNAs 
(circRNAs) belongs to the highly conserved functional products encoded by the genome and 
represent an important class of  regulators in many crucial biological processes in 
developmental and differentiation processes and play key roles in many diseases.
It is estimated that miRNAs constitute nearly 1% of  all predicted genes in mammalian 
genomes, and approximately >60% of  all mammalian protein-coding genes can be regulated 
by miRNAs (Bartel 2009). To date, 2656 human miRNAs have been found according to 
miRbase (version 22; University of  Manchester, Manchester, UK; http://www.mirbase.org/). 
These follow nomenclature rules outlined in Table 1.10 (Desvignes et al. 2015).
Table 1.10: Nomenclature rules for miRNAs.
Example miRNA:  hsa-miR-133a-1-5p
hsa Homo sapiens. The first three letters signify the organism. 
miR/mir
The capitalization of the “R” infers that the miRNA is the mature sequence, opposed to “r” which refers to 
the miRNA precursor, the genomic locus, the primary transcript, or the extended hairpin that includes the 
precursor.
133
Named sequentially. The same number is used for miRNA of different species that are orthologous but 
conveys no information about functionality.
a Paralogous miRNAs that differ in 1 or 2 nt.
1 miRNAs with identical sequences are transcribed from distinct precursor sequences and genomic loci.
-5p/-3p the same mature miRs originate from opposite arms of the same pre-miRNA
*
Previously，one of the duplex mature miRs was believed to be degraded has been conventionally named 
with an asterix suffix, but now suffixes -3p and -5p were adopted
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1.2.2 miRNA Biosynthesis and Mechanisms of Action
miRNA biogenesis consists of  multiple steps of  processing involving both nuclear and 
cytoplasmic compartments (Figure 1.23). The canonical miRNA processing pathway starts 
with encoding of  primary miRNA transcript (pri-miRNA) from different regions of  the 
genome typically by RNA polymerase II (RNAPII). The majority of  miRNA genes are 
intergenic. 
Figure 1.23: microRNA Biosynthesis. Source: Noncoding RNA: RNA Regulatory Networks in 
Cancer (Chan and Tay 2018).
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However, about 20-40% of human miRNA genes originate in the introns of  protein and 
non-protein genes, or the exons of  long protein-coding transcripts and are therefore
transcribed and regulated along with their host genes (Aravin et al. 2003; Ambros et al. 2003).
For miRNA genes organized in clusters, the pri-miRNA can be monocistronic or 
polycistronic (Desvignes et al. 2015). Pri-miRNAs are subsequently cleaved by the 
microprocessor complex DROSHA–DGCR8 resulting in a precursor hairpin. The pre-
miRNA is then exported from the nucleus by RAN: GTP: XPO5. Approximately 70 bp pre-
miRNA hairpin structures in the nucleus are subsequently exported to the cytoplasm by an
Exportin-5-mediated mechanism where they are further processed by the Dicer–TRBP 
complex to form the mature 22 nt miRNA duplexes. In the cytoplasm, the miRNA duplex 
is unwound, and the passenger strand is released and discarded. The mature single-stranded
miRNA is then incorporated into the miRNA-containing RNA-induced silencing complex 
(miRISC) resulting in a precursor hairpin-the pre-miRNA, which is exported from the 
nucleus by RAN: GTP: XPO5. Once in the cytoplasm, DICER1 ribonuclease, in complex 
with one of  the double-stranded RNA-binding proteins, TARBP2 or PRKRA (PACT), 
cleaves the pre-miRNA hairpin to its mature double-stranded length of  around 22 
nucleotides. The RNA-induced silencing complex (RISC)-loading complex, comprising of  
DICER1, TARBP2 (or PRKRA) and one of  the Argonaute proteins (AGO1-4), loads the 
functional strand of  the mature miRNA into the RISC and the passenger strand is degraded. 
DICER1 and TARBP2/PRKRA then dissociate leaving the mature RISC consisting of  
AGO1-4 and miRNA. The miRNA then guides the RISC to silence target mRNAs through 
mRNA cleavage, translational repression or deadenylation. (Figure 1.24). Special cases of  
miRNA-like sequences from non-canonical biogenesis pathways including DROSHA-
independent miRNAs (e.g. miRtrons), Dicer-independent miRNAs (e.g. miR-451), and 
pathways from other non-coding RNA genes (e.g. snoRNA or lncRNA) could be accepted 
as miRNAs (Desvignes et al. 2015).
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Figure 1.24: Post-transcriptional modes of miRNA action. miRNAs may promote 
degradation of mRNA via deadenylation and decapping or mRNA cleavage as well as repress translation 
of  mRNAs by initiation or elongation block (Chan and Tay 2018).
miRNAs were primarily introduced to exert negative regulatory effects on genes via the 
interaction between a miRNA-containing RISC complex and the 3’UTR of  its target mRNA, 
causing either mRNA cleavage, translational repression (initiation or elongation block) or 
mRNA deadenylation followed by decapping and degradation of  the mRNA. In addition to 
3′UTR targeting, miRNAs were reported to be involved in gene activation which can also 
enhance protein translation during amino acid starvation by targeting 5′UTR of  mRNAs 
encoding ribosomal proteins. As another nonclassical example, miR-483-5p, embedded 
within the IGF2 gene, induces the transcription of  its host gene by binding to the 5′UTR 
region. Understanding of  the mechanisms of  action of miRNAs has significantly expanded 
in the last few years, with discoveries demonstrating unexpected complexities of their 
regulative manner, such as promoter binding, protein binding, or direct interaction with other 
ncRNAs, or even relocalization in the nucleus. This localization supports the already proven 
hypothesis that miRNAs can alternatively regulate transcriptional processes at a DNA level. 
For example, human miR-373 binds to the E-cadherin (CDH1) promoter, thereby inducing 
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its expression (Ambros 2003). miRNAs have also been found to favour protein expression 
(in addition to downregulating it) (Vasudevan et al. 2007). Finally, besides mRNAs, miRNAs 
can target different types of  ncRNAs, some of  them being highly conserved among species 
such as the ultra-conserved genes or poorly conserved such as the pseudogenes (Salmena et 
al. 2011; Calin et al. 2007). 
miRNAs also work as secreted molecules that trigger a receptor‐mediated response in a 
different cell or tissue. They have the ability to be released into the extracellular environment 
within exosomes (cell‐derived vesicles originated by the inward budding in the plasma 
membrane generating multivesicular bodies) which are present in many and perhaps all 
biological fluids. In this way, they can act as "hormones" (Cortez et al. 2011). Similarly, 
exosomes have been shown to modulate tumour microenvironments by releasing miRNAs 
in a coordinated manner. miR‐21 and miR‐29a can be transported through exosomes and 
can act as direct agonists of  Toll‐like receptors (TLRs). By binding as ligands to receptors
of  the TLR family in immune cells, these miRNAs were shown to trigger a TLR‐mediated 
prometastatic inflammatory response (such as secretion of  interleukins) which could favour 
tumour growth and metastasis (Lehmann et al. 2012; Fabbri et al. 2012). A better 
understanding of the diversity of  mechanism of miRNA’s action may provide solutions for 
intervention in the future.
1.2.3 miRNAs involved in gastric cancer progression
The number of  animal miRNAs gradually expanded during long-term evolution, their
expression pattern changed in various species, tissue or cell settings. Recent studies have 
identified a number of  miRNAs with aberrant expression in gastric cancer (Xie et al. 2018)
(Appendix 7). For example, the comparison of  miRNAs deregulated in gastric cancer 
revealed a significant increase of  several tumour-associated miRNAs such as miR-21, -25 
and -106a and miRNAs from the miR-17-92 cluster (Link et al. 2012). Eight miRNAs 
(including miR-100, -143 and −145) were upregulated specifically in diffuse-type, while four 
miRNAs (miR-202, -373, -494 and −498) in intestinal-type gastric cancer (Song et al. 2012).
Comparison between diffuse-type gastric cancers compared with intestinal-type gastric 
cancers, uncovered largely downregulations of  hsa-let7d*, hsa-miR-328, hsa-miR-32*, hsa-
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miR-1227, hsa-miR-206, hsa-miR-1229, hsa-miR-595, and hsa-miR-631.
Some miRNAs are significantly enriched in clusters in discrete genomic regions. The 
clustering patterns suggest that miRNAs in the same cluster might be transcribed in a 
polycistronic manner, and miRNAs in the same cluster were hypothesized to regulate 
functionally related genes. There is accumulating evidence suggesting that epigenetic and 
genetic defects in noncoding RNAs play crucial roles in tumour initiation, progression, 
invasion, and metastasis. For miRNAs, extensive studies explored their deregulation, function 
and underlining mechanisms and correlated these with progression and prognosis of  gastric 
cancer, using miRNAs’ microarray and bioinformatics analysis together with in vitro or in vivo
experiments. Overexpressed oncogenic microRNAs that target tumour suppressor genes or 
reduction of  tumour suppressor miRNAs versus targeting oncogenes could synergistically
promote progression, resist apoptotic signals, and promote cell invasion and tumour
metastasis (Ueda et al. 2010; Song and Meltzer 2012). Among these high-throughput studies, 
several clusters of  miRNAs exhibited consistent deregulation, highlighting their significant 
roles in fine tuning the transcriptome during distinct status setting or response to specific 
stimuli promoting gastric cancer progression. 
miRNAs are exported from cells both within and outside the exosomes (Iguchi et al. 2010). 
Exosomes act as mediators of  cell cell communication (Rani et al. 2011; Ahmed and Xiang 
2011) and are carriers for functional miRNA delivery (M. Yang et al. 2011; Pegtel et al. 2010).
There is considerable interest in using exosomes in clinical applications as biomarkers and/or 
as potential therapeutic tools (Bobrie et al. 2011; Zomer et al. 2010).
More recently, circular RNAs, characterized by the formation of  a covalently closed 
continuous RNA loop, are drawing renewed attention in cancer research. Moreover, 
noncoding RNAs are stable in bodily fluids such as serum, plasma, gastric juice, and even in 
exosomes, making them promising non- or less invasive gastric cancer biomarkers.
1.2.4 Diagnostic potential of microRNAs in gastric cancer
Over the past decade, the emergence of miRNA research has firmly established this 
molecular family as a key component in cells. Expression levels of  certain miRNAs are 
altered in many diseases. Identification of tumour-specific genetic alterations in the miRNA 
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processing machinery, such as in the genes encoding TARBP2, AGO2, Dicer, and Exportin‐
5 (XPO5) provide strong evidence of  deregulated miRNAs being relevant in cellular 
transformation processes (Abelson et al. 2005). Exploiting their roles as potential biomarkers 
to predict, diagnose or monitor disease including cancer has become a focus for researchers 
around the globe. This is being driven by the importance of  early cancer diagnosis and the 
need to be able to distinguish between different forms of  cancer. Alongside altered 
expression under different disease states, miRNAs have other features that make them ideally 
suited as biomarkers. miRNAs are present in biofluids including blood, urine, and saliva, 
allowing relatively non-invasive sample collection. In addition to their accessibility, miRNAs 
are highly stable in biofluids and in collected samples making miRNAs relatively easy to work 
with and assay via a range of  different methods.
Discovering miRNA expression patterns that are unique to a particular cancer is an 
important first step in identifying biomarker signatures which will be effective in its detection. 
A particular problem with cancer is the difficulty of  determining whether the cancer is an 
aggressive form that requires immediate treatment or low-grade cancer. In gastric cancer, 
studies on miRNA profiling of  cancer versus normal tissues showed significant changes and 
defined commonly altered miRNAs. Profiling of  miRNAs by various methods has allowed 
for the identification of  signatures associated with the diagnosis, staging, disease progression, 
prognosis, and response to treatment of  gastric cancer. For example, a five-microRNA 
signature in plasma (consistently elevated miR-1, miR-20a, miR-27a, miR-34 and miR-423-
5p) was established by comparing 160 cancer-free controls, 124 patients with gastric non-
cardia adenocarcinoma (GNCA) and 36 patients diagnosed gastric cardia adenocarcinoma 
(GCA). For GNCA, an area under the receiver operating characteristic (ROC) curves (AUCs) 
ranged from 0.850 to 0.925 and 0.694 to 0.790 in the training and validation phases, 
respectively (Abelson et al. 2005). Masahiro et al. reported that plasma miR-18a 
concentrations were significantly higher in gastric cancer patients than in healthy controls. 
Furthermore, plasma miR-18a levels were significantly reduced in postoperative samples 
compared to in preoperative samples (Tsujiura et al. 2015). A similar study indicated that 
plasma miRNA-199a-3p could be novel a potential diagnostic biomarker for early gastric
cancer (Li et al. 2013).
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Significant analytical challenges using miRNAs in cancer and disease diagnostics remains, 
such as identification of  robust, reproducible and economic methods of detecting
expression of  miRNAs, and selection of  reference genes. There is no currently known 
extracellular reference RNA for cell free miRNA analysis. Moreover, the assessment of  
sample quantity and quality is more challenging for miRNAs than for message RNAs, for 
which the sizes and relative abundance of  ribosomal RNAs can be used to check RNA 
integrity. In conclusion, validation of  specific miRNA signatures as biomarkers could be a 
critical milestone in diagnostics.
1.2.5 Therapeutic potential of microRNAs in cancer
By blocking the function of  targeted mRNAs in specific cell types or microenvironment
conditions, miRNAs could represent a valid option for treating patients with certain cancers 
in the future. 
The advantages of using miRNAs (compared with other gene-silencing therapies) includes
the fact that it is an innate product and can be metabolised in human cells and likewise. 
miRNAs can target multiple genes from the same pathway and therefore their action can 
occur at multiple levels in the same pathway, thereby significantly reducing the development 
of  resistance. For example, miR-17-5p and miR-20, both of  which have increased expression 
in gastric cancer patients, have 2 anti-proliferative targets: p21 and TP53INP1 (Wang et al. 
2013). Therefore, a personalized therapy based on the identification of  patients with 
upregulated miR-17-5p/miR-20a cluster expression and p21 and TP53INP1 protein 
reduction in gastric cancer patients can be envisioned. These types of  therapies are very 
specific for patients having these molecular characteristics in the same cells. Patients with 
high levels of  miR-17-5p/miR-20a but normal levels of  p21 and TP53INP1 or conversely 
with normal levels of  miRNAs but abnormal levels of  these anti-proliferative tumour
suppressors should be excluded from clinical trials targeting miR-17-5p/ miR-20a. Strategies 
for miRNA targeting are based on either restoring miRNA levels or blocking miRNA 
function with oligonucleotide-based strategies. A targeted approach to replenish the 
expression levels of  particular miRNAs is restoring the level and function of  one or a limited 
number of  miRNAs, usually located within a cluster (such as miR-15a and miR-16-1 at 
13q14.3), either with miRNA mimics or with miRNAs encoded in expression vectors. 
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miRNA mimic molecules are double-stranded sequences with 100% similarity to the 
endogenous miRNA, which can be delivered by nanoparticles and thereby are expressed in 
the cells. This approach is particularly attractive because nanoparticles can be coated with 
antibodies that recognize tumour-specific antigens, therefore allowing a tumour-specific 
delivery of  the miRNA of  interest Recently, a clinical trial of  MRX34 (Mirna Therapeutics, 
TX, USA) constructed a miR-34 mimetic using nanoparticles coated with a neuroblastoma-
specific antidisialoganglioside GD2 antibody to restore miR-34 expression in cancer cells. 
The agent was used to treat liver cancer and liver metastasis of  other cancers in phase I 
clinical trial. The therapy has proved to be effective in the inhibition of  neuroblastoma
tumour growth in a murine orthotopic xenograft model (Tivnan et al. 2012). Moreover, 
MRX34, a liposome-formulated mimic of  the tumour suppressor miR-34, has been 
developed in a clinical phase 1 trial for patients with advanced or metastatic liver cancer. 
Preclinical studies have already shown that tail vein injection of  MRX34 reduced tumour
growth and significantly enhanced survival with a favourable safety profile in orthotopic 
mouse models of  hepatocellular carcinoma (Bader 2012). In a pre-clinical study of  non-small
cell lung cancer (NSCLC), MRX34 treatment significantly reduced the expression of  the 
checkpoint signal PD-L1 and increased infiltrating CD8+ cells in tumour tissues (Cortez et 
al. 2016). However, the MRX34 clinical trial was stopped in 2016 since multiple serious 
immune-related side effects were observed in patients. So, the safety of  MRX34 still requires
further research (Beg et al. 2017). 
Current strategies for inhibitory targeting of  microRNAs are mainly based on antisense 
oligonucleotides (so‐called anti‐miRNAs), comprised of  locked nucleic acids (LNA) along 
with tiny LNA anti-miRNA constructs, antagomirs, and miRNA sponges. Miravirsen 
(SPC3649), an LNA against miR-122, is the first miRNA target therapy tested in a clinical 
trial for the treatment of  hepatitis C virus infection. This recently completed phase 2a trial 
showed that SPC3649 exhibited robust antiviral activity in a dose-dependent manner
(Lindow and Kauppinen 2012). More impressively, 4 of  9 patients treated at the highest dose 
(7 mg/kg) with SPC3649 reached undetectable levels of  hepatitis C virus RNA (consequently 
decreasing the possibility of  developing hepatocellular carcinoma) (Janssen et al. 2013). The 
effectiveness of  antimiR‐122 treatment proved the plausibility of  LNA-based therapeutics 
and encourages the development of  other specific miRNA-targeting therapeutic strategies
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(Berindan-Neagoe et al. 2014).
Conversely, miRNA also plays critical roles in drug resistance. An increasing number of  
studies have demonstrated that miRNA can significantly influence drug transporters, drug-
metabolizing enzymes, transcription factor and nuclear receptors. Wang and colleagues
determined that exosomes serving as nanoparticles could deliver anti-miR-214 to reverse 
chemoresistance to cisplatin in gastric cancer (Wang et al. 2018). Related miRNAs may also 
include miR-21, whose reduction was also proved to have a significant impact on increasing
the anti-proliferative effects and apoptosis induced by Cisplatin (Yang et al. 2013). Meanwhile, 
miR-200c inhibits transforming growth factor-β (TGF-β)-induced-EMT to restore 
trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer. 
Nevertheless, non-specific cytotoxicity, poor biocompatibility, low delivery efficacy and 
unexpected off-target effect have remained as challenges for carrying miRNAs in vivo. Thus,
treatment based on miRNA therapy should be explored with better specificity (Hao et al. 
2017).
1.3 miR-140-5p and miR-140-3p
The human mir-140 primary transcript, located at 16q22.1, is an intron-retained RNA co-
expressed with a Wwp2-C isoform. Two mature miRNAs, miR-140-5p and miR-140-3p, 
were processed and produced with different seed sequences, and were predicted to target 
different genes. As shown in Figure 1.25, miR-140-5p originates from the 5-prime arm of  
the hairpin of  the precursor, while miR-140-3p comes from the 3-prime arm. Like many 
other miRNAs, the abundance of  the miR-140-5p and miR-140-3p stands are different 
according to tissues type or species (Kenyon et al. 2019; Gibson and Asahara 2013; Griffiths-
Jones et al. 2006; Ambros et al. 2003). The mechanism of  strand selection is still unknown. 
It has been verified in both a bone matrix gelatine (BMG) rat model and Genome-Wide 
MicroRNA and Gene Analysis of  mesenchymal stem cell chondrogenesis, that miR-140-5p 
might have more important functions than miR-140-3p (Barter et al. 2015; Min et al. 2015).
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Figure 1.25: miR-140 sequence in human and mouse. A. In human, sequence of  the miR-
140 precursor (pre-miR-140) stem-loop located in intron 16 of  the WWP2 gene. Seed sequence is
represented in bold format. B. A schematic illustration demonstrating Wwp2 and pre-miR-140 loci are 
on mouse chromosome 8. Black boxes indicate exons of  Wwp2, and the red box indicates the pre-miR-
140 gene. (Adapted from previous publication (Inui et al. 2018; Tardif  et al. 2013))
Previous reports have shown that miR-140-5p and miR-140-3p are almost exclusively 
specific to chondrocytes and have been a focus of  cartilage miRNA research to date. The 
mir-140-deficient mice manifested a mild skeletal phenotype, with short stature and low body 
weight, as well as craniofacial deformities characterized by a short snout and domed skull, 
supporting the notion that mir-140 is a tissue-specific miRNA important in cartilage 
development. Furthermore, mir-140-deficient mice showed age-related osteoarthritis (OA)-
like changes characterized by proteoglycan loss and fibrillation of  articular cartilage. However,
transgenic mice overexpressing miR-140 in cartilage were resistant to antigen-induced 
arthritis (Papaioannou et al. 2015; Araldi and Schipani 2010; Miyaki et al. 2010). Several 
studies have also clarified that miR-140-5p exhibited the largest expression difference 
between human articular chondrocytes and mesenchymal stem cells (Karlsen et al. 2014; 
Miyaki et al. 2010; Miyaki et al. 2009). Gene Ontology (GO) analysis on the transcriptome
data with input lists of  statistically significant up- or downregulated genes after either stable 
miR-140-5p inhibition in differentiating mesenchymal stem cells or transient miR-140-5p 
overexpression in dedifferentiating articular chondrocytes showed that miR-140-5p 
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negatively regulated genes involved in cytoskeleton remodelling and cell division, but
positively regulated genes related to extracellular regions and the extracellular matrix (Karlsen 
et al. 2014). Additionally, miRNA-140-5p inhibits MSCs proliferation by targeting CXCL12 
during TGF-β3-induced chondrogenic differentiation. TGF-β3 induced significant elevation 
of  miR-140-5p followed by markedly decreased CXCL12 inhibited mesenchymal stem cell’s
viability. It is worth noting that miR-140-5p was also significantly upregulated during cellular 
senescence in mesenchymal stem cells (Yoo et al. 2014).
Furthermore, miR-140-5p is among the candidate miRNAs which can function in vivo to 
suppress Fibroblast Growth Factor 9 (FGF9) as lung development progresses from 
pseudoglandular to canalicular stages. Disruption of  this progress or lack of epithelial Dicer1
increased FGF9 expression in pulmonary mesenchymal hyperplasia and a multicystic 
architecture which is histologically and molecularly indistinguishable from Type I 
Pleuropulmonary Blastoma (PPB) (Yin et al. 2015). In addition, downregulation of  miR-140-
5p could have a role during pancreatic development. It may enhance OASIS expression and 
activation in modulating extracellular matrix production, such as extracellular sulfated 
proteoglycans, which regulate pancreatic endocrine differentiation during development by 
inhibiting endocrine cell (β and α cell) development (Zertal-Zidani et al. 2007) and provide 
help for the developing pancreas against physiological endoplasmic reticulum (ER) stress
(Vellanki et al. 2010). A similar phenomenon was shown in toxicity studies where OASIS 
protects pancreatic β-cell lines and the C6 glioma line from tunicamycin and thapsigargin
(Vellanki et al. 2010) and protect astrocytes from kainic acid toxicity (Chihara et al. 2009), 
which all are known to induce ER stress.
miR-140-3p demonstrates highest expression in human primary articular chondrocytes at 
early passages compared with their dedifferentiated counterparts (Yan et al. 2011; Crowe et 
al. 2016). miR-140-3p was also the most highly expressed microRNA in osteoarthritic 
cartilage, playing a protective role against inflammation in chondrocytes (Crowe et al. 2016).
Corresponding targets of  miR-140-3p included ADAMTS-5 and runt-related transcription 
factor 2 (RUNX-2) (Le et al. 2013). Differential expression of  miR-140-3p was found in 
hematopoietic lineages and may be associated with platelet production and activation
(Collares et al. 2013).
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Research on understanding inflammation has suggested that miR-140-5p and miR-140-3p 
may play critical roles in the adaptive and innate immunity (O'Neill et al. 2011; Shimokawa 
et al. 1998; Davidson-Moncada et al. 2010). They have also been reported as key components 
in T cell differentiation, modulating the inflammatory response and activating toll-like 
receptor pathways in macrophages (O'Neill et al. 2011; Shimokawa et al. 1998). Toll-like 
receptors (TLRs) are pattern recognition receptors which regulate innate immunity and 
defend against invading microorganisms (Sabroe et al. 2003). TLRs also mediate 
autoimmunity. Upon stimulation, TLRs initiate downstream signalling pathways and lead to 
the secretion of  inflammatory chemokines and cytokines (Liu et al. 2014). miR-140-5p 
downregulated TLR22 may be associated with or trigger a Th2 type immune response
(Valenzuela-Munoz et al. 2017). Lipopolysaccharides (LPS) treatment suppressed miR-140-
5p expression thus induced the high expression of  TLR4 resulting in dramatically increasing
the number of  the Th17 cells as well as the release of  IL-6, IL-17 and IL-22 (Dileepan et al. 
2016; Newcomb and Peebles 2013; Sethi et al. 2013; Kowalski et al. 2008). After an injury 
such as radiation-treatment, miR-140-5p played a key role in maintaining this balance by 
regulating macrophage polarization towards M1 macrophages, and antagonizing TGF-β1 
activation, which promoted normal tissue repair and prevented the development of  fibrosis. 
In the absence of  miR-140, M2 macrophages prevail and with constant wound healing of  
lung tissue, scar tissue accumulated and contributed to the development of  fibrosis (Duru et 
al. 2016).
miR-140-3p negatively regulates nuclear factor-κB (NF-κB) inflammatory signaling by 
regulating the expression of  nuclear receptor coactivator 1 (NCOA1) and nuclear receptor-
interacting protein 1 (NRIP1), both of  which are NF-κB co-activators (Takata et al. 2011).
NF-κB and AP-1 activated TNF-α which further augmented CD38 expression in human
airway smooth muscle (ASM) cells. CD38 is a cell-surface protein expressed in human ASM 
cells, generating calcium-mobilizing second messenger molecules such as cyclic ADP-ribose, 
contributing to airway hyper-responsiveness and the process of  Asthma (Guedes et al. 2015). 
Inflammation also plays a key role in coronary artery disease (CAD) and other manifestations 
of  atherosclerosis (Hansson 2005). To identify differentially regulated miRNAs in whole 
blood in patients with coronary artery disease, a microarray study was conducted in 12 
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patients with CAD and 12 healthy control subjects. miR-140-3p, showed a rising trend, 
accompanied by significantly reduced expression of  target genes associated with 
mitochondrial dysfunction and oxidative phosphorylation (Taurino et al. 2010). Upregulation 
of  miR-140-3p was also discovered in the coronary sinus blood of  acute coronary syndrome 
(ACS) patients, and this elevation was likely mainly derived from peripheral blood 
mononuclear cells, including monocytes, circulating endothelial cells (CECs) and 
lymphocytes (Li et al. 2017), which was, however, related to higher death rates in ACS of
CAD patients (Karakas et al. 2017). Ellagic acid and breviscapine inhibited cell apoptosis and 
decreased fibrosis area and infarct area after acute myocardial infarction (AMI) by up-
regulating miR-140-3p and inhibiting MKK6 and subsequent TLR4 pathway (Wei et al. 2017).
In other respects, miR-140-5p was found to be upregulated in inhibition of  biological 
pathways associated with anabolic metabolisms, such as adipogenesis, cholesterol 
biosynthesis, triacylglycerol synthesis, and insulin signaling (Craig et al. 2014). A marked 
increase of  circulating miR-140-5p was shown in morbidly obese patients; while surgery-
induced weight loss and food restriction led to a decrease of  miR-140-5p (Gat-Yablonski et 
al. 2013). Pioglitazone can decrease miR-140-5p expression and increase HDAC7 expression
in insulin resistance and adiposity patients (Liu et al. 2016). 
Emerging evidence also revealed an altered expression of  miR-140-5p and miR-140-3p in 
different malignancies. Downregulation of  miR-140-5p was reported in NSCLC, primary 
breast cancer, colon cancer, hepatocellular carcinoma (HCC), osteosarcoma, chordomas and 
lymphoma et al. Overexpression of  miR-140-5p was reported to inhibit cell proliferation, 
and cell cycle arrest in both colon cancer cell lines and a cancer stem cell line (Song et al. 
2009). Mosakhani et al. (2012) found that upregulation of  miR-140-5p was significantly 
associated with poorer OS in metastatic colon cancer patients with wild-type KRAS/BRAF.
TGFβ signaling regulates tumour progression by a tumour cell-autonomous mechanism or 
through a tumour–stroma interaction and has either a tumour-suppressing or tumour-
promoting function depending on cellular context (Ikushima and Miyazono 2010). miR-140-
5p could suppress the TGFβ pathway through targeting Smad3 (Butz et al. 2011; Pais et al. 
2010). TGFβ receptor 1 (TGFBR1) and FGF9 are also direct targets for miR-140-5p. 
Silencing TGFBR1 and FGF9 by small interfering RNA (siRNA) resembled the phenotype 
resulting from the ectopic miR-140-5p expression, while overexpression of  TGFBR1 and 
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FGF9 attenuated the effect of  miR-140-5p on HCC growth and metastasis (H. Yang et al. 
2013). An increasing body of  evidence supports a stepwise model for the progression of  
breast cancer from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). 
Cancer stem cells (CSCs) are thought to be already programmed in pre-malignant DCIS 
lesions and these tumour-initiating cells may determine the phenotype of  DCIS. miRNA 
profiling of  normal mammary stem cells and cancer stem-like cells from DCIS tumours 
revealed that miR-140-5p is significantly downregulated in cancer stem-like cells (basal-like 
DCIS) compared with normal stem cells, linking miR-140 and dysregulated stem cell circuitry. 
Targets of  miR-140-5p, SOX9 and ALDH1, were the most significantly activated stem-cell 
factors in DCIS stem-like cells (Li et al. 2014b; Wolfson et al. 2014; Yan et al. 2008). Targeted 
therapies (tamoxifen) are only able to reduce DCIS risk in patients with oestrogen receptor 
α (ERα)-positive disease (Li et al. 2014b). These may link to the restoration of  miR-140-5p
after release from the suppression by ERα. Exosomal levels of  miR-140-5p from stem cell 
populations can be rescued by treatment with sulforaphane (Li et al. 2014b). In gastric cancer, 
Cha et al. (2018) and Wu et al. (2019) have successively reported decreased miR-140-5p 
expression in gastric cancer tissues, and its positive correlation with advanced stage and poor 
clinical overcome. WNT1-mediated Wnt-β-catenin and THY1-mediated Notch signalling 
pathway were identified to be responsible for lower miR-140-5p induced increased 
proliferation, migration, invasion and impaired apoptosis of  GC. Besides, Yu et al. (2019) 
discussed miR-140-5p participated in regulation of  NDRG3 and contributed to 
5‑fluorouracil resistance in gastric cancer. However, it was reported that miR-140 exhibited 
significantly higher expression levels in post-neoadjuvant chemotherapy specimens 
compared with pre-neoadjuvant chemotherapy biopsies in breast cancer, and exhibited 
significantly even higher expression levels in the ineffective group compared to the effective
group after neoadjuvant chemotherapy which indicated a poorer survival in breast cancer 
patients (Chen et al. 2016). Retinoblastoma (Rb) depletion or inactivation in soft tissue 
sarcoma cells exhibited slower proliferation and less efficient BrdU incorporation. However, 
much higher spherogenic activity and aggressive behavior both in vitro and vivo. miR-140-5p
appeared to be positively controlled by Rb and to antagonize the effect of  Rb depletion 
through targeting IL-6 (Yoshida et al. 2017). The induction of  IL-6 secretion and subsequent 
autocrine/paracrine activation of  STAT3 signalling supports the self-renewal activity of  not 
only cancer cells (Sansone et al. 2007; Korkaya et al. 2012; Marotta et al. 2011) but also 
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embryonic stem cells or induced pluripotent stem cells (Takahashi and Yamanaka 2016; 
Brady et al. 2013). Furthermore, the promoting role of  miR-140-5p to chemotherapy-
induced autophagy was determined by in osteosarcoma cells. miR-140-5p expression was 
highly induced during chemotherapy of  osteosarcoma cells, and this was accompanied by 
up-regulated autophagy. The increased miR-140-5p expression levels up-regulated anticancer 
drug-induced autophagy in osteosarcoma cells and ameliorated anticancer drug-induced cell 
proliferation and decreased viability decrease (Wei et al. 2016).
Significant upregulation of  miR-140-3p was found in metastatic nodal tissues compared to 
nonmetastatic oral squamous cell carcinoma, and its expression had a strong negative 
correlation with their DNA copy numbers and a negative correlation with their target genes. 
Ingenuity Pathway Analysis on the expression of  its target genes revealed a network 
associated with cell cycle, connective tissue development, and cellular function and 
maintenance. The central regulators in this pathway are p53, NF-κB, and HDAC1 (Serrano 
et al. 2012). In line with this study, highly expressed miR-140-3p has been demonstrated to 
control stemness of  breast cancer cells as well. Contrary to the effect of  the canonical hsa-
miR-140-3p, overexpression of  the 5'isomiR-140-3p led to a decrease in cell viability. The 
latter observation was supported by cell cycle analysis, where the 5'isomiR-140-3p but not 
the hsa-miR-140-3p caused cell cycle arrest in G0/G1-phase. Additionally, 5'ismoiR-140-3p 
overexpression was found to cause a decrease in cell migration (Salem et al. 2016). Up-
regulated miR-140-3p was shown in metastatic renal cell carcinoma comparing to localized 
renal cell carcinoma (Zhu et al. 2016). Overexpression of  miR-140-3p likewise correlated 
with recurrence and tumour invasion in patients with spinal chordoma (Gulluoglu et al. 2016; 
Zou et al. 2014). However, one controversial paper reported that increased expression of  
miR-140-3p predicted improved breast cancer survival (Chang et al. 2016).
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1.4 Aims and objectives of this study
The aims of  the present study are: 
1) To examine the expression of  deregulated miRNAs and prognostic related miRNAs in 
gastric cancer and their implication in the subtype classification of  gastric cancer subtypes;
2) To select and clarify the role(s) of  one or two miRNA(s) in gastric tissues and evaluate its 
or their potential as clinically relevant prognostic biomarker(s). 
3) To determine its or their impact on the functions of  gastric cancer cells via an in vitro cell 
model, which may contribute to its/their role(s) in the disease;
4) To discuss possible underlying molecular mechanism in its deregulation of  gastric cancer.
Objective 1: Determination of  miRNAs expression pattern in gastric cancer and their clinical 
relevance. The expression analysis of  miRNAs sequencing data from the TCGA cohort
(n=436) of  gastric cancer tissue samples will be performed. 
Objective 2: Expression of  miR-140-5p and miR-140-3p will be determined using real-time
quantitative PCR in two independent gastric cancer patients’ cohorts with or without 
neoadjuvant chemotherapy, respectively. The association with histopathological and clinical 
characteristics will be evaluated accordingly. Additional analyses will be performed on 
relevant public gene expression array data to further validate our findings.
Objective 3: Function of miR-140-5p and miR-140-3p on gastric cancer cells. 
This will be achieved initially by studying the behavior, in particular proliferation, migration, 
invasion and drug response of  different gastric cell lines in response to transfection with 
miRNA overexpression miRNA mimics or inhibitors. 
Objective 4: Molecular mechanisms. 
According to the Gene Set Enrichment Analysis (GSEA) analysis, a computational method 
that determines whether an a priori defined set of  transcriptome shows statistically 
significant, concordant differences between two biological states (a specific miRNA
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upregulation and suppression) from TCGA, combining with the clinical relevance analysis 
and related cell behaviour alteration, cell cycle-related molecular mechanism will be 
investigated by determining expression and activation of  candidate molecules.
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Chapter 2. 
Materials and Methods 
93
2.1 Clinical cohort study
2.1.1 Gastric cancer cohort patient selection and tissue collection
Pairs of  primary human gastric cancer tissue and corresponding normal gastric tissue (>5 
cm away from tumour margin) were collected from surgical specimens of informed, 
consenting patients in 2 independent clinical cohorts. The first one included 70 gastric cancer 
patients who did not receive any pre-treatment before surgery from the Beijing Cancer 
Hospital from January 2004 to December 2010, and the second cohort contained 87 gastric 
cancer patients (diagnosed and histologically confirmed with stage IIIA, IIIB, or IV [M0]) 
attending the Beijing Cancer Hospital neoadjuvant chemotherapy clinic trial from January 
2002 to December 2006. This study was conducted according to the principles of  the 
Declaration of  Helsinki and was approved by the Ethics Committee of  The Beijing Cancer 
Hospital. After gastrostomy, resected specimens were processed routinely for macroscopic 
pathological assessment, then tissue samples sectioned at 20 µm thickness for RNA
extraction, reverse transcription and transcript expression analysis using quantitative 
polymerase chain reaction (qPCR) were placed in labelled cryo vials, frozen in liquid nitrogen 
and stored in the research laboratory at -80°C until required for processing and analysis. The 
remaining surgical specimen was fixed in formalin for further wax blocking and section 
examination; the subsequent report was obtained for data stratification. Gastric cancer stage 
was classified according to the 2010 TNM classification recommended by the AJCC (7th 
edition). Patient records were reviewed in the context of  clinicopathological and follow-up 
information. The median follow-up period was 21.7 months.
2.1.2 Preparation of tissue samples
Multiple sections of  frozen tissue samples from the same patient sample biopsy were ground
using a Leica CM1900 Cryostat (Leica Biosystems, Newcastle Upon Tyne, UK). 100 mg of  
homogenized sections were mixed thoroughly in 1 mL ice-cold TRI reagent (Sigma-Aldrich, 
Poole, UK) using a handheld homogenizer (Cole Palmer, London, UK). RNA was 
subsequently extracted according to the manufacturer's instructions. Following extraction, 
RNA was resuspended in diethyl pyrocarbonate (DEPC) water and quantified using a 
spectrophotometer (WPA UV 1101, Biotech, Cambridge, UK). Five micrograms of  RNA 
samples were prepared for miRNA assay analysis, the remaining samples were subsequently 
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standardized before undertaking the reverse transcription reaction using an iScript cDNA 
synthesis kit (Bio-Rad Laboratories, Hemel Hemstead, UK) to generate cDNA.
2.1.3 General compounds
The general compounds used in this study and their sources are listed in Appendix 2.
2.1.4 General plastic consumables, hardware and software
The general plastic consumables, hardware, and software used in this study and their sources
are listed in Appendix 3.
2.2 Cell lines
Six gastric cancer cell lines and a pair of  colon cancer cell lines were used for the study. 
MKN7, MKN74, MKN45 and NUGC4 which have differing p53 status and established 
from gastric carcinomas, were purchased from RIKEN BioResource Centre CELL BANK 
(Ibaraki-ken, 305-0074 Japan); AGS and HGC27 were purchased from the American Type 
Culture Collection (ATTC, Rockville, Maryland, USA). The HCT116 p53 Wild type cell line 
and HCT116 p53 Knock-out cell line were provided by Professor M.C. Bibby (Cancer 
Research Unit, University of  Bradford, UK) and routinely maintained in our lab. All 
information regarding these cell lines is listed in Table 2.1. 
Table 2.1: Cell Lines, Origin and Additional Information. 1WT: Wild Type, 2stable: Microsatellite
Cell 
lines
Derived 
from
Morphology Culture 
Properties
Donor information Population 
Doubling 
Time
Passage 
number 
used
Lauren 
type Original Differentiation p53 Others age gender race
Gastric Cancer Cell Lines
AGS Primary cancer Intestinal Epithelial Poorly WT
1 Stable2 Adherent 54 Female Caucasian 18-20 hrs. 10-18
NUGC4 Primary cancer Diffuse Signet ring cell Poorly WT Stable
2 Adherent 35 Female Asian 2-3 days 2-5 
MKN7
Metastatic 
site（lymph 
nodes）
Intestinal Tubular adenocarcinoma Well
Missense
mutation 
(278)
HER-2 
positive Adherent 39 Male Asian 1 week 2-6 
MKN74
Metastatic 
site
（liver）
Intestinal Tubular adenocarcinoma Moderately 
Missense 
mutation 
(251)
? Adherent 37 Male Asian 3 days 2-6 
MKN45
Metastatic 
site
（liver）
Diffuse Epithelial ?
p53 
Missense 
mutation
(110)
CEA 
highly 
producing
Adherent 62 Female Asian 60 hrs. 2-5 
HGC27
Metastatic 
site（lymph 
nodes）
? ? Undifferentiated
p53 
frameshift
(152)
Stable2 Adherent ? ? Caucasian 16-20 hrs. 18-23
Colon Cancer Cell Lines
HCT116 
p53 WT
Metastatic 
site ? Epithelial
WT Unstable(MSI-
high), 
CEA 
highly 
producing
Adherent
48 Male Caucasian
1-2 daysHCT116 
p53 KO
Deleted 
of the 
exon2
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2.3 Primers
Primers were designed or based on previous publications and blasted online 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). Details for primers for conventional real-time
quantitative PCR (qPCR) are listed in table 2.2. An additional Z sequence, written in bold, 
acts as a fluorescent tag in qPCR reactions and were synthesized by Sigma-Aldrich (Poole, 
Dorset, UK). The stock primer solution was prepared according to the datasheet provided 
and stored at -20˚C，the working solution was diluted either 1 in 10 or 1 in 100 (for the Z 
sequence).
Table 2.2: Primers used in the current study to quantify gene expression
Gene Primer The sequence of Primer (5'->3')
size 
(bp)
Tm 
(˚C)
CCND1 F1 AATGACCCCGCACGATTTC
191 59 
ZR1 ACTGAACCTGACCGTACATCAGGTTCAGGCCTTGCAC
F8 TGTGCTGCGAAGTGGAAACC
405 61 
R8 CCATTTGCAGCAGCTCCTCG
DNMT1 F1 CGTGGTGGTGGATGACAAG
150 60 
ZR1 ACTGAACCTGACCGTACAGGCTCCCCGTTGTAGGAGAT
F8 GTGGGGGACTGTGTCTCTGT
676 59 
R8 TGCTGCCTTTGATGTAGTCG
MDM2 F1 GTTATCTCAGTGCCTTTTGC
101 58 
ZR1 ACTGAACCTGACCGTACAAACAGACACATGTTCTACCC
F8 CCTTCGTGAGAATTGGCTTC
462 57 
R8 CATACTGGGCAGGGCTTATTC
p21 F1 CTGGAGACTCTCAGGGTCGAA
66 60 
ZR1 ACTGAACCTGACCGTACAGCGTTTGGAGTGGTAGAAATCT
F8 GCGATGGAACTTCGACTTTG
352 58 
R8 GGGCTTCCTCTTGGAGAAGAT
p53 F1 CTGTCATCTTCTGTCCCTTC
172 60 
ZR1 ACTGAACCTGATGGAATCAACCCACAGCTGCA
F8 AGACCCAGGTCCAGATGAAG
484 59 
R8 CACCACACTATGTCGAAAAGTGT
GAPDH
F1 AAGGTCATCCATGACAACTT
87 55 
ZR1 ACTGAACCTGACCGTACAGCCATCCACAGTCTTCTG
F8 GGCTGCTTTTAACTCTGGTA
475 55 
R8 GACTGTGGTCATGAGTCCTT
2.4 Antibodies
Primary antibodies used in this study are shown in Table 2.3
Table 2.3: Primary antibodies used in Western Blot. Secondary antibodies used were either horseradish peroxidase (HRP) conjugated anti-mouse (A9044) or anti-
rabbit (A0545) IgG antibodies from Sigma-Aldrich (Poole, Dorset, UK), in a dilution of  1 in 2000.
Antibody
The molecular
weight (kDa)
Target Species Company
Catalog
number
Dilution
MDM2 90 
Raised against amino acids 154-167 of MDM2 of human origin for 
detection of MDM2, MDM2 p60 cleavage product and p53-MDM2 
complexes by WB
mouse 
monoclonal
Santa Cruz 
Biotechnology 
Inc.
sc-965
1 in
1000
p53 53 
Specifically recognizes the N-terminal epitope mapping between 
amino acid residues 11-25 of p53 of human origin, which could be 
used for detection of wild-type and mutant p53 under denaturing and 
non-denaturing conditions of human origin by WB.
mouse 
monoclonal
Santa Cruz 
Biotechnology
sc-126 1 in 500
p21 21 
Specific for an epitope mapping between amino acids 124-164 at the 
C-terminus of p21 of human origin
mouse 
monoclonal
Santa Cruz 
Biotechnology
sc-
271610
1 in 500
BAX 23 Amino acids 1-171 of Baxα rabbit 
monoclonal
Santa Cruz 
Biotechnology
sc-7480 1:500
GAPDH 37 
GAPDH purified from rabbit muscle. recommended for detection of 
GAPDH of human origin by WB
Mouse 
monoclonal
Santa Cruz 
Biotechnology Inc
sc-
32233
1 in 
2000
9 3
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2.5 Mimics and inhibitors
The ready-to-use MISSION miRNAs (Sigma-Aldrich, Poole, Dorset, UK): hsa-miR-140-5p 
(HMI0214), hsa-miR-140-3p (HMI0215) and the negative control mimic (HMC0003, 
sequence from Caenorhabditis elegans with no homology to human gene sequences) mimics
were diluted in DEPC water to produce a stock concentration of  20 μM and used at a 
working concentration of  20 nM. MISSION® Synthetic microRNA inhibitors: miR-140-5p 
(HSTUD0214), hsa-miR-140-3p (HSTUD0215), and negative control inhibitor (cel-miR-
243-3p, NCSTUD002) were diluted in DEPC water to produce a stock concentration of  10 
μM and used at a working concentration of  10 nM.
2.6 Preparation for standard reagents and solutions
2.6.1 General laboratory used materials 
Phosphate buffered saline (PBS)
One PBS tablet (Sigma-Aldrich) was dissolved in 200 mL of  purified water to make a working 
concentration (containing 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 
pH 7.20 - 7.60). This was then autoclaved and aliquoted accordingly. 
2.6.2 Materials for cell culture use
0.25% Trypsin-EDTA
A 10X stock of  Trypsin-EDTA (Sigma-Aldrich) was diluted to a 1X solution with PBS. This 
was aliquoted and stored at -20℃ until use.
Antibiotics
Five millimolars of  100X antibiotics containing 10,000 U/mL penicillin, 10 mg/mL 
streptomycin, 25 μg/mL amphotericin was added to 500 mL growth media to make a final 
working concentration at 100 U/mL, 0.1 g/mL, streptomycin and 0.25 μg/mL amphotericin.
2.6.3 Materials for molecular biology
0.05% DEPC water (Diethyl pyrocarbonate)
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A working solution of  0.05% DEPC water was prepared by dissolving 250 μL of  DEPC was 
added to 500 mL of  distilled water, left for 24 hrs and then autoclaved.
2.6.4 Materials for bacterial transformation
LB broth
LB broth was made by dissolving 10 g tryptone, 10 g NaCl and 5 g yeast extract in 1 liter of  
distilled water. After being adjusted pH to 7.0, the media was autoclaved prior to storage at 
4°C until use. Appropriate antibiotics for colony selection were added prior to use.
LB Agar
LB agar was prepared by dissolving 10 g tryptone, 5 g yeast extract, 15 g agar and 10 g NaCl 
in 1 liter of  distilled water. The pH was adjusted to 7.0 and the media was autoclaved and 
solid at room temperature. To prepare LB agar dishes, the agar was melted by heating in a
microwave to reach a liquid state. And when it cooled to approximately 65°C, the appropriate 
antibiotic for colony selection was added, then poured into 10cm2 Petri dishes. Once 
solidified, the plates were kept at 4°C until use.
2.6.5 Materials for western blot
Lysis buffer
The 100 mL lysis buffer containing NaCl 150 mM (0.87 g), TRIS base 50 mM (0.61 g), EGTA 
5 mM (0.19 g), Triton X-100 1% (1 mL) was purchased from Melford Laboratories, UK. A 
protease inhibitor cocktail tablet (Roche) was added and the solution was aliquoted and 
stored at -20°C until use.
10% Ammonium Persulphate (APS)
One gram of  APS (Melford Laboratories Ltd, UK) was dissolved in 10 mL of  distilled water 
and stored at 4°C until use for up to 2 weeks. 
10% Sodium dodecyl sulfate (SDS)
Ten grams of  SDS (Sigma-Aldrich) was dissolved in 100 mL of  distilled water and was stored 
at room temperature.
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Running Buffer
One liter of  10X Tris-Glycine SDS buffer (Sigma-Aldrich) was added to 9 L of  distilled water.
Transfer Buffer
One liter of  10X Tris-Glycine concentrate buffer (Sigma-Aldrich) was added to 7 L of  
distilled water and 2 L of  methanol (Fisher Chemical, Leicestershire).
0.01% TBS-Tween (TBS-T)
For the washing solution, 500 μL of  Tween20 (Melford Laboratories Ltd, UK) was added to 
500 mL of  1X TBS and mixed thoroughly. 
Blocking buffer
Non-fat dried milk (Marvel) was dissolved in 1X TBS-T to a final concentration of  5% 
(weight /volume) used for blocking membranes.
2.7 Cell culture, maintenance, and storage
2.7.1 Growth media
AGS, HGC27, HCT116 cell lines are cultured in Dulbecco’s Modified Eagle’s Medium 
(Sigma-Aldrich, Dorset, UK), supplemented with 10% fetal calf  serum (FCS) (Sigma-Aldrich, 
Dorset, England, UK) and 1 × penicillin/streptomycin antibiotics (Sigma-Aldrich, Dorset, 
UK). The other cell lines are maintained in RPMI-1640 Medium (Sigma-Aldrich, Dorset, UK) 
and supplemented with FCS and antibiotics. 
2.7.2 Cell maintenance
Cells were grown in culture flasks and incubated at 37˚C and 5% CO2 in a humidified 
incubator.  Cells were cultured in 6-well-plates, 25cm2 or 75cm2 tissue culture flasks 
(Greiner Bio-One Ltd, Gloucestershire, UK) with loosely fitted caps. Mycoplasma 
contamination in cell cultures was estimated using EZ-PCR Mycoplasma Test Kit (Biological 
Industries, Israel). Cell medium was changed every 2-3 days and sub-cultured once they 
reached a confluence of  approximately 85-90%. All cell work was carried out aseptically, 
using a Class II Laminar Flow Cabinet with sterile and autoclaved equipment and 
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consumables.
2.7.3 Trypsinisation of adherent cells and cell counting
Cell medium was aspirated, and the cells were briefly rinsed with sterile PBS before detaching
adherent cells. Depending on the amount and characteristics of  cells were cultured, 0.5-2 ml 
of  Trypsin/EDTA (0.01% trypsin, 0.05% EDTA in borate buffered saline, BSS) was used 
to detach adherent cells and they were incubated at 37˚C for 2-5 minutes. Once disassociated,
cells were collected in the appropriate medium containing FBS to stop the trypsinization
reaction and transferred to 20 ml universal containers (Greiner Bio-One Ltd, Gloucestershire, 
UK) before being centrifuged at 1200 rpm for 5 minutes. The supernatant was then aspirated, 
and the cell pellet was resuspended in an appropriate amount of  medium. Cells were either 
split and transferred to fresh tissue culture flasks for re-culturing or counted using Counter 
II FL Automated Cell Counter (Thermo Fisher Scientific, Waltham, MA USA) and then 
seeded at an appropriate concentration of  cells for experimental requirements.
2.7.4 Frozen storage of cell stocks
Cells were trypsinized as previously described (section 2.7.3) and resuspended in medium 
containing 10% Dimethyl sulphoxide (DMSO; Sigma-Aldrich, Dorset, UK) at a cell density 
of  about 106 cells/ml. The cell suspension was then divided into 1 mL aliquots and
transferred into cryo-vials (Grenier Bio-One, Germany) pre-labelled with cell names, date of  
storing, owner’s name and was then wrapped in protective tissue paper or loaded into frozen
storage box containing isopropanol, before being stored at -80 ˚C or in liquid nitrogen tanks 
for long-term preservation.  
2.7.5 Resuscitation of cells
After being removed from frozen storage, cryo-vials were thawed immediately in a 37 ˚C
water bath. Once melting, cells are transferred into a universal container containing 9 mL of  
normal culture medium and being centrifuged at 1000 rpm for 5 minutes. The supernatant 
was then aspirated to remove the traces of  DMSO from the cells. The cell pellet was 
resuspended in 5 mL of  the medium before being transferred to a fresh 25 cm2 tissue culture 
flask left overnight in normal culture conditions. After 24 hours, the revived cells were 
examined under the microscope to visually assess the viability of  the adherent cells. The 
medium was aspirated and replaced with fresh medium. The flask was returned to the 
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incubator and the previous standard subculture techniques were carried out when necessary.
2.8 Methods for isolation and quantification of genetic material
2.8.1 RNA Extraction
The TRI Reagent® (Sigma-Aldrich, Poole, Dorset, England, UK), containing phenol and 
guanidine isothiocyanate which can break the protein-protein interactions and combine with 
the inactivation of  cellular nucleases, was employed for RNA extraction. According to the 
manufacturer’s instructions, cell medium was replaced with TRIzol® Reagent (1 mL for 5-
10×105 cells). After addition of  the reagent, this homogenate was passed several times 
through pipetting to form a homogenous lysate and then transferred in a 1.5 mL Eppendorf. 
Samples were left for 5 minutes at room temperature to ensure complete dissociation of  
nucleoprotein complexes. This was followed by the addition of  100 μL of  1-Bromo-3-
chloropropane (Sigma-Aldrich, Poole, Dorset, England, UK), vigorous shaking for 15 
seconds and incubation at room temperature for 15 min. The resulting homogenate was then 
centrifuged at 12,000 x g for 15 minutes at 4 °C. Under these acidic conditions, 
Centrifugation separates the homogenate into 3 phases: a pink organic phase (containing 
protein), a white interphase (containing DNA), and a colourless upper aqueous phase 
(containing RNA). This aqueous phase, which should constitute around 40-50% of  the total 
volume, was then carefully removed and transferred into a fresh tube, before adding 0.5 mL
of  isopropanol (Sigma-Aldrich, Inc., Poole, Dorset, England, UK), and incubating for 10 
minutes at room temperature. After centrifuging the samples at 12, 000 x g for 10 minutes at 
4 ˚C, the RNA precipitate forms as a white pellet could be seen on the side and bottom of  
the tube. The supernatant was then aspirated, and the RNA pellet was washed by vortexing 
it with 1 mL of  75% ethanol (3:1 ratio of  pure ethanol and diethylpyrocarbonate, DEPC, 
water) and subsequently vortexing and centrifuging the samples at 7, 500 x g for 5 minutes 
at 4 ˚C. After the ethanol was aspirated, the pellets were further air-dried at room temperature
for 5 mins to remove any remaining traces of  ethanol. DEPC water was pre-warmed at 55
˚C in a Techne, Hybridiser HB-1D drying oven (Wolf  Laboratories, York, UK), then dissolve 
the RNA pellet in 20-50 μL (depending on pellet size) in pre-warmed DEPC water by 
repeated pipetting for a short while.
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2.8.2 Genomic DNA extraction
In order to assess the status of  miR-140 in different cell lines used in this study, again, the 
TRI-reagent was applied for this procedure. Cells were lysed and separated into three 
different phases as elucidated previously. The aqueous RNA phase overlaying the DNA 
interphase was carefully removed to improve the quality of  the DNA isolated. The DNA 
was precipitated from the interphase and organic phase by adding 0.3 mL of  100% ethanol 
per 1 mL of  TRI-Reagent used and mixing by inversion. The mix was allowed to stand for 
2-3 minutes at room temperature before being centrifuged at 2, 000 x g for 5 minutes at 4
˚C. The supernatant was discarded, and the DNA pellet was washed twice in 1 mL of  0.1 M 
trisodium citrate, 10% ethanol solution for every 1 mL of  TRI-reagent used to remove 
phenol from the DNA. During each wash, DNA pellet was allowed to stand for at least 30 
minutes. With occasional mixing. Samples were centrifuged again at 2, 000 x g for 5 minutes 
at 4 ˚C and the DNA pellet was resuspended in 1.5 mL of  75% ethanol per 1 mL of  TRI-
reagent and left to stand for 20 minutes at room temperature. The DNA pellet was air-dried 
for 5-10 minutes and dissolved by repeated slow pipetting with a micropipette in 8 mM 
NaOH (0.1 mL to the DNA isolated from fully confluent 25 cm2 flask). 
2.8.3 Spectrophotometric quantification of RNA and DNA
Once isolation was completed, the concentration and purity of  the RNA and DNA were
measured by a NanoPhotometer (Implen, München, Germany). The absorbance measure 
unit is the wavelength (λ) and some typical values are reported below: 
λ = 230 nm: the wavelength of  absorption of  complex carbohydrates and phenols;
λ = 280 nm: the wavelength of  absorption of  proteins;
λ = 260 nm: the wavelength of  absorption of  nucleic acids;
λ = 320 nm: the wavelength of  absorption of  other contaminants. 
Two μL sample was used to detect single-stranded RNA (μg/μL) at the wavelength of  260
nm, using DEPC water as a blank. The purity of  RNA is evaluated by the ratio of  the 
readings at 260 nm and 280 nm (A260 / A280) and at 260 nm and 230 nm (A260 / A230).
The A260 / A280 ratio provides an estimate of  the purity of  RNA with respect to 
contamination by protein and its value must be higher than 1.7. The A260 / A230 ratio 
provides an estimate of  the purity of  RNA with respect to contamination by solvent (phenol, 
salts) and its value must not be fewer than 2.2. Contaminations may decrease the efficiency 
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of  the following reactions, mainly by the inhibition of  the enzymes. DNA was also measured 
using the NanoPhotometer, set to measure double-stranded DNA at 260 nm. After the 
purification and quantification, the RNA samples are ready to be used immediately or they 
can be stored at -80⁰C for later use.
2.8.4 Reverse transcription (RT) of mRNA
To measure genes expression at transcription level, 500 ng of  RNA (cDNA synthesis, as 
measured by real-time PCR, has a linear relationship to the input RNA across this range.) 
was converted into complementary DNA (cDNA) using the GoScript™ Reverse 
Transcription System (Promega Corporation, Madison, USA), following the protocol 
outlined below. 
The required volume of  isolated RNA containing the desired quantity of  RNA was made up 
to 9 µL with PCR water in a thin walled 0.2 mL PCR tube. 1 µL of  RT primer was added 
and the resultant mixture was heated at 70°C for 5 minutes to denature the secondary 
structure of  RNA allowing more effective reverse transcription. 
Table 2.4.1: Reverse transcription PCR preparation 1
Component 1 reaction (μL)
RNA template (up to 2 µg) X
RT primer 1.0
RNAse/DNAse free water X
Final volume 5
Oligo-dT primers which bind to the polyA tail of  messenger RNA were preferentially used 
in this process. Following this incubation period, the PCR tube was immediately placed on 
ice. The RT mix was made up using the following components:
Table 2.4.2: Reverse transcription PCR preparation 2
Component 1 reaction (μL)
GoScript™ 5X Reaction Buffer 4.0
MgCl2 (final concentration 25 mM) 2.0
dNTP mix 10 mM 1.0
RNAse/DNAse free water 7.0
GoScript™ Reverse Transcriptase 1.0
Final volume 15.0
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10 µL of  the above RT mix was added to each of  the samples on ice. After briefly cortex 
and a pulse spin, the resultant mixture was incubated at 25°C for 5 minutes, 42°C for 60
minutes and 75°C for 20 minutes. The cDNA was diluted in nuclease-free water in the ratio 
1:8. cDNA Samples were added to PCR or qPCR amplification or stored at -20°C until use.
2.8.5 General polymerase chain reaction (PCR)
General PCR was performed using GoTaq Green Master Mix (Promega, Madison, USA) and 
specific primers designed for the identification of  the gene targets, which were synthesized
by Sigma (Sigma-Aldrich, Dorset, UK). Reactions for each sample were set up in 0.2 mL
PCR tube or a 96 well plate, as shown below:
Table 2.5: General PCR preparation
Component 1 reaction (μL)
2X GoTaq Green Master Mix 8.0
Forward primer (10 pmol) 1.0
Reverse primer (10 pmol) 1.0
Nuclease-free water 5.0
cDNA template 1.0
Final volume 16.0
Once set up, the prepared reactions were briefly mixed and centrifuged. All reactions were 
run alongside a negative control, which consisted of  using nuclease-free water instead of  the 
cDNA template to ensure there was no contamination of  the master mix. A loading control 
probing for GAPDH expression was also run for each sample to confirm similar cDNA 
quantities in each reaction prepared. 
The PCR tubes or 96 well plates were placed in a 2720 Thermal Cycler (Applied Biosystems, 
Paisley, UK). PCR conditions for MDM2 and GAPDH primers were optimized as:
Step 1 – Initial denaturation at 94 ˚C for 5 minutes
Followed by 25-42 cycles of:
Step 2 – Denaturing step at 94 ˚C for 30 seconds
Step 3 – Annealing step at 55 ˚C for 30 seconds
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Step 4 – Extension step at 72 ˚C for 1.5 minutes
And finally:
Step 5 – Final extension at 72 ˚C for 10 minutes
2.8.6 Agarose gel electrophoresis and visualization
Samples were loaded onto 0.8% to 2.5% agarose gels (Melford Chemicals, Suffolk, UK), 
depending on the predicted size of  the DNA products. Weigh out the appropriate mass of  
agarose into an Erlenmeyer flask, UK), and add the appropriate volume of  1X Tris-borate-
EDTA (TBE) buffer. Melt the agarose/buffer mixture by heating in a microwave, at 30 s 
intervals, remove the flask and swirl the contents to mix well. Repeat until the agarose has 
completely dissolved. SYBR Safe Gel Stain (Invitrogen, Paisley, UK) was then added at a 
ratio of  1:10000. The agarose was left to cool slightly before being poured into the removable 
gel tray and it was allowed to place an appropriate comb into the gel mold to create the wells.
Once set, the gel was submerged in 1X TBE buffer and the comb was removed. 10 µL of  
the PCR samples were loaded in each well, alongside 5 µL of  a 100 bp or 1 Kb DNA ladder 
(Genscript, Piscataway, USA). Attach the leads of  the gel box to the power supply, double 
checking the cathode (black leads) should be closer the wells than the anode (red leads). The
samples were subjected to electrophoresis using a power pack (Gibco, Paisley, UK) at 100 V, 
90 mA, 50 W for 30 minutes (or until the dye has migrated to an appropriate distance). Gels 
were visualized and imaged using a U: Genius gel doc system (Syngene, Cambridge, UK).
2.8.7 Real-time quantitative polymerase chain reaction (RT-qPCR)
Quantitative PCR with a heat stable DNA polymerase could detect the products of  the 
reaction from the first cycle in which the amplified target becomes detectable (threshold 
cycle, Ct) and thus generate a more accurate and reproducible result than the traditional end-
point PCR. The Ct value is inversely correlated with the starting amount of  target genes. In 
the current study, qPCR was performed using the Amplifluor ™ Universal Detection System 
(Intergen®, New York, USA). This system is based on molecular energy transfer from an 
excited fluorophore (fluorescein) to an acceptor moiety [4-(4’-dimethylaminophenylazo) 
sulfonic acid (DABSYL)] that quenches the fluorescence emission. The fluorophore and 
acceptor are tethered together via an oligonucleotide primer called UniPrimer™. 
Amplifluor™ UniPrimer™ hairpin primers are designed in such a way that a fluorescent 
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signal is only generated when the primer is unfolded during its incorporation into an 
amplification product.
Contained within the UniPrimer™ is a 3’-18 base oligonucleotides of tail called a Z sequence, 
which acts as a universal PCR primer. The fluorophore and acceptor are located at the 5’ end. 
In order to use the UniPrimer™, the Z sequence is added to the 5’ end of  a target-specific 
primer. The UniPrimer™ can then anneal to the Z’ sequence in an amplicon generated in 
the initial cycles of  the PCR reaction. As the UniPrimer™ is incorporated, the hairpin 
becomes unfolded, quenching can no longer occur and then a fluorescence signal that 
directly correlates to the amount of  amplified DNA is produced. An illustration showing 
how the Amplifluor™ Universal detection system using the UniPrimer™ detection system 
works is shown in Appendix 4.
The components of  each qPCR reaction are shown in Table. 2.6 Each sample was loaded 
into a 96 well plate (Applied Biosystems™, Life Technologies Ltd, Paisley, UK), covered with 
MicroAmp® Optical Adhesive film (ThermoFisher Scientific, Life Technologies Ltd, Paisley, 
UK) and run alongside a podoplanin (PDPL) standard of  a known transcript number 
(ranging from 101 to 108). PDPL is a lymphangiogenesis marker, which acted as a reference 
control gene to ensure any differences observed were not due to technical errors and allowed 
normalization of  results from different plates. GAPDH is an enzyme of  ~37kDa that 
catalyses the sixth step of  glycolysis and thus serves to break down glucose for energy and 
carbon molecules. Because the GAPDH gene is often stably and constitutively expressed at 
a high level in most tissues and cells, it is considered a housekeeping gene and is commonly 
used as a reference point for the analysis of  expression levels of  other genes. The 96 well 
plate was placed in an iCycler Thermal Cycler which uses a light source to excite the 
fluorescent molecules in the wells and an image intensifier and a 350,000-pixel charge-
coupled device (CCD) detector to image all 96 wells every second and detect fluorescent 
light. 
An example of the amplification plot and standard curve produced using qPCR is shown in 
Appendix 5.
Each cDNA sample was diluted 1:8 with ddH2O. RT-qPCR performed using TaqMan® 
Universal PCR Master Mix (Applied Biosystems, Paisley, UK) and Universal Primer 
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(Intergen®, New York, USA), with forward and fluorescent tagged reverse primers designed 
for target gene amplification. Reactions for each sample were loaded in a 96 well plate with 
triplicates, as shown in Table 2.6. 
Table 2.6: qPCR preparation
Component 1 reaction (μL)
2X IQ Master Mix 5.0
Forward primer (10 pmol) 0.3
Reverse primer (1 pmol) 0.3
Universal primer (10 pmol) 0.3
cDNA template 1.0
ddH2O 3.1
Final volume 10.0
The plate was covered with optically clear Microseal® (BioRad Laboratories, California, USA) 
and placed in a StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, Waltham, 
MA USA) at the following parameters: initial denaturation for 10 minutes at 95 ˚C; followed 
by 85 cycles of  denaturation at 95 ˚C for 10 seconds, annealing at 55 ˚C for 30 seconds and 
elongation at 72°C for 10 seconds.  Results were analyzed using ΔΔCT normalization to 
the housekeeping gene, GAPDH. 
2.8.8 miRNA reverse Transcription and real-time PCR
The reverse transcription for mature miRNA quantification was performed using TaqMan™ 
Advanced miRNA cDNA Synthesis Kit (Applied Biosystems, UK). Each reaction containing 
5 ng RNA sample was set up in a 0.2 mL PCR tube (ABgene, Surrey, UK) and the 
manufacturer’s protocol was adjusted as follow:
Perform the poly (A) tailing reaction, to modify mature miRNA by adding a 3’ adenosine 
tail to the miRNA.
Table 2.7.1: miRNA reverse transcription PCR preparation 
Component 1 reaction (μL)
10X Poly (A) Buffer 0.5
ATP 0.5
Poly (A) Enzyme 0.3
RNase-free water 1.7
RNA sample (5 ng) 2.0
Final volume 5.0
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The reaction plate or tubes are placed into a 2720 Thermal Cycler (Applied Biosystems, 
Paisley, UK), then incubate using the following settings and standard cycling: polyadenylation 
at 37 ˚C for 45 minutes, 65 ˚C for 10 minutes and Hold at 4°C, then proceed to Ligation 
Reaction, which allows the miRNA with poly(A) tail undergoes adaptor ligation at the 5’ end
and the adaptor could act as the forward-primer binding site for the following miR-Amp 
reaction .
Table 2.7.2: miRNA reverse transcription PCR preparation.
Component 1 reaction (μL)
5X DNA Ligase Buffer 3.0
50% PEG 8000 4.5
25X Ligation Adaptor 0.6
RNA Ligase 1.5
RNase-free water 0.4
Poly(A) tailing reaction product. 5.0
Final volume 15.0
Samples were incubated in a thermal cycler using the following settings and standard cycling:
ligation at 16 ˚C for 60 minutes, following setting up and mixing with the reverse 
transcription (RT) reaction immediately as below:
Table 2.7.3: miRNA reverse transcription PCR preparation
Component 1 reaction (μL)
5X RT Buffer 6.0
dNTP Mix (25 mM each) 1.2
20X Universal RT Primer 1.5
10X RT Enzyme Mix 3.0
RNase-free water 3.3
Adaptor ligation reaction product 15.0
Final volume 30.0
The reaction plate or tubes are placed into a thermal cycler, then incubated using the 
following settings and standard cycling: reverse transcription at 42 ˚C for 15 mins, stop 
reaction at 85 ˚C for 5 minutes; In this step, a Universal RT primer binds to the 3’ poly(A) 
tail and the miRNA is reverse transcribed. The resulting cDNA will be suitable for all 
TaqMan® Advanced miRNA Assays. The last step is preparing the miR-Amp reaction to 
improve detection of  miRNA targets.
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Table 2.7.4: miRNA reverse transcription PCR preparation
Component 1 reaction (μL)
2X miR-Amp Master Mix 25.0
20X miR-Amp Primer Mix 2.5
RNase-free water 17.5
RT reaction products 5.0
Final volume 45.0
PCR amplification was performed following parameters: enzyme activation for 5 minutes at 
95˚C; followed by 14 cycles of  denature at 95 ˚C for 3 seconds, annealing and extending at 
60°C for 30 seconds, finally stop the reaction at 99 ˚C for 10 minutes. The undiluted miR-
Amp reaction products were proceeded to performing the real-time PCR or stored at –20
˚C for up to 2 months.
Before performing real-time PCR, cDNA templates were diluted 1:10 with ddH2O. Each 
reaction was performed as follows:
Table 2.8: qPCR preparation
Component 1 reaction (μL)
TaqMan® Fast Advanced Master Mix (2X) 10.0
TaqMan® Advanced miRNA Assay (20X) 1.0
RNase-free water 4.0
Diluted cDNA template 5.0
Final volume 20.0
The reaction plate was loaded in the StepOnePlus™ instrument (Thermo Fisher Scientific, 
Waltham, MA USA), at the following conditions: enzyme activation at 95°C for 20 seconds, 
following 40 cycles denature at 95 ˚C for 1 second and anneal/extend at 60°C for 20 seconds. 
Results were transformed by 2-ΔΔCt, where: ΔCt = target gene Ct – housekeeping gene, Ct 
ΔΔCT = ΔCt experimental group – ΔCt mean of  the negative control group. Our 
examination of  hsa-miR-423-5p verified it was relatively consistent and moderately abundant 
across stomach tissues and gastric cancer cell lines. Thus hsa-miR-423-5p was chosen as an 
endogenous control for normalization.
Table 2.9: miRNA assay information
Assay name Target Sequence
hsa-miR-423-5p 5′-UGAGGGGCAGAGAGCGAGACUUU-3′
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hsa-miR-140-5p 5′-CAGUGGUUUUACCCUAUGGUAG-3′
hsa-miR-140-3p 5′-UACCACAGGGUAGAACCACGG-3′
2.9 Methods for protein extraction and detection
2.9.1 Protein extraction
Cells were seeded into 6-well-plates. Upon reaching sufficient confluency, cells were washed 
with ice-cold PBS twice and scraped with 80 uL cell lysis buffer on ice. The cell suspension 
was transferred to a 2 mL Eppendorf tube and followed by being placed on a Labinoco 
rotating wheel (Wolf  Laboratories, York, UK) for 1 hour rolling at 25 rpm. The lysates were 
then centrifuged at maximum speed (15,000 x g) in a benchtop Eppendorf  microcentrifuge 
for 30 minutes at 4 ˚C. The supernatant was then transferred to a new 1.5 mL 
microcentrifuge tube for determination of  protein quantification.
2.9.2 Determination of protein concentration 
For a typical protein assay, a chemical reagent is added to the protein sample, producing a 
colour change in the sample solution. This colour change is quantitated with a 
spectrophotometer or microplate reader and compared to a standard curve of  known 
concentrations of  protein versus their absorbance after reaction with the reagent. The 
amount of  protein in the unknown sample is determined by interpolation, reading the 
concentration of  protein on the standard curve that corresponds to its absorbance.
2.9.2.1 Preparation of diluted albumin (BSA) standards
A standard curve was made by preparation of  diluted bovine serum albumin (BSA) standards. 
Dilute the contents of  1mL of  10 mg/mL BSA into several clean vials, as shown in Table 
2.10. 
Table 2.10: Preparation of diluted BSA Standards
Vial
Volume of Diluent
(µL)
Volume and Source of 
BSA (µL)
Final BSA Concentration
(µg/mL)
1 0 300 of Stock 10,000
2 100 400 of Stock 8,000
3 325 325 of Stock 5000
4 325 325 of Vial 2 4000
5 325 325 of Vial 3 2500
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6 325 325 of Vial 4 2000
7 325 325 of Vial 6 1000
8 400 100 of Vial 5 500
9 400 100 of Vial 7 200
10 375 375 of Vial 9 100
11 400 100 of Vial 10 25 
12 400 0 Blank = 0
2.9.2.2 Preparation of the working reagent 
The colorimetric Bio-Rad Detergent Compatible Protein Assay Kit was used to determine 
protein concentration. These assay solutions include the Reagent A (alkaline copper tartrate 
solution), Reagent S (surfactant solution), and Reagent B (Folin reagent). Prepare working 
reagent by mixing 50 parts of  Reagent A with 1 part of  Reagent S (50:1, Reagent A: S).
The following formula was used to determine the total volume of  Bio-Rad required: (# 
standards + # unknowns) × (# replicates) × (25 µL per sample) = total volume working 
reagent required
Five microliters of  standards and unknown samples in triplicate were pipetted into 96-well -
plate. 25 µL of  working reagent was added to each well and gently mixed. 200 µL of  Reagent 
B was subsequently added into each well. The samples were mixed thoroughly using a 
microplate mixer and incubated at room temperature for 15 mins. Then the absorbance was 
measured at 630 nm (available at 405-750 nm) using the ELx800 plate reading 
spectrophotometer (Bio-Tek, WolfLaboratories, York, UK). After calculating the 
concentration by comparing the reading to BSA standard curve, samples were diluted into 
the same concentration (4 µg/µL) with lysis buffer, and aliquoted into several 0.5 mL 
Eppendorf tubes. One of  them was further mixed with 2X SDS Laemmli Buffer (Sigma-
Aldrich) at a ratio of  1:1. The samples were then denatured at 100 ˚C for 5 minutes and spun
down briefly before loading onto the SDS-PAGE gel. The remaining aliquots were stored at 
-80°C for up to one month.
2.9.3 SDS Polyacrylamide gel electrophoresis (SDS-PAGE) for protein separation
The percentage of  the gel used was dependent on the molecular weight (MW) of  the desired
protein to be detected. As shown in Table 2.11.
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Table 2.11: Protein size and gel percentage selection
Protein MW range (kDa) Recommended gel (%)
10-80 14%
20-150 12%
30-200 10%
40-250 8% 
60-300 6% 
For a 10% resolving gel, Table 2.12 depicts the components and volumes used. For the 5% 
stacking gel, Table 2.13 depicts the components and volumes used.
Table 2.12: Components and volumes for a 10% resolving gel
Solution Component volume (mL)
H2O 5.9
30% acrylamide mix (Sigma-Aldrich, St Louis, 
USA)
5.0
1.5 M Tris-HCl (pH 8.8) 3.0
10% SDS 0.15
10% Ammonium persulfate 0.15
N, N, N′, N′-tetramethylelthylenediamine
(TEMED, Sigma- Aldrich St Louis, USA)
0.006
Table 2.13: Components and volumes for a 5% stacking gel
Solution Component volume (mL)
H2O 3.4
30% acrylamide mix (Sigma-Aldrich, St Louis, USA) 0.83
0.5 M Tris-HCl (pH 6.8) 0.63
10% SDS 0.05
10% Ammonium persulfate 0.05
TEMED (Sigma- Aldrich St Louis, USA) 0.005
The resolving gel was added between two glass plates held in place by a loading cassette up 
to 1.5 cm below the top edge of  the plate. To produce a smooth level surface, the gel was
coved by water and allow to polymerize at room temperature. Once the resolving gel had set 
totally, the overlaid water was poured out and the excess was removed by using a piece of  
filter paper. The stacking gel was prepared according to Table 2.13 and added above the 
resolving gel. A well-forming Teflon comb was then inserted, and the gel was allowed to 
polymerize at room temperature. The cassette was then placed into a gel electrophoresis 
apparatus filled with running buffer before removing the wells’ comb. 5 µL of  a protein MW 
marker (BLUeye Prestained Protein Ladder, 10-250 kDa, GeneDireX, Belgium) and 20 µg 
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pre-heated protein sample were loaded. The gel was run at a constant voltage of  80 V for 
100 minutes (until the blue indicator strip reached the end).
2.9.4 Transfer of proteins to polyvinylidene fluoride membrane and membrane 
blocking
Once the SDS-PAGE was completed, the protein samples were transferred to an 
Immobilon® PVDF membrane (Merck Millipore, MA, USA) using a SemiDry system. A 
piece of  PVDF membrane cut to the same size as the resolving gel was activated in methanol 
for 5 minutes. Simultaneously, six pieces of  similarly sized filter papers were soaked in 1X
transfer buffer. Three of  these sheets were placed one at a time onto the bottom graphite 
base electrode of  an SD20 SemiDry Maxi System blotting unit (SemiDry, Wolf  Laboratories, 
York, UK). The SDS-PAGE gel cassette was removed from the tank and the glass plates 
gently pried using a scalpel and the resolving gel was carefully transferred on top of  the
PVDF membrane, alongside the remaining three sheets of  filter paper. Following removing 
air bubbles between each layer by rolling a roller over the top filter paper, electroblotting was 
carried out at a constant current of  500 mA (approximately 15 V) for 90-120 minutes. (Figure 
2.1 from Nature Protocol Exchange: https:// www.nature.com/ protocol exchange/
protocols/ 2925)
Figure 2.1: The arrangement of paper, gel and nitrocellulose membrane. A. The membrane is 
oriented nearest to the positive electrode while the gel is situated towards the negative electrode. B. 
Representative diagrams of the transfer sandwitch setup for semi-dry transfer. The SDS-bound negatively 
charged proteins with thus migrate out of the gel and onto the membrane. Source: 
https://protocolexchange.researchsquare.com/article/nprot-2925/v1
Once the transfer was completed, membranes were transferred into a universal container and 
incubated in 5% (w/v) blocking buffer (5 g of  fat-free milk powder (Marvel) in 100 mL of  
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0.1% TBS-Tween) for at least one hour to ensure non-specific binding of  the primary 
antibody. The universals were kept on a rolling platform (Wolf  Laboratories, York, UK).
2.9.5 Immuno-blotting of proteins
Primary antibodies were diluted in TBS-T according to Table 2.3. After the blocking, the 
membrane was incubated with the primary antibody at 4°C overnight with constant rotation. 
Membranes were then washed three times (5 minutes each) using 0.1% TBS-Tween with 
constant rotation. The secondary antibody was chosen according to the source of  the 
primary antibody. 2.5 µL of  HRP-conjugated secondary antibody was diluted 5 mL 0.1% 
TBS-Tween. The membrane was then incubated in the secondary antibody for 1 hour at 
room temperature with constant rotation.
Chemiluminescence was performed using a luminol/ peroxide based enhanced 
chemiluminescence (ECL) reagent (SupersignalTM West Pico, Thermo Fisher Scientific, 
Waltham, MA USA). The ECL reagent enables low picogram or high femtogram detection 
of  antigen by oxidizing luminol in the presence of  HRP and peroxide. This reaction 
produces a prolonged chemiluminescence that can be visualized on X-ray film or an imaging 
system. According to the manufacturer's instruction, 100 µL of  ECL reagent was required 
to per cm2 of  membrane area. After 5 minutes of incubation, the chemiluminescent signal 
from the HRP-conjugated antibody was detected using G: Box (Syngene, Cambridge, UK), 
composed of  an illuminator and a camera connected to a computer. Briefly, the membrane 
was placed on the black Chemiluminescence Exposure Screen. The imager calculates and 
displays the exposure time with maximum dynamic range and minimum pixel saturation. 
Images were captured and further analyzed by Image J software (National Institute of  Health, 
NY, USA, https://imagej.nih.gov/ij/, 1997-2016) for band quantification. 
2.10 Methods for cell functional assays
2.10.1 Transfection of miRNA mimic/ inhibitor into Cell Lines
Following seeding of 3 x 105 cells/well in 6-well-plate, cells were incubated until adherent. 
20 pmol of  MISSION miRNA-140-5p, miRNA-140-3p or Negative Control mimic (Sigma, 
St. Louis, USA) was transfected the cell line using 7.5 μL Lipofectamine® 3000 reagent per 
well with Opti-MEM, according to manufacturer’s instructions (Invitrogen, Thermo Fisher, 
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UK).  
2.10.2 Proliferation assay using thiazolyl blue tetrazolium bromide (MTT)
Cell proliferation in response to treatment with miRNA mimics was measured using MTT
(Sigma-Aldrich, St. Louis, MO, USA) assay. The MTT assay involves the conversion of  the 
water-soluble MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) to an 
insoluble formazan. The formazan is then solubilized, and the concentration determined by 
optical density at 570 nm. MTT solution was made by diluting 100 mg of  MTT in 20 mL of  
PBS and was filter sterilized through a 0.2 μm sterile filter (Sartorius AG, Göttingen, 
Germany) to produce a working concentration of  5 mg/mL. Following 12 hours of  
treatment of  cells with mimics or inhibitors, cells were harvested, pelleted and resuspended. 
Using 96-well-plate, 3000 cells in 100 μL of  complete media were plated per well of  six 96 
well plates using at least six repeats for each cell line and a negative control. The plates were 
incubated at 37 ˚C and 5% CO2 for a period of  12, 24, 36, 48 and 64 hours respectively. At 
each time point, 10 μL of  MTT solution was added directly to the well.  Following a 4-hour 
incubation period at 37˚C, the media was poured out gently and blotted the excess liquid 
with a piece of  tissue paper. To solubilize formazan crystals, lysis buffer was mixed by 10 g 
SDS in 100 mL H2O with 83 μL of 37% HCl under the fume hood. 100 µL of  the SDS-HCl 
lysis solution was added to each well and mixed thoroughly using the pipette. Absorbance 
was read at 570 nm (Bio-Rad 550 microplate reader; Bio-Rad Laboratories Inc., Hercules, 
CA, USA).
2.10.3 Scratch assay for migration
Migration reflects cell motility in a 2D pattern such as a basal membrane, extracellular matrix 
or on plastic plates. Via wound healing assay, the speed of  wound closure and cell migration 
can be quantified by taking snapshot pictures with a regular inverted microscope at several 
time intervals.
Sufficient cells (1x106/well) were seeded into a 6-well plate and allowed to adherent overnight 
to form a confluent monolayer in the incubator. The scratch wound was made in a linear 
fashion with a sharp sterile pipette tip and washed twice with PBS to remove floating cells. 
The cells were re-cultured in 2 mL of new media and cell migratory behaviour was
documented every 1 hour using the EVOS® Cell Imaging time-lapse microscopy system
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(Life Technologies, Paisley, UK). The size of  the wounds was subsequently measured with 
ImageJ software.
2.10.4 Transwell invasion assay
Invasive migration is a fundamental function underlying cellular processes such as 
angiogenesis, immune response, metastasis, and invasion of  cancer cells. Cell invasion assays 
monitor cell movement penetrating a barrier which consists of  basement membrane 
components.  Matrigel® (BD Biosciences, NJ USA) was used to mimic extracellular 
matrices (Figure 2.2). 
Figure 2.2: In vitro Matrigel® invasion assay. Cells seeded at the top chamber and 
chemoattractant or different cell line in the bottom chamber – outcome: number of  cells migrated to the 
bottom chamber, compared to controls. Source: Adapted from http://cellomaticsbio.com/molecule-
testing.php
2.10.5 Flow cytometry cell cycle assay
Flow cytometry was carried out for cell cycle analysis by quantitation of  DNA content. 
Propidium iodide (PI), one of  the DNA-binding dyes, is used in this analysis. Cells must be 
fixed or permeabilized to allow entry of  the dye which is otherwise actively pumped out by 
living cells. Alcohol is a dehydrating fixative which also permeabilizes. This will allow easy 
access of  the dye to the DNA and gives good profiles (low coefficient of  variation, CV). 
With fixed cells, samples may be accumulated, stained and analyzed at the conclusion of  an 
experiment. Alcohol-fixed cells are stable for several weeks at 4°C. 
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When the cells were grown to 80% confluent, cell medium and PBS used to wash cells were 
collected in labeled 20 mL universal containers (Greiner Bio-One Ltd, Gloucestershire, UK);
Meanwhile, cells were trypsinized and plated in the incubator until disassociation. Then, cells 
are harvested into universals using pre-collected cell medium and PBS to neutralize
trypsinization reaction. The suspension was centrifuged at 1500 × rpm for 5 minutes. The 
cell pellet was fixed in 10 mL iced 70% ethanol. Samples were pipetted thoroughly to ensure 
fixation of  all cells and minimize clumping and stored at 4 ˚C for 30 min or until analysis. 
Spin at 850 g in a centrifuge and spinning out of  ethanol carefully to avoid cell loss when 
discarding the supernatant. 50 µL of  a 100 µg/ml sock of  RNase was added to ensure only 
DNA, not RNA, will be stained. 200 µL PI (from 50 µg/ml stock solution) was added before 
cell cycle measurement. Flow cytometry analysis was performed on a Cyflow® flow 
cytometer (Partec, New Jersey, USA). Data were analyzed using FCS Express 4 Flow 
Research Edition (De Novo Software, California, USA). 
Gating for live cells was carried out using forward scatter area (FCS-A) and side scatters area 
(SSC-A). FCS-A measures the size whereas the SSC-A measures the cell granularity. Next 
gating for single cells was performed using the FSC-A and forward scatter height (FSC-W) 
to eliminate doublet cells (Figure 2.3) From this gate the cell cycle histogram was made using 
fluorochrome channel PerCP-CY5-5-A against cell count. From here the percentage of  cells 
in G1, S and G2 phase could be calculated (Figure 2.4).
Figure 2.3: Scattering system in FACS. Forward and side scatter data can be used to classify 
samples by size (FSC) and by internal complexity (SSC). Source: Flowcytometrynet 
https://www.flowcytometry net.com/
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Figure 2.4: Relationship between the cell cycle and the DNA histogram. Source: http:// 
flowbook.denovosoftware.com/ chapter-6-DNA-analysis
2.10.6 Cytotoxicity assays using MTT
To determine the effects of  5FU and cisplatin on cell proliferation, growth assay based on 
the enzymatic reduction of  the tetrazolium salt MTT by metabolically active cells. Cell 
growth was determined as described previously, with a few modifications. Briefly, 104 cells 
were seeded per well of  96-well plates, in 100 μL of  steroid-stripped medium (without 
additions). Cells were allowed to attach for 24 hrs, after which 8 wells were assayed 
immediately to establish time 0 (t0). To the remaining wells, 100 μL of  culture medium were 
added either alone or supplemented with increasing concentrations of 5FU (ranging from 
1.2 μM to 153.6 μM) or Cisplatin (0.78 μM to 100 μM); Cells were then incubated for 2 days
at 37 °C in the incubator. At the end of  the incubations, 10 μL of  5 mg /mL MTT were 
added to each well and cells were further incubated for 4 hr. at 37 ˚C. After carefully removing 
the medium, 100 μL of  the SDS-HCl lysis solution was added to each well and mixed
thoroughly using the pipette. Absorbance was read at 570 nm (Bio-Rad 550 microplate reader; 
Bio-Rad Laboratories Inc., Hercules, CA, USA). Wells containing medium alone served as 
blanks. The results were expressed as the mean ±standard error of  the mean (SEM) of  at 
least 3 independent experiments, each with 6 replicate wells per cell line per cytotoxic
condition.
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2.11 Statistical analysis
Transcript levels from qPCR experiments are reported as mean ± SEM unless otherwise 
stated in results. Other data are presented as mean ± standard deviation (SD). The Mann-
Whitney test was used to analyze data where medians are presented, students t-test was used 
to analyze data where means are presented. Each experiment was conducted at least 3 times
unless otherwise stated, and representative examples are shown. Unpaired t-tests and 2-way 
ANOVA tests were used to statistically analyze differences between treated and control 
groups. Differences from 3 independent repeats of  an experiment were considered to be 
statistically significant at p<0.05. 
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Chapter 3. 
The miRNAs Profiling of Gastric 
Cancer Progression
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3.1 Chapter Introduction
Chapter 1 described the importance of  miRNAs as critical regulators of  global mRNA 
expression in tumourigenesis and cancer progression. Recent miRNA expression profiling 
studies suggested the clinical use of  miRNAs as potential prognostic biomarkers in various 
malignancies. Among 2588 identified human miRNAs, 352 have been shown to be either 
increased or decreased in gastric cancer tissues compared with non-tumour adjacent mucosa, 
with 120 miRNAs reported in 2 or more of  the studies (Kuo et al. 2015; Shrestha et al. 2014). 
Upregulation of  miR-21, miR-25, miR-92, miR-223 and downregulation of  miR-375 and 
miR-148a were some of  the most consistently altered microRNAs in gastric cancer despite 
marked variability in study designs and specimen types (Shrestha et al. 2014).
Thus far, dysregulation of  miRNAs in gastric cancer has been reported to be associated with 
histology, Epstein-Barr virus infection, chemotherapy response, progression and metastasis
(Huang et al. 2015; Li et al. 2018; Kim et al. 2011; Treece et al. 2016; Katada et al. 2009).
A number of  miRNAs were further proposed to be potential prognostic biomarkers for 
gastric cancer patients, such as miR-1, miR-20b, miR-150, miR-214, miR-375, let-7g, miR-
125-5p, miR-146a, miR-218, miR-433, miR-451 and miR-200b/c (Katada et al. 2009). 
Moreover, a seven-miRNA signature (miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-
5p, and miR-126) has recently been identified as an independent predictor for relapse-free 
survival among patients with gastric cancer (Li et al. 2010).
The possible drawback of these studies, however, is that a limited number of  around 300 
microRNAs have been chosen for the custom microarrays. This is merely 10% of  the total 
number of  human microRNAs registered on miRbase. As well as limitations in the dynamic 
range, sensitivity, and specificity of  the microarray data themselves, different technological 
detection platforms, small sample size, different sample origins, and various methods 
employed for data processing and analysis may result in significant variations (Ding et al. 
2017).
With the growing power and reducing cost of  next-generation sequencing and 
bioinformatics, the launch of  TCGA, as well as other large-scale cancer genome projects,
have provided a comprehensive and multi-dimensional database of  the key genomic and 
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epigenomic changes in cancer which are readily achieved and accessed. Bioinformatic
analysis of  TCGA datasets has been shown to be an outstanding tool in identifying genetic 
and epigenetic changes related to clinical outcomes. 
The aim of  this chapter was to identify potential therapeutic target miRNAs in gastric cancer. 
In order to reduce the variables, the present study only investigated the expression RNA 
sequencing data of  gastric tissues. The miRNA dataset deposited by TCGA was used to 
identify differentially expressed miRNAs (DEMs). Then prognosis related miRNAs were 
selected according to both a generalized linear model (glm) and linear model (lm) analysis
and further confirmed via Kaplan-Meier method and log-rank test. 
3.2 Materials and methods
3.2.1 miRNA, mRNA expression profiles, and clinical information
The Illumina HiSeq profile dataset of  1881 miRNA (436 tumour samples and 41 non-
tumour samples), mRNA expression (375 tumour samples and 32 non-tumour samples) and 
corresponding clinical dataset from 443 cases were downloaded from the TCGA database 
(https://portal.gdc.cancer.gov/projects/TCGA) up to June 2017. A customized R script to 
match patients’ tumour and normal samples in the same case was applied to generate four 
tabular data files (tumour and normal each for miRNA and mRNA expression profiles) for 
gastric cancer patients.
3.2.2 Differentially expressed miRNAs (DEMs) screening
Only those mature miRNAs that had expression values in 90% of  samples were further 
evaluated. This led to a subsequent analysis of  377 mature miRNAs. The differentially 
expressed miRNAs were screened out between patient and control samples applying linear 
model fitting and eBays approach. Briefly, eBayes function uses linear fitting of  individual 
genes to build a hierarchical Bayes model, which estimates the probability of  their differential 
expressions. It uses data-defined global priors to shrink the sample variances toward a 
common value and, therefore, enhance the statistical power and accuracy. Differential 
expression analysis was performed by three approaches. At first, raw reads were analyzed 
using R package DESeq2. In order to circumvent the multiple testing problems, which may 
induce false-positive results, the Benjamin-Hochberg procedure was used to control the false
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discovery rate (FDR) by adjusting the raw P-values (Benjamini et al. 1995). miRNAs with 
Log2 fold change <-1 or >1 (P<0.05，after FDR adjusted) were considered as differentially 
expressed miRNAs and were selected. Secondly, student’s test was performed to further 
compare the difference of  miRNAs expression by measuring RPKM (reads per kilobase of  
exon model per million reads) between primary tumour samples (TP) and tissue normal 
samples (NT) in both paired manner (41 TP vs 41 NT) and unpaired manner (436 TP vs 41
NT). The DEMs for further prognostic analysis were those in the overlap of  the three groups.
3.2.3 Prognosis-related DEMs determination
Both a generalized linear model (glm) and linear model (lm) analysis were performed between 
the miRNA HiSeq dataset and OS. The miRNAs with FDR less than 0.05 and those 
possessing matching directionalities to survival in both the glm and lm analyses were 
overlapped. Finally, the miRNAs with the lowest FDR values in both analyses were chosen 
as miRNAs of  interest. The Kaplan-Meier method and log-rank test were also applied to 
further assess the clinical relevance of  16 miRNAs of  interest. Comparisons between 
patients with low and high miRNA expression were made by separating patients into low 
and high expression group based on the median value of  each miRNA’s expression. Survival 
analysis was performed using GraphPad Prime v 6.0 (GraphPad Software, San Diego, CA). 
Log-rank P＜0.05 was considered statistically significant.
3.3 Results
3.3.1 Demographics study
A total of  443 gastric cancer patients were enrolled in this study. 41 had paired tissues 
examined in TCGA, while 402 had only tumour samples available. The characteristics of  the
subsets of  41 paired cancer tissues with adjacent normal mucosa or 402 cancer tissues 
without matched normal mucosa are listed in Table 3.1. No significant differences were 
observed between these two groups in the distribution of  age (P=0.73, Fisher’s exact test) 
and gender (P=0.1, Fisher’s exact test). TCGA is comprised of  a multi-race population. More 
than half of  the samples obtained were White, 20% were Asian and the remainder were
Black or African and native Hawaiian or other Pacific Islanders (P=0.61, Fisher’s exact test). 
All gastric cancer cases in this study were adenocarcinomas. However, the distribution of  
tumour stage and the primary treatment response rate differed between the two groups. The 
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percentage of  stage II patients in the paired and unpaired group are 46.34% and 27.61%, 
respectively; In contrast, the stage III patients in the first and second group are 19.51% and 
43.53%, respectively. Similarly, the percentage of  patients presenting stable disease in paired 
group is 29.27%, compared to 13.18% in the unpaired group. We thus further performed
three different algorithms including paired and unpaired analyses.
Table 3.1: Patients’ demographics: characteristics of  gastric cancer patient with paired tumour tissues 
and normal samples or with only tumour tissues. NA, not available. P values were calculated by Fisher’s 
exact test.
Variable
Gastric cancer patients 
with paired tissues 
(n = 41), n (%) 
Gastric cancer patients 
with only tumour tissue
(n = 402), n (%) 
P value
Gender 0.73
Male 25 (60.98) 260 (64.68)
Female 16 (39.02) 142 (35.32)
Age (years) 0.51
≥65 26 (63.41) 227 (56.47)
＜65 15 (36.59) 170 (42.29)
NA 5 (1.24)
Race 0.61
Asian 10 (24.39) 79 (19.65)
Black or African 1 (2.44) 12 (2.99)
White 22 (53.66) 255 (63.43)
NA 8 (19.51) 56 (13.68)
H. pylori infection 0.20 
Yes 1 (2.44) 19 (4.73)
No 11 (26.83) 157 (39.05)
NA 29 (70.73) 226 (56.22)
Histology 0.63
Intestinal 15 (36.59) 176 (43.79)
Diffuse 8 (19.51) 77(19.15)
NA 18 (43.90) 149 (39.07)
TNM stage 0.01
I 9 (21.95) 50 (12.44)
II 19 (46.34) 111 (27.61)
III 8 (19.51) 175 (43.53)
IV 4 (9.76) 40 (9.95)
NA 1 (2.44) 26 (6.47)
Lymph-node status 0.36
No metastasis 16 (39.02) 116 (28.86)
Metastasis 24 (58.54) 268 (66.67)
NA 1 (2.44) 18 (4.47)
Primary therapy outcome 0.04
Complete remission 20 (48.78) 221 (54.98)
Partial Remission 0 (0.0) 6 (1.49)
Stable or progressive 12 (29.27) 53 (13.18)
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NA 9 (21.95) 122 (30.35)
Recurrence 0.10
Yes 5 (12.20) 107 (26.62)
NO 26 (63.41) 234 (58.21)
NA 10 (24.39) 61(15.17)
3.3.2 Screening of DEMs
We evaluated samples by cluster analysis and searched for miRNAs with altered expression 
in primary tumour samples (TP) and tissue normal samples (NT) using different expression 
analyses. At first, we conducted one-way hierarchical clustering analysis using Principal
Component Analysis to verify correct segregation of  patients’ and control samples (Figure 
3.1) and observed that libraries of  three normal tissues clustered with tumour samples, 
however, several tumour samples clustered with normal samples. The linear fitting model
assuming the common dispersion for all the miRNAs revealed that not only one cluster 
distributed in either tumour samples or neighbouring normal tissues (Figure 3.2). Generally,
the miRNAs exhibited heterogeneous between tumours and normal tissues and harboured 
homogeneity among tumours or normal tissues.
Figure 3.1: Cluster analysis. One-way hierarchical clustering using Principal Component Analysis 
(PCA) to verify the correct segregation of  patients’ and control samples in the miRNA-Seq analysis. PCA 
summarizes the major variation that is contained in many dimensions into a reduced number of  
uncorrelated dimensions. Two principal components which identified those variables that express a large 
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amount of  variation (25% and 18% respectively) were chosen to represent the difference between TP and 
NT. The plot on the first 2 principal components shows an interesting separation of  the NT group along 
the first component. PC1 denotes principal component 1, PC2 denotes principal component 2.
Next, we employed three differential expression analyses with both raw data and normalized 
data to identify miRNAs with altered expression between gastric cancer tissues and non-
cancerous tissues. We used the DESeq2 package which bases the estimation of  the dispersion 
on calculated mean-variance relationships in the dataset provided. It is thought to be a 
powerful method for analysing RNA-Seq data (Bencurova et al. 2017). DESeq2 identified 
288 differentially expressed miRNAs. Paired t-test and unpaired t-test identified 321 and 304
deregulated miRNAs respectively (Figure 3.3). The overlap analysis generated 207 
differentially expressed miRNAs, among which 65 miRNAs were downregulated and 142 
miRNAs were upregulated (Appendix 8). These candidate miRNAs are chosen to study 
further.
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Figure 3.2: Differences comparison based on miRNAs and Correlations. The 
differentially expressed miRNA pattern in paired tissue samples was further demonstrated in an eBayes
based linear model. The labels adjacent to the heatmap far right column and bottom row were used to 
denote a label for each sample. In this plot the distance between labels (samples) corresponded exactly to 
the colours of  the dendrogram clusters. The darker the square was, the closer the compared samples were. 
Four TP patterns and three NT patterns were subgrouped according to their general distances for all 
miRNAs examined. .
Figure 3.3: Significantly deregulated miRNAs in student’s t-tests (P＜0.00001). A. Unpaired t-test analysis between 436 primary gastric cancer tissues and 
matched normal stomach tissues. B. Paired t-test analysis. Error bars represent standard error.
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3.3.3 DEMs associated with Overall Survival of gastric cancer patients
Prediction of  survival is one of  the main functions of  prognostic biomarkers. Both the glm 
and lm function of  R was applied to identify prognostically relevant miRNAs in gastric 
cancer. In the glm analysis, the expression revealed 37 mature miRNAs were correlated with 
gastric cancer patient’s survival (FDR<0.05). The lm analysis revealed 18 such miRNAs. The 
directionality of  the two lists of  miRNAs was compared and overlapped to yield 16 common 
miRNAs (Table 3.2). High expression of 10 miRNAs (hsa-mir-549a, hsa-mir-514a-1, hsa-
mir-21, hsa-mir-514a-3, hsa-mir-4326, hsa-mir-493, hsa-mir-34b, hsa-mir-1255a, hsa-mir-455 
and hsa-mir-671) were correlated with poor prognosis. Six miRNAs (hsa-mir-140, hsa-mir-
328, hsa-mir-193a, hsa-mir-28, hsa-mir-129-2 and hsa-mir-5683) were positively associated 
with better OS rate. Furthermore, we performed an unpaired t-test for each miRNA to 
compare their expression in different stage tumours, and we found miR-21, miR-140, miR-
193a and miR-4326 showed significant correlation with gastric cancer progression (Figure 
3.4).
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Figure 3.4: Stage-related miRNAs in student’s t-tests. Statistical analysis compared the 
miRNAs’ expression between stage I-II and stage III-IV, the results revealed miR-21 and miR-140 are 
both significantly and positively correlated with gastric cancer stage. Shown are representative results of  
unpaired t-test analysis. Error bars represent standard error. **** represent p<0.0001 and * represents 
p<0.05.
Table 3.2: Prognostic related miRNAs. Information on 16 miRNAs associated with OS of  gastric cancer patients. Derived from the overlap result of glm analysis and 
lm analysis. 
miRNAs Mean Log2 fold change Expression comparison P value Prognosis P value
hsa-mir-549a 2.297475 2.954531 6.19E-13 0.027
hsa-mir-514a-1 1.900981 2.093362 2.99E-06 0.007
hsa-mir-21 974536.9 1.878363 8.95E-74 0.005
hsa-mir-514a-3 1.897514 1.752371 7.48E-05 0.023
hsa-mir-4326 33.39163 1.278167 1.28E-07 0.007
hsa-mir-493 49.48034 0.874156 3.09E-10 0.032
hsa-mir-34b 3.388662 0.869264 0.000187 0.031
hsa-mir-1255a 1.896506 0.860887 0.005471 0.022
hsa-mir-455 874.2628 0.779891 3.41E-05 0.007
hsa-mir-671 24.5909 0.708348 1.21E-08 0.031
hsa-mir-140 3622.466 -0.9567 4.58E-19 0.046
hsa-mir-328 66.30372 -0.99735 2.41E-11 0.03
hsa-mir-193a 624.3456 -1.14638 1.28E-19 0.044
hsa-mir-28 21953.87 -1.17633 2.77E-23 0.021
hsa-mir-129-2 20.10709 -1.60691 7.94E-08 0.011
hsa-mir-5683 16.02191 -2.88421 6.49E-19 0.028
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3.4 Discussion
The data presented here, and previous literature have suggested miRNAs are deregulated in 
gastric cancer and even indicate distant or progressive disease. In this study, comparisons 
between gastric cancer samples and normal stomach tissues from TCGA dataset generated 
207 differentially expressed miRNAs in line with the studies from Ding et al. (Ding et al. 
2017) and Shrestha et al. (Shrestha et al. 2014). (Table 3.3).
Table 3.3: Consistently deregulated miRNAs in three independent studies. This table shows 
the 12 deregulated miRNAs which feature in all three studies. Dark grey= those miRNAs which were 
downregulated in at least two of  three studies. Light grey= those miRNAs were upregulated in two of  
three studies. No colour= those miRNAs showed contrary expression patterns in the systematic review 
comparing to those in the other 2 studies. FC stands for fold change.
Current study Ding et al. Shrestha et al.
miRNA log2 FC miRNA logFC hsa-miRNA Median FC
hsa-mir-490 -3.3 hsa-mir-490 -4.8 hsa-mir-133b -2.40
hsa-mir-133b -2.8 hsa-mir-133b -3.4 hsa-mir-139 -1.84
hsa-mir-139 -2.3 hsa-mir-139 -2.6 hsa-mir-490 -1.51
hsa-mir-29c -1.8 hsa-mir-100 -1.5 hsa-mir-29c -1.32
hsa-mir-100 -1.3 hsa-mir-29c -1.5 hsa-mir-188 -
hsa-mir-200b 1.2 hsa-mir-19a 1.2 hsa-mir-135b 0.67
hsa-mir-188 1.5 hsa-mir-335 1.2 hsa-mir-100 1.09
hsa-mir-19a 1.6 hsa-mir-200b 1.5 hsa-mir-18a 1.18
hsa-mir-335 1.6 hsa-mir-21 1.5 hsa-mir-200b 1.31
hsa-mir-21 1.9 hsa-mir-188 1.6 hsa-mir-335 1.97
hsa-mir-18a 2.1 hsa-mir-18a 1.8 hsa-mir-19a 2.00
hsa-mir-135b 3.3 hsa-mir-135b 3.2 hsa-mir-21 2.02
We found that miR-490 was the most pronounced downregulated miRNAs followed by miR-
1/-133 family, miR-139 and miR-383. The miR-196 family and miR-21 were the most 
commonly and significantly upregulated miRNAs in gastric cancer. miR-490 and miR-1/133 
family were found to be involved in the multistage cascade of  gastric carcinogenesis (Shen 
et al. 2015). Upregulated miR-196a in gastric cancer promoted cell proliferation by 
downregulating p27(kip1) (Sun et al. 2012). In addition, increased circulating miR-196a in 
patient serum was associated with gastric cancer disease status and relapse (Tsai et al. 2012). 
Co-activation of  miR-196b and HOXA10 characterized a poor-prognosis subgroup of  
patients with gastric cancer (Lim et al. 2013), in which miR-196b decreased levels of  E-
cadherin, but drastically induced vimentin, MMP2, and MMP9, implying activation of  EMT
(Liao et al. 2012). miR-21 has been identified as the best hit in a number of  medium-scale 
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and high-scale profiling experiments designed for the detection of  miRNAs dysregulated in 
cancer (Chan et al. 2005). In a large-scale profiling of  miRNA expression in 540 human 
samples derived from 363 specimens representing six types of  solid tumours and 177 
respective normal control tissues, miR-21 was the only miRNA up-regulated in all types of  
the analysed tumours, including breast, colon, lung, pancreas, prostate, and stomach(Volinia 
et al. 2006). Generally, miR-21 expression levels are also very high in most cancer cell lines 
of  various origins, and in some lines, it accounts up for 15-25% of  the cellular miRNA 
content (Landgraf  et al. 2007). Therefore, abundant miR-21 may be a general, albeit not 
universal, feature of  tumour cells. 
Based on these deregulated miRNAs, we further explored which of  them were significantly 
correlated with patients’ survival. The analysis revealed 16 miRNAs among which miR-140-
5p, miR-328, miR-193a, miR-28 miR-129-2 and miR-5683 potentially acted as tumour 
suppressors and were positively correlated with better survival. Although their 
downregulation has been demonstrated in gastric cancer (Kim et al. 2011, Huo 2017), their 
roles in disease progression and prognosis remained to be defined by more evidence from in 
vitro and in vivo studies. Since miR-21 and miR-140 showed significant differences in 
expression between early and advanced gastric cancer, and miR-21 has been widely examined 
and demonstrated in various disease, including gastric cancer, we selected miR-140-5p for 
further analysis. It is worth noting that though miR-140-5p was downregulated in tumour 
tissues compared to normal samples, its downregulation correlated with gastric cancer 
progression but only reached a boundary statistic value. However, a higher level of  miR-140-
5p was more likely to appear in advanced gastric cancer tissues, reflecting its multiple 
identities in gastric cancer progression. Moreover, Kim et al. demonstrated that higher miR-
140-5p in tumour samples from chemo-treated gastric cancer patients were correlated with 
chemosensitivity (Kim et al. 2011). miR-140-5p is well established to have decreased 
expression in many forms of  cancer including; lung, breast, and colon et al. Most of  the 
functional pathways influenced by miR-140-5p have so far implicated it in tumour-
suppressing, these included SOX9 and ALDH1, which were significantly activated in CSCs. 
miR-140-5p could also target IL-6, which activates STAT3 signalling supports the self-
renewal activity of cancer cells. The role of  miR-140-5p in gastric cancer is yet to be 
established. To define the role of  miR-140-5p in gastric cancer, the next step is to perform 
quantitive analysis of  miR-140-5p expression level on independent human gastric cancer 
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cohort with a view to identifying whether miR-140-5p are deregulated in gastric cancer and 
its correlation with clinicopathological features.
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Chapter 4. 
Expression of miR-140-5p and miR-
140-3p in Gastric cancer and Their
Clinical Relevance
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4.1 Chapter Introduction
The human mir-140 primary transcript generates two mature miRNAs, miR-140-5p and 
miR-140-3p. Initially reported in zebrafish, miR-140-5p and miR-140-3p are evolutionarily 
conserved among vertebrates suggesting that these miRNAs occupy an important biological 
role. Their expression in chondrocyte differentiation and cartilage tissue homeostasis is well 
documented (Hong and Reddi 2013). Generally, the precursor microRNAs are designated 
mir (lower case r) as in mir-140, whereas the mature microRNAs are designated miR (upper 
case R). When relative expression levels are known the microRNA with low expression (i.e., 
the degraded strand) is designated by an asterisk, as in miR‐140*, which in this case is the 
same as miR-140-3p. However, miR-140-5p and miR-140-3p like many other miRNAs, the 
abundance of  the -5p and -3p stands are different according to tissues type or species
(Ambros et al. 2003; Griffiths-Jones et al. 2006; Gibson and Asahara 2013; Kenyon et al. 
2019). Although miR-140-5p and miR-140-3p have identical seed sequences, the roles of
miR-140-5p and miR-140-3p are complementary to one another in chondroplasia (Kenyon 
et al. 2019; Tao et al. 2017), in the development of  Rheumatoid Arthritis and other 
autoimmune disease (Peng et al. 2016; Li et al. 2017) and in cancer progression as well
(Flamini et al. 2017; Kong et al. 2015; Li and He 2014). We thus tried to explore the 
expression pattern of  both miR-140-5p and miR-140-3p in the current study. It has been 
reported that miR-140-5p and -3p appear to function as either tumour-suppressing or 
tumour-promoting factors in cancer progression. It is clear that a large number of  cellular 
context-dependent factors contribute to the dynamic regulatory roles of  miR-140-5p/3p. 
Against this background, the rest part of  this study aimed to examine the role of  miR-140-
5p and 3p in gastric cancer. The first objective was set to determine their deregulation pattern 
by comparing tumour samples and adjacent non-tumour tissues in an independent cohort. 
In this chapter, we aimed to explore the expression and association of  miR-140-5p and miR-
140-3p using in Silico analysis and qPCR detection in an independent cohort and to associate 
such expression with the clinical pathological characteristics of  gastric cancer patients.
4.2 Materials and methods
4.2.1 Tissue samples from two independent gastric cancer patients’ cohorts.
The collection of  tissue samples has been described in Chapter 2. The first cohort (n=70), 
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composed of  gastric cancer patients who did not receive any treatment before sample 
collection, were used to compare miR-140-5p and -3p expression between stomach tumour 
and non-tumour samples, and their association with disease progression such as tumour size, 
metastasis status and patients’ OS. The second cohort was made of  87 patients who received 
5FU based neoadjuvant chemotherapy, the comparison would be mainly between patients’ 
tumour samples with chemoresponse and those without response from chemotherapy. 
4.2.2 RNA extraction and miR-140-5p/3p detection
RNA was extracted using TRI Reagent® See 2.8.1; The reverse transcription for mature 
miRNA quantification was performed using TaqMan™ Advanced miRNA cDNA Synthesis 
Kit and qPCR was performed using miR-140-5p and miR-140-3p assay with triplicate 
reactions for each sample. miR-423-5p was used as the endogenous control. See 2.8.8.
4.2.3 Statistical analysis
Associations between miR-140-5p/3p expression and clinical characteristics were assessed 
with either the Student’s t-test, One-way ANOVA or Mann-Whitney test. The predicted 
probability of  survival with gastric cancer was used as a surrogate marker to establish the 
ROC curve. The Kaplan-Meier method and log-rank test were used for describing the 
survival curve. The area under the curve (AUC) was used as an accuracy index for evaluating 
the predictive performance of  the selected miRNA signature. Univariate Cox regression 
analysis was used to evaluate the hazard ratio (HR) of  miRNA and clinical variables for 
patient survival. Multivariate Cox regression analysis was conducted to test for independent 
prognostic factors of  OS, which was defined as the time from the operation date to the date 
of  death or final follow-up. Student’s t-test, One-way ANOVA or Mann-Whitney test were 
performed using the statistical software Prism 6.0 (GraphPad Software, San Diego, CA 
Software, La Jolla, CA), and all the other statistical tests were performed with SPSS version 
23.0. Statistical significance was defined as p<0.05.
4.3 Results
4.3.1 In Silico analysis of miR-140-5p expression in gastric cancer 
Using the normalized data from RNAseq in TCGA cohort (released June 2017), in which 
only miR-140-5p was available, the expression of  miR-140-5p in gastric cancer was first 
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evaluated by determining its levels based on the comparison between gastric cancer (n=435) 
and the paired adjacent non-tumour gastric tissues (n=41). Clinical and pathological 
information together with average miR-140-5p expression level is shown in Table 4.1. 
Compared to adjacent normal tissues miR-140-5p reduced in gastric tumours (P=0.048) 
(Table 4.1 and Figure 4.1). 
Figure 4.1: The miRNA-140-5p expression between NT and TP. A. Paired analysis showed 
a significant decrease trend in primary tumour tissue compared to adjacent normal sample. B. Unpaired
analysis between gastric cancer and normal tissues showed a general decline of  miR-140-5p in gastric 
cancer tissues as well.
Compared to diffuse type gastric cancers, a lower level of  miR-140-5p was shown in intestinal 
type gastric cancer tissue samples (P=0.11), and it could be even lower in poorer 
differentiated intestinal gastric cancers (P=0.14) or gastric cancers with metastasis (P=0.03). 
A relatively higher expression of  miR-140-5p was observed in tumours from younger 
patients (P=0.16), and higher miR-140-5p was correlated with advanced tumour stage in the 
whole patient group and those with tumour metastases in the intestinal type of  gastric cancer
(Table 4.1).
Table 4.1: miR-140 expression in gastric cancer cohort from TCGA.
Whole (n=435) Intestinal type (n=186) Diffuse type (n=72)
N Mean ± SEM P value N Mean ± SEM P value N Mean ± SEM P value
0.048 0.232 0.404
Tumour 435 865.5 ± 14.86 186 873.1 ± 28.41 72 965.2 ± 53.81
Normal 41 962.5 ± 22.61 15 999.0 ± 112.8 3 1188 ± 49.56 
Gender 0.701 0.401 0.784
Male 280 870.8 ± 23.83 124 890.3 ± 37.95 42 952.7 ± 65.63 
Female 155 855.7 ± 30.87 62 839.5 ± 38.94 30 982.9 ± 92.03
Age 0.161 0.792 0.694
≥65 247 839.4 ± 24.73 115 876.7 ± 38.78 28 992.1 ± 77.31
＜65 183 893.3 ± 29.53 68 860.9 ± 41.70 44 948.2 ± 73.61
Differentiation 0.163 0.135 0.751
High-Moderate 107 794.8 ± 86.94 101 940.4 ± 45.24 2 1073 ± 206.8
Poor 280 887.8 ± 24.37 81 850.6 ± 35.74 70 977.3 ± 50.28 
Histology 0.224
Intestinal 186 873.3 ± 28.41
Diffuse 72 965.2 ± 53.81 0.106
Signet ring type 11 968.0 ± 78.44 0.984
TNM staging 0.048 0.436 0.995
1-2 185 837.0 ± 24.81 70 847.7 ± 37.78 28 953.2 ± 84.65 
3-4 223 914.3 ± 29.00 113 893.4 ± 39.62 40 952.5 ± 66.10
Node status 0.927 0.738 0.492
Node negative 128 878.6 ± 36.31 49 892.4 ± 55.86 9 616.5 ± 25.55
Node positive 288 874.8 ± 22.80 131 870.6 ± 33.90 33 657.5 ± 29.85
Metastasis 0.099 0.032 0.967
Yes 30 981.7 ± 85.90 14 1086 ± 154.4 8 958.9 ± 142.1
No 402 858.8 ± 19.30 172 856.0 ± 27.83 64 966.0 ± 58.23 
Clinical outcomes 0.885 0.703 0.555
Alive 264 863.2 ± 24.81 115 864.8 ± 38.11 44 990.8 ± 69.56
Dead 171 868.8 ± 28.96 71 887.2 ± 41.95 28 925.1 ± 85.86
Primary therapy response 0.912 0.858 0.7839
Complete/ Partial Remission 244 910.9 ± 26.33 105 908.7 ± 40.92 38 984.0 ± 67.37 
Stable / Progressive Disease 89 905.3 ± 40.47 41 921.9 ± 54.68 22 950.0 ± 113.2
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We then analyzed the association of  miR-140-5p expression level with OS in gastric cancer
patients. Since adjacent normal samples’ transcriptional levels likely provided complementary 
information on patient survival, the expression level changes of  miRNAs between tumour
and paired nontumour samples may be more correlated with cancer relapse and survival than 
absolute expression levels in tumour samples alone (Huang et al. 2016). Receiver operating
characteristic (ROC) curves were further employed to calculate the optimal cut-off  value for 
miR-140-5p in discriminating tumour tissues from non-tumour samples. The areas under the 
curve (AUC) were 0.576 (95% confidence interval (CI): 0.484 to 0.668, p=0.108). According
to the analysis result, > 964.3 was set as cut off  value for miR-140-5p overexpression, the 
other way around was set as miR-140 low expression (Figure 4.2). 
Figure 4.2: miR-140-5p expression in gastric cancer. A ROC curve of  miR-140-5p as 
discriminators between gastric cancer and normal tissues. B.C.D. Comparisons of  miR-140-5p 
expression in whole patients and patients’ different subtypes of  gastric cancer.
Prognosis differed between patients with low miR-140-5p expression and those with high 
miR-140-5p expression. Kaplan-Meier curve and log-rank analysis showed that low miR-
140-5p expression positively correlated with poor gastric cancer patients’ survival (OS: HR, 
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1.42; 95% CI, 1.01 to 1.91; P < 0.001 Figure 4.3 A; DFS: HR, 1.456; 95% CI, 0.9918 to 2.081; 
P=0.056 Figure 4.4 A). This observation was also shown in the intestinal subtype of  gastric 
cancer (OS: HR, 1.70; 95% CI, 0.9958 to 2.901; P=0.121 Figure 4.3 B; DFS: HR, 1.418; 95% 
CI, 0.8000 to 2.480; P=0.24 Figure 4.4 B), but not in those with diffuse subtype (Figure 4.3 
C, 4.4 C). 
Figure 4.3: Kaplan–Meier OS analysis for patients with miR-140-5p high or miR-140-
5p low gastric cancer tissues. A. In the analysis included total patients, patients with high miR-140-
5p expression (median survival 46.9 months) showed better OS versus low miR-140-5p expression in 
gastric cancer tissues (median survival 26.08 months). B. The analysis for patients with the intestinal type 
of  gastric cancer showed a similar trend, a better clinical outcome for patients with higher miR-140-5p 
expression (median survival 58.23 months) compared to those with miR-140-5p lower expression (median 
survival 34.26 months). C. For patients with the diffuse type of  gastric cancer, there is no significant 
difference between patients with higher miR-140-5p and those with lower miR-140-5p. Abbreviations:
INT, intestinal type of  gastric cancer; Diff, diffuse type of  gastric cancer.
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Figure 4.4: Kaplan–Meier DFS analysis for patients with miR-140-5p high or miR-
140-5p low gastric cancer tissues. A. The analysis included total patients, with almost approached 
significance, patients with high miR-140-5p expression (undefined) tended to show better DFS versus low 
miR-140-5p expression in gastric cancer tissues (median survival 38.9 months). B. The analysis for patients 
with the intestinal type of  gastric cancer showed a similar trend, a better clinical outcome for patients with 
higher miR-140-5p expression (undefined) compared to those with miR-140-5p lower expression (median 
survival 45.2 months). C. For patients with the diffuse type of  gastric cancer, higher miR-140-5p (median 
survival 24.21 months), however, indicated shorter DFS; Those patients with lower miR-140-5p exhibited 
a longer DFS (median survival 55.06 months). Abbreviations: INT, intestinal type of  gastric cancer; Diff, 
diffuse type of  gastric cancer.
We further compared the OS for two different histological groups of  patients-there was no 
statistically significant difference in OS between patients with the diffuse type or with the 
intestinal type of  gastric cancer (Figure 4.5 A). However, when we combined the 
discrimination of  miR-140-5p expression, patients with intestinal type and higher miR-140-
5p expression showed the best OS, whereas patients with intestinal type and lower miR-140-
5p expression showed a worse OS (Figure 4.5 B). 
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Figure 4.5: Kaplan–Meier survival analysis for patients with different histological 
types and different miR-140-5p expression. A. The comparison between gastric cancer patients 
with intestinal subtype or with diffuse subtype showed no significant differences statistically. B. Although 
the comparison did not statistical significantly difference, gastric cancer patients with intestinal subtype 
and high miR-140-5p expression showed the best survival with undefined median survival. Individuals 
with diffuse type but high miR-140-5p expression showed a poor OS.
141
The multivariate Cox regression forward stepwise likelihood ratio (LR) analysis for the whole 
patients showed TNM stage, age, tumour differentiation, miR-140-5p expression and 
primary treatment response provided independent prognostic information (Table 4.2). 
Table 4.2: Cox regression analysis for comparison of gastric cancer patients OS.
Abbreviations: HR, hazard ratio; EGJ, esophagogastric junction.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI P HR 95% CI P
Stage 0.01 0.02
Stage I 0.23 0.08-0.64 0.01 0.24 0.08-0.69 0.01
Stage II 0.36 0.17-0.76 0.01 0.34 0.15-0.74 0.01
Stage III 0.60 0.33-1.11 0.10 0.47 0.24-0.91 0.03
Stage IV reference
Age 0.09 0.01
＜65 0.68 0.43-1.07 0.54 0.34-0.85
≥ 65 reference
Differentiation 0.06 0.01
Well to moderate 0.66 0.41-1.02 0.49 0.30-0.81
Poor reference
Primary treatment <0.001 <0.001
Non-response 3.661 2.352-5.699 3.57 2.26-5.64
Response reference
miR-140-5p 0.07 0.02
High expression 0.65 0.41-1.03 0.58 0.31-0.83
Low expression reference
Gender 0.52
Male 1.16 0.74-1.83
Female reference
Histology 0.16
Intestinal type 0.44 0.19-1.03 0.06
Diffuse type 0.49 0.20-1.20 0.12
Signet ring type reference
Anatomical site 0.64
EGJ 0.34 0.40-2.15 0.23
Funds 0.64 0.23-1.53 0.28
Body 0.88 0.44-1.71 0.68
Antrum reference
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Higher TNM stage, older age, lower tumour differentiation grade and miR-140-5p low 
expression were significantly associated with poorer OS, while patients with response to 
primary chemotherapy treatment response were associated with better OS. In the DFS 
analysis (Table 4.3), patients’ responses to primary chemotherapy treatment and miR-140-5p 
status were both independent factors. Chi-square was used to further clarify the association 
between miR-140-5p suppression and clinical, characteristics (Table 4.4). We found that 
decreased miR-140-5p significantly correlated with tumour histology, and distant metastasis. 
Table 4.3: Cox regression analysis for comparison of gastric cancer patients DFS.
Abbreviations: HR, hazard ratio; EGJ, esophagogastric junction.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI P HR 95% CI P
Primary treatment <0.001 <0.001
Non-response 6.83 4.17-11.12 7.23 4.39-11.91
Response reference
miR-140-5p 0.26
High expression 0.76 0.48-1.21 0.60 0.36-0.98 0.04 
Low expression reference
Stage 0.09 0.51
Stage I 0.29 0.11-0.78 0.01 0.53 0.18-1.46 0.21
Stage II 0.54 0.26-1.13 0.10 0.80 0.36-1.78 0.59
Stage III 0.59 0.31-1.12 0.11 0.66 0.34-1,28 0.22
Stage IV reference reference
Age 0.53
＜65 1.16 0.73-1.82
≥ 65 reference
Differentiation 0.67
Well to moderate 0.91 0.57-1.43
Poor reference
Gender 0.15 0.08
Male 1.44 0.88-2.35 1.57 0.93-2.62
Female reference reference
Histology 0.18 0.15
Intestinal type 0.47 0.19-1.18 0.11 0.72 0.27-1.92 0.56
Diffuse type 0.63 0.24-1.67 0.35 1.21 0.43-3.40 0.72
Signet ring type reference reference
Anatomical site 0.30
EGJ 0.30 0.04-2.32 0.24
Funds 0.74 0.32-1.67 0.46
Body 1.10 0.58-2.10 0.77
Antrum reference
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Table 4.4: Relationship between miR-140-5p suppression and clinicopathological features in 
gastric cancer patients.
miR-140-5p suppression Chi-
square
Pa
Positive (%) Negative (%)
Gender 0.64 0.52
Male 97(34.6) 183(65.4)
Female 49(31.6) 106(68.4)
Age(years) 0.53 0.59
≥65 79(32.0) 168(68.0)
<65 63(34.4) 120(65.6)
Tumour location 1.45 0.15
Cardia 30(28.0) 77(72.0)
Non-cardia 110(35.7) 198(64.3)
Histology 4.57 0.03
Intestinal 62(33.33) 124(66.67)
Diffuse 30(41.67) 42(58.33)
Signet ring type 7(63.6) 4(36.4)
Differentiation 1.19 0.23
Well-moderate 51(30.7) 115(69.3)
Poor 91(35.0) 169(65.0)
Depth of invasion 0.63 0.53
T1-T2 34(29.8) 80(70.2)
T3–T4 112(36.0) 199(64.0)
Lymph node involvement 0.57 0.57
No 47(36.4) 82(63.6)
Yes 97(33.6) 192(66.4)
Distant metastasis 1.945 0.05
No 131(32.6) 271(67.4)
Yes 15(50.0) 15(50.0)
TNM stage 0.70 0.87
I 22(38.6) 35(61.4)
II 42(32.8) 86(67.2)
III 62(34.4) 118(65.6)
IV 16(37.2) 27(62.8)
Primary treatment response 0.48 0.63
Yes 92(37.7) 152(62.3)
No 31(34.8) 58(65.2)
aChi -square test
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We then performed Cox univariate and multivariate analyses in intestinal gastric cancer and 
diffuse gastric cancer separately. Primary treatment response was a critical independent 
protective factor in all groups. The results of  intestinal-type gastric cancer patients’ group 
revealed miR-140-5p expression was an independent prognosis factor in both OS analysis 
and DFS analysis. Patients with tumour located in the body of  the stomach were more likely 
to have longer DFS survival than gastric cancer patients with tumour located at other sites 
(Table 4.5 and 4.6). In the Chi-square analysis, miR-140-5p suppression showed a positive 
trend in a relationship with lymph node involvement, distant metastasis, and tumour stage, 
but it did not reach statistical significance.
Table 4.5: Cox regression analysis for comparison of the intestinal type of gastric cancer 
patients OS. Abbreviations: HR, hazard ratio; EGJ, esophagogastric junction.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI P HR 95% CI P
Primary treatment <0.001 <0.001
Non-response 3.08 1.83-5.18 3.261 1.90-5.59
Response reference
miR-140-5p 0.01
High expression 0.52 0.30-0.88 0.57 0.33-0.99 0.05 
Low expression reference
Stage 0.02 0.01
Stage I 0.10 0.02-0.43 <0.001 0.08 0.02-0.35 <0.001
Stage II 0.45 0.21-0.96 0.04 0.42 0.19-0.93 0.03
Stage III 0.72 0.39-1.33 0.30 0.57 0.28-1.16 0.12
Stage IV reference
Age 0.03 <0.001
＜65 0.55 0.32-0.93 0.39 0.22-0.68
≥ 65 reference
Differentiation 0.61 0.01
Well to moderate 0.61 0.38-0.98 0.51 0.31-0.87
Poor reference
Gender 0.40
Male 0.81 0.50-1.32
Female reference
Anatomical site 0.82
EGJ 0.61 0.24-1.59 0.31
Funds 0.75 0.36-1.59 0.46
Body 0.94 0.58-1.60 0.83
Antrum reference
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Table 4.6: Cox regression analysis for comparison of the intestinal type of gastric cancer 
patients DFS. Abbreviations: HR, hazard ratio; EGJ, esophagogastric junction.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI P HR 95% CI P
Primary treatment <0.001 <0.001
Non-response 7.06 3.84-12.95 7.74 3.84-12.95
Response reference
miR-140-5p 0.15 0.03 
High expression 0.66 0.37-1.17 0.52 0.29-0.93
Low expression reference
Stage 0.09 0.44
Stage I 0.17 0.05-0.61 <0.001 0.67 0.08-5.41 0.71
Stage II 0.53 0.23-1.24 0.15 0.33 0.09-1.21 0.10
Stage III 0.64 0.31-1.29 0.21 1.08 0.45-2.57 0.87
Stage IV reference
Age 0.58
＜65 1.17 0.68-2.00
≥ 65 reference
Differentiation 0.79
Well to moderate 1.08 0.62-1.89
Poor reference
Gender 0.70
Male 1.12 0.62-2.02
Female reference
Anatomical site 0.41
EGJ 0.69 0.28-1.70 0.42
Funds 0.85 0.39-1.82 0.67
Body 0.51 0.27-1.00 0.05
Antrum reference
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Male patients with diffuse-type gastric cancer had a shorter DFS and OS than female (Table 
4.7 and 4.8). Additionally, the analysis also implied that diffuse type of  gastric cancer patients 
with a fundus tumour had a risk of  death approximately twice higher compared to those 
with tumours at other sites. Different from the intestinal type of  gastric cancer, miR-140-5p 
downregulation in the contingency analysis was positively correlated with local infiltration 
depth of  tumour; Similarly, low levels of  miR-140-5p were seen in tumours depending on
their differentiation and in patients with older age but lacked statistical significance (Table 
4.9 and 4.10).
Table 4.7: Cox regression analysis for comparison of diffuse type of gastric cancer patients 
OS. Abbreviations: HR, hazard ratio; EGJ, esophagogastric junction.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI P HR 95% CI P
Primary treatment <0.001 <0.001
Non-response 4.78 2.05-11.37 4.78 2.01-11.37
Response reference
miR-140-5p 0.93
High expression 0.97 0.44-2.11
Low expression reference
Stage 0.11 0.26
Stage I 0.31 0.07-1.39 0.13 0.53 0.11-2.55 0.43
Stage II 0.19 0.05-0.73 0.02 0.27 0.07-1.03 0.06
Stage III 0.40 0.13-1.24 0.11 0.39 0.13-1.23 0.11
Stage IV reference
Age 0.42
＜65 0.72 0.33-1.59
≥ 65 reference
Differentiation 0.27
Well to moderate 3.20 0.47-25.18
Poor reference
Gender 0.29 
Male 2.05 0.89-4.76
Female reference
Anatomical site 0.90
EGJ 0.65 0.08-5.03 0.68
Funds 1.60 0.45-5.67 0.47
Body 0.98 0.40-2.40 0.97
Antrum reference
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Table 4.8: Cox regression analysis for comparison of diffuse type of gastric cancer patients 
DFS. Abbreviations: HR, hazard ratio; EGJ, esophagogastric junction.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI P HR 95% CI P
Primary treatment <0.001 <0.001
non-response 9.16 3.43-24.42 8.21 3.02-22.32
response reference
Gender 0.03 0.05
male 2.74 1.08-6.98 2.68 1.02-7.04
female reference
miR-140-5p 0.93
high expression 1.04 0.47-2.32
low expression reference
Stage 0.36 0.73
Stage I 0.23 0.04-1.40 0.11 0.59 0.09-3.96 0.58.
Stage II 0.35 0.09-1.41 0.14 0.57 0.13-2.44 0.45
Stage III 0.49 0.13-1.78 0.28 0.46 0.12-1.78 0.26
Stage IV reference
Age 0.91
＜65 0.95 0.39-2.30
≥ 65 reference
Differentiation 0.54
well to moderate 1.89 0.24-14.45
poor reference
Anatomical site 0.66
EGJ 0.77 0.10-6.09 0.81
Funds 2.33 0.73-7.41 0.15
Body 1.05 0.40-2.75 0.91
Antrum reference
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Table 4.9: Relationship between miR-140-5p suppression and clinicopathological features in 
gastric cancer patients with intestinal type.
miR-140-5p suppression Chi-
square
Pa
Positive (%) Negative (%)
Gender 0.54 0.58
Male 43(34.6) 81(65.4)
Female 19(31.6) 43(68.4)
Age(years) 0.42 0.67
≥65 39(32.0) 76(68.0)
<65 21(34.4) 47(65.6)
Tumour location 0.53 0.59
Cardia 12(28.0) 28(72.0)
Non-cardia 49(35.7) 93(64.3)
Differentiation 0.22 0.82
High-moderate 34(30.7) 67(69.3)
Poor 26(35.0) 55(65.0)
Depth of invasion 0.12 0.91
T1-T2 17(29.8) 35(70.2)
T3–T4 45(36.0) 89(64.0)
Lymph node involvement 1.14 0.25
No 20(36.4) 30(63.6)
Yes 41(33.6) 9166.4)
Distant metastasis 1.38 0.17
No 55(32.6) 117(67.4)
Yes 7(50.0) 7(50.0)
TNM stage 2.00 0.15b
I 12(38.6) 14(61.4)
II 16(32.8) 28(67.2)
III 25(34.4) 64(65.6)
IV 8(37.2) 16(62.8)
Primary treatment response 0.12 0.90
Yes 37(34.8) 68(65.2)
No 14(37.7) 27(62.3)
aChi-square test. bChi-square test for trend
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Table 4.10: Relationship between miR-140-5p suppression and clinicopathological features 
in gastric cancer patients with diffuse type.
miR-140-5p suppression Chi-
square P
aPositive (%) Negative 
(%)
Gender 0.73 0.47
Male 19(45.2) 23(54.8)
Female 11(36.7) 19(63.3)
Age(years) 1.14 0.25
≥65 14(50.0) 14(50.0)
<65 16(36.4) 28(63.6)
Tumour location 0.35 0.72
Cardia 4(36.4) 7(63.6)
Non-cardia 24(42.1) 33(57.9)
Differentiation 0.81 0.23
High-moderate 1(50.0) 1(50.0)
Poor 28(41.8) 39(58.2)
Depth of invasion 1.932 0.05
T1-T2 4(22.2) 14(77.8)
T3–T4 26(48.1) 28(51.9)
Lymph node involvement 0.19 0.85
No 7(43.8) 9(56.2)
Yes 23(41.1) 33(58.9)
Distant metastasis 0.51 0.61
No 26(56.3) 38(43.7)
Yes 4(50.0) 4(50.0)
TNM stage 0.9183 0.33b
I 2(28.6) 5(71.4)
II 9(42.9) 12(57.1)
III 15(44.1) 19(55.9)
IV 4(57.1) 3(42.9)
Primary treatment response 0.83 0.41
Yes 18(47.3) 20(52.7)
No 8(36.4) 14(63.6)
aChi-square test. bChi-square test for trend
4.3.2 Analysis of miR-140-5p/3p expression in an indication of gastric cancer 
progression from cohort without neoadjuvant chemotherapy
Further exploration was carried out on the involvement of  miR-140-5p/3p in the disease 
progression of  gastric cancer in an independent cohort containing 70 patients who did not 
receive any treatment before tissue collection. In line with the finding in TCGA analysis, 
reduced expression of  miR-140-5p was observed in tumour tissues compared with adjacent 
non-tumour samples, especially in Borrmann I-II type of  gastric cancer (Table 4.11). A
decreased miR-140-5p expression was seen in the relatively localized tumour (Borrmann I-
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II) compared with diffuse tumour samples (Borrmann III-IV). Interestingly, higher miR-
140-5p expression was found in male patients with Borrmann I-II gastric cancer, but for the 
Borrmann III-IV patients higher miR-140-5p are more likely happened in female patients. A
trend of  reduced expression of  miR-140-5p was prone in older patients. However, a relatively
lower expression of  miR-140-5p was seen in the early stage of tumours compared with later 
stage, which thought showed a reverse trend in Borrmann III-IV type patients, the result was 
not statistically significant. 
We also compared miR-140-3p expression in these gastric cancer patients. Comparing to
adjacent non-tumour samples, the level of  miR-140-3p showed a decreased trend in paired 
tumoural tissues and mainly occurred in Borrmann I-II patients. Although no significant 
correlation was found between miR-140-3p expression and other clinical parameters, similar 
to miR-140-5p, lower expression of  miR-140-5p was more likely to be seen in the early stage 
of  tumours compared with later stage in Borrmann I-II patients, while the opposite in 
Borrmann III-IV patients.
We further compared patients’ OS with different miR-140-5p expression level (Figure 4.6). 
Patients with lower miR-140-5p in tumour samples compared to paired normal samples was 
regarded as miR-140-5p low, whereas tumours harbouring a higher or equal level of  miR-
140-5p was viewed as miR-140-5p high. A higher miR-140-5p was significantly correlated 
with better OS for the total patients involved in the current study. Subgroup analysis revealed 
that patients with Borrmann I-II are more likely to benefit from higher miR-140-5p 
expression. On the contrary, higher miR-140-5p expression indicated an even worse 
prognosis in gastric cancer patients with Borrmann III-IV subtypes. When both the 
expression status of  miR-140-5p and miR-140-3p was considered, patients with suppression 
in both miR-140-5p and miR-140-3p showed the poorest survival (Figure 4.7A). The 
combined analysis of  miR-140-5p/3p expression level with tumour Borrmann classification 
revealed that patients having Borrmann I-II type gastric cancer and having none or one of  
the low expression of  miR-140-5p/3p in the tumour samples had the best OS, however when 
both miR-140-5p and miR-140-3p were downregulated in tumour tissues, patients would 
suffer a worse prognosis regardless of  their histological types (Figure 4.7 B). 
Table 4.11: miR-140-5p expression in non-neoadjuvant chemotherapy cohort from Beijing
Whole (n=70) Borrmann I II (n=48) Borrmann III IV (n=22)
N Mean ±SEM P value N Mean ± SEM P value N Mean ±SEM P value
<0.001 <0.001 0.26
Tumour tissue 70 1.73 ± 0.39 48 1.07 ± 0.19 22 3.18 ± 1.14
Normal tissue 70 3.78 ± 0.44 48 3.42 ± 0.51 22 4.57 ± 0.86
Gender 0.85 0.47 0.41
Male 53 1.69 ± 0.38 35 1.16 ± 0.24 18 2.73 ± 0.99 
Female 17 1.87 ± 1.14 13 0.84 ± 0.32 4 5.18 ± 4.82 
Age 0.11 0.40 0.22
≥65 32 1.06 ± 0.26 23 0.90 ± 0.24 9 1.48 ± 0.69
＜65 38 2.30 ± 0.68 29 1.23 ± 0.30 9 4.35 ± 1.82
Differentiation 0.17 0.08 0.39
High-Moderate 13 0.59 ± 0.33 9 1.23 ± 0.23 4 3.65 ± 1.36
Poor 57 1.95 ± 0.47 39 0.38 ± 0.19 18 1.08 ± 1.06
Histology 0.01
Borrmann I-II 48 1.07 ±0.20
Borrmann III-IV 22 3.18 ±1.14
TNM staging 0.36 0.62 0.32
1-2 18 1.12 ± 0.28 14 1.22 ± 0.33 4 0.75 ± 0.47 
3-4 52 1.95 ± 0.52 34 1.01 ± 0.24 18 3.18 ± 1.36
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Table 4.12: miR-140-3p expression in non-neoadjuvant chemotherapy cohort from Beijing
Whole (n=70) Borrmann I II (n=48) Borrmann III IV (n=22)
N Mean ±SEM P value N Mean ± SEM P value N Mean ±SEM P value
0.09 0.08 0.66 
Tumour tissue 70 0.12 ± 0.10 48 0.12 ± 0.01 22 0.12 ± 0.02
Normal tissue 70 0.14 ± 0.08 48 0.14 ± 0.01 22 0.13 ± 0.01
Gender 0.50 0.58 0.72
Male 53 0.12 ± 0.01 35 0.21 ± 0.02 18 0.12 ± 0.02
Female 17 0.10 ± 0.02 13 0.10 ± 0.03 4 0.10 ± 0.06
Age 0.41 0.78 0.28
≥65 38 0.11 ± 0.02 25 0.12 ± 0.02 13 0.15 ± 0.04
＜65 32 0.13 ± 0.02 23 0.11 ± 0.02 9 0.10 ± 0.02
Differentiation 0.88 0.70 0.75
High-Moderate 13 0.12 ± 0.01 9 0.12 ± 0.02 4 0.12 ± 0.03
Poor 57 0.11 ± 0.03 39 0.10 ± 0.03 18 0.14 ± 0.04
Histology 0.89
Borrmann I-II 48 0.12 ± 0.01
Borrmann III-IV 22 0.12 ± 0.02
TNM staging 0.33 0.11 0.42
1-2 18 0.14 ± 0.02 14 0.15 ± 0.02 4 0.08 ± 0.04 
3-4 52 0.11 ± 0.01 34 0.10 ± 0.02 18 0.13 ± 0.03
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Figure 4.6: Kaplan–Meier OS analysis for patients with miR-140-5p high or miR-140-
5p low gastric cancer tissues （Beijing cohort）. A. The analysis included total patients showed 
a trend that patients with high miR-140-5p expression (median survival 42.87 months) are more likely to 
have better OS versus low miR-140-5p expression in gastric cancer tissues (median survival 33.17 months). 
B. The analysis for patients with relative local disease (Borrmann I-II) showed a similar trend as that in 
total population, a better clinical outcome for patients with higher miR-140-5p expression (undefined 
median survival) compared to those with miR-140-5p lower expression (median survival 35.37 months). 
C. For patients with more invasive gastric cancer, higher miR-140-5p (median survival 15.72 months), 
however, indicated shorter OS; Those patients with lower miR-140-5p exhibited a longer OS (median 
survival 18.5 months). 
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Figure 4.7: Kaplan–Meier OS analysis for patients with various miR-140-5p/3p status 
in gastric cancer tissues. A. The analysis included all the patients, patients with tumour harbouring 
both suppressing in miR-140-5p and -3p expression showed a trend to have a worse OS than patients with 
either miR-140-5p suppression or miR-140-3p or with no suppression of  neither. B. Further analysis 
based on Borrmann classification showed that the OS significantly declined in the patients, whose tumours 
were localized but were suppressed in both miR-140-5p/3p. Abbreviations: BI-II O/N, one of  none 
suppression of  miR-140-5p/3p in Borrmann I-II type; BI-II BO, Borrmann I-II type with both 
suppressed miR-140-5p and miR-140-3p; BIII-IV O/N, one of  none suppression of  miR-140-5p/3p in 
Borrmann III-IV type; BIII-IV BO, Borrmann III-IV type with both suppressed miR-140-5p and miR-
140-3p.
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Table 4.13: Cox regression analysis for comparison of OS in gastric cancer patients without 
neoadjuvant chemotherapy. Abbreviations: HR, hazard ratio.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI p HR 95% CI P
Stage 0.07 0.05
Stage I-II 0.41 0.14-1.17 0.40 0.14-1.15
Stage III-IV reference
Age <0.001 0.01
＜65 0.36 10.19-0.71 0.37 0.20-0.70
≥ 65 reference
Histology 0.01 0.01
Borrmann I-II 0.40 0.19-0.83 0.40 0.20-0.78
Borrmann III-IV reference
R0 surgical margin 0.05 0.04
No 2.33 0.99-5.45 2.30 1.03-5.11
Yes reference
Vascular invasion 0.05 0.04
No 0.43 0.19-1.00 0.45 0.21-0.98
Yes reference
Low miR-140-5p/3p 0.10 0.08
None or one 0.52 0.24-1.14 0.54 0.27-1.07
Both reference
Gender 0.85
Male 1.09 0.46-2.58
Female reference
Differentiation 0.82
Well to moderate 1.15 0.43-2.84
Poor reference
Anatomical site
Cardia
Non-cardia reference
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4.3.3 Analysis of miR-140-5p/3p expression related to gastric cancer treatment from 
cohort with neoadjuvant chemotherapy
A previous microarray-based study enrolling 87 patients diagnosed with metastatic gastric 
cancer who received fluorouracil and cisplatin chemo treatment, revealed that higher 
expression of  miR-140-5p in pre-treated tumour samples was significantly correlated with a 
delayed time to progression indicating chemotherapy-related survival benefits. However, 
miR-140-5p was functionally validated to reduce cell proliferation through G1 and G2 phase 
arrest mediated in part through the suppression of  HDAC4 (Song et al. 2009) and be 
important in contributing to chemoresistance to 5FU based chemotherapy in colorectal 
cancer (Yang et al. 2017). Additionally, miR-140-5p was demonstrated to be overexpressed 
in CD133+HiCD44+Hi colon cancer stem-like cells and, by reducing its expression, the
chemoresistance of CD133+HiCD44+Hi colon cancer stem-like cells to 5FU treatment can be 
halted (Ju 2010). This led to a question of  how miR-140-5p and miR-140-3p are involved in 
the chemo response of  gastric cancer patients. To answer this, an analysis of  miR-140-5p/3p 
expression in chemosensitive tumour tissues and chemoresistant tumour samples, as well as 
their corresponding normal stomach tissues, was performed, using another gastric cancer 
cohort in which tissues samples of  patients were collected after 5FU based neoadjuvant 
chemotherapy from Beijing Cancer Hospital. Neoadjuvant chemotherapy (NAC) is defined 
as chemotherapy administered before locoregional treatment, such as surgery and/or 
irradiation. It is well established that NAC plays an important role in downstaging tumours, 
eliminating micrometastases, and relieving tumour-related symptoms in patients with locally 
advanced gastric cancer (Yang et al. 2015). NAC increases the surgical resectability rate as 
well as the quality of  surgery if  the gastric cancer cell is sensitive to chemotherapy (Chen et 
al. 2018). As shown in Figure 4.8, among all subjects involved, 30 patients (37.04%) had 
higher miR-140-5p and miR-140-3p (tumour versus adjacent non-tumour) expressions, and 
46 patients had either increased miR-140-5p or increased miR-140-3p. Patients with a 
pathological complete response or partial response exhibited a higher expression of  either 
miR-140-5p or miR-140-3p in the tumour samples. Patients with pathological complete 
response or partial response showed a trend to have a better OS compared with patients with
stable or progressive disease (Figure 4.9 B HR=0.52, 95% CI: 0.30–0.89, P=0.116), however, 
it is not an independent indicator for patients’ OS (Table 4.13). The Kaplan-Meier analysis, 
however, demonstrated that patients with at least one alteration in miR-140-5p or miR-140-
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3p could have a significantly increased OS (HR=0.56, 95% CI: 0.32-0.93, p=0.018). 
Furthermore, the Cox analysis also indicated that higher expression of  miR-140-5p or miR-
140-3p could be a potential independent prognostic factor although it only showed a 
boundary statistically significance (Figure 4.9 A Table 4.13). Subgroup analysis revealed that 
if  pathological response was achieved, patients with either miR-140-5p or miR-140-3p 
upregulation and those without alterations had similar survival (P=0.738). In contrast, 
patients with residual disease (RD) would have worse OS if  they did not have any alterations 
in neither miR-140-5p nor miR-140-3p compared with patients having at least one alteration
in them (P < 0.05) (Figure 4.10).  
Figure 4.8: miR-140-5p and miR-140-3p and neoadjuvant treatment response of 
gastric cancer. The levels of  miR-140-5p and miR-140-3p were determined by qPCR in a cohort of  
gastric cancer patients receiving chemotherapy before surgery. Shown are miR-140-5p and miR-140-3p 
levels (mean ± standard deviation) and the comparisons of  miR-140-5p or miR-140-3p in gastric tumours
of  complete response, partial response, and non-response from the drug treatment via One-way ANOVA. 
** represent P<0.01, * represents P<0.05. 
158
Figure 4.9: A Kaplan-Meier 5-year OS estimation in patients with different miR-140-
5p/3p status. The miRs’ expression level was determined according to ROC analysis. Tumours with 
higher miR-140-5p or miR-140-3p showed a trend to have a better prognosis in comparison with primary 
tumours without any alterations in neither miR-140-5p nor miR-140-3p (the relative expression was 
calculated using the expression of  tumour sample divided by that of  paired normal tissues). However, the 
difference was not statistically significant (P=0.18). B. Kaplan-Meier 5-year OS estimation in patients 
with different responses to chemotherapy. Neoadjuvant chemotherapy although not statistically 
significant, may increase long-term survival among patients who showed a complete or partial response 
(both are defined as a response according to a previous systematic review (Muhich and Boothroyd 1989)).
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Figure 4.10: miR-140-5p/3p status and OS in different subtypes of gastric cancer 
patients. Among the 59 patients with complete response or partial response to NACT, 25 patients had 
tumours that expressed higher miR-140-5p or -3p, and 24 were alteration negative; their 5-year OS did 
not significantly differ. In contrast, patients with residual disease (RD) had worse OS if  they had no 
upregulation in miR-140-5p nor miR-140-3p (n=17) compared with patients with increased miR-140-5p 
or -3p (n=11).
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Table 4.14: Cox regression analysis for comparison of OS in gastric cancer patients with 
neoadjuvant chemotherapy. Abbreviations: HR, hazard ratio.
Parameters
Univariate analysis Multi variate analysis
HR 95% CI P HR 95% CI P
T stage 0.01 0.01
T3 2.72 1.23-6.00 2.87 1.38-5.95
T4 reference
N stage 0.18 0.08
N0 2.27 0.70-23.82 2.64 0.89-3.89
N1-N3 reference
M stage 0.39
M0 1.66 0.52-5.26
M1 reference
Response 0.63
No 1.18 0.60-2.35
Yes reference
Age 0.12 0.01
＜65 0.56 0.28-1.15 0.37 0.20-0.70
≥ 65 reference
Gender 0.65
Male 0.85 0.41-1.73
Female reference
Anatomical site 0.89
Non-cardia 1.05 0.50-2.21
Cardia reference
Histology 0.01 0.01
Borrmann I-II 2.43 1.29-4.55 2.23 1.22-4.10
Borrmann III-IV reference
R0 surgical margin <0.001 <0.001
No 0.12 0.04-0.40 0.20 0.10-0.38
Yes reference
Vascular invasion 0.11 0.04
No 0.53 0.23-1.16 0.58 0.31-1.09
Yes reference
Completed periods 0.26
No 1.53 0.76-3.19
Yes reference
Differentiation 0.24
Well to moderate 0.61 0.27-1.39
Poor reference
Higher miR-140-5p/3p 0.09 0.07
None 1.89 0.91-3.93 1.68 0.96-2.93
At least one reference
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4.4 Discussion
The roles of  miR-140-5p and -3p in maintenance of  cartilage tissue, embryonic development, 
regeneration and repair and in immune response and chronic inflammation have been 
extensively demonstrated. miR-140-5p and 3p play roles of tumour suppression and have
attracted attention as both possible biomarkers and potential therapeutic targets in epithelial-
derived carcinoma such as lung cancer, breast cancer, colon cancer and ovarian cancer et al., 
as well as in other types of  malignant tumour, like sarcomas, melanoma, lymphoma, and
leukemia. However, higher miR-140-5p expression was significantly associated with poorer 
OS in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-
type KRAS and BRAF (Mosakhani et al. 2012). It was reported the miR-140-5p exhibited 
significantly higher expression levels in post-neoadjuvant chemotherapy specimens 
compared with pre-neoadjuvant chemotherapy biopsies in breast cancer and exhibited 
significantly even higher expression levels in the ineffective group comparing to the effective
group after neoadjuvant chemotherapy which indicated a poorer survival in breast cancer 
patients (Chen et al. 2016). Upregulation of  miR-140-3p was found in metastasis nodal
tissues comparing to the nonmetastatic oral squamous cell carcinoma (Serrano et al. 2012).
Elevated miR-140-3p was also found in the milk of  the milk stasis plus breast neoplasm 
patients and contributed to breast carcinogenesis (Gu et al. 2014). Moreover, highly 
expressed miR-140-3p was also shown to control stemness of  breast cancer cells (Salem et 
al. 2016). These suggest downregulation of  miR-140-5p or-3p or their joint action underlines
tumour aggressiveness in a tissue, stage or cell context-dependent manner. To address the 
specific roles of  miR-140-5p and miR-140-3p in gastric cancer, the expression of  miR-140-
5p in gastric cancer (The Cancer Genome Atlas, https://cancergenome.nih.gov/) was 
initially analyzed. A slight decrease in miR-140-5p was observed in the whole population 
(n=435). Interestingly, an ascending trend was noticed in intestinal type of  gastric cancer, 
especially patients with metastasis. In the survival analysis, patients with higher miR-140-5p 
are more likely to experience longer DFS and OS, particularly in patients with intestinal type. 
Although patients with intestinal gastric cancer were supposed to have a better survival than 
those with diffuse type, we did not see that in the TCGA cohort. Moreover, when we 
compared prognosis considering both their histological subtype and miR-140-5p status, the 
log-rank analysis revealed that patients with intestinal subtype and higher miR-140-5p 
expression had the best OS. On the contrary, patients with intestinal subtype but a 
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downregulated miR-140-5p had even worse OS compared to patients with the diffuse type 
of  gastric cancer. Cox analysis indicated lower miR-140-5p expression status together with 
later stage, older age, worse differentiation and non-response from primary treatment were
independent OS risk factors for the whole cohort of  gastric cancer patients and those with
intestinal-type gastric cancer patients, it’s worth nothing that miR-140-5p downregulation 
was an independent risk factor for DFS of  intestinal gastric cancer patients. 
In this study, reduced expression of  miR-140-5p and -3p was observed in gastric cancer
(n=70) compared with paired adjacent normal gastric tissues (n=70). Consistent with the 
findings in the TCGA cohort, deregulated miR-140-5p also showed correlation with age,
tumour differentiation and tumour growth pattern. Borrmann classification instead of  
Lauren classification was recorded for these patients, thus Borrmann type I and II tumours 
were considered the localized type and Borrmann type III and IV were considered infiltrative 
type in accordance with previous study (Saito et al. 2013). Subgroup analysis based on the 
Borrmann classification indicated that, in line with the results we found in TCGA cohort, 
poorer survival is more likely observed in patients with lower miR-140-5p expression, 
especially in the localized type of  gastric cancer. In the infiltrative type of  gastric cancer,
conversely, lower miR-140-5p may suggest a better survival. The combined analysis of  both 
miR-140-5p and -3p expression and Borrmann’s classification indicated that localized type 
of  gastric cancer with none or only one deregulation of  either miR-140-5p or miR-140-3p 
suggested best survival benefit for gastric cancer patients. However, localized type of  gastric 
cancer with both deregulation of  miR-140-5p and miR-140-3p expression manifested an OS 
as poor as an infiltrative type of  gastric cancer. Similar results were reported in astrocytoma
in which miR-140-5p was significantly lower in the diffuse astrocytoma’s tumour samples as 
compared to the non-neoplastic brain tissues. However, during the spontaneously progress 
from diffuse astrocytoma of  World Health Organization (WHO) grade II to anaplastic 
astrocytoma WHO grade III or secondary glioblastoma WHO grade IV, miR-140-5p, 
alongside other 11 miRNAs, was elevated in a progressive manner. In addition, upregulation 
of  its median expression levels was also increased in secondary glioblastomas as compared 
to low-grade gliomas (Malzkorn et al. 2010). Upregulation of  miR-140-5p, along with 
enriched genes in extracellular matrix (ECM)-receptor interaction, ribosome, and focal 
adhesion pathways were thought to be important in recurrence of  glioblastoma (Bo et al. 
2015). Microarrays examination and OS analysis in metastatic colorectal cancer with a genetic
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background of  wild-type KRAS/BRAF also indicated that increased miR-140-5p 
significantly correlated with poor OS (Mosakhani et al. 2012). In oestrogen-stimulated breast 
cancer cells, miR-140 restoration reduced the CD44high/CD24low subpopulation frequency, 
which is referred to the tumour-initiating cells. However, in the absence of  oestrogens, miR-
140 overexpression had little to no impact on tumour-initiating cell frequency (Zhang et al. 
2012). miR-140-5p expression was elevated in invasive ductal carcinomas (P=0.002), whereas 
basal-like tumours had decreased expression of  miR-140-5p compared to other tumours 
(P=0.008). Lymph node-positive samples showed an approximately 13-fold increase in miR-
140-5p expression compared to lymph node-negative tissue (P=0.049) (Gullu et al. 2015). 
Samples with no immunohistochemical staining for IGFBP5 showed increased miR-140-5p 
expression (P=0.009) (Zhang et al. 2012). All of  the above evidence again emphasized the 
context-specific role of  miR-140-5p.
Furthermore, we determined the pattern of  miR-140-5p and -3p expression in this gastric 
cancer patient cohort who received 5FU based NAC to evaluate their predictive roles in 
chemoresponse. We found there was a significantly increased expression of  miR-140-5p/3p 
in malignant tumours compared with adjacent normal tissue, and even higher in responsive 
tumour tissues. Survival analysis revealed that patients with no response from the NAC 
treatment but armed with either higher miR-140-5p or miR-140-3p expression (compared to 
paired normal tissues) could still have a chance for long-term survival. 
Taken together, the results suggested that miR-140-5p and miR-140-3p may play specific or 
even contrasting roles in gastric cancer with different biological background (intestinal vs. 
diffuse, or Borrmann I-II (localized) vs. Borrmann III-IV (infiltrative)). Generally, miR-140-
5p and miR-140-3p played tumour suppressing roles in gastric cancer, and more advanced
tumours in the late stage (AJCC Stage III and Stage IV) had a decreased miR-140-5p/3p 
expression in comparison with tumours at early stages of  the disease (Stage I and Stage II).
Current cohort analysis also hinted a complementary function for this pair of  miRNA 
duplexes. However, further investigation should be performed to validate this finding in a 
larger cohort with a well-documented histological description for subgroup analysis. Also, 
since a big variance was seen in our q-PCR examination, an improvement should be made in 
optimizing the endogenous reference and enhancing the accuracy for quantitative assessment. 
Higher expression of  miR-140 associated with 5FU chemoresistance was found in small cell 
lung carcinoma cell lines (Polley et al. 2016), in osteosarcoma tumour xenografts, and in 
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CD133(+hi) CD44(+hi) colon cancer stem-like cells, probably due to slower proliferating 
rate (Song et al. 2009). It was also suggested that increased miR-140-5p expression levels up-
regulated anticancer drug-induced autophagy in osteosarcoma cells and ameliorated the 
anticancer drug-induced cell proliferation and viability decrease. Besides, miR-140-5p is 
highly expressed in erlotinib-resistant cells (mesenchymal type A549) and is predicted to 
target the TGFβ receptor and Smad2 (Wong and Wang 2015; Bryant et al. 2012). TGFβ may 
act in a pro-tumourigenic, pro-EMT fashion in erlotinib-resistant cells, but may play an anti-
EMT and protective role in erlotinib-sensitive cells (epithelial type PC9) because inhibition 
of  TGFβ did not induce a complete EMT transition in these cells, indicating that the 
perpetual activation of  ERK and AKT signals from active EGFR signalling may rely on basal 
activation from TGFβRII in order to persist (Krentz Gober et al. 2017). It was not surprising
that miR-140-5p, as one of  the upstreamers of  TGFβ, could play dual roles in the response 
to cytotoxic stress. The gain of  function of  K-ras mutations, non-functional p53, as well as
deregulated TGFβ are well documented for their roles in the induction and potentiation of
tumourigenesis. The definite correlation between miR-140-5p and -3p and these factors 
contributes to the tumourigenesis of  gastric cancer warrant further investigation. 
Taken together, these results show that the expression of  miR-140-5p and -3p is reduced in 
specific subtypes of gastric cancer. This is associated with the disease progression and poor 
prognosis. Current findings from gastric cancer tissue samples led to a further investigation 
for their functional roles in gastric cancer cells, which is supposed to help to elucidate how 
and when miR-140-5p and -3p exert their protective roles on gastric cancer progression. This
subject is discussed in subsequent chapters.
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Chapter 5
The Influence of miR-140-5p and -3p 
overexpression on the cellular 
functions of human gastric cancer cell 
lines
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5.1 Chapter Introduction
In the initial investigation, reduced expression of  miR-140-5p and -3p was evident in 
intestinal gastric cancer. The down-regulation of  miR-140-5p and -3p may correlate with 
progression of  intestinal gastric cancer during the tumourigenesis, as such a trend was 
observed in MKN7 with high differentiation, MKN74 with moderate differentiation and 
AGS with low differentiation. Furthermore, intestinal-type gastric cancer patients with lower 
expression of  miR-140-5p exhibited a shorter OS, suggesting its implication in the prognosis 
of  the disease.
The most fundamental trait of  cancer cells involves their ability to sustain chronic 
proliferation, which is usually sustained by proliferative signaling conveyed in large part by 
growth factors that bind cell-surface receptors, typically containing intracellular tyrosine 
kinase domains. In normal cells, the activation of  intracellular tyrosine kinase proceeds to 
emit signals via branched intracellular signaling pathways that regulate progression through 
the cell cycle as well as cell growth (increases in cell size) in a highly specific and localized 
fashion properly. However, cancer cells acquire the capability to sustain proliferative signaling
in a number of  alternative ways, mainly through gaining excessive growth advantages and 
disruptions of  negative-feedback mechanisms that attenuate cell proliferation (Hanahan and 
Weinberg 2011).
The most virulent form of cancer is not only a disease of  uncontrolled cell growth but also 
a disease of  uncontrolled cell migration. Metastasis, viewed as another hallmark of  cancer, 
involves the spread of  cancer cells from the primary tumour to surrounding tissues and to 
distant organs and the remains the leading cause of  mortality among cancer patients (Labelle 
and Hynes 2012; Seyfried and Huysentruyt 2013). Cancer cells must complete several 
complex sequential steps to metastasize successfully, namely, detachment from the primary
tumour, intravasation into the vascular system (whether directly or via lymphatics and lymph 
nodes), survival while in transit through the circulation, initial arrest, extravasation, initial 
seeding, and survival and proliferation in the target tissue (Labelle and Hynes 2012). Tumour
cells that succeed in forming metastases may have acquired the necessary traits to complete 
these steps while still in the primary tumour, either autonomously or as a result of  changes 
induced by inflammation, stromal cells or other environmental conditions (e.g., hypoxia, 
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mechanical forces) present in the primary tumour (Joyce and Pollard 2009). 
Deregulated cell migration, along with proliferation, adhesion, and invasion, is an integrated 
process that is essential for cancer metastasis. Migration takes place throughout embryonic 
development and also participates in angiogenesis, immune responses, and wound repair
(Horwitz and Webb 2003). For example, chondroprogenitors present in the synovium may 
facilitate their migration into the superficial zone of  cartilage in response to articular surface 
injury (Jayasuriya and Chen 2015). The classic model of  cell migration on planar surfaces 
describes various physicochemical events, including those initiated by a stimulus that activates 
a set of  signalling pathways leading to cell polarization and a rapid reorganization of  actin 
filaments and microtubules. Cells advance by protruding their membrane at their leading cell 
border, which is followed by dynamic substrate adhesion via integrin adherence to the 
substrate. Membrane retraction at the lagging cell edge finishes the cycle, which is then 
repeated in rapid succession. The summation of  this process results in cell migration. Cell 
migration is indeed complex; it requires that events such as those described above, and other 
allied functions be highly coordinated in time and space to keep the cell moving forward
(Morales 2007). Cell invasion, related to cell migration, is not only determined by the cell’s 
ability to change and reorganize its cellular morphology, but also the potential to degrade the 
extracellular matrix (ECM) (Justus et al. 2014). Scratch assays (or wounding assays), are
performed by creating a cell-free gap, or “scratch”, on a confluent cell monolayer upon which 
cells at the edge of  the opening move inward to close the scratch (Zaritsky et al. 2015). Cell 
polarization is correlated with the direction of  the maximal principal stress, maximum shear 
stress drives cell polarity (He et al. 2015; Zaritsky et al. 2015).
Several studies have identified the roles of  miR-140-5p and -3p in the regulation of  cell 
functions in various malignancies. Restoration of  miR-140-5p induced p53 and p21 
expression accompanied with G1 and G2 phase arrest in colon cancer, osteosarcoma (Song 
et al. 2009), and pancreatic cancer (Liang et al. 2017). Ectopic overexpression of  hsa-miR-
140-5p in colorectal cancer cell lines decreased Smad2 expression, leading to decreased 
proliferation and cell invasion, and increased cell cycle arrest in vitro, and abolished tumour
formation and metastasis in vivo (Zhai et al. 2015). Moreover, lower miR-140-5p expression 
correlated with increased expression of  cyclin E which promoted cellular proliferation in 
non-small cell lung cancer (Xie et al. 2018). E2 phosphorylated oestrogen receptor α (ERα) 
could suppress miR-140-5p expression, which targets SOX2, leading to enhancement of  
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breast tumour-initiating cell survival (Vazquez-Martin et al. 2013). Gain-of-function 
experiments in glioma revealed that miR-140-5p overexpression inhibited proliferation, 
induced cell cycle arrest at the G0/G1 phase, and enhanced apoptosis (Cui et al. 2017). In 
gastric cancer, miR-140-5p was reported to inhibit SOX4 directly, which might be one of  its 
mechanisms in suppressing gastric cancer cell proliferation (Zou and Xu 2016). In erlotinib 
(an EGFR inhibitor) resistant non-small cell lung cancer cells miR-140-5p were highly 
expressed and might associate with a mesenchymal-like phenotype (Krentz Gober et al. 2017). 
Transient transfection of  miR-140-3p inhibitors showed anti-proliferative effect on 
chordoma cell lines U-CH1 (retain a wild-type allele of  p53 gene, one allele of  p53 had a 
mutation-carrying a C > G substitution at nucleotide residue 412 within exon 4) (Jager et al. 
2017; Kato et al. 2011) and U-CH2 (p53 proficient) (Li et al. 2011; Zhang et al. 2017), but 
had no effect on MUG-Chor1 cell viability. Nevertheless, upregulation of  miR-140-3p with 
miR-140-3p mimics did not affect the cell proliferation or apoptosis (Gulluoglu et al. 2016). 
Low expression of  miR-140-5p or miR-140-3p was associated with enhanced colony 
formation, invasion and xenograft formation in biliary tract cancer (Yu et al. 2016), basal-like 
DCIS (Li et al. 2014a), poorly differentiated gastric cancer (Fang et al. 2017), oesophageal 
squamous cell carcinoma (Zhang et al. 2018) and lung cancer (Kong et al. 2015).
Considering the paradoxical expression pattern and role in the regulation of  the cellular
function of  miR-140-5p and -3p in different tumour types, we aimed to decipher the 
expression and function of  miR-140-5p and -3p in gastric cancer cells with the different
molecular backgrounds. Gain/loss of  function assays of  miR-140-5p and -3p were employed 
to compare differences in cell behaviors, including cell proliferation, cell cycle distribution, 
migration, invasion, and drug-induced cell proliferation of  four gastric cancer cell lines AGS, 
NUGC4, MKN45, and HGC27.
5.2 Materials and methods
5.2.1 Cell lines
Intestinal gastric cancer cell lines AGS (wtp53), diffuse gastric cancer cell lines NUGC4 
(wtp53), and MKN45 (mutp53) and HGC27 (mutp53) were used in this study. All these 
cancer cell lines were cultured in DMEM medium with 10% FBS and antibiotics (Chapter 
2.1). 
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5.2.2 Transfection of miR-140-5p and -3p mimics
Overexpression of  miR-140-5p and -3p was conducted through chemical transfection of  
miR-140-5p and -3p mimics with Lipofectamine 3000. Transfection efficiency was 
confirmed by real-time PCR before cell function assays. All the experiments were performed 
within 96 hours following transfection (Refer to chapter 2.1).
5.2.3 RNA isolation, cDNA synthesis, RT-PCR, and qPCR
RNA was extracted using a Tri Reagent kit (Sigma-Aldrich, Poole, Dorset, UK), miR-
transcription was then converted by the GoScriptTM Reverse Transcription System kit 
separately (Refer to chapter 2.3).
5.2.4 In vitro cell proliferation assay
Twelve hours after transfection, cells from the six-well plate were trypsinised and counted as 
described in chapter 2.10.2. Six replicates were set up for each cell lines with three different 
transfection groups in one 96-well plate, Thus the cell pellet was resuspended at 1×106 cells 
/36 mL normal media and 100 µL of  this suspension/well were seeded in six 96-well plates 
(Greiner Bio-One Ltd., Gloucestershire, UK). Since serum present in the culture medium 
can generate background, the outer wells empty were filled with 100 µL normal media but 
no cells, following the same layout. The plates were incubated for 6h, 12h, 24h, 48h, 72h,
and 96h respectively. Following incubation, 10 µL of  5 mg/mL MTT solution was added to
each well for both experimental and control plates, which were then left in a normal 
incubator for 4h. After the purple precipitate was visible, the medium was removed. The 
remaining purple crystals were dissolved in 100 µL of  acidified isopropanol and the 
absorbance for each plate was read at 540 nm using an ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf  laboratories, York, UK). The blank plate’s absorbance 
was subtracted from that of  the plates which contained cells, to eliminate background 
interference from the absorbance readings. Cell viability rate was calculated according to the 
following formula: Cell viability (%) = A540 (sample)/A540 (control) × 100.
5.2.5 In vitro cell colony assay
Only a fraction of  seeded cells retains the capacity to produce colonies (Franken et al. 2006). 
Clonogenic assay or colony formation assay is an in vitro cell survival assay based on the 
ability of  a single cell to grow into a colony. A colony is defined to consist of  at least 50 cells. 
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Single suspended cells were seeded in six-well plates at 300 cells per well. After one week, 
the colonies were stained with 800 uL of  0.5% crystal violet for 10 min and washed with tap 
water carefully. The number of  colonies was counted under the microscope.
5.2.6 In vitro wound scratch assay
Cells were suspended and seeded into each well of  a 6-well plate at a full confluence cell 
density (1.2-2.0×106). After the cells attached to the bottom and formed a monolayer, linear 
wounds were scratched with a 10 uL pipette tip at the centre of  the monolayer and the 
detached cells were carefully washed off  with PBS thrice. Afterward, 2 mL of  DMEM 
(Gibco BRL, USA) containing 2%FBS (Gibco BRL, USA) was added into each well, and the 
wounds were photographed at 0 and every 2 hours for 24 hours using EVOS® Imaging 
system and the wound closure area of  each scratch wound was measured by Image J (National 
Institutes of  Health, NY, USA). 
5.2.7 In vitro transwell migration assay
The chemo-stimuli induced migration assay was performed using Transwell chamber 
(PIEP12R48, Millipore, UK). 2×104 cells were seeded into Transwell inserts (pore size, 8μm) 
in a 24-well plate. After 24-hour incubation, the cells that had migrated through and moved 
onto the other side of  the insert were fixed with 4% formaldehyde and stained with crystal 
violet. Cells which had migrated were then counted under a microscope.
5.2.8 In vitro cell invasion assay
For invasion assay, the chamber was coated with Matrigel, and the following steps were 
similar to migration assay. 2×104 cells were seeded into Transwell inserts (pore size, 8μm). 
After incubation, cells that had invaded through the Matrigel and migrated on to the other 
side of  the insert were fixed and stained with crystal violet, and then counted under a 
microscope.
5.2.9 Cell cycle assays for flow cytometry
The analysed cells grown in the logarithmic phase were washed 2 X with PBS, then 
trypsinised. Cells, cell medium and washed PBS were harvested together and spun at 850 g
for 5 minutes and then resuspended in 5 mL of  ice cold 70% v/v Ethanol followed by being
left at 4°C. Following this, cells were again centrifuged using the same conditions and then 
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washed twice in PBS. 50 µL of  a 100 µg/mL sock of  RNase was added to each sample, 200 
µL of  50 µg/mL propidium iodide (PI) was added to stain DNA content. Cells were then 
incubated at room temperature in the dark for 15 minutes. Following this, samples were run 
on the BD FACSCanto™ II flow cytometer (Becton, Dickinson and Company, UK.) using 
the FL3 channel (575 nm).
5.2.10 Cell cytotoxic assays
Cells were replanted in 96-well plates at 5 ×103 cells/well in hexad in 100 μL of  medium. 
After cell adherence, 5FU (ranging from 2 to 100 μM) was added and incubated for 48 h. 
The following steps are similar to a proliferation assay. A complete medium control without 
cells was used to determine background density of  serum with drug solvent. 
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5.3 Results
5.3.1 miR-140-5p, - 3p expression and the overexpression of miR-140-5p, -3p in 
gastric cancer cell lines
The expression of miR-140-5p and -3p has been detected in six gastric cancer cell lines 
originated from human carcinoma including intestinal gastric cancer cell lines MKN7, 
MKN74, and AGS; and diffuse gastric cancer cell lines NUGC4, MKN45, HGC27. Mature 
miR-140-5p and -3p transcripts were determined using RT-PCR. Overall, miR-140-5p and -
3p showed almost equally distribution in all examined gastric cancer cell lines (Figure 5.1). 
In the intestinal group, the degree of decline of miR-140-5p and -3p was related to the degree 
of cells’ differentiation. Such a trend was not seen in the three diffuse gastric cancer-derived 
cell lines. AGS, NUGC4, MKN45, and HGC27 were included in preliminary experiments 
for transient overexpression of miR-140-5p or -3p. Initial tests showed that overexpression 
of miR-140-5p and -3p was well established in all four of these cell lines by qPCR. (Figure 
5.1). 
Figure 5.1: miR-140-5p and -3p expression in gastric cancer cell lines and 
overexpression of miR-140-5p and -3p respectively in AGS, NUGC4, MKN45, and 
HGC27. (A) Expression of miR-140-5p and -3p in gastric cancer cell lines were examined using qPCR. 
Reagents used in miRNA reverse transcription step and in real-time PCR step were used as negative 
controls to exclude any contamination in the PCR reactions, and miR-423-5p was used as an internal
control according to the manual direction from TaqMan. (B) Expression of miR-140-5p and -3p in AGS, 
NUGC4, MKN45 and HGC27 gastric cancer cells transfected with miRNAs’ mimics were determined 
using RT-PCR. 
173
5.3.2 Effects of miR-140-5p and -3p on proliferation of gastric cancer cells
Cancer is characterized by abnormal cellular proliferation. Combinations of  defined growth-
promoting molecules under chemically defined conditions have revealed an important aspect 
of the molecular events leading to cell proliferation. In particular, the availability of  defined 
mitogenic molecules has opened up the possibility of  exploring the molecular and 
physiological properties of  the cellular receptors related to growth control, and the nature 
of  the intracellular signals (e.g. ion fluxes, cyclic nucleotides and cytoskeletal changes) capable 
of  eliciting or modulating a mitogenic response (Phillips 2015). Candidate drugs for solid
tumours are commonly evaluated predominantly by their ability to induce tumour shrinkage. 
Progression in solid cancer is conventionally defined as an increase in tumour size, and, in a 
superficial sense, the equating of  therapeutic efficacy with tumour shrinkage is 
understandable (Gandalovicova et al. 2017).
To evaluate the influence of  miR-140-5p and -3p on proliferation of  gastric cancer, we used 
the MTT assay which examined NAD(P)H-dependent cellular oxidoreductase enzyme 
activity to reflect the number of  viable cells present. Overexpression of  miR-140-5p or miR-
140-3p led to a distinct result in gastric cancer cell lines’ proliferation (Figure 5.2). For p53
wild-type gastric cancer cell lines AGS and NUGC4, overexpression of  miR-140-5p/3p 
resulted in a significant reduction of  proliferation in both cell lines to varying degrees. In 
AGS, the decrease started from 24 hours after miR-140-5p or miR-140-3p mimic transfection 
and kept consistent to the end of  the assay. For NUGC4, a marginal decrease was only 
exhibited after two days following transfection compared to the mimic negative control (NC 
mimic) with the difference statistically significant (Figure 5.2). In reverse, in HGC27 lines, 
no significant difference in cell proliferation was found during 96 hours’ observation, 
However, for MKN45 cell lines, a significant reduction of  cells was only seen at 96 hours  
(Figure 5.2). 
Figure 5.2: Overexpression of miR-140-5p or 3p resulted in a significant reduction of proliferation in AGS and NUGC4 cells, but little or no
influence on the growth of in MKN45 and HGC27 cells. Cells were maintained for 6h, 12h, 24h, 48h, 72h, and 96h respectively. Sextuplet was set for each cell 
lines. The proliferation rate (%) was calculated as: Absorbance (Day X) / Absorbance (Day 1) × 100 (%). Shown are representative results n=3. Error bars represent standard 
deviation. **** represent p<0.0001, *** represent p<0.001 and ** represent p<0.01, respectively.
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5.3.3 Effect of miR-140-5p/3p on colony formation of gastric cancer cells
The proliferation assay with MTT reflects cells’ metabolic state. Colony formation assay, on 
the other hand, measures the ability to expand and form colonies at a low seeding density, 
providing a fine visualization in terms of  highlighting the pro-survival/pro-apoptosis balance 
of  given perturbations. Clonogenic potential does not necessarily parallel rapid growth, such 
that prematurely senescent cells do not form colonies but are metabolically active. Since the 
turnover time of  transfected miRNA mimics was thought to be caused by cell division 
instead of  miRNA decay. After considering the possible dilution effect caused by cell division
(Jin et al. 2015), the results from the one-week colony formation assay indicated that over-
expression of  miR-140-5p via mimics transfection significantly suppressed the potential of  
cell colony formation in NUGC4 cells (doubling time, 2-3 days), but again did not show 
significant impact on the colony formation on HGC27 and MKN45(Figure 5.3). However, 
for the AGS cell lines, cells spread out in the dishes instead of  forming any colonies.
Figure 5.3: Overexpression of miR-140-5p or 3p significantly decrease of colony 
formation only in NUGC4 cell line. Three hundred cells were maintained for 1 week. The colony 
formation rate (%) was calculated as: Colony number (miR-140-5p/miR-140-3p mimic) / Colony number 
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(NC mimic) × 100 (%). Shown are representative results of one experiment out of three performed. Error 
bars represent standard deviation. **** represent p<0.0001.
5.3.4 Effect of miR-140-5p/3p on cell cycle of gastric cancer cells
To further confirm the proliferation suppression function of  miR-140-5p and -3p on gastric 
cancer cells, the cell cycle progress was investigated of  all four gastric cancer cells, and in a 
pair of  colon cancer cell lines, HCT116 p53 Wild-type (WT) and HCT116 p53 Knock-out
(KO), by flow cytometric analysis. 
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Figure 5.4: Flow cytometric analysis of cell cycle arrest after interfering miR-140-
5p/3p expression in gastric and colon cancer cell lines. Mean percentage of cells ± SD 
were shown. With miR-140-5p overexpression, a slight but significant increase of G1 phase with or 
without marked decrease in S phase was seen in NUGC4 (p53 wt) and HCT116 (p53 wt) cell line, a
similar trend was also seen in AGS cell line (p53 wt) and in MKN45 cell line (p53 missense mutation). 
Reversely, a decrease of G1 phase but increased trend in S phase was seen in HGC27 cell line. No 
obvious change was seen in HCT (p53 KO) cell line. Only AGS cells showed increased G1 phase with 
miR-140-3p overexpression, which showed even more remarkable impact than miR-140-5p 
overexpression. Error bars represent standard deviation. * represent p<0.05, ** represent p<0.01. 
As shown in Figure 5.4, In wt-p53 cancer cell lines transfected with negative control mimics, 
around 40% of  the cells were in the G0/G1 phase, and 55% and 15% of  cells were in S 
phase and G2/M phase, respectively. While, in cells transfected with miR-140-5p mimics, 
there was a definite increase in the percentage of  cells in G0/G1 phase (about 55%), as well 
as a decrease in the percentage of  cells in S phase (about 40%) and G2/M phase (5-10%). A 
slight but significant G1/S arrest was also seen MKN45 cells harbouring functional mut-p53. 
No change was seen in HCT116 KO cells, in HGC27 cells even a decrease in G0/G1 phase 
was observed. These results imply that overexpression of  miR-140-5p or miR-140-3p 
induced cell cycle arrest at G1/S phase of  gastric cancer cells might depend on cells’ status 
and functions of  p53.
5.3.5 Effect of miR-140-5p/3p on the migration of gastric cancer cells
During cancer metastasis, cancer cells migrate and spread to distant organs and form a new 
mass. In the current study, both wound scratch and trans-well migration assays were 
performed to assess the impact of  overexpression of  miR-140-5p or -3p on the motility of  
gastric cancer cells. In the wound scratch assay, a cell-free area is created in a confluent 
monolayer by physical exclusion. The exposure to the cell-free area induces the cells to 
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migrate into the gap (Rodriguez et al. 2005). A sequence of  representative images from a 
wound healing assay carried out on the confluent cells’ monolayer were captured for analysis. 
As shown in Figure 5.5, during the 24-hour incubation, miR-140-5p overexpression in AGS 
and NUGC4 cell lines reduced the cells’ migration in comparison with the control cells. 
Although for AGS cells, significant reduction was seen nearly 12 hours after wounding, for 
NUGC4 cells, a decreased trend showed at the very beginning of  the migration assay. For 
miR-140-3p overexpression, only NUGC4’s motility was weakened. Overexpression of  
either miR-140-5p or miR-140-3p strengthened the migration of HGC27 cells. No 
significant difference was found in the MKN45 cell lines.
This result was also in agreement with the other measurement of  cell motility using the trans-
well migration assay. The ability of  cell migration was determined by measuring the number 
of  cells which had migrated to the bottom of  the insert from the upper culture chamber 
over a period of  12 hours. The result showed that significantly decline in motility in AGS 
and NUGC4 gastric cancer cells as a result of  miR-140-5p overexpression. No significant 
difference was found in the MKN45 cell lines. HGC27, in contrast, showed a higher motility 
after miR-140-5p overexpression. For miR-140-3p mimic transfection, there was no 
significant difference shown in all four gastric cancer cells. Furthermore, NUGC4 AND 
MKN45 two diffuse type originated cell lines exhibited an impaired ability to initiate the 
migration process. (P<0.01) (Figure 5.6).
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Figure 5.5: Effect of miR-140-5p and -3p on migration of gastric cancer cells. A wound 
assay was performed using the EVOS live cell analysis system. The migration was measured by the rate of 
gap closure via Image J software. The wound closure rate (%) was calculated as Gap area (Hour X) / Gap 
area (Hour 0) × 100 (%). Ten repeats were evaluated for each cell line in each experiment. Shown are the 
average percentage of the closure of the wounds. Error bars represent standard deviation. **** represent 
p<0.0001, *** represent p<0.001 and ** represent p<0.01, respectively.
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Figure 5.6: Effect of miR-140-5p and -3p overexpression on the migration of gastric 
cancer cells using trans-well migration assay. Representative images of migrated cells are 
shown above the bar graph. **** represent p<0.0001, *** represent p<0.001 and ** represent p<0.01, 
respectively. N.A. stands for no significance. Error bars are the standard deviation. 
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5.3.6 Effect of miR-140-5p and -3p on invasion of gastric cancer cell 
The gain of an invasive phenotype is the most important cancer feature and the one that 
distinguishes malignant from benign tumours (Lazebnik 2010). In vitro, trans-well invasion 
assay was undertaken to determine whether miR-140-5p/3p is involved in regulation of 
invasiveness of gastric cancer cells. This assay is similar to the Trans-well migration but with 
Matrigel coating in the insert. The invasive ability of cells was determined by measuring the 
number of cells that attached to the matrix, invade into and through the matrix, and migrate 
towards a chemoattractant. Figure 5.7 shows that AGS, NUGC4, and MKN45 with 
upregulation of miR-140-5p or miR-140-3p showed significant impairment in their 
invasiveness. Overexpression of miR-140-5p/3p, however, had no influence on the invasive 
capacity of HGC27 cancer cells. 
Figure 5.7: Impact of overexpression of miR-140-5p and -3p on invasive capacity of 
gastric cancer cell lines. Representative images of invade cells after staining and absorbance 
measured by dissolving the crystal violet stained invaded cells (bar graph). **** represent p<0.0001, *** 
represent p<0.001 and ** represent p<0.01, respectively. N.A. stands for no significance. Three 
experiments were performed. Error bars represent standard deviation.
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5.3.7 Effect of miR-140-5p and -3p on chemotherapeutic drug-induced cell 
proliferation inhibition of gastric cancer cells
As previously mentioned, higher miR-140-5p is associated with chemoresistance in patients 
treated with 5FU based chemotherapy. To investigate the role of  miR-140-5p and -3p in 
anticancer drug-induced apoptosis/autophagy in gastric cancer cells, miRNA expression 
levels were first analyzed by q-PCR in gastric cancer following treatment with 5FU. Elevated 
miR-140-5p and -3p were demonstrated in AGS and NUGC4 following treatment with 5FU
(Figure 5.8). The cell viability of  gastric cancer cells that had been treated with 5FU and 
transfected with miR-140-5p/3p mimics or inhibitors, was determined using the MTT assay. 
As shown in Figure 5.8, transfection with miR-140-5p mimic resulted in growing drug 
resistance in NUGC4 cell line. Upregulation of  IC50 with also shown in AGS and MKN45
transfected with miR-140-5p, but it did not reach the statistical significance. However, 
upregulation of  miR-140-5p increased chemosensitivity in the HGC27 cell line. In 
accordance with these results, miR-140-5p inhibitor gave rise to a marked increase in 
sensitivity after treatment with 5FU in the AGS and NUGC4 cell lines. As shown in Figure
5.8, miR-140-3p mimic transfection resulted in a dose-dependent amelioration of  5FU
induced cell proliferation inhibition in NUGC4 cell lines but had no impact on other three 
cell lines. Accordingly, miR-140-3p inhibitor decreased chemoresistance in NUGC4 cell line, 
but not other cells transfected with miR-140-3p inhibitors.
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Figure 5.8: Impact of overexpression of miR-140-5p/3p on the drug-induced 
proliferation inhibition of gastric cancer cell lines. Cells were maintained for 48 hours with a 
series of gradient concentration 5FU, and the half maximal inhibitory concentration (IC50) for each cell 
line was determined by multi-proportion dilution method. Six wells were set for each cell lines. Non-linear 
regression with a sigmoidal fit model was used (GraphPad Prism). Shown are representative results of one 
experiment out of three being performed. Error bars represent standard deviation. **** represent 
p<0.0001, *** represent p<0.001 and ** represent p<0.01, respectively. 
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5.4 Discussion
This chapter has focused on the effect that the expression pattern of  miR-140-5p and miR-
140-3p has on the phenotypic behaviour of gastric cancer cell lines by proliferation, cell cycle, 
wound scratch, trans-well migration, invasion and apoptosis assays. Upregulated expression 
of  miR-140-5p indicates a favorable clinical prognosis in patients with the intestinal type of  
gastric cancer. An in vitro assay also suggested the tumour suppressor role of  miR-140-5p in 
intestinal gastric cancer. These are in agreement with the results Fang et al. demonstrated 
previously (Fang et al. 2017). However, since the current study employed a different method 
for colony formation (without pre-coated plates by agarose) compare to the previous study, 
the colony formation assay failed to reflect the miR-140-5p and -3p impacts on AGS cell line. 
However, in the diffuse type of  gastric cancer cell lines, we observed a negative regulating 
role in cell’s aggressiveness played by miR-140-5p in NUGC4 cell line with wild-type of  p53
and MKN45 cell lines with mutant but functional p53. Although not much significant results 
were found in HGC27 cell line transfected with mimic-5p, a significant inhibition of  invasion 
was shown in all examined cell lines, suggesting a strong inhibitory role of  miR-140-5p in 
cells’ invasive ability, despite a slight facilitation of the migration of  HGC27. 
The effect of  miR-140-3p on tumourigenesis has previously been only focused in NSCLC
and breast cancer. The inhibitory effect of  miR-140-3p on cell growth and cell invasion has 
been demonstrated in NSCLC by downregulating ATP8A1, which participates in the 
transportation of  exposure phosphatidyl-serine, which is a sign of  early apoptosis back to 
the inner layer, and in the formation of  membrane ruffles regulating cell motility, via both in 
vitro and in vivo assays (Dong et al. 2016). The shorter 3’UTR of  its target genes, for example,
Ki-67, may play an important role in its function in cancer (Yan et al. 2018). Furthermore, 
analysis of  miRNA-seq data from breast cancer cell lines, identified six pairs of  highly 
expressed miRNAs and associated 5'isomiRs. Among them, hsa-miR-140-3p was of  
particular interest because its 5'isomiR showed higher expression compared to the canonical 
miRNA annotated in miRbase. It was found that both the hsa-miR-140-3p and 5’isomiR-
140-3p were higher in ER-negative (ER-) patients. Triple negative breast cancer patients 
showed a trend towards better survival among patients with higher expression levels of  both 
hsa-miR-140-3p and 5’isomiR-140-3p. But it is the 5'isomiR-140-3p but not the hsa-miR-
140-3p caused cell cycle arrest in G0/G1-phase, and decreased cell migration. This suggested 
the highly expressed 5'isomiR of  hsa-miR-140-3p contributes to the tumour-suppressive 
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effects by reducing breast cancer proliferation and migration, and the endogenous canonical 
hsa-miR-140-3p reflected the expression level of  this isomiR (Salem et al. 2016). In the 
current study, overexpression of  miR-140-3p in gastric cancer cells had a similar 
antiproliferative effect as miR-140-5p overexpression to AGS and NUGC4 cell lines, but no 
influence on HGC27 and MKN45 cell lines. Also, miR-140-3p exerted an anti-invasive effect 
on all the cell lines except HGC27 cells. It is noticeable that, both miR-140-5p and miR-140-
3p could target ADAMTS-5, one of  the matrix‐degrading enzymes (Swingler et al. 2012).
To be mentioned, interfering expression of  miR-140-5p/miR-140-3p with miRNA mimics 
or inhibitor only showed marginal or no influence on cell cycle analysis assessed by flow 
cytometry, which could be explained by two possibilities. First, although the proliferation
changed greatly by miR-140-5p overexpression based on our MTT assay, the MTT assay 
measures metabolic activity (mainly succinate dehydrogenase) to reflect cell viability, which
could be affected by not cell cycle arrest, but cell senescence and cell apoptosis. Since both 
miR-140-5p and miR-140-3p are involved in cartilage development and arthritis, the second 
possibility is that miR-140-5p and miR-140-3p may exert complementary roles in a identical 
cell signalling pathway, although target different genes.
In conclusion, the downregulation of  miR-140-5p and miR-140-3p observed in human 
gastric intestinal-type cancer suggests its tumour suppressor role in regulating the cellular 
functions that are acquired by cancer cells during the disease progression, as reported in most 
other tumours (Wang et al. 2017; Hu et al. 2016; Tan et al. 2011; Kawaguchi et al. 2017; Yan 
et al. 2008). In contrast, miR-140-5p was upregulated in tumours compared to matched 
normal tissue in pancreatic cancers, a high expression of  miR-140-3p is also reported to be 
associated with worse progression in clear cell renal cell carcinoma (Guan et al. 2018). These 
in vitro assays demonstrated the complex roles that miR-140-5p and miR-140-3p do exert in 
tumour development. In addition, the inhibitory role of  miR-140-5p overexpression in the 
cell cycle is possibly the underlying mechanism for chemoresistance, especially for cell cycle-
dependent anti-proliferative drug 5FU. 
The combination of  fluoropyrimidine and platinum is used worldwide for the treatment of  
patients with advanced or metastatic gastric cancer in both the adjuvant and neoadjuvant 
setting. Fluoropyrimidines, particularly 5FU, still represent the backbone of gastric cancer 
chemotherapy, with response rates varying from 31% - 48%. Our results provide data that is 
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suggestive that this should be taken into account when selecting therapies in chemo-sensitive 
patients. In order to further determine the role of  miR-140-5p and miR-140-3p in gastric cancer, 
the following chapter will focus on the mechanisms of  their inhibitory effect on gastric cancer 
cells.
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Chapter 6.  
The Molecular Mechanism 
Underlying Deregulated miR-140-
5p Expression in Human Gastric 
cancer
188
6.1 Introduction
The previous chapter has shown that upregulation of  miR-140-5p may inhibit proliferation, 
adhesion, invasion, and migration of  AGS and NUGC4 gastric cancer cell lines but had little 
or no inhibitory effect in MKN45 and HGC27. The diverse outcomes of  miR-140-5p in vitro
assays of  gastric cancer cell lines echoed its variable function in gastric cancer tumour tissue 
analysis. Also, as discussed in Chapter 4, although-140-5p was generally accepted as a tumour
suppressor in the tumourigenesis of lung cancer, breast cancer, and colorectal cancer etc., a 
pro-oncogenic role of  miR-140-5p has also been implicated depending on different cell 
context. Molecules and pathways involved in these different roles played by miR-140-5p in 
gastric cancer are likely to be subspecies specific but are yet to be investigated. It has been
reported that loss of  miR-140-5p led to an impairment of  chondrocyte proliferation (Song 
et al. 2009) via upregulation of  SP1, a critical transcription factor in the inhibition of  the cell 
cycle via the activation of  the p15INK4b and p21Waf1/Clip promoters in vitro (Yang et al. 
2011). Tumour cells ectopically transfected with miR-140-5p showed upregulation of  p53 
and p21 expression accompanied with G1 and G2 phase arrest only in cell lines containing 
wild-type of  p53. Furthermore, miR-140-5p suppresses tumour cell migration and invasion 
by targeting ADAM10-mediated Notch1 signalling pathway in hypopharyngeal squamous 
cell carcinoma (Jing et al. 2016). Targets of  miR-140-5p, SOX9 and ALDH1 were the most 
significantly activated stem-cell factors in DCIS stem-like cells in breast cancer (Q. Li et al. 
2014b; Wolfson et al. 2014; Yan et al. 2008). A decreased level of  IGFBP-5, a miR-140-5p 
target (Tardif  et al. 2009), is related to disease recurrence in lung cancer (Shersher et al. 2011)
and to tamoxifen resistance in breast cancer. These may link to the restoration of  miR-140-
5p after releasing from the suppression by ERα. Exosomal levels of  miR-140-5p from stem 
cell populations can be rescued by treatment with sulforaphane (Q. Li et al. 2014b). Moreover, 
miR-140-5p appeared to be positively controlled by Rb and to antagonize the effect of  Rb 
depletion through targeting IL-6 (Yoshida et al. 2017). Rb depletion or inactivation in soft 
tissue sarcoma cells exhibited slower proliferation and less efficient BrdU incorporation, but 
much higher spherogenic activity and aggressive behavior both in vitro and in vivo. The 
induction of  IL-6 secretion and subsequent autocrine/paracrine activation of  STAT3 
signalling supports the self-renewal activity of  not only cancer cells (Marotta et al. 2011; 
Korkaya et al. 2012; Sansone et al. 2007), but also embryonic stem cells or induced 
pluripotent stem cells (Brady et al. 2013; Takahashi and Yamanaka 2016). With regard to 
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miR-140-5p in gastric cancer progression, there are still relatively few studies available and 
discrepancy was found between these studies. Plasma miR-140-5p was significantly higher in 
gastric cancer patients than in healthy controls (Shin et al. 2015). Aberrantly downregulated 
miR-140-5p in cancer tissue, compared with that in adjacent normal tissues, was determined 
by both q-PCR and in situ hybridization (ISH) in tissue microarrays (Fang et al. 2017). ISH 
analysis in 144 gastric cancer tissues revealed 32.6% of  the GC tissues showed reduced 
staining intensities of  miR-140-5p. Zhai et al. demonstrated that overexpression of  miR-140-
5p abolished tumour formation and metastasis in gastric cancer cells by directly targeting 
YES proto-oncogene 1 (YES1) which upregulated Src signalling (Fang et al. 2017). Based on 
these contrasting reports, the exact mechanism of action for miR-140-5p needs to be further 
investigated. The aim of  this chapter is to explore the pathways activated in miR-140-5p 
deregulation in gastric cancer progression.
6.2 Materials and methods
6.2.1 Materials
The primers used in this chapter are shown in Table 2.4, including MDM2, p53, p21, PTEN, 
and GAPDH. Details of  antibodies for detection of  MDM2, p53, p21, BAX, and GAPDH 
are shown in Table 2.5.
6.2.2 Online prediction of miR-140-5p targets. 
To identify functionally related pathways and genes that are associated with a miR-140-5p 
based gastrin cancer phenotype, we associated miR-140-5p expression with transcriptome 
for patients with accessible RNAseq information from TCGA and the Gene Set Enrichment 
Analysis (GSEA). This database contains full access to the complete list of  gene expression 
values and was employed to cross-compare prior lists of  differentially expressed genes
between gastric cancer patients with higher miRNA-140-5p expression (n=17) and lower 
miRNA-expression (n=54). According to the indicated pathway, the direct targets of  both 
miR-140-3p and miR-140-5p have been investigated by using the bioinformatics approach 
and in silico tools TargetScan, mirTarbase, and miRWalk. The literature review together with
the RNA-sequencing and protein array data from transfection with the biotinylated mimics
were obtained in a previous study carried out in the host lab (Flamini et al. 2018) and were 
merged to specify targets of  miR-140-5p. 
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6.2.3 Determining the expression of p53-related signaling molecules using PCR and 
Western blot.
Since the cell cycle-related pathway was highlighted and MDM2 was indicated as a potential 
target of  miR-140-5p, the p53-related pathway was chosen for further analysis. Both RNA 
and protein were extracted from gastric cancer cell lines transiently infected with miR-140-
5p or miR-140-3p mimic. The samples were analysed using either Western blot or PCR to 
detect the expression level of  these molecules. The methods used were as described in 
section 2.4 and 2.5.
6.2.4 Statistical analysis
Correlation between miR-140-5p and -3p and other genes in gastric cancer tissue samples 
was assessed using the Spearman correlation test via GraphPad Prime v 6.0 (GraphPad 
Software, San Diego, CA). 
6.3 Results
6.3.1 Integrative analysis of miRNA and mRNA expression in intestinal versus 
diffuse miR-140-5p downregulated gastric cancer. 
Gene enrichment analysis (GESA) of  mRNA expression was obtained using the GAGE 
package on KEGG pathways. High expression of  miR-140-5p strongly indicated an 
interaction between tumour cells and factors such as immune response, ECM biogenesis and 
VEGF signaling pathway (Table 6.1). Pathways related to cell biological behaviours assumed
absolute superiority, which included autophagy and cell adhesion (Table 6.2). Genes with 
reversed transcriptional trend in the phenotype with miR-140-5p suppression or not are 
summarized in Figure 6.1. Given our in vitro cell model only showed the loss of  miR-140-5p 
in gastric cancer progression, we focused on the genes specifically activated during miR-140-
5p suppression in the analysis. The genes positively regulated in miR-140-5p suppression 
phenotype included RTC, which E6 contributing to the immortalization epithelial cells
(Sherman et al. 2002), cell cycle regulator gene CTNN3 (Mizamtsidi et al. 2018), Cab39
regulating responses to metabolic stress and promoting survival, in part by activating AMP-
activated protein kinase (AMPK) and mTOR pathway(Shackelford and Shaw 2009), cell 
adhesion-related BVES-AS1 (Xing et al. 2018) and ILK promoting cell survival in a p53-
dependent manner (Hausmann et al. 2015). KIF13B involved in aberrant cytokinesis (Wu et 
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al. 2013). The enhanced cell survival associating pathway was the most representative feature 
in this phenotype. 
Table 6.1: The top 20 signalling pathway in gastric cancer associated with miR-140-5p upregulation in GSEA by KEGG. 
ES denotes enrichment score, which reflects the degree to which a gene set is overrepresented at the top or bottom of  a ranked list of  genes. A positive ES indicates gene 
set enrichment at the top of  the ranked list. NES denotes the normalized enrichment score. By normalizing the enrichment score, GSEA accounts for differences in gene 
set size and in correlations between gene sets and the expression dataset; therefore, the normalized enrichment scores (NES) can be used to compare analysis results across 
gene sets.
Pathway Name Size ES NES P
Primary immunodeficiency 35 0.62 1.60 0.07
Glycosaminoglycan biosynthesis chondroitin sulfate 22 0.58 1.56 0.07
Vegf signaling pathway 74 0.33 1.46 0.02
Intestinal immune network for IgA production 43 0.56 1.45 0.16
Ribosome 82 0.64 1.44 0.18
Homologous recombination 28 0.51 1.43 0.14
Complement and coagulation cascades 67 0.40 1.42 0.10
PPAR signaling pathway 69 0.35 1.38 0.07
Phenylalanine metabolism 17 0.44 1.36 0.11
B cell receptor signaling pathway 74 0.38 1.33 0.17
T cell receptor signaling pathway 107 0.35 1.29 0.18
FC epsilon ri signaling pathway 78 0.30 1.26 0.16
Alanine aspartate and glutamate metabolism 32 0.36 1.25 0.18
Spliceosome 122 0.43 1.23 0.30
Fc gamma r mediated phagocytosis 91 0.30 1.17 0.26
Leukocyte transendothelial migration 116 0.28 1.16 0.25
Chemokine signaling pathway 184 0.28 1.12 0.30
DNA replication 36 0.44 1.11 0.41
Cell adhesion molecules cams 128 0.31 1.11 0.34
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Table 6.2: The top 20 signalling pathway in gastric cancer associated with miR-140-5p suppression in GESA by KEGG.
Pathway Name Size ES NES P
Arrhythmogenic right ventricular cardiomyopathy 74 -0.51 -1.70 0.02
Regulation of autophagy 33 -0.43 -1.54 0.03
Hypertrophic cardiomyopathy hcm 83 -0.46 -1.52 0.04
Adherens junction 73 -0.40 -1.51 0.03
Long term depression 68 -0.37 -1.42 0.06
Dilated cardiomyopathy 90 -0.43 -1.39 0.11
Nicotinate and nicotinamide metabolism 21 -0.43 -1.37 0.09
Riboflavin metabolism 16 -0.47 -1.37 0.12
Pantothenate and coa biosynthesis 16 -0.47 -1.35 0.14
Oocyte meiosis 109 -0.34 -1.35 0.12
Vascular smooth muscle contraction 114 -0.38 -1.32 0.18
Vasopressin regulated water reabsorption 44 -0.37 -1.31 0.15
Long term potentiation 69 -0.35 -1.30 0.13
Phosphatidylinositol signalling system 76 -0.36 -1.30 0.15
Erbb signalling pathway 87 -0.33 -1.27 0.16
MAPK signalling pathway 263 -0.28 -1.26 0.11
Focal adhesion 199 -0.33 -1.25 0.21
Fatty acid metabolism 42 -0.42 -1.25 0.21
Linoleic acid metabolism 26 -0.42 -1.22 0.21
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Figure 6.1: Heat Map of the top 50 features for miR-140-5p accumulating or 
decreasing phenotypes. Red represents positive correlation and blue represents negative correlation. 
The top row labelled samples enrolled in the analysis. Yellow=those patients’ tumours harbouring higher 
miR-140-5p, Grey=those patients with lower miR-140-5p. The far-right column listed the genes that were 
positively correlated with higher miR-140-5p expression or lower miR-140-5p expression, respectively.
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6.3.2 Target prediction for miR-140-5p 
Identifying target mRNAs of  miRNAs is an important step in elucidating the function of  
miRNAs, yet this step has proven computationally difficult due to the complexity of  the 
miRNA–target interactions. Several target prediction programs have been developed, but the 
overlap between sets of  predicted target genes for a given miRNA by different programs is
unsatisifacted. Nevertheless, these target prediction programs are very useful to define 
potential targets that can be validated experimentally. Rather than switching off  their targets 
completely, miRNAs fine-tune their expression thus playing an important role in tumour
formation, development, differentiation, metabolism, and disease progression. miRNAs are 
incorporated into the RNA-induced silencing complex (RISC) and guide this complex to 
specific mRNAs that contain miRNA target sites, which can fall into three categories. 5′-
Dominant canonical target sites show perfect complementarity to the seed sequence of  the 
miRNA (nucleotides 2–8) and extensive base pairing to the rest of  the miRNA. 5′-dominant 
seed only target sites are also perfectly complementary to the seed sequence but have a 
limited base pairing with the rest of  the miRNA. 3′-compensatory target sites do not have a 
perfect match to the seed sequence but are compensated by extensive base pairing with the 
3′-half  of  the miRNA. Target sites are usually in the 3′-UTR of  mRNAs but there are 
examples of  target sites in other regions as well, and their flanking regions can also influence 
interaction with miRNAs. Translation of  mRNAs targeted by miRNAs is repressed and the 
steady-state level of  some but not all mRNA targets is also reduced. 
The online prediction with different algorithms generated a list of  more than 6000 potential
targets of  miR-140-5p in total, among which 3593 were predicted by at least two algorithms. 
However, the commonest predicted targets revealed by all the tools were only 13 (Appendix 
11). And we further merged the online predicted genes with the altered transcriptomic and 
proteomic data from a lung cancer cell line (A549) following the transfection of  negative, 
miR-140-5p and miR-140-3p miRNA mimics (Flamini et al. 2017). 
The putative target genes were classified according to the Gene Ontology (GO) categories 
(Figure. 6.2). Most of  the targets were shown related to regulation of  growth, cell cycle, cell 
apoptosis and development. Given the results of  our previous cell function assays and GSEA 
analysis, MDM2, which was predicted by online prediction tools and suggested as a potential 
target of  miR-140-5p in the literature (Nicolas et al. 2008) was further chosen as the object 
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for further validation. 
MDM2 was originally identified as one of  three mdm genes whose expression is increased 
more than 50-fold in the spontaneously transformed mouse BALB/c cell line and was later 
proven to be the reason for the transformation (Fakharzadeh et al. 1991). Via binding to the 
tumour suppressor p53, MDM2 inhibits p53 transactivation function by engaging its amino-
terminal transactivation domain via related N-terminal hydrophobic pockets (Momand et al. 
1992; Laurie et al. 2006; Kussie et al. 1996). The wild type p53 is involved in the sensing of  
cell stress and DNA damage, resulting in regulation of  the cell cycle and apoptosis. An 
interaction between the central acidic domain of  MDM2 and the speciÀc DNA-binding 
domain of  p53 is essential for p53 ubiquitination via the RING domain of  MDM2 and leads 
to proteasomal degradation of  p53; this keeps p53 levels and activity low in unstressed cells. 
Mice which do not possess the mdm2 gene die before embryonic implantation due to 
inappropriate apoptosis, with a total phenotypic rescue being possible through simultaneous 
deletion of the p53 gene. Moreover, mice which express just 30% of  the normal levels of  
MDM2 exhibited decreased body weight and defects in haematopoiesis. These in vivo
experiments have provided compelling evidence towards the importance of  the MDM2/p53 
interaction. Of  note, this interaction could be disrupted by multiple transcriptional 
modification. Besides, MDM2 has also been shown to affect translation of  p53, by 
interacting directly with the mRNA encoding p53 itself  and by targeting RPL26, which, upon 
DNA damage, can associate with p53 mRNA and increased its protein expression (Manfredi 
2010). The E3 ubiquitin ligase activity of  MDM2 depends on an intact carboxy-terminal the 
really interesting new gene (RING) finger domain. The p53-interaction domain is situated at 
the amino terminus, which in turn binds to the amino transactivation domain of  p53. 
Although many short MDM2 proteins encoding just the carboxyl terminus of  MDM2, 
without the p53-binding domain, have been identified, in many cases, the frequency of  
MDM2 deregulation is higher in tumours that retain wild-type p53 (Wade et al. 2013). The 
p53 protein transcriptionally activates many genes, including the mdm2 gene. Therefore, p53 
is regulated at protein level by MDM2, but once active, p53 activates the transcription of  the 
mdm2 gene, locking the proteins into a tight negative feedback loop and resulting in 
oscillation of  the cellular levels of  the two proteins. Thus, MDM2 and p53 levels plays a crucial 
role in regulating cell proliferation and apoptosis, loss of  MDM2 leads to an active p53 which 
may determine the vital status of  the cell or embryo. Intriguingly, single-nucleotide 
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polymorphism (SNP) in the MDM2 promoter increased MDM2 expression and altered the
oscillation relationship. Similarly, point mutations in the two p53-binding sites of  the Mdm2 
promoter that were introduced into the endogenous Mdm2 locus resulted in increased response 
to DNA damage, although p53 degradation kinetics in various tissues remained similar to the 
wild-type control. This highlights the importance of  understanding the distinct roles of  MDM2 
in different tissues (Karni-Schmidt et al. 2016). Apart from its involvement in p53-dependent 
activities, MDM2 has p53-independent activities, including induction of  stemness by 
supporting polycomb repressor functions and K48-linked ubiquitination of  the Notch 
antagonist Numb (Todoric et al. 2017). A study of  human sarcomas and bladder cancers 
found tumours which overexpressed MDM2 and mutant p53 and the patients possessing 
both of  these abnormalities had a poorer prognosis than those with just one (Onel and 
Cordon-Cardo 2004; Cordon-Cardo et al. 1994). Given its role as a negative regulator of  p53, 
as well as its overexpression in human tumours, the notion of  Mdm2 as an oncogene is quite 
reasonable. Nevertheless, as reviewed by Manfredi (2010), there is a growing body of  
evidence to suggest that Mdm2 may also exert effects as a tumour suppressor in certain
experimental conditions. In gastric cancer, MDM2 promoter polymorphism is associated 
with both an increased susceptibility to gastric carcinoma and poor prognosis (Ohmiya et al. 
2006). Amplified MDM2 gene is associated with chromosomal instability (Lee et al. 2014).
The previous chapter has shown that miR-140-5p restoration resulted in inhibition of  in 
vitro cell cycle progress and proliferation of  gastric cancer cells. Together with the role of  
MDM2-p53 interaction in the regulation of  cell cycle and apoptosis, we hypothesised that 
one of  the mechanisms by which miR-140-5p influence the growth rate of  gastric cancer 
cells is via the suppression of  MDM2 and activation of  p53. 
0 5 1 0 1 5 2 0
n e g a t i v e  r e g u l a t i o n  o f  a p o p to s i s
p o s i t i v e  r e g u l a t i o n  o f  m o l e c u l a r  fu n c t i o n
c e l l  a c t i v a t i o n
r e g u l a t i o n  o f  t r a n s fe r a s e  a c t i v i ty
h e m o p o i e t i c  o r  l y m p h o i d  o r g a n  d e v e l o p m e n t
r e g u l a t i o n  o f  c e l l  d e a th
u r o g e n i ta l  s y s te m  d e v e l o p m e n t
r e g u l a t i o n  o f  p r o g r a m m e d  c e l l  d e a th
p o s i t i v e  r e g u l a t i o n  o f  c e l l u l a r  c o m p o n e n t  o r g a n i z a t i o n
p o s i t i v e  r e g u l a t i o n  o f  c e l l  s i z e
g l a n d  d e v e l o p m e n t
p o s i t i v e  r e g u l a t i o n  o f  k i n a s e  a c t i v i ty
r e g u l a t i o n  o f  a p o p to s i s
p o s i t i v e  r e g u l a t i o n  o f  p r o te i n  k i n a s e  a c t i v i ty
l e u k o c y te  a c t i v a t i o n
p o s i t i v e  r e g u l a t i o n  o f  c e l l  p r o j e c t i o n  o r g a n i z a t i o n
a n t i -a p o p to s i s
p o s i t i v e  r e g u l a t i o n  o f  c e l l  g r o w th
p o s i t i v e  r e g u l a t i o n  o f  g r o w th
p o s i t i v e  r e g u l a t i o n  o f  t r a n s fe r a s e  a c t i v i ty
F o ld  E n r ic h m e n t
Figure 6.2: The Gene Ontology (GO) category analysis of merged predicted targets of miR-140-5p from in silico analysis, RNA seq and 
Protein array data. The relative expression was adopted from the RNA seq results by Nicolas (Nicolas et al. 2011).
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6.3.3 Possible link between miR-140-5p and MDM2 in gastric cancer tumour tissues
The possible correlation between miR-140-5p and MDM2 was first evaluated in gastric 
cancer patients’ transcriptome data from TGCA using the Spearman correlation test. A 
significant negative correlation was seen between miR-140-5p and MDM2 (Figure 6.3). 
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Figure 6.3: Correlation between miR-140-5p and MDM2 in gastric cancer (TCGA).
To validate this discovery, a similar correlation analysis was performed in the gastric cancer 
patients’ cohort from Beijing Cancer Hospital. The negative correlations between miR-140-
5p and MDM2, and between miR-140-3p and MDM2 was also observed but did not reach 
statistical significance. Interestingly, miR-140-5p and miR-140-3p showed significant co-
expression pattern in our analysis (Table 6.3).
Table 6.3: Correlation between miR-140-5p/3p and MDM2 in gastric cancer (Beijing cohort).
Note: Cor = Correlation coefficient. N= Number of samples
mir-140-3p MDM2
miR-140-5p Cor=0.54
P<0.00
N=75
Cor=-0.11
P=0.34
N=76
miR-140-3p Cor=-0.14
P=0.22
N=81
P<0.01
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6.3.4 miR-140-5p and miR-140-3p overexpression and p53 signaling
The negative correlation between miR-140-5p and MDM2 was observed in tumour tissue 
analysis in both cohorts of  gastric cancer. We then used qPCR and Western blots to address 
whether the correlation is associated with deregulation of  downstream genes and signaling
pathways.
The expression of  MDM2, its direct target p53 and the downstream effector p21 were firstly 
determined by qPCR in gastric cancer cell lines under normal conditions. The results showed 
increased p21 expression at the transcriptional level. There was no significant difference at 
the mRNA level in the expression of  MDM2 or p53 in miR-140-5p overexpressed cells 
compared with corresponding negative control. (Figure 6.4). 
Figure 6.4: One-way ANOVA comparations of relative expression of MDM2, p53, 
and p21 in miR-140-5p and miR-140-3p overexpression gastric cancer cell lines. Shown 
are representative results n=3. Error bars represent standard deviation. ** represent p<0.01, respectively.
To detect whether miR-140-5p affects the expression of  MDM2 at the protein level, we 
examined the expression of  MDM2 and its object of  action using Western blot. A decreased 
MDM2 expression was seen in miR-140-5p or -3p overexpressing cells compared to 
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corresponding transient transcription of  the negative control. Conversely, the increased 
protein level of  p53 was seen in all examined gastric cancer cell lines following miR-140-5p 
or -3p expression. In the examination of  p21 expression, increased p21 was only seen in 
AGS and NUGC4 cell lines which harbored wild-type p53, suggesting that miR-140-5p or 
miR-140-3p may have a role in MDM2/p53/p21 signaling (Figure 6.5).
Figure 6.5: The expression of MDM2, p53, and p21 in the miR-140-5p and miR-140-
3p overexpression gastric cancer cell lines. Quantification of  immunoblots was performed 
using the ImageJ software, after densitometric analysis of  the corresponding bands detected upon 
revelation with a peroxidase-coupled secondary antibody.
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MDM2, as a chief  negative regulator of  p53 (Bond et al. 2005), restrains p53 activity by firstly 
binding and cutting off  p53 from p53 target gene promoters (Momand et al. 1992). It 
contains a RING domain with E3 ubiquitin ligase activity which can ubiquitinate p53,
resulting in p53 degradation through a negative feedback loop (Chen et al. 1995). Thus, 
MDM2 can induce a rapid tumour growth by inhibiting p53 signaling pathways, which is in 
agreement with our cell proliferation assay. However, the cytotoxic assay in our study 
suggested an augmented cell resistance to 5FU treatment in gastric cancer cell lines with wild-
type p53. To clarify the role of  p53 in drug-induced apoptosis, we explored the apoptosis-
related genes’ expression in NUGC4 and AGS cell lines. Western blots showed a relative 
mildly reduced MDM2 in the miR-140-5p overexpressing cells after treating with 5FU. 
Induced p53 was observed in all the cell lines with 5FU treatment, but comparison in 
different transfection groups did not differ. However, the proapoptotic factor BAX showed 
a slightly decrease in AGS miR-140-5p overexpressing cells and a significantly decline in 
NUGC4 miR-140-5p overexpression cells. (Figure 6.6). 
Figure 6.6: Abated activation of MDM2/p53/BAX signaling in miR-140-5p overexpression cells 
was determined using Western blot. 
The inconsistency shown from the tissue sample analysis, where miR-140-5p upregulation 
indicated a chemosensitive promoting role in NACT gastric cancer cohort, provoked further 
analysis to compare the miR-140-5p expression status in negative control transfected cells 
and in miR-140-5p mimic transfected cells after 5FU stimulating. The qPCR result 
demonstrated that a high-level miR-140-5p showed a relatively slower and lesser upregulation 
of  miR-140-5p compared to the upregulated level of  miR-140-5p in negative control 
transfected cells, pre- and post-treated with 5FU (Figure 6.7). 
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Figure 6.7: 5FU induced miR-140-5p upregulation in cells with higher miR-140-5p 
before treatment. Results are triplicated analysis from two independent experiments.
6.4 Discussion
Generally, malignant cells acquire the ability to undergo de-regulated mitogenesis, to resist 
proapoptotic insults, and to invade through tissue boundaries during progression. Several 
aberrant cellular signalling pathways orchestrate these malignant traits in any particular type 
of  cancer tissues (Giancotti 2014). MDM2, as well as its homolog MDMX, is best 
understood as a negative regulator of  the p53 tumour suppressor to exert oncogenic activity,
although it has additional p53-independent roles (Karni-Schmidt et al. 2016). The p53 
protein consists of  two N-terminal transactivation domains followed by a conserved proline-
rich domain, a central DNA binding domain, and a C terminus encoding its nuclear 
localization signals and an oligomerization domain needed for the transcriptional activity. In 
normal and unstressed cells, p53 protein is maintained at low levels by a series of  regulators 
including MDM2 (Kubbutat et al. 1997; Haupt et al. 1997). However, p53 is stabilized in 
response to various cellular stresses. For instance, DNA damage promotes p53 
phosphorylation, blocking MDM2-mediated degradation (Shieh et al. 1997). Largely through 
its function as a sequence-specific transcriptional factor, p53 regulates a plethora of  genes 
whose products mediate a variety of  cellular pathways. The best-understood functions of  
p53 focus on its ability to promote cell cycle arrest and apoptosis. Indeed, from the early 
1990s, seminal studies showed that p53 is crucial for a reversible G1 phase checkpoint, which 
is mediated, in part, by its ability to transcriptionally activate the p21 cyclin-dependent kinase 
inhibitor gene. p53 can also promote apoptosis, relying on the induction of  pro-apoptotic 
BCL-2 family members whose action facilitates caspase activation and cell death. An ever-
growing body of  work suggests that p53 also controls additional “non-canonical” programs 
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that contribute to its effects. As examples, p53 can modulate autophagy, alter metabolism, 
repress pluripotency and cellular plasticity, and facilitate an iron-dependent form of  cell 
death known as ferroptosis. The p53 response is remarkably flexible and depends on the cell 
type, its differentiation state, stress conditions, and collaborating environmental signals.
Approximately 30% of  gastric cancers have been found to have p53 mutation or deletion. 
MDM2 expression is positively regulated by p53 transactivation by a feedback loop. 
Amplified MDM2 has been reported in more than 10% of  gastric cancers. 
Our initial analysis via GESA and online prediction tool to determine the cellular signaling 
pathways that are altered in gastric cancer according to miR-140-5p status found an 
enrichment of  cell cycle pathway related transcriptome alteration, which was in line with the 
omics-based findings in a previous study of  miR-140-5p in lung cancer. Especially, MDM2
was suggested as a potential target of  miR-140-5p. 
In this study, we aimed to investigate changes in MDM2 and its downstream signalling in 
gastric cancer cell lines with miR-140-5p overexpression. The co-expression analysis in the 
TCGA cohort and the Beijing cohort of  samples revealed a negative correlation between 
miR-140-5p expression and MDM2 in both cohorts. It was initially indicated that 
downregulation of  miR-140-5p might contribute to disease progression of  gastric cancer via 
increasing MDM2 expression. We then showed that forced miR-140-5p expression by 
transient transfection of  mimic did not influence MDM2 expression at the transcriptional 
level in gastric cancer cells, but we saw a significant reduction of MDM2 at translational 
levels. Due to the possible limitation in recapitulating the actions of  endogenous miRNAs 
via transfection of  miRNA mimic (Jin et al. 2015), whether miR-140-5p directly suppresses 
MDM2 expression is yet to be elucidated. Meanwhile, p53 was upregulated, as was the p21, 
but only in cells with an intact p53 function. This suggested that miR-140-5p was involved 
in the transcriptional regulation of  MDM2 via a direct or indirect way. Additionally, such a 
regulation may lead to different cell response, at least partly depending on p53 status. For 
example, miR-140-5p overexpression leading to a slight but significant cell cycle arrest in 
both AGS and NUGC4 cell lines which harbour wild-type p53. Although both AGS and 
NUGC4 are p53 functional cell lines, there is some difference in the cell functions and 
protein alterations between these two cell lines after miR-140-5p transfection. This may be 
explained by the fact that most miRNAs exert mild repression on many targets and act as 
rheostats, fine-tuning the expression of  hundreds of  genes to reinforce cell fate decisions 
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brought about through other mechanisms (Vidigal and Ventura 2015); Secondly, there is an 
emerging paradigm that miRNA can be not only cell-type or tissue-specific “signatures” for 
certain normal or cancerous tissues, but also functional or inoperative to certain genes 
depending on the molecular and cellular context (Zhang et al. 2015). For example, AGS is a 
TGF-β/Smad/cMyc activated cell line other than NUGC4 cell line (Periasamy et al. 2014)
and TGF-β receptor I and SMAD3 were experimentally validated as miR-140-5p’s direct 
targets (Pais et al. 2010; Zhang et al. 2015). Interestingly, accumulation of  miR-140 could 
also be transiently suppressed by TGF-β (Pais et al. 2010; Tardif  et al. 2013).
We then focused on whether regulation of  miR-140-5p on MDM2 still conserved during 
cells’ response to 5FU, a cell-cycle-dependent cytotoxic drug. We found that 5FU treatment 
resulted in lower MDM2 expression and upregulated p53. However, miR-140-5p upregulated 
cells did not induce as much p53 accumulation as paired control cells without miR-140-5p 
overexpression before drug treatment. Moreover, a decreased BAX was shown in cells with 
upregulated miR-140-5p. Although current analysis supported MDM2 as a possible target of  
miR-140-5p, this requires further work to determine the direct target site(s) and confirmed 
with an intervention such as a dual-luciferase reporter gene system. A rescue analysis could 
be considered in a miR-140-5p stably transfected cell model which could provide more 
evidence about the interaction between miR-140-5p and MDM2 and its downstream 
effectors. The correlation between miR-140-5p/3p expression and protein expression and 
activation of  MDM2/P53 in human gastric cancer tissues collecting before and after drug 
treatment should be further examined using immunochemical or other techniques. Morover
qPCR analysis suggested that miR-140-5p did not increase after 5FU treatment in an already 
higher miR-140-5p cell type. However, this was only implied in an in vitro cell model with a 
transient transfection. Further evaluation in a stable transfection situation and in vivo mice 
model should be investigated to evaluate this reaction following treatment with 5FU. In 
addition, ectopic expression in the current study addressed the question of  whether miR-
140-5p can exert a specific function on cell cycle-related genes, while loss-of-function studies 
are still required to test whether it is also necessary for these functions.
During cytotoxic-induced cellular stress, p53-mediated processes can be antagonistic: cancer 
cell growth in G1 phase may lead to an impairment of  5FU which exerts its anticancer 
effects through inhibition of  thymidylate synthase (TS) and incorporation of  its 
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metabolites into RNA and DNA mainly in S (synthesis) phase (Focaccetti et al. 
2015). Additionally p53 could also modulate autophagy which has the potential to 
delay apoptosis (Thorburn et al. 2014), However, it was reported that in situations 
where p53 failed to repress glycolysis, apoptosis would be favoured (Duan et al. 
2015). Thus, the molecular interaction between distinct biochemical processes 
controlled by p53, as well as its translocation sites (Park et al. 2016; S. Wang et al. 
2017) might be explored to elicit different biological outcomes.
Taken together, our study provided evidence that miR-140-5p regulated the cell cycle through 
an MDM2/p53 regulatory feedback loop, which may contribute to the promotion of  cell 
proliferation and anti-apoptosis, although further investigations remain necessary. 
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Chapter 7. 
General Discussion
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Extensive evidence has suggested that miRNAs are crucial regulators of  gastric 
carcinogenesis and progression via alteration of  cell growth, cell cycles, apoptosis, and cell 
migration. Several groups have analyzed the global miRNA content in gastric cancer with 
the use of varying amounts of tumour samples, diverse reference samples as well as various 
types of  large-scale methods. Current progress in understanding the role of  specific miRNAs 
recognized as deregulated in gastric cancer cells has been reviewed (Pan et al. 2013; Liang et 
al. 2017; Hao et al. 2017). The comprehensive multi-platform genomics data generated by 
TCGA provides a large-scale miRNA profiling of  gastric cancer for both tumour and 
adjacent normal samples, and is the largest of  its type worldwide (Chu et al. 2016). As shown 
in the TCGA analysis, integrative miRNA expression analyses could be useful for the 
identification of  subclasses and subtype-specific drivers of  expression changes of  gastric 
cancer (Cancer Genome Atlas Research 2014; Liu et al. 2018).
Figure 7.1: The techniques used in this study
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In this study (Figure 7.1 Technical Route), we investigated the genome-wide miRNA 
expression pattern in gastric cancer from TCGA database. Three analytical approaches
(linear model fitting, unpaired and paired t-test) were performed for analysis of  differentially 
expressed miRNAs in gastric cancer tissues and adjacent to tumour stomach samples. 
Moreover, we conducted both the generalized linear model and the linear model in order to 
discover potential gastric cancer biomarkers, not only to distinguish gastric cancer tissues 
from normal stomach, but also to provide therapeutic or prognostic biomarkers. We 
identified 16 potentially novel prognostic miRNA biomarkers of gastric cancer, out of  which 
ten were negatively correlated, and six were positively correlated with OS of  gastric cancer 
patients. Although their expression and role in gastric cancer need further experimental 
investigation, computational analysis indicated that these miRNAs seemed to be potential 
prognostic biomarkers for gastric cancer. miR-140 in particular, seemed to be interesting in 
terms of  its downregulation in tumour tissues compared to normal samples, but higher 
expression in advanced gastric cancer tissues, reflecting its multiple identities in gastric cancer 
progression. Very few studies have taken into account the different histological subtypes of  
gastric cancer, miR-140-5p although generally accepted as a tumour suppressor in many 
cancers, including non-small cell lung cancer (Wang et al. 2017; Tang et al. 2017; Flamini et 
al. 2017; Zhang et al. 2016; Dong et al. 2016; Tan et al. 2011; Hu et al. 2016; Yuan et al. 2013),
primary breast cancer (Yan et al. 2008; Kawaguchi et al. 2017; Yan et al. 2018; Q. Li et al. 
2014a; Wolfson et al. 2014; Gullu et al. 2015; Gernapudi et al. 2015), colorectal cancer (Song 
et al. 2009; Zhai et al. 2015; J. Li et al. 2018; L. Yu et al. 2016; Piepoli et al. 2012) gastric 
cancer (Fang et al. 2017), oesophageal cancer (Li et al. 2014), epithelial ovarian cancer (Su et 
al. 2016; Lan et al. 2015; Iorio et al. 2007), basal cell carcinoma of  the skin (Sand et al. 2012b), 
cutaneous squamous cell carcinoma (Sand et al. 2012a), hepatocellular carcinoma (Yang et al. 
2013) osteosarcoma (Song et al. 2009; Xiao et al. 2017; Wei et al. 2016; Gu et al. 2016), 
gliomas (Malzkorn et al. 2010; Zhao et al. 2016), glioblastoma (Bo et al. 2015), and T-cell 
acute lymphoblastic leukaemia (Correia et al. 2016). By targeting various targets, miR-140-5p 
has shown to critically involved in tumour cell proliferation, apoptosis, vascularization, 
migration, and invasion. These previously confirmed targets include HDAC4, Sp1, IGF1R, 
MMD, TGFBR1, Smad2, Smad3, FGF9, BMP2, SOX2, SOX9, Slug, and ADAMTS5
(Summarized in Table 7.1). 
However, miR-140-5p has also been implicated as having a possible oncogenic role in splenic 
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hemangiosarcoma (Grimes et al. 2016), chordomas (Bayrak et al. 2013), clear cell renal cell 
carcinoma (Guan et al. 2018), and Hodgkin lymphoma (Khare et al. 2017). Moreover, its 
upregulation was correlated with malignant progression of  gliomas (Malzkorn et al. 2010), 
disease recurrence in lung cancer (Shersher et al. 2011), and to chemoresistance in breast 
cancer (Ahn et al. 2010; Chen et al. 2016). A miRNA profiling study on salivary gland
tumours showed that miR-140-5p was downregulated in tumour subtypes with low malignant 
potential but showed an upregulation trend in histological subtypes with high malignant 
potential (Bostjancic et al. 2017). 
miR-140-5p/3p is encoded within intron 16 of  Wwp2, an E3 ubiquitin ligase on 
chromosome 16q22.1 (Inui et al. 2018). Extensive studies have demonstrated its role in 
mediating embryonic development and regeneration, especially in cartilage development
(Miyaki et al. 2010; Araldi and Schipani 2010; Papaioannou et al. 2015; Mahboudi et al. 2018; 
Plociennikowska et al. 2015), such as by targeting CXCL12 (Thorpe et al. 2010), IGF-I(Pando 
et al. 2014), TLR-4 (Sun et al. 2017), and FGF9 (Yin et al. 2015). MiR-140-deficient mice 
manifested a mild skeletal phenotype, with short stature and low body weight, as well as 
craniofacial deformities characterized by a short snout and domed skull, supporting the 
notion that miR-140 is a tissue-specific miRNA significant in chondrocyte development and 
maintenance and ECM synthesis (Miyaki et al. 2010; Araldi and Schipani 2010; Papaioannou 
et al. 2015; Papaioannou et al. 2013). miR-140-5p also play an important role in various 
inflammatory diseases, such as osteoarthritis (Iliopoulos et al. 2008; Gabay and Clouse 2016), 
asthma (Guedes et al. 2015), pulmonary arterial hypertension (Rothman et al. 2016) and 
chronic inflammation induced oxidative stress injury such as coronary artery disease
(Marques et al. 2016) and type 2 diabetes (Ortega et al. 2014). In vivo studies of  miR-140-
deficient mice showed age-related osteoarthritis-like changes characterized by proteoglycan 
loss and fibrillation of  articular cartilage, and by 12 months, miR-140-deficient mice showed 
severe structural cartilage defects, while transgenic mice with overexpressed miR-140 in 
cartilage were resistant to antigen-induced arthritis, which indicates suppression of  miR-140 
expression and plays an important role in diseases associated with cartilage destruction
(Miyaki et al. 2010). Targets of  miR-140-5p, HDAC4, BMP2, SMAD3, IGFBP5, and Adamts-
5, were all responsible for enhanced cartilage destruction (Tardif  et al. 2013; Clemmons et 
al. 2002). In this present study, the role played by miR-140-5p/3p in gastric cancer was 
examined.
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7.1 Deregulated miRNAs in gastric cancer
With the latest released TCGA data, we utilized distinct analysing algorithms (DESeq2, glm 
and lm) compared to existing research (Shrestha et al. 2014; Ding et al. 2017) and identified 
a new group of  DEMs and prognostic related DEMs in primary gastric cancer. In all 207 
differentially expressed miRNAs were determined in this study, among which 65 miRNAs 
were downregulated and 142 miRNAs were upregulated.
Almost simultaneously, Ding et al. (2017) explored dysregulated miRNAs in gastric cancer 
by using the raw counts of  miRNA expression data of  41 paired tumour and normal tissues 
cancer from TCGA. miRNA expression was normalized by the R/Bioconductor package 
edgeRv. Their results discovered 138 differentially expressed miRNAs (logFC > 1 or logFC 
< −1, P < 0.05 after FDR adjustment). We compared results and found 100 miRNAs which 
are consistently deregulated in both analyses (Appendix 8). There is no optimal pipeline for 
the variety of  different applications and analysis scenarios in which RNA-seq can be used. 
Independent comparison studies have demonstrated that the choice of  method (or even the 
version of  a software package) can markedly affect the outcome of  the analysis and that no 
single method is likely to perform favourably for all datasets. Repetition of  important 
analyses using more than one package should be considered to improve the reliability of  
differential gene expression analysis (Conesa et al. 2016). 
According to the system review by Shrestha et al. (2014) a total of  352 differentially expressed 
microRNAs were reported in 14 miRNA expression profiling studies which compared 
gastric cancer tissues with normal tissues. 120 microRNAs were reported in at least in two 
studies, which is similar to the comparative analysis between Ding et al.’s (2017) work and 
ours. Among the 120 differentially expressed miRNAs, 69 miRNAs had a consistent
direction of  expression, in which 41 were reported to be upregulated and 28 down-regulated. 
The review indicated that in the group of  consistently reported miRNAs from 14 various 
publications, miR-21 was reported upregulated in 10 studies followed by miR-25, miR-92, 
and miR-223 upregulated in eight studies. miR-375 and miR-148a were found downregulated 
in six and five studies, respectively, followed by miR-638 in four studies. Of  note, miR-107 
and miR-103 were reported in nine and eight studies, respectively, but their expression was 
inconsistent (Shrestha et al. 2014). We further overlapped this vote ranking results with our 
analysis and Ding et al.’s, and 18 and 17 consistently deregulated miRNAs were found 
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respectively (Appendix 8). 12 miRNAs were reported in all three analyses (Table 3.3). Among 
these, downregulation of  miRNA-100 and upregulation of  miR-188 were demonstrated on 
TCGA data, however, they represented a contrary tendency in the review analysis. The 
unsatisfactory agreement between results obtained from different tools might be due to 
different parameter settings, especially for genes that are expressed at low levels. As RNA-
seq has become the standard method for transcriptome analysis, but the technology and tools 
are continuing to evolve. The heterogeneity of  tumour characteristics between tumours is 
equally deserving of  attention. 
Lymph node metastasis (LNM) is one of  the most important risk factors of  gastric cancer 
recurrence after curative surgery. The 5-year survival rates of  pathological N stages were as 
follows: N0 (83.5%), N1 (57.8%), N2 (27.4%), and N3 (11.4%). As a result, pathological N
stage is one of  the independent prognostic factors of  gastric cancer (Fang et al. 2011). 
Moreover, the occurrence of  lymph node metastases after endoscopic submucosal dissection 
(ESD) in patients with gastric cancer leads to a poor prognosis. Using logistic regression, Liu 
et al. identified miR-100 and other 3 miRNAs (miR-27b, miR-128, and miR-214) which were 
associated with LNM in GC patients. Expression of  miR-27b, miR-128, miR-100, and miR-
214 were down-regulated in GC samples with LNM (Liu et al. 2017). Similarly, miRNA 
microarray analyses were performed for 5 patients with LNM and 5 patients without LNM 
and found that miR-188-5p as well as miR-451, miR-497, miR-1207-5p, miR-30a-5p, let-7e, 
let-7g, let-7f, miR-96, and let-7a significantly dysregulated between patients with or without 
LNM. However, further confirmation demonstrated that, with the exception of  miR-1207-
5p, there was no significant correlation between lymph node metastasis and the expression
of  other miRNAs (Huang et al. 2015).
In Yepes et al.’s (2016) study aimed to characterize miRNA expression profiles and identify 
key miRNAs related to gastric carcinogenesis and histopathological traits, using co-
expression networks and supervised analysis, miR-100 together with miR-195, let-7c, miR-
140, miR-99a, and miR-125b, was determined to be highly correlated with the diffuse subtype. 
Despite the evident morphological differences that allow classification of  tissues into 
intestinal and diffuse subtypes, the expression patterns that differentiate these subtypes are 
subtle. This may become much clearer when the correlations between genes and progression 
characteristics, such as TNM staging are analyzed. 
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Another aspect of  this study on DEMs of  TCGA gastric cancer subgroups (Appendix 9) 
also as well demonstrated such variability. A large proportion of  DEMs distributed across 
four subtypes of  gastric cancer (EBV, MSI, GS, and CIN). Some of  them exhibited distinct 
expression in specific subgroups. For example, EBV subgroup exhibited suppressed miR-
193a-5p downregulation and upregulated miR-181a-2-3p, miR-134-5p, miR-199b-5p miR-
199a-5p/3p and miR-217. Decreased miR-143-5p, miR-125b-5p, miR-26a-5p, miR-140-3p, 
miR-30d-5p and increased miR-135b-5p were only characterized in the CIN subgroup. The 
GS subgroup featured a lack of  miR-582-3p, miR-10a-5p, but gain of  let7f-5p, miR-361-3p, 
let-7d-3p, miR-15b-3p, and miR-155-5p expressions. In the MSI group, non-downregulated 
miRNA but unique upregulation of  miR-16-5p, miR-29b-3p, miR-24-3p, miR-484, miR-128-
3p, let-7i-5p, miR-223-3p and miR-200b-5p were detected. 
With regard to prognosis related miRNAs, except for miR-21, we discovered 15 more 
miRNAs related to gastric cancer patients’ outcome based on current analysis methods. 
Among 6 downregulated miRNAs, miR-5683 has been reported to be implicated in 
maintaining the differentiated state of  muscle cells (Doerrenberg et al. 2017) and was also 
pinpointed to be one of  down-regulated miRNAs in TCGA based gastric cancer analysis by 
Huo (Doerrenberg et al. 2017). Down-regulated miR-28 in gastric cancer samples compared 
with normal stomach tissue samples was also found by Kim et al. (Kim et al. 2011). A former 
study defined that miR-28-5p and miR-28-3p had distinct effects on colorectal cancer cells
(Almeida et al. 2012). However, their roles in gastric cancer were not yet demonstrated. miR-
193a (Lujambio et al. 2007; Ando et al. 2009), and miR-129 are reported in methylation
associated gastric cancer, their low expression was associated with poor clinicopathological 
features (Tsai et al. 2011), miR 34b was also distinguished as a methylation-associated 
miRNA (Tsai et al. 2011), but in our study, it was upregulated and had a negative relationship 
with gastric cancer outcomes. Upregulated miR-328 is widely underexpressed in many 
cancers and contributes to tumour resistance to chemotherapy (Li et al. 2010). Macrophage-
derived reactive oxygen species play a role in suppressing miR-328 targeting CD44 in cancer 
cells and promote redox adaptation (Ishimoto et al. 2014). High miR-140-5p levels have been 
detected in the plasma of  gastric cancer patients (Shin et al. 2015), whereas low miR-140-5p 
level was found in cancerous tissues compared with that in adjacent gastric mucosa tissues
(Zou and Xu 2016). Lower expression of  miRNA-140-5p is associated with decreased 
chemosensitivity, but no significant change was found between tumour and non-tumour 
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tissue samples (Kim et al. 2011). A recent study also demonstrated that downregulated miR-
140-5p in gastric cancer was significantly correlated with reduced OS of  these patients (Fang 
et al. 2017). 
Amongst the ten upregulated miRNAs, increased hsa-miR-671-5p in gastric cancer tissues 
was found in a microarray-based analysis (Zhang et al. 2015), and miR 671 5p played as an 
onco-miR in epithelioid sarcoma (Papp et al. 2014). However, decreased expression of  miR-
671-5p was reported in invasive ductal carcinoma (IDC) compared to normal in 
microdissected formalin-fixed, paraffin-embedded (FFPE) tissues (Tan et al. 2016). Hansen
et al. (2013) also reported that miR-671-directed cleavage of  ciRS-7 results in prompt and 
efficient repression of  miR-7 targets and acted as a tumour suppressor in such cases. High 
levels of  miR-455-3p in gastric cancer tissues compared to their matching references has 
been confirmed by qPCR (Su et al. 2012). Nonetheless, miR-455-5p was found to act as a 
tumour suppressor in gastric cancer by down-regulating RAB18 (Liu et al. 2016). The role 
of  miR-1255a seems to be double-sided. It presented contrary expression trends in different 
bladder cancer cell lines (Tatarano et al. 2011), and it was downregulated by Atorvastatin in 
PC3 prostate cancer cells (Peng et al. 2013). As for miR-493, although Zhou et al. found that 
expression levels of  miR-493 were strongly down-regulated in gastric cancer, and its 
downregulation was associated with clinical stage and the presence of  LNM (Zhou et al. 
2015). Tambe et al. (2016) demonstrated that high miR-493-3p levels were associated with 
reduced survival of  ovarian and breast cancer patients with aggressive tumours, especially in 
the paclitaxel therapy arm. Upregulation of  miR-4326 was also reported in Li et al.’s (2017)
study, and they further demonstrated miR-4326 might be associated with race, with a lower 
level of  miR-4326 more common in Asian patients. In metastatic renal cell carcinoma, 
upregulated miR–4326, was among a group of  miRNAs that could define patients not only 
associated with short PFS and OS, but also with a poor response to tyrosine kinase inhibitors 
(TKI) (Garcia-Donas et al. 2016). miR-514a was found to be an EMT-inducing miRNA in 
gastric cancer (Yanaka et al. 2015). Upregulated miR-514a targeted the tumour suppressor 
NF1 and modulated BRAFi sensitivity in melanoma (Stark et al. 2015). Conversely, miR-
514a-3p served as a tumour suppressor which could inhibit cell proliferation and EMT was 
demonstrated in clear cell renal carcinoma (Ke et al. 2017) and human testicular germ cell 
tumours (Ozata et al. 2017). Upregulation of  miR-549 was associated with colorectal 
carcinogenesis (Hamfjord et al. 2012) and oral cancer developed from oral leucoplakia (Zhu 
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et al. 2015) and may indicate tumours of  glial origin if  discovered in patients’ serum (Drusco
et al. 2018). 
In the integrative analysis of  prognostic related DEMs, it is inappropriate to interpret the 
variation of  a continuous variable in the same way as the variation of  a binary variable. 
Different modelling assumptions need to be taken into consideration. We applied the 
framework introduced by Mo et al. (2013). Categorical observations are modelled as 
multivariate binomial or multinomial random variables. Count data are modelled as 
multivariate Poisson variables, and continuous measures such as miRNAs’ expression are 
modelled as multivariate normal. Given the proper distributional assumptions for these 
diverse types of  bioinformatic variables, glm for a non-linear relationship for the distribution 
of  these variables and lm for the linear relationship were performed to identify those DEMs 
representing distinct roles in gastric cancer patients’ survival. Like previous studies, increased 
levels of  miR-21 in both blood and tumour tissues indicate a significantly worse prognosis 
in OS, as well as DFS, than those with decreased expression levels (Xu et al. 2012; Komatsu 
et al. 2013).
Bioinformatic analysis of  DEMs, potential and validated targets of  miRNA and the 
subsequent analysis of  activation of  downstream pathways clustered by target genes are 
promising strategies for gaining insights into plausible biomarkers and key events involved 
in cancer development and progression. However, both biological factors and analytical 
factors could affect the actual performance of  the DEMs analysis. In this study, we did not 
set exclusion criteria so some tissues samples without completed data and cases of  other 
malignancies were enrolled. Therefore, it is essential to interrogate these candidate genes 
subsequently with other pathological features and validate them systematically by PCR or 
other independent experimental approaches before utilizing them as useful clinical 
biomarkers. 
7.2 Deregulated miR-140-5p expression in gastric cancer is associated with disease 
progression in gastric cancer
To determine the role of  miR-140-5p in gastric cancer, the expression of  miR-140-5p was 
conducted by detailed analysis from TCGA. The result showed a significantly reduced 
expression of  miR-140-5p in gastric cancers compared with adjacent non-tumour tissues,
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especially in intestinal gastric cancer. This result was in line with the observations from a 
qPCR examination conducted on paired gastric tumour tissue samples from the Beijing
cohort which presented a reduced expression of  miR-140-5p in gastric cancers, particularly 
the less infiltrative gross type (Borrmann I-II) of  tumour samples with a predominantly 
intestinal histological type (Chen et al. 2016). A decreased miR-140-5p expression was also 
observed in relatively localized tumour (Borrmann I-II) compared with that in more 
infiltrative tumour samples (Borrmann III-IV). Univariate and multivariate analysis have 
suggested that miR-140-5p could serve as a prognostic biomarker in gastric cancer. 
Decreased miR-140-5p and miR-140-3p expression in tumour tissues may be linked to a 
shorter life expectancy for gastric cancer patients even those with earlier disease and/or lower 
malignant potential subtypes. 
In our further analysis of  the role of  miR-140-5p/3p in the cohort of  gastric cancer tissue 
samples having been treated with 5FU based NAC, it was demonstrated that reduced 
expression of  miR-140-5p/3p in treated tumour tissues compared with that in treated 
normal tissues was associated with drug resistance of  gastric cancer. Further analyses showed 
that even in the no response group, gastric cancer patients with a higher level of  miR-140-
5p in treated tumour samples could still have a relatively better OS. The findings of  this study 
have demonstrated that miR-140-5p/3p may act as tumour suppressor in intestinal gastric 
cancer in comparison with diffuse type. This again highlights that miR-140-5p/3p plays 
different roles in different malignancies which might be cancer specific and even cell specific. 
Despite data indicating that miR-140-5p/3p can, in principle, control a wide variety of  
biological processes, the physiological settings in which one or more processes predominate 
are incompletely understood and deserve more systematic study. The exact molecular and 
cellular events associated with the deregulated expression of  miR-140-5p/3p in gastric 
cancer are yet to be identified.
7.3 Overexpression of miR-140-5p/3p inhibited malignant traits of gastric cancer 
cells based on specific cell context
To understand how altered expression of  miR-140-5p/3p in gastric cancer is associated with 
tumourigenesis, disease progression and prognosis, its impact on cellular function of  gastric 
cancer cells was examined in this study. Expression of  miR-140-5p and -3p was determined 
in six gastric cancer cell lines, as described in section 5.2.1. In the intestinal group of  cancer 
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cell lines, decreased expression of  miR-140-5p/3p was noted, which was in agreement with 
the findings we had on cohort analysis. Overexpression of  miR-140-5p or 3p in four cell 
lines (AGS, NUGC4, MKN45 and HGC27) resulted in decreased proliferation and colony 
formation only in cell lines harbouring wild-type p53: AGS and NUGC4. Cell cycle analysis 
revealed an increased G1 phase but decreased S phase in AGS, NUGC4 and human 
colorectal cancer cell lines with wild type p53 (HCT116 p53 wt), which suggests a G1/S cell 
cycle arrest. Interestingly MKN45 with a missense mutation in p53 gene but was 
demonstrated to have a functional p53 (Chen et al. 2016) also showed cell cycle arrest at the 
G1/S as well. These observations were consistent with the results from a study on human 
osteosarcoma and colon cancer cells (
Song et al. 2009). 
Besides its inhibition role on cell growth, overexpression of  miR-140-5p/3p had a 
prohibiting impact on cell migration in AGS and NUGC4. However, an interesting finding 
was seen in HGC27 cell lines, which reflected an oncomiR role of  miR-140-5p in this specific 
cell type. Notably, significantly restrained invasive ability was observed in all the examined 
cell lines, considering the inconsistent role of miR-140-5p on cell motility, this may indicate 
a profound part of  miR-140-5p in curbing ECM degradation ability in gastric cancer cells. It 
is interesting, but may not be surprising, that miR-140 is regarded as a cartilage-specific 
miRNA. Knockout studies have revealed miR-140 to be an essential factor in osteoarthritis 
development, as miR-140-/- mice showed osteoarthritis-like changes such as accelerated 
proteoglycan loss and ECM degradation, while mice overexpressing miR-140 were protected 
against degradation of  proteoglycans and COL2 in a model of  antigen-induced arthritis
(Miyaki et al. 2010). In the same study, the aggrecanase ADAMTS5 was shown to be a target 
of  miR-140, and it was suggested that this could explain the protective role of  miR-140 in 
ECM degradation.
7.4 Effective chemotherapy response is accompanied by enhanced expression of 
miR-140-5p and -3p in gastric cancer
In the tissue analysis, elevated expression of  miR-140-5p or miR-140-3p was detected in 
tumours with complete or partial response to 5FU based NAC treatment compared to their 
corresponding normal stomach tissues. The augmented expression of  miR-140-5p or miR-
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140-3p was associated with favourable prognosis even in the non-responsive patients. 
However, in the gastric cancer cell models, a pre-overexpressed miR-140-5p induced 
significant chemoresistance in NUGC4 and MKN45 cells, and an increased IC50 was shown 
in AGS cells but did not reach a statistical significance. In the mechanism exploring analysis, 
we found that a pre-upregulated miR-140-5p before drug treatment did not result in enough 
p53 upregulation comparing to the control cells, which may partly explain the abatement in 
cell apoptosis. Our results indicated a quantity dependent p53 induced apoptosis during 
cytotoxic stress in gastric cancer cells. Further in vitro and in vivo apoptosis assay, as well as 
corresponding mechanism examination, are required to elucidate this particular aspect, which 
may provide a new potential strategy for the stratification of  patients who can benefit from 
specific drug treatment and also candidate targets to increase chemosensitivity. 
7.5 Reduced miR-140-5p/3p is associated with enhanced MDM2 signalling through 
upregulation of its protein expression 
P53 is the most frequently mutated gene in human cancer (Kastenhuber and Lowe 2017). 
Half  of  the gastric cancer patients were reported to show p53 somatic mutations. MDM2 
functions as an oncogene mainly due to its major negative regulator role of  p53. Studies have 
repeated the central importance of  MDM2 as a p53 regulator, demonstrating that very early 
embryonic lethality of  Mdm2-null mice was fully rescued in a p53-null background
(Fakharzadeh et al. 1991; Montes de Oca Luna et al. 1995; Jones et al. 1995). A recent study 
investigating the role of  MARCH7, a RING domain-containing ubiquitin E3 ligase, in 
interacting and maintaining the stability of  MDM2, also strengthened the concept that direct
or indirect MDM2 destabilization could enhance p53 accumulation and p21 induction in 
normal cells and in DNA-damage treated cells (Zhao et al. 2018). In addition, MDM2 is 
involved in a number of  pathways that regulate cell proliferation and apoptosis, playing a 
p53-independent role. MDM2. In a study of  Cao et al. (2019), MDM2 was proven to promote 
genome instability by ubiquitinating the transcription factor HBP1. Overexpression-induced 
cell death following ionizing radiation could be abolished by overexpression of  HBP1, which 
delays DNA break repair and causes cell death in a p53-independent manner. However, 
MDM2 has also been shown to regulate the expression of  the anti-apoptotic protein XIAP 
by binding to its mRNA that enhances XIAP translation, leading to the increased expression 
of  XIAP, which led to an MDM2-dependent prevention of  cell death via caspase-mediated 
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apoptosis (Gu et al. 2009).
By using n gastric cancer cell lines, we showed that overexpression of  miR-140-5p decreased 
protein but not mRNA levels of  MDM2. Corresponding changes of  p53 and downstream 
p21, if  a functional p53 existed, were also seen in the miR-140-5p overexpression cell lines. 
Upon being treated with 5FU, the miR-140-5p overexpressing cells presented a less enhanced 
activation of  p53, and lacked BAX, compared with cells transfected with negative control 
mimics. Intriguingly, we also observed an increased apoptosis in HGC27 cell line with 
nonsense mutation of  p53, suggesting a MDM2-mediated apoptosis in a p53-independent 
manner. Involvement of  MDM2/p53 in the miR-140-5p and -3p overexpressing cells 
resulted in cell cycle arrest and suppression of  proliferation. Metastatic potential is yet to be 
elucidated, for example via eliminating p53 by siRNA or CRISPR/Cas9 system. On the other 
hand, targets of  miR-140-5p participating migration should be investigated in a p53 
dependent manner as well. 
7.6 Conclusion and perspectives
In this study, reduced expression of  miR-140-5p was observed in gastric cancer tissues and 
was associated with advanced disease progression, those with distant metastases and poor 
prognosis, especially in intestinal histological gastric cancer. In vitro function assays through 
miR-140-5p and miR-140-3p overexpression demonstrated the inhibitory roles of  miR-140-
5p and -3p in proliferation, migration and invasion of  gastric cancer cells with wild-type p53.
However, its overexpression may cause an increased migration ability in HGC27 cells with 
mutant p53. Although this association between mutant p53 and aggressive phenotype needs 
further clarification, this suggests that miR-140-5p/3p exhibited a putative tumour 
suppressor in some cases of  gastric cancer. Elevated chemoresistance was also observed in 
the miR-140-5p overexpressing gastric cancer cell lines with wild-type p53 and following 
5FU treatment. Accordingly, miR-140-5p depletion by miR-140-5p inhibitor promoted 
chemosensitivity. Further examination showed that pre upregulated miR-140-5p resulted in 
a less effective activation in accelerating p53 and BAX expression. This study again 
highlighted that miR-140-5p and -3p may have multiple cell identities based on cellular 
context or specific molecular subgroups.
Questions raised by this study include;
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1. Through what mechanism is miR-140 expression controlled in different types of  gastric 
cancer? 
2. What is the functional significance of  miR-140 in gastric cancer in vivo? Does miR-140 
alter cancer cells phenotype? Does miR-140 play a role in communication between gastric 
cancer cells and cells in their surrounding microenvironment, such as stromal cells or 
immune cells?
3. If  gastric cancer cells express miR-140 to protect against apoptosis, can this be reversed 
by other drugs that are not cycle-dependent? 
4. What is the association between different mutant p53 type and aggressive phenotype of  
gastric cancer?
It is yet to be revealed if  miR-140 or p53 alone are sufficient to influence cell fate in response 
to chemotherapy. We have shown that miR-140-5p provides a mechanism through MDM2 
which p53 can be manipulated; however, there are many other factors which influence p53 
expression and function and need to be explored. We have identified constitutional MDM2 
decreasing along with miR-140-5p upregulation in gastric cancer cells, the direct interacting 
target site, or interacting approach and where this modulation occurs are yet unexplored.
Like many other potentially exciting therapies in cancer, the efficiency of  therapy between 
individuals differs for unexplained reasons and declines over time. The relevance of  miRNA 
functional heterogeneity and variants of  its effector protein may help to understanding 
differences in disease patterns between otherwise identical patients and even provide 
potential therapeutic strategy or targets. 
221
References
ABELSON, J. F. et al. 2005. Sequence variants in SLITRK1 are associated with Tourette's syndrome. 
Science, 310, 317-20.
ABNET, C. C. et al. 2015. Diet and upper gastrointestinal malignancies. Gastroenterology, 148, 1234-
1243 e4.
ADJEI, A. A. 1999. A review of the pharmacology and clinical activity of new chemotherapy agents 
for the treatment of colorectal cancer. Br J Clin Pharmacol, 48, 265-77.
AHMED, K. A. and XIANG, J. 2011. Mechanisms of cellular communication through intercellular 
protein transfer. J Cell Mol Med, 15, 1458-73.
AHN, B. Y. et al. 2010. Genetic screen identifies insulin-like growth factor binding protein 5 as a 
modulator of tamoxifen resistance in breast cancer. Cancer Res, 70, 3013-9.
AHN, S. et al. 2017. High-throughput Protein and mRNA Expression-based Classification of Gastric 
Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. 
Am J Surg Pathol, 41, 106-115.
AIRD, I. et al. 1953. A relationship between cancer of stomach and the ABO blood groups. Br Med J,
1, 799-801.
AL-BATRAN, S. E. et al. 2008. Phase III trial in metastatic gastroesophageal adenocarcinoma with 
fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft 
Internistische Onkologie. J Clin Oncol, 26, 1435-42.
AL-BATRAN, S. E. et al. 2016. Histopathological regression after neoadjuvant docetaxel, oxaliplatin,
fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients 
with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from 
the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol, 17, 1697-1708.
ALISON, M. R. et al. 2012. Cancer stem cells: in the line of fire. Cancer Treat Rev, 38, 589-98.
ALMEIDA, M. I. et al. 2012. Strand-specific miR-28-5p and miR-28-3p have distinct effects in 
colorectal cancer cells. Gastroenterology, 142, 886-896 e9.
ALTINI, C. et al. 2015. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with 
conventional contrast enhancement computed tomography. Medicine (Baltimore), 94, e864.
AMBROS, V. 2003. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. 
Cell, 113, 673-6.
AMBROS, V. et al. 2003. A uniform system for microRNA annotation. RNA, 9, 277-9.
AMIEVA, M. and PEEK, R. M., JR. 2016. Pathobiology of Helicobacter pylori-Induced Gastric 
Cancer. Gastroenterology, 150, 64-78.
AMIRI, M. et al. 2011. The decline in stomach cancer mortality: exploration of future trends in seven 
European countries. Eur J Epidemiol, 26, 23-8.
ANDERSON, W. F. et al.. 2010. Age-specific trends in incidence of noncardia gastric cancer in US 
adults. JAMA, 303, 1723-8.
ANDO, T. et al. 2009. DNA methylation of microRNA genes in gastric mucosae of gastric cancer 
patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer, 124, 2367-
74.
ANG, T. L. and FOCK, K. M. 2014. Clinical epidemiology of gastric cancer. Singapore Med J, 55,
621-8.
222
ARALDI, E. and SCHIPANI, E. 2010. MicroRNA-140 and the silencing of osteoarthritis. Genes Dev,
24, 1075-80.
ARAVIN, A. A. et al. 2003. The small RNA profile during Drosophila melanogaster development. 
Dev Cell, 5, 337-50.
ASCHENBRENNER, L. et al. 2004. Uncoated endocytic vesicles require the unconventional myosin,
Myo6, for rapid transport through actin barriers. Mol Biol Cell, 15, 2253-63.
BADER, A. G. 2012. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet,
3, 120.
BANG, Y. J. et al. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone 
for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a 
phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97.
BARTEL, D. P. 2009. MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.
BARTER, M. J. et al. 2015. Genome-Wide MicroRNA and Gene Analysis of Mesenchymal Stem Cell 
Chondrogenesis Identifies an Essential Role and Multiple Targets for miR-140-5p. Stem Cells, 33,
3266-80.
BAYRAK, O. F. et al. 2013. MicroRNA expression profiling reveals the potential function of 
microRNA-31 in chordomas. J Neurooncol, 115, 143-51.
BEG, M. S. et al. 2017. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice 
weekly in patients with advanced solid tumours. Invest New Drugs, 35, 180-188.
BEIER, U. H. and GOROGH, T. 2005. Implications of galactocerebrosidase and galactosylcerebroside 
metabolism in cancer cells. Int J Cancer, 115, 6-10.
BENCUROVA, P. et al. 2017. MicroRNA and mesial temporal lobe epilepsy with hippocampal 
sclerosis: Whole miRNome profiling of human hippocampus. Epilepsia, 58, 1782-1793.
BENJAMINI, Y., HOCHBERG, Y. 1995. Controlling the false discovery rate: a practical and 
powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B. 57 (1): 289–
300.
BERINDAN-NEAGOE, I. et al. A. 2014. MicroRNAome genome: a treasure for cancer diagnosis and 
therapy. CA Cancer J Clin, 64, 311-36.
BERLTH, F. et al. 2014. Pathohistological classification systems in gastric cancer: diagnostic 
relevance and prognostic value. World J Gastroenterol, 20, 5679-84.
BERNAL, M. et al. 2012. Implication of the beta2-microglobulin gene in the generation of tumour
escape phenotypes. Cancer Immunol Immunother, 61, 1359-71.
BERTUCCIO, P. et al. 2009. Recent patterns in gastric cancer: a global overview. Int J Cancer, 125,
666-73.
BHATTACHARYYA, A. et al. 2014. Oxidative stress: an essential factor in the pathogenesis of 
gastrointestinal mucosal diseases. Physiol Rev, 94, 329-54.
BIASCO, G. et al. 1993. Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter 
pylori in dyspeptic patients. J Clin Pathol, 46, 826-8.
BITTONI, A. et al. 2015. Three drugs vs two drugs first-line chemotherapy regimen in advanced 
gastric cancer patients: a retrospective analysis. Springerplus, 4, 743.
BO, L. J. et al. 2015. Bioinformatics analysis of miRNA expression profile between primary and 
recurrent glioblastoma. Eur Rev Med Pharmacol Sci, 19, 3579-86.
BOBRIE, A. et al. 2011. Exosome secretion: molecular mechanisms and roles in immune responses. 
Traffic, 12, 1659-68.
223
BOKU, N. et al. 2009. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in 
metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol, 10, 1063-9.
BOLAND, C. R. and YURGELUN, M. B. 2017. Historical Perspective on Familial Gastric Cancer. 
Cell Mol Gastroenterol Hepatol, 3, 192-200.
BOLKE, E. et al. 2008. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J 
Med, 358, 1965; author reply 1965.
BOND, G. L. et al. 2005. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr 
Cancer Drug Targets, 5, 3-8.
BORCH, K.,et al. 2000. Changing pattern of histological type, location, stage and outcome of surgical 
treatment of gastric carcinoma. Br J Surg, 87, 618-26.
BORRMANN, R. 1926 Geschwülste des Magens and Duodenums. In: Borchardt, H., Borrmann, R. 
and Christeller, E., Eds., Verdauungsschlauch: Erster Teil Rachenund Tonsillen, Speiserohre Magen 
und Darm, Bauchfell, Springer, Vienna, 812-1054.
BOSTJANCIC, E. et al. 2017. Expression, Mutation, and Amplification Status of EGFR and Its 
Correlation with Five miRNAs in Salivary Gland Tumours. Biomed Res Int, 2017, 9150402.
BRADY, C. A. et al. 2011. Distinct p53 transcriptional programs dictate acute DNA-damage 
responses and tumour suppression. Cell, 145, 571-83.
BRADY, J. J. et al. 2013. Early role for IL-6 signalling during generation of induced pluripotent stem 
cells revealed by heterokaryon RNA-Seq. Nat Cell Biol, 15, 1244-52.
BRYANT, J. L.,et al. 2012. A microRNA gene expression signature predicts response to erlotinib in 
epithelial cancer cell lines and targets EMT. Br J Cancer, 106, 148-56.
BUTZ, H. et al. 2011. MicroRNA profile indicates downregulation of the TGFbeta pathway in 
sporadic non-functioning pituitary adenomas. Pituitary, 14, 112-24.
CALDAS, C. et al. 1999. Familial gastric cancer: overview and guidelines for management. J Med 
Genet, 36, 873-80.
CALIN, G. A. et al. 2007. Ultraconserved regions encoding ncRNAs are altered in human leukemias 
and carcinomas. Cancer Cell, 12, 215-29.
CAMARGO, M. C. et al. 2011. Divergent trends for gastric cancer incidence by anatomical subsite in 
US adults. Gut, 60, 1644-9.
CAMILLERI, M. et al. 2017. Gastrointestinal Complications of Obesity. Gastroenterology, 152,
1656-1670.
CANCER GENOME ATLAS RESEARCH, N. 2014. Comprehensive molecular characterization of 
gastric adenocarcinoma. Nature, 513, 202-9.
CANCER REARCH. 2016a. Stomach cancer mortality statistics. Available at: 
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/stomach-cancer/mortality [Accessed: 4 March 2018].
CANCER RESEARCH. 2016b. Survival by stage. Avilable at: http://about-
cancer.cancerresearchuk.org/about-cancer/stomach-cancer/survival [Accessed 20 June 2019]
CAO, D. et al. 2002. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of 
this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of 
fluoropyrimidines. Cancer Res, 62, 2313-7.
Cao Z. et al. 2019. MDM2 promotes genome instability by ubiquitinating the transcription factor 
HBP1. Oncogene. 38, 4835-4855
CARNEIRO, F. et al. 1994. T (Thomsen-Friedenreich) antigen and other simple mucin-type 
carbohydrate antigens in precursor lesions of gastric carcinoma. Histopathology, 24, 105-13.
224
CARNEIRO, F. et al. 1995. New elements for an updated classification of the carcinomas of the 
stomach. Pathol Res Pract, 191, 571-84.
CARNINCI, P. et al. 2005. The transcriptional landscape of the mammalian genome. Science, 309,
1559-63.
CARVALHO, J. et al. 2012. Lack of microRNA-101 causes E-cadherin functional deregulation 
through EZH2 up-regulation in intestinal gastric cancer. J Pathol, 228, 31-44.
Cha Y. et al. 2018. MicroRNA-140-5p suppresses cell proliferation and invasion in gastric cancer by 
targeting WNT1 in the WNT/beta-catenin signaling pathway. Oncology letters. 16, 6369-6376.
CHAN, J. A. et al. S. 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. 
Cancer Res, 65, 6029-33.
CHAN, J. J. and TAY, Y. 2018. Noncoding RNA:RNA Regulatory Networks in Cancer. Int J Mol Sci,
19.
CHANG, H. et al. 2015. Different microRNA expression levels in gastric cancer depending on 
Helicobacter pylori infection. Gut Liver, 9, 188-96.
CHANG, J. T. et al. 2016. Identification of MicroRNAs as Breast Cancer Prognosis Markers through 
the Cancer Genome Atlas. PLoS One, 11, e0168284.
CHEN, J. et al. 1995. Regulation of transcription functions of the p53 tumour suppressor by the mdm-
2 oncogene. Mol Med, 1, 142-52.
CHEN, M. H. et al. 2016. A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by 
Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 
Clinical Trial. Medicine (Baltimore), 95, e2565.
CHEN, X. et al. 2016. The role of miRNAs in drug resistance and prognosis of breast cancer formalin-
fixed paraffin-embedded tissues. Gene, 595, 221-226.
CHEN, Y. et al. 2018. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A 
meta-analysis. Medicine (Baltimore), 97, e10634.
CHEN, Y. C. et al. 2016. Clinicopathological Variation of Lauren Classification in Gastric Cancer. 
Pathol Oncol Res, 22, 197-202.
CHEUNG, D. Y. 2017. Atrophic Gastritis Increases the Risk of Gastric Cancer in Asymptomatic
Population in Korea. Gut Liver, 11, 575-576.
CHEUNG, K. S. et al. 2018. Long-term proton pump inhibitors and risk of gastric cancer development 
after treatment for Helicobacter pylori: a population-based study. Gut, 67, 28-35.
CHIARAVALLI, A. M. et al. 2012. Histotype-based prognostic classification of gastric cancer. World 
J Gastroenterol, 18, 896-904.
CHIHARA, K.,et al. 2009. Increased vulnerability of hippocampal pyramidal neurons to the toxicity 
of kainic acid in OASIS-deficient mice. J Neurochem, 110, 956-65.
CHOI, Y. J. et al. 2018. Correction: The relationship between drinking alcohol and esophageal, gastric 
or colorectal cancer: A nationwide population-based cohort study of South Korea. PLoS One, 13,
e0197765.
CHOWDHURY, U. R. et al. 2009. Emerging role of nuclear protein 1 (NUPR1) in cancer biology. 
Cancer Metastasis Rev, 28, 225-32.
CHU, A. et al. 2016. Large-scale profiling of microRNAs for The Cancer Genome Atlas. Nucleic 
Acids Res, 44, e3.
CHU, E. et al. 1993. Regulation of thymidylate synthase in human colon cancer cells treated with 5-
fluorouracil and interferon-gamma. Mol Pharmacol, 43, 527-33.
225
CLEMMONS, D. R. et al. 2002. Inhibition of insulin-like growth factor binding protein 5 proteolysis 
in articular cartilage and joint fluid results in enhanced concentrations of insulin-like growth factor 1 
and is associated with improved osteoarthritis. Arthritis Rheum, 46, 694-703.
COATI, I. et al. 2015. Autoimmune gastritis: Pathologist's viewpoint. World J Gastroenterol, 21,
12179-89.
COBURN, N. et al. 2018. Staging and surgical approaches in gastric cancer: A systematic review. 
Cancer Treat Rev, 63, 104-115.
COCCOLINI, F. et al. 2014. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis 
of randomized trials. Eur J Surg Oncol, 40, 12-26.
COKKINIDES, V. E. et al. 2012. Cancer-related risk factors and preventive measures in US 
Hispanics/Latinos. CA Cancer J Clin, 62, 353-63.
COLLABORATORS, G. B. D. R. F. 2016. Global, regional, and national comparative risk assessment 
of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: 
a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1659-1724.
COLLARES, C. V. et al. 2013. Identifying common and specific microRNAs expressed in peripheral 
blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res Notes,
6, 491.
COLQUHOUN, A. et al. 2015. Global patterns of cardia and non-cardia gastric cancer incidence in 
2012. Gut, 64, 1881-8.
CONESA, A. et al. 2016. A survey of best practices for RNA-seq data analysis. Genome Biol, 17, 13.
CONTEDUCA, V. et al. 2013. H. pylori infection and gastric cancer: state of the art (review). Int J 
Oncol, 42, 5-18.
COPUR, S. et al. 1995. Thymidylate synthase gene amplification in human colon cancer cell lines 
resistant to 5-fluorouracil. Biochem Pharmacol, 49, 1419-26.
CORDON-CARDO, C. et al. 1994. Molecular abnormalities of mdm2 and p53 genes in adult soft 
tissue sarcomas. Cancer Res, 54, 794-9.
CORREA, P. 1992. Human gastric carcinogenesis: a multistep and multifactorial process--First 
American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res, 52,
6735-40.
CORREA, P. 2011. Gastric cancer: two epidemics? Dig Dis Sci, 56, 1585-6; author reply 1586.
CORREA, P. and PIAZUELO, M. B. 2011. Helicobacter pylori Infection and Gastric 
Adenocarcinoma. US Gastroenterol Hepatol Rev, 7, 59-64.
CORREA, P. and PIAZUELO, M. B. 2012. The gastric precancerous cascade. J Dig Dis, 13, 2-9.
CORREIA, N. C. et al. 2016. microRNAs regulate TAL1 expression in T-cell acute lymphoblastic 
leukemia. Oncotarget, 7, 8268-81.
CORTEZ, M. A. et al. 2011. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat 
Rev Clin Oncol, 8, 467-77.
CORTEZ, M. A. et al. 2016. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst, 108.
CRAIG, P. M. et al. W. 2014. Profiling hepatic microRNAs in zebrafish: fluoxetine exposure mimics 
a fasting response that targets AMP-activated protein kinase (AMPK). PLoS One, 9, e95351.
CRICK, F. 1970. Central dogma of molecular biology. Nature, 227, 561-3.
CRISTESCU, R. et al. 2015. Molecular analysis of gastric cancer identifies subtypes associated with 
distinct clinical outcomes. Nat Med, 21, 449-56.
226
CROWE, N. et al. 2016. Detecting new microRNAs in human osteoarthritic chondrocytes identifies 
miR-3085 as a human, chondrocyte-selective, microRNA. Osteoarthritis Cartilage, 24, 534-43.
CUI, Y. et al. 2017. Long Noncoding RNA HOXA11-AS Functions as miRNA Sponge to Promote 
the Glioma Tumourigenesis Through Targeting miR-140-5p. DNA Cell Biol, 36, 822-828.
CUNNINGHAM, D. et al. 2006. Perioperative chemotherapy versus surgery alone for resectable 
gastroesophageal cancer. N Engl J Med, 355, 11-20.
CUNNINGHAM, D. et al. 2008. Capecitabine and oxaliplatin for advanced esophagogastric cancer. 
N Engl J Med, 358, 36-46.
CZOPEK, J. P. et al. 2003. EBV-positive gastric carcinomas in Poland. Pol J Pathol, 54, 123-8. 
DAI, Y. and WANG, W. H. 2006. Non-steroidal anti-inflammatory drugs in prevention of gastric 
cancer. World J Gastroenterol, 12, 2884-9.
DANAEI, G. et al. 2005. Causes of cancer in the world: comparative risk assessment of nine 
behavioural and environmental risk factors. Lancet, 366, 1784-93.
DANN, C. E. et al. 2001. Insights into Wnt binding and signalling from the structures of two Frizzled 
cysteine-rich domains. Nature. 412, 86-90.
DAVIDSON-MONCADA, J.,et al. 2010. MicroRNAs of the immune system: roles in inflammation 
and cancer. Ann N Y Acad Sci, 1183, 183-94.
DAWSON, M. A. et al. 2009. Clinical and immunohistochemical features associated with a response 
to bortezomib in patients with multiple myeloma. Clin Cancer Res, 15, 714-22.
DE ANGELIS, R. et al. 2014. Cancer survival in Europe 1999-2007 by country and age: results of 
EUROCARE--5-a population-based study. Lancet Oncol, 15, 23-34.
DE MARTEL, C. et al. 2012. Global burden of cancers attributable to infections in 2008: a review and 
synthetic analysis. Lancet Oncol, 13, 607-15.
DE ROZIERES, S. et al. 2000. The loss of mdm2 induces p53-mediated apoptosis. Oncogene, 19,
1691-7.
DE VRIES, A. C. et al. 2008. Gastric cancer risk in patients with premalignant gastric lesions: a 
nationwide cohort study in the Netherlands. Gastroenterology, 134, 945-52.
DEMICCO, E. G. et al. 2011. The dichotomy in carcinogenesis of the distal esophagus and 
esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod 
Pathol, 24, 1177-90.
DERAKHSHAN, M. H. et al. 2015. In healthy volunteers, immunohistochemistry supports squamous 
to columnar metaplasia as mechanism of expansion of cardia, aggravated by central obesity. Gut, 64,
1705-14.
DESVIGNES, T. et al. 2015. miRNA Nomenclature: A View Incorporating Genetic Origins,
Biosynthetic Pathways, and Sequence Variants. Trends Genet, 31, 613-626.
DIASIO, R. B. and HARRIS, B. E. 1989. Clinical pharmacology of 5-fluorouracil. Clin 
Pharmacokinet, 16, 215-37.
DILEEPAN, M. et al. 2016. MicroRNA Mediated Chemokine Responses in Human Airway Smooth 
Muscle Cells. PLoS One, 11, e0150842.
DING, B. et al. 2017. A novel microRNA signature predicts survival in stomach adenocarcinoma. 
Oncotarget, 8, 28144-28153.
DING, L. et al. 2010. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation 
by targeting JAK2. Cell Res, 20, 784-93.
227
DINIS-RIBEIRO, M. et al. 2012. Management of precancerous conditions and lesions in the stomach 
(MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European 
Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade 
Portuguesa de Endoscopia Digestiva (SPED). Endoscopy, 44, 74-94.
DJEBALI, S. et al. 2012. Landscape of transcription in human cells. Nature, 489, 101-8.
DOERRENBERG, M. et al. 2017. T-cell acute lymphoblastic leukemia in infants has distinct genetic 
and epigenetic features compared to childhood cases. Genes Chromosomes Cancer, 56, 159-167.
DONEHOWER, L. A. 2014. Insights into wild-type and mutant p53 functions provided by genetically 
engineered mice. Hum Mutat, 35, 715-27.
DONG, W. et al. 2016. MiR-140-3p suppressed cell growth and invasion by downregulating the 
expression of ATP8A1 in non-small cell lung cancer. Tumour Biol, 37, 2973-85.
DRUSCO A. et al. 2018. Circulating Micrornas Predict Survival of Patients with Tumours of Glial 
Origin. EBioMedicine, 30, 105-112.
DUAN, L. et al. 2015. p53-regulated autophagy is controlled by glycolysis and determines cell fate. 
Oncotarget, 6, 23135-56.
DULAK, A. M. et al. 2013. Exome and whole-genome sequencing of esophageal adenocarcinoma 
identifies recurrent driver events and mutational complexity. Nat Genet, 45, 478-86.
DURU, N. et al. 2016. Loss of miR-140 is a key risk factor for radiation-induced lung fibrosis through 
reprogramming fibroblasts and macrophages. Sci Rep, 6, 39572.
EL-OMAR, E. M. 2001. The importance of interleukin 1beta in Helicobacter pylori associated disease. 
Gut, 48, 743-7.
ERICKSEN, R. E. et al. 2014. Obesity accelerates Helicobacter felis-induced gastric carcinogenesis 
by enhancing immature myeloid cell trafficking and TH17 response. Gut, 63, 385-94.
FABBRI, M. et al. 2012. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory 
response. Proc Natl Acad Sci U S A, 109, E2110-6.
Fakharzadeh, S. S. et al. 1991. Tumourigenic potential associated with enhanced expression of a gene 
that is amplified in a mouse tumour cell line. EMBO J, 10, 1565–1569.
FANG, W. L. et al. 2011. Comparison of the survival difference between AJCC 6th and 7th editions 
for gastric cancer patients. World J Surg, 35, 2723-9.
FANG, Z. et al. 2017. miR-140-5p suppresses the proliferation, migration and invasion of gastric 
cancer by regulating YES1. Mol Cancer, 16, 139.
FERLAY J, S. I. et al. 2013. GLOBOCAN 2012 v 1.0, Cancer incidence and mortality worldwide: 
IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013]. 
Available from: http://globocan.iarc.fr. [Online].  2018].
FERLAY, J. et al. 2015. Cancer incidence and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012. Int J Cancer, 136, E359-86.
FERRO, A. et al. 2018a. Tobacco smoking and gastric cancer: meta-analyses of published data versus 
pooled analyses of individual participant data (StoP Project). Eur J Cancer Prev, 27, 197-204.
FERRO, A. et al. 2018b. Alcohol intake and gastric cancer: Meta-analyses of published data versus 
individual participant data pooled analyses (StoP Project). Cancer Epidemiol, 54, 125-132.
FERRO, A. et al. 2014. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 
2015, and incidence by subtype. Eur J Cancer, 50, 1330-44.
FLAMINI, V. et al. 2018. Distinct mechanisms by which two forms of miR-140 suppress the 
malignant properties of lung cancer cells. Oncotarget, 9, 36474-36491.
228
FLAMINI, V., et al 2017. Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung 
Cancer. Anticancer Res, 37, 4319-4327.
FOCACCETTI, C. et al. 2015. Effects of 5-fluorouracil on morphology, cell cycle, proliferation,
apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One, 10,
e0115686.
FOCK, K. M. et al. 2009. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. 
J Gastroenterol Hepatol, 24, 1587-600.
FONTHAM, E. T. 2009. Infectious diseases and global cancer control. CA Cancer J Clin, 59, 5-7.
FORD, A. C. et al. 2014. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy 
asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled 
trials. BMJ, 348, g3174.
FORD, H. E. et al. 2014. Docetaxel versus active symptom control for refractory oesophagogastric 
adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol,
15, 78-86.
FOX, J. G. and WANG, T. C. 2007. Inflammation, atrophy, and gastric cancer. J Clin Invest, 117, 60-
9.
FRANKEN, N. A. et al. 2006. Clonogenic assay of cells in vitro. Nat Protoc, 1, 2315-9.
FUCHS, C. S. et al. 2014. Ramucirumab monotherapy for previously treated advanced gastric or 
gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet, 383, 31-39.
GABAY, O. and CLOUSE, K. A. 2016. Epigenetics of cartilage diseases. Joint Bone Spine, 83, 491-
4.
GALIATSATOS, P. et al. 2017. Low yield of gastroscopy in patients with Lynch syndrome. Turk J 
Gastroenterol, 28, 434-438.
GANDALOVICOVA, A. et al. 2017. Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises 
and Challenges. Trends Cancer, 3, 391-406.
GARCIA-DONAS, J. et al. 2016. Deep sequencing reveals microRNAs predictive of antiangiogenic 
drug response. JCI Insight, 1, e86051.
GAT-YABLONSKI, G. et al. 2013. Nutritional catch-up growth. World Rev Nutr Diet, 106, 83-9.
GERNAPUDI, R. et al. 2015. Targeting exosomes from preadipocytes inhibits preadipocyte to cancer 
stem cell signaling in early-stage breast cancer. Breast Cancer Res Treat, 150, 685-95.
GIANCOTTI, F. G. 2014. Deregulation of cell signaling in cancer. FEBS Lett, 588, 2558-70.
GIBSON, G. and ASAHARA, H. 2013. microRNAs and cartilage. J Orthop Res, 31, 1333-44.
GLAZER, R. I. and LLOYD, L. S. 1982. Association of cell lethality with incorporation of 5-
fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol 
Pharmacol, 21, 468-73.
GLOBAL BURDEN OF DISEASE CANCER COLLABORATION. 2017. Global, Regional, and 
National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-
Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden 
of Disease Study. JAMA Oncol, 3, 524-548.
GASTRIC (Global Advanced/Adjuvant Stomach Tumour Research International Collaboration) 
Group. 2013. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data 
meta-analysis. Eur J Cancer, 49, 1565-77.
Goel, H.L. and Mercurio, A. M. 2013. VEGF targets the tumour cell. Nature reviews Cancer. 13, 871-
882.
229
GONG, E. J. et al. 2018. Characteristics of non-cardia gastric cancer with a high serum anti-
Helicobacter pylori IgG titer and its association with diffuse-type histology. PLoS One, 13, e0195264.
GONZALEZ, C. A. et al. 2012. Fruit and vegetable intake and the risk of gastric adenocarcinoma: a 
reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) 
study after a longer follow-up. Int J Cancer, 131, 2910-9.
GONZALEZ, C. A. et al. 2003. Smoking and the risk of gastric cancer in the European Prospective
Investigation Into Cancer and Nutrition (EPIC). Int J Cancer, 107, 629-34.
GOSEKI, N. et al. 1992. Differences in the mode of the extension of gastric cancer classified by 
histological type: new histological classification of gastric carcinoma. Gut, 33, 606-12.
GREEN, P. H. and O'TOOLE, K. M. 1982. Early gastric cancer. Ann Intern Med, 97, 272-3. 
GRIFFITHS-JONES, S. et al. 2006. miRBase: microRNA sequences, targets and gene nomenclature. 
Nucleic Acids Res, 34, D140-4.
GRIMES, J. A. et al. 2016. A comparison of microRNA expression profiles from splenic 
hemangiosarcoma, splenic nodular hyperplasia, and normal spleens of dogs. BMC Vet Res, 12, 272.
Gu L. et al. 2009. Regulation of XIAP translation and induction by MDM2 following irradiation. 
Cancer cell. 15, 363-375.
GU, R. et al. 2016. Biological roles of microRNA-140 in tumour growth, migration, and metastasis of 
osteosarcoma in vivo and in vitro. Tumour Biol, 37, 353-60.
GU, Y. Q. et al. 2014. miRNA profiling reveals a potential role of milk stasis in breast carcinogenesis. 
Int J Mol Med, 33, 1243-9.
GUAN, L. et al. 2018. Biomarker identification in clear cell renal cell carcinoma based on miRNA-
seq and digital gene expression-seq data. Gene, 647, 205-212.
GUEDES, A. G. et al. 2015. CD38 and airway hyper-responsiveness: studies on human airway smooth 
muscle cells and mouse models. Can J Physiol Pharmacol, 93, 145-53.
GUILFORD, P. et al. 1998. E-cadherin germline mutations in familial gastric cancer. Nature, 392,
402-5.
GULLU, G. et al. 2015. Clinical significance of miR-140-5p and miR-193b expression in patients 
with breast cancer and relationship to IGFBP5. Genet Mol Biol, 38, 21-9.
GULLUOGLU, S. et al. 2016. The potential function of microRNA in chordomas. Gene, 585, 76-83.
HA, M. et al. 2012. A case of Cowden syndrome diagnosed from multiple gastric polyposis. World J 
Gastroenterol, 18, 861-4.
HAMFJORD, J. et al. 2012. Differential expression of miRNAs in colorectal cancer: comparison of 
paired tumour tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One, 7,
e34150.
HANAHAN, D. and WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. Cell, 144,
646-74.
HANSEN, T. B. et al. 2013. Circular RNA and miR-7 in cancer. Cancer Res, 73, 5609-12.
HANSON, B. J. and HONG, W. 2003. Evidence for a role of SNX16 in regulating traffic between the 
early and later endosomal compartments. J Biol Chem, 278, 34617-30.
HANSSON, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med,
352, 1685-95.
HANSSON, L. E. et al. 1996. The risk of stomach cancer in patients with gastric or duodenal ulcer 
disease. N Engl J Med, 335, 242-9.
230
HAO, N. B.et al. 2017. The role of miRNA and lncRNA in gastric cancer. Oncotarget, 8, 81572-
81582.
HAUPT, Y. et al. 1997. Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-9.
HAUSMANN, C. et al. 2015. ILKAP, ILK and PINCH1 control cell survival of p53-wildtype 
glioblastoma cells after irradiation. Oncotarget, 6, 34592-605.
HE, S. et al. 2015. Dissecting Collective Cell Behavior in Polarization and Alignment on 
Micropatterned Substrates. Biophys J, 109, 489-500.
HELICOBACTER and CANCER COLLABORATIVE, G. 2001. Gastric cancer and Helicobacter 
pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut, 49, 347-
53.
HILL, B. T. and BASERGA, R. 1975. The cell cycle and its significance for cancer treatment. Cancer 
Treat Rev, 2, 159-75.
HONG, E. and REDDI, A. H. 2013. Dedifferentiation and redifferentiation of articular chondrocytes 
from surface and middle zones: changes in microRNAs-221/-222, -140, and -143/145 expression. 
Tissue Eng Part A, 19, 1015-22.
HORIE, N. et al. 1995. Functional analysis and DNA polymorphism of the tandemly repeated 
sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct 
Funct, 20, 191-7.
HORWITZ, R. and WEBB, D. 2003. Cell migration. Curr Biol, 13, R756-9.
HOUGHTON, J. A. et al. 1995. Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate 
influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res, 1,
723-30.
HSU, P. I. et al. 1997. Correlation of serum immunoglobulin G Helicobacter pylori antibody titers 
with histologic and endoscopic findings in patients with dyspepsia. J Clin Gastroenterol, 25, 587-91.
HU, B.et al. 2012. Gastric cancer: Classification, histology and application of molecular pathology. J 
Gastrointest Oncol, 3, 251-61.
HU, L. et al. 2016. Integrative microRNA and gene profiling data analysis reveals novel biomarkers 
and mechanisms for lung cancer. Oncotarget, 7, 8441-54.
HUANG, K. H.et al. 2015. The correlation between miRNA and lymph node metastasis in gastric 
cancer. Biomed Res Int, 2015, 543163.
HUANG, Q. et al. 2015. Differences in Clinicopathology of Early Gastric Carcinoma between 
Proximal and Distal Location in 438 Chinese Patients. Sci Rep, 5, 13439.
HUANG, X.et al. 2016. Transcriptional Profiles from Paired Normal Samples Offer Complementary 
Information on Cancer Patient Survival--Evidence from TCGA Pan-Cancer Data. Sci Rep, 6, 20567.
HUANG, X. Z. et al. 2017. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric 
cancer risk: A dose-response meta-analysis. Oncotarget, 8, 4781-4795.
HUO, Q. 2017. Analysis of expression profile of miRNA in stomach adenocarcinoma. J BUON, 22,
1154-1159.
HUSZNO, J. et al. 2012. Mucin secretion activity of gastric cancer as a prognostic factor: a 
clinicopathological analysis. Contemp Oncol (Pozn), 16, 159-64.
HUTVAGNER, G. et al. 2001. A cellular function for the RNA-interference enzyme Dicer in the 
maturation of the let-7 small temporal RNA. Science, 293, 834-8.
HWANG, S. W.et al. 2010. Preoperative staging of gastric cancer by endoscopic ultrasonography and 
multidetector-row computed tomography. J Gastroenterol Hepatol, 25, 512-8. 
231
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. 1994a. IARC working group on 
the evaluation of carcinogenic risks to humans: some industrial chemicals. Lyon, 15-22 February 
1994. IARC Monogr Eval Carcinog Risks Hum, 60, 1-560.
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. 1994b. Schistosomes, liver flukes 
and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 
Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum, 61, 1-241.
IGUCHI, H. et al. 2010. Secretory microRNAs as a versatile communication tool. Commun Integr 
Biol, 3, 478-81.
IHRE, B. J. et al. 1964. Ulcer-Cancer of the Stomach. A Follow-up Study of 473 Cases of Gastric 
Ulcer. Gastroenterologia, 102, 78-91.
IIZASA, H. et al. 2012. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses, 4, 3420-39.
IKOMA, N. et al. 2018. Evaluation of the American Joint Committee on Cancer 8th edition staging 
system for gastric cancer patients after preoperative therapy. Gastric Cancer, 21, 74-83.
IKUSHIMA, H. and MIYAZONO, K. 2010. TGFbeta signalling: a complex web in cancer progression. 
Nat Rev Cancer, 10, 415-24.
ILIOPOULOS, D. et al. 2008. Integrative microRNA and proteomic approaches identify novel 
osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One, 3, e3740.
IMAI, S. et al. 1994. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-
Barr virus latent infection protein. Proc Natl Acad Sci U S A, 91, 9131-5.
INSTITUTE, N. C. 2017. Survival by Stage, Cancer Stat Facts: Stomach Cancer [Online] [Online].  
[Accessed 5th April 2018].
INSTITUTE, N. C. 2018. Cancer Stat Facts: Stomach Cancer [Online]. [Online]. Available: 
Available at: https://seer.cancer.gov/statfacts/html/stomach.html [Accessed 15 Augest 2018].
INUI, M. et al, H. 2018. Dissecting the roles of miR-140 and its host gene. Nat Cell Biol, 20, 516-518.
IORIO, M. V. et al. 2007. MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699-707.
ISHIMOTO, T. et al. 2014. Macrophage-derived reactive oxygen species suppress miR-328 targeting 
CD44 in cancer cells and promote redox adaptation. Carcinogenesis, 35, 1003-11.
ISHIOKA, K. et al. 2018. Association between ALDH2 and ADH1B polymorphisms, alcohol drinking 
and gastric cancer: a replication and mediation analysis. Gastric Cancer, 21, 936-945.
ISOBE, T. et al. 2015. Characteristics and prognosis of mucinous gastric carcinoma. Mol Clin Oncol,
3, 44-50.
JACKSON, C. et al. 2007. Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs 
postoperative chemoradiotherapy. Oncology (Williston Park), 21, 1084-7; discussion 1090, 1096-8, 
1101.
JACKSON, L. M. et al. 2000. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated 
human gastric mucosa. Gut, 47, 762-70.
JAGER, D. et al. 2017. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and 
sacral chordomas. Sci Rep, 7, 2032.
JANSSEN, H. L. et al. 2013. Treatment of HCV infection by targeting microRNA. N Engl J Med, 368,
1685-94.
JAPANESE GASTRIC CANCER Association. 2011. Japanese classification of gastric carcinoma: 3rd 
English edition. Gastric Cancer, 14, 101-12.
JAYASURIYA, C. T. and CHEN, Q. 2015. Potential benefits and limitations of utilizing 
chondroprogenitors in cell-based cartilage therapy. Connect Tissue Res, 56, 265-71.
232
JEMAL, A. et al. 2011. Global cancer statistics. CA Cancer J Clin, 61, 69-90.
JEMAL, A. et al. 2006. Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30.
JEURNINK, S. M. et al. 2012. Variety in vegetable and fruit consumption and the risk of gastric and 
esophageal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer,
131, E963-73.
JIMENEZ FONSECA, P. et al. 2017. Lauren subtypes of advanced gastric cancer influence survival 
and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. Br 
J Cancer, 117, 775-782.
Jin H.Y. et al. 2015. Transfection of microRNA Mimics Should Be Used with Caution. Frontiers in 
genetics. 6, 340.
JING, P. et al. 2016. MicroR-140-5p suppresses tumour cell migration and invasion by targeting 
ADAM10-mediated Notch1 signaling pathway in hypopharyngeal squamous cell carcinoma. Exp Mol 
Pathol, 100, 132-8.
JOHNSTON, P. G. and KAYE, S. 2001. Capecitabine: a novel agent for the treatment of solid tumours. 
Anticancer Drugs, 12, 639-46.
JONES, S. N. et al. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. 
Nature, 378, 206-8.
JORGENSEN, J. T. 2010. Targeted HER2 treatment in advanced gastric cancer. Oncology, 78, 26-33.
JOYCE, J. A. and POLLARD, J. W. 2009. Microenvironmental regulation of metastasis. Nat Rev 
Cancer, 9, 239-52.
JU, J. 2010. miRNAs as biomarkers in colorectal cancer diagnosis and prognosis. Bioanalysis, 2, 901-
6.
JUNG, K. W. et al. 2017. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence 
in 2014. Cancer Res Treat, 49, 292-305.
JUSTUS, C. R. et al. 2014. In vitro cell migration and invasion assays. J Vis Exp.
KAKIUCHI, M. et al. 2014. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric 
carcinoma. Nat Genet, 46, 583-7.
KAMOSHIDA, S. et al. 2005. Immunohistochemical demonstration of fluoropyrimidine-metabolizing 
enzymes in various types of cancer. Oncol Rep, 14, 1223-30.
KAMPSCHOER, G. H. et al. 1989. Changing patterns in gastric adenocarcinoma. Br J Surg, 76, 914-
6.
KANDOTH, C. et al. 2013. Mutational landscape and significance across 12 major cancer types. 
Nature, 502, 333-339.
KANEKO, S. and YOSHIMURA, T. 2001. Time trend analysis of gastric cancer incidence in Japan 
by histological types, 1975-1989. Br J Cancer, 84, 400-5.
KANG, G. H. et al. 2002. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant 
methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric 
carcinoma. Am J Pathol, 160, 787-94.
KANG, J. H. et al. 2012. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III 
trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol,
30, 1513-8.
KANG, J. Y. et al. 2002. Risk of gastric carcinoma in patients with atrophic gastritis and intestinal 
metaplasia. Gut, 51, 899.
233
KARAKAS, M. et al. 2017. Circulating microRNAs strongly predict cardiovascular death in patients 
with coronary artery disease-results from the large AtheroGene study. Eur Heart J, 38, 516-523.
KARIMI, P. et al. 2014. Gastric cancer: descriptive epidemiology, risk factors, screening, and 
prevention. Cancer Epidemiol Biomarkers Prev, 23, 700-13.
KARLSEN, T. A. et al. 2014. microRNA-140 targets RALA and regulates chondrogenic 
differentiation of human mesenchymal stem cells by translational enhancement of SOX9 and ACAN. 
Stem Cells Dev, 23, 290-304.
Karni-Schmidt O. et al. 2016. The Roles of MDM2 and MDMX in Cancer. Annual review of pathology. 
11, 617-644
KASTENHUBER, E. R. and LOWE, S. W. 2017. Putting p53 in Context. Cell, 170, 1062-1078.
KATADA, T. et al. 2009. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol,
34, 537-42.
KATO, I. et al. 1992. Atrophic gastritis and stomach cancer risk: cross-sectional analyses. Jpn J 
Cancer Res, 83, 1041-6.
KATO, T. A. et al. 2011. In vitro characterization of cells derived from chordoma cell line U-CH1 
following treatment with X-rays, heavy ions and chemotherapeutic drugs. Radiat Oncol, 6, 116.
KATTAN, M. W. et al. 2003. Postoperative nomogram for disease-specific survival after an R0 
resection for gastric carcinoma. J Clin Oncol, 21, 3647-50.
KAURAH, P. et al. 2007. Founder and recurrent CDH1 mutations in families with hereditary diffuse 
gastric cancer. JAMA, 297, 2360-72.
KAWAGUCHI, T. et al. 2017. Overexpression of suppressive microRNAs, miR-30a and miR-200c 
are associated with improved survival of breast cancer patients. Sci Rep, 7, 15945.
KAWAMURA, H. et al. 2001. A clinicopathologic study of mucinous adenocarcinoma of the stomach. 
Gastric Cancer, 4, 83-6.
KE, X.et al. 2017. MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by 
targeting EGFR in clear cell renal cell carcinoma. Am J Transl Res, 9, 5332-5346.
KENYON, J. D. et al. 2019. Analysis of -5p and -3p Strands of miR-145 and miR-140 During 
Mesenchymal Stem Cell Chondrogenic Differentiation. Tissue Eng Part A, 25, 80-90.
KEUM, N. et al. 2016. Association of Physical Activity by Type and Intensity With Digestive System 
Cancer Risk. JAMA Oncol, 2, 1146-53.
KHARE, D. et al. 2017. Plasma microRNA profiling: Exploring better biomarkers for lymphoma 
surveillance. PLoS One, 12, e0187722.
KIM, C. H. et al. 2011. miRNA signature associated with outcome of gastric cancer patients following 
chemotherapy. BMC Med Genomics, 4, 79.
KIM, G. H. et al. 2016. Screening and surveillance for gastric cancer in the United States: Is it needed? 
Gastrointest Endosc, 84, 18-28.
KOIZUMI, W. et al. 2008. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced 
gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol, 9, 215-21.
KOMATSU, S. et al. 2013. Prognostic impact of circulating miR-21 in the plasma of patients with 
gastric carcinoma. Anticancer Res, 33, 271-6.
KONG, X. M. et al. 2015. MicroRNA-140-3p inhibits proliferation, migration and invasion of lung 
cancer cells by targeting ATP6AP2. Int J Clin Exp Pathol, 8, 12845-52.
KORKAYA, H. et al. 2012. Activation of an IL6 inflammatory loop mediates trastuzumab resistance 
in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell, 47, 570-84.
234
KOWALSKI, M. L. et al. 2008. Increased responsiveness to toll-like receptor 4 stimulation in 
peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis. Mediators 
Inflamm, 2008, 132732.
KRENTZ GOBER, M. et al. 2017. A microRNA signature of response to erlotinib is descriptive of 
TGFbeta behaviour in NSCLC. Sci Rep, 7, 4202.
KUBBUTAT, M. H. et al. 1997. Regulation of p53 stability by Mdm2. Nature, 387, 299-303.
KUFE, D. W. and MAJOR, P. P. 1981. 5-Fluorouracil incorporation into human breast carcinoma 
RNA correlates with cytotoxicity. J Biol Chem, 256, 9802-5.
KUMAR, R. D. et al. 2016. Unsupervised detection of cancer driver mutations with parsimony-guided 
learning. Nat Genet, 48, 1288-94.
KUNISAKI, C.et al. 2006. Clinicopathologic characteristics and surgical outcomes of mucinous 
gastric carcinoma. Ann Surg Oncol, 13, 836-42.
KUO, W. T. et al. 2015. Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA 
Expression Using TCGA Datasets. J Clin Med, 4, 1798-814.
KUSSIE, P. H. et al. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumour suppressor 
transactivation domain. Science, 274, 948-53.
KWAK, H. W. et al. 2014. Characteristics of gastric cancer according to Helicobacter pylori infection 
status. J Gastroenterol Hepatol, 29, 1671-7.
LA VECCHIA, C. et al. 1992. Family history and the risk of stomach and colorectal cancer. Cancer,
70, 50-5.
LABELLE, M. and HYNES, R. O. 2012. The initial hours of metastasis: the importance of cooperative 
host-tumour cell interactions during hematogenous dissemination. Cancer Discov, 2, 1091-9.
LADNER, R. D. 2001. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr 
Protein Pept Sci, 2, 361-70.
LAN, H. et al. 2015. miR-140-5p inhibits ovarian cancer growth partially by repression of PDGFRA. 
Biomed Pharmacother, 75, 117-22.
LANDGRAF, P. et al. 2007. A mammalian microRNA expression atlas based on small RNA library 
sequencing. Cell, 129, 1401-14.
LARSSON, S. C. et al. 2006. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric,
and pancreatic cancer: a meta-analysis. Gastroenterology, 131, 1271-83.
LAUREN, P. 1965. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called
Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol 
Scand, 64, 31-49.
LAURIE, N. A. et al. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature, 444, 61-6.
LAZEBNIK, Y. 2010. What are the hallmarks of cancer? Nat Rev Cancer, 10, 232-3.
LE, L. T. et al. 2013. Review: the role of microRNAs in osteoarthritis and chondrogenesis. Arthritis 
Rheum, 65, 1963-74.
LEE, J. H. et al. 2018. Body mass index and mortality in patients with gastric cancer: a large cohort 
study. Gastric Cancer, 21, 913-924.
LEE, Y. C. et al. 2016. Association Between Helicobacter pylori Eradication and Gastric Cancer 
Incidence: A Systematic Review and Meta-analysis. Gastroenterology, 150, 1113-1124 e5.
LEE, Y. S. et al. 2014. Genomic profile analysis of diffuse-type gastric cancers. Genome Biol, 15, R55.
LEHMANN, S. M. et al. 2012. An unconventional role for miRNA: let-7 activates Toll-like receptor 
7 and causes neurodegeneration. Nat Neurosci, 15, 827-35.
235
LEHTOLA, J. 1978. Family study of gastric carcinoma; With special reference to histological types. 
Scand J Gastroenterol Suppl, 50, 3-54.
LEVI, Z. et al. 2018. Body mass index at adolescence and risk of noncardia gastric cancer in a cohort 
of 1.79 million men and women. Cancer, 124, 356-363.
LI, C. et al. 2013. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric 
cancer. J Surg Oncol, 108, 89-92.
LI, C. Y. et al. 2017. Identification and functional characterization of microRNAs reveal a potential 
role in gastric cancer progression. Clin Transl Oncol, 19, 162-172.
LI, H. et al. 2017. MiR-140-5p inhibits synovial fibroblasts proliferation and inflammatory cytokines 
secretion through targeting TLR4. Biomed Pharmacother, 96, 208-214.
LI, J. et al. 2018. MicroRNA-140 Inhibits the Epithelial-Mesenchymal Transition and Metastasis in 
Colorectal Cancer. Mol Ther Nucleic Acids, 10, 426-437.
LI, M. et al. 2013. Helicobacter pylori infection synergizes with three inflammation-related genetic 
variants in the GWASs to increase risk of gastric cancer in a Chinese population. PLoS One, 8, e74976.
LI, M. et al. 2017. Time trends of esophageal and gastric cancer mortality in China, 1991-2009: an 
age-period-cohort analysis. Sci Rep, 7, 6797.
LI, Q. et al. 2014a. Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ 
(DCIS) lesions. J Biol Chem, 289, 1303-12.
LI, Q. et al. 2014b. Downregulation of miR-140 promotes cancer stem cell formation in basal-like 
early stage breast cancer. Oncogene, 33, 2589-600.
LI, T. et al. 2018. Identification of hub genes with prognostic values in gastric cancer by bioinformatics 
analysis. World J Surg Oncol, 16, 114.
LI, W. and HE, F. 2014. Monocyte to macrophage differentiation-associated (MMD) targeted by miR-
140-5p regulates tumour growth in non-small cell lung cancer. Biochem Biophys Res Commun, 450,
844-50.
LI, W. et al. 2014. Down-regulation of miR-140 induces EMT and promotes invasion by targeting 
Slug in esophageal cancer. Cell Physiol Biochem, 34, 1466-76.
LI, W. Q. et al. 2010. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with 
miRNA-328 may decrease their chemoresistance. Med Sci Monit, 16, HY27-30.
LI, X. et al. 2011a. Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer 
and its clinical significance. Oncol Rep, 26, 1431-9.
LI, X. et al. 2011b. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumour
suppressor EPB41L3. Mol Cancer Res, 9, 824-33.
LI, X. et al. 2010. Survival prediction of gastric cancer by a seven-microRNA signature. Gut, 59, 579-
85.
LI, X. D. et al. 2017. Elevated plasma miRNA-122, -140-3p, -720, -2861, and -3149 during early 
period of acute coronary syndrome are derived from peripheral blood mononuclear cells. PLoS One,
12, e0184256.
LI, Z. et al. 2011. Differential DNA damage responses in p53 proficient and deficient cells: cisplatin-
induced nuclear import of XPA is independent of ATR checkpoint in p53-deficient lung cancer cells. 
Int J Biochem Mol Biol, 2, 138-145.
LIANG, L. et al. 2017. Identification of the key miRNAs associated with survival time in stomach 
adenocarcinoma. Oncol Lett, 14, 4563-4572.
LIANG, S. et al. 2017. The lncRNA XIST interacts with miR-140/miR-124/iASPP axis to promote 
pancreatic carcinoma growth. Oncotarget, 8, 113701-113718.
236
LIANG, Y. X. et al. 2013. Characteristics and prognosis of gastric cancer in patients aged >/= 70 years. 
World J Gastroenterol, 19, 6568-78.
LIAO, Y. L. et al. 2012. Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells. 
Carcinogenesis, 33, 760-9.
LIM, J. Y. et al. 2013. Overexpression of miR-196b and HOXA10 characterize a poor-prognosis 
gastric cancer subtype. World J Gastroenterol, 19, 7078-88.
LINDAHL, T. 1974. An N-glycosidase from Escherichia coli that releases free uracil from DNA 
containing deaminated cytosine residues. Proc Natl Acad Sci U S A, 71, 3649-53.
LINDBLAD, M. et al. 2005. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric 
cancer. Cancer Epidemiol Biomarkers Prev, 14, 444-50.
LINDOW, M. and KAUPPINEN, S. 2012. Discovering the first microRNA-targeted drug. J Cell Biol,
199, 407-12.
LINK, A. et al. 2012. Macro-role of microRNA in gastric cancer. Dig Dis, 30, 255-67.
LIU, H. T. et al. 2017. Prognostic Value of microRNA Signature in Patients with Gastric Cancers. Sci 
Rep, 7, 42806.
LIU, H. Z. et al. 2016. Pioglitazone up-regulates long non-coding RNA MEG3 to protect endothelial 
progenitor cells via increasing HDAC7 expression in metabolic syndrome. Biomed Pharmacother, 78,
101-109.
LIU, J. et al. 2018. Identification of key miRNAs and genes associated with stomach adenocarcinoma 
from The Cancer Genome Atlas database. FEBS Open Bio, 8, 279-294.
LIU, J. et al. 2016. MiR-455-5p acts as a novel tumour suppressor in gastric cancer by down-regulating 
RAB18. Gene, 592, 308-15.
LIU, T. et al. 2009. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting 
prohibitin. Cancer Lett, 273, 233-42.
LIU, X. and MELTZER, S. J. 2017. Gastric Cancer in the Era of Precision Medicine. Cell Mol 
Gastroenterol Hepatol, 3, 348-358.
LIU, Y. et al. 2014. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev 
Allergy Immunol, 47, 136-47.
LIU, Y. et al. 2013 MicroRNA-140 promotes adipocyte lineage commitment of C3H10T1/2 
pluripotent stem cells via targeting osteopetrosis-associated transmembrane protein 1. The Journal of 
biological chemistry. 288, 8222-8230.
LORDICK, F. et al. 2014. Unmet needs and challenges in gastric cancer: the way forward. Cancer 
Treat Rev, 40, 692-700.
LORDICK, F. et al. 2013. Capecitabine and cisplatin with or without cetuximab for patients with 
previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. 
Lancet Oncol, 14, 490-9.
LUJAMBIO, A. et al. 2007. Genetic unmasking of an epigenetically silenced microRNA in human 
cancer cells. Cancer Res, 67, 1424-9.
LUO, H. et al. 2009. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin 
Cancer Res, 28, 82.
LUTZ, M. P. et al. 2012. Highlights of the EORTC St. Gallen International Expert Consensus on the 
primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies 
for subtypes of early gastroesophageal cancer. Eur J Cancer, 48, 2941-53.
MA, J. et al. 2016. Lauren classification and individualized chemotherapy in gastric cancer. Oncol 
Lett, 11, 2959-2964.
237
MA, X. et al. 2018. Clinicopathological Characteristics and Prognoses of Elderly Gastric Cancer 
Patients after R0 Resection: A Multicenter Study in China. J Environ Pathol Toxicol Oncol, 37, 81-
91.
MACDONALD, J. S. et al. 2001. Chemoradiotherapy after surgery compared with surgery alone for 
adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345, 725-30.
MACHADO, A. M. et al. 2009. Helicobacter pylori infection induces genetic instability of nuclear 
and mitochondrial DNA in gastric cells. Clin Cancer Res, 15, 2995-3002.
MACHADO, J. C. et al. 1999. E-cadherin gene mutations provide a genetic basis for the phenotypic 
divergence of mixed gastric carcinomas. Lab Invest, 79, 459-65.
MACKINTOSH, C. E. and KREEL, L. 1977. Anatomy and radiology of the areae gastricae. Gut, 18,
855-64.
MAEHARA, Y. 2003. S-1 in gastric cancer: a comprehensive review. Gastric Cancer, 6 Suppl 1, 2-
8.
MAEHARA, Y. et al. 1992. Prognosis for surgically treated gastric cancer patients is poorer for 
women than men in all patients under age 50. Br J Cancer, 65, 417-20.
MAHBOUDI, H. et al. 2018. Enhanced chondrogenesis differentiation of human induced pluripotent 
stem cells by MicroRNA-140 and transforming growth factor beta 3 (TGFbeta3). Biologicals, 52, 30-
36.
MALFERTHEINER, P. et al. 2007. Current concepts in the management of Helicobacter pylori 
infection: the Maastricht III Consensus Report. Gut, 56, 772-81.
MALZKORN, B. et al. 2010. Identification and functional characterization of microRNAs involved 
in the malignant progression of gliomas. Brain Pathol, 20, 539-50.
MARCHET, A. et al. 2011. Validation of the new AJCC TNM staging system for gastric cancer in a 
large cohort of patients (n = 2,155): focus on the T category. Eur J Surg Oncol, 37, 779-85.
MARIETTE, C. et al. 2011. Oesophagogastric junction adenocarcinoma: which therapeutic approach? 
Lancet Oncol, 12, 296-305.
Manfredi, J. J. et al. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene 
and a tumour suppressor. 2010. Genes & development, 24, 1580-1589
MAROTTA, L. L. et al. 2011. The JAK2/STAT3 signaling pathway is required for growth of 
CD44(+)CD24(-) stem cell-like breast cancer cells in human tumours. J Clin Invest, 121, 2723-35.
MARQUES, F. Z. et al. 2016. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur 
J Heart Fail, 18, 1000-8.
MARSH, S. et al. 2001. Polymorphism in the thymidylate synthase promoter enhancer region in 
colorectal cancer. Int J Oncol, 19, 383-6.
MARSHALL, B. J. and WARREN, J. R. 1984. Unidentified curved bacilli in the stomach of patients 
with gastritis and peptic ulceration. Lancet, 1, 1311-5.
MARSHALL, B. J. and WINDSOR, H. M. 2005. The relation of Helicobacter pylori to gastric 
adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation,
treatment, and prevention. Med Clin North Am, 89, 313-44, viii.
MATSUDA, T. et al. 2011. Population-based survival of cancer patients diagnosed between 1993 and 
1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol, 41, 40-51.
MATSUZAKA, M. et al. 2016. High Mortality Rate of Stomach Cancer Caused Not by High 
Incidence but Delays in Diagnosis in Aomori Prefecture, Japan. Asian Pac J Cancer Prev, 17, 4723-
4727.
238
MCCREDIE, M. et al. 1999. Cancer mortality in migrants from the British Isles and continental 
Europe to New South Wales, Australia, 1975-1995. Int J Cancer, 83, 179-85.
MENG Y. et al. 2017. MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting 
HMGN5 and autophagy. Scientific reports. 7, 416.
MEYN, R. E. et al. 1980. Cycle-dependent anticancer drug cytotoxicity in mammalian cells 
synchronized by centrifugal elutriation. J Natl Cancer Inst, 64, 1215-9.
MEZHIR, J. J et al. 2011. Positive peritoneal cytology in patients with gastric cancer: natural history 
and outcome of 291 patients. Indian J Surg Oncol, 2, 16-23.
MIN, Z. et al. 2015. MicroRNAs associated with osteoarthritis differently expressed in bone matrix 
gelatin (BMG) rat model. Int J Clin Exp Med, 8, 1009-17.
MING, S. C. 1977. Gastric carcinoma. A pathobiological classification. Cancer, 39, 2475-85.
MIWA, M. et al. 1998. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which 
generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer 
tissue. Eur J Cancer, 34, 1274-81.
MIYAKI, S. et al. 2009. MicroRNA-140 is expressed in differentiated human articular chondrocytes 
and modulates interleukin-1 responses. Arthritis Rheum, 60, 2723-30.
MIYAKI, S. et al. 2010. MicroRNA-140 plays dual roles in both cartilage development and 
homeostasis. Genes Dev, 24, 1173-85.
MIZAMTSIDI, M. et al. 2018. Diagnosis, management, histology and genetics of sporadic primary 
hyperparathyroidism: old knowledge with new tricks. Endocr Connect, 7, R56-R68.
MO, Q. et al. 2013. Pattern discovery and cancer gene identification in integrated cancer genomic data. 
Proc Natl Acad Sci U S A, 110, 4245-50.
MOCELLIN, S. and PASQUALI, S. 2015. Diagnostic accuracy of endoscopic ultrasonography (EUS) 
for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev,
CD009944.
MOEHLER, M. et al. 2015. International comparison of the German evidence-based S3-guidelines on 
the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including 
adenocarcinoma of the lower esophagus. Gastric Cancer, 18, 550-63.
MOMAND, J. et al. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and 
inhibits p53-mediated transactivation. Cell, 69, 1237-45.
MONTES DE OCA LUNA, R. et al. 1995. Rescue of early embryonic lethality in mdm2-deficient 
mice by deletion of p53. Nature, 378, 203-6.
MOORE, S. C. et al. 2016. Association of Leisure-Time Physical Activity With Risk of 26 Types of 
Cancer in 1.44 Million Adults. JAMA Intern Med, 176, 816-25.
MORALES, T. I. 2007. Chondrocyte moves: clever strategies? Osteoarthritis Cartilage, 15, 861-71.
MOSAKHANI, N. et al. 2012. MicroRNA profiling predicts survival in anti-EGFR treated 
chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Cancer Genet,
205, 545-51.
MOTTET D. et al. 2009. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells 
through a Sp1-dependent, p53-independent mechanism. Oncogene.28, 243-256.
MUHICH, M. L. and BOOTHROYD, J. C. 1989. Synthesis of trypanosome hsp70 mRNA is resistant 
to disruption of trans-splicing by heat shock. J Biol Chem, 264, 7107-10.
MUTA, H. et al. 1996. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J 
Cancer Res, 87, 843-8.
239
NAKAMURA, K. et al. 1992. Pathology and prognosis of gastric carcinoma. Findings in 10,000 
patients who underwent primary gastrectomy. Cancer, 70, 1030-7.
NAUMANN, M. and CRABTREE, J. E. 2004. Helicobacter pylori-induced epithelial cell signalling 
in gastric carcinogenesis. Trends Microbiol, 12, 29-36.
NEMATI, A. et al. 2012. Case-control study of dietary pattern and other risk factors for gastric cancer. 
Health Promot Perspect, 2, 20-7.
NEWCOMB, D. C. and PEEBLES, R. S., JR. 2013. Th17-mediated inflammation in asthma. Curr 
Opin Immunol, 25, 755-60.
NGUYEN, T. L. et al. 2013. Autoimmune gastritis mediated by CD4+ T cells promotes the 
development of gastric cancer. Cancer Res, 73, 2117-26.
NICOLAS, F. E. et al. 2008. Experimental identification of microRNA-140 targets by silencing and 
overexpressing miR-140. RNA, 14, 2513-20.
NICOLAS, F. E. et al. 2011. mRNA expression profiling reveals conserved and non-conserved miR-
140 targets. RNA Biol, 8, 607-15.
NISHIKAWA, J. et al. 2017. The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated 
Gastric Cancer. Int J Mol Sci, 18.
NOH, S. H. et al. 2014. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy 
(CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol, 15, 1389-96.
NOMURA, A. M. et al. 2003. Case-control study of diet and other risk factors for gastric cancer in 
Hawaii (United States). Cancer Causes Control, 14, 547-58.
NOONE AM, H. N. et al. 2017 SEER Cancer Statistics Review, 1975-2015 [Online]. National Cancer 
Institute. Bethesda, MD. Available: https://seer.cancer.gov/csr/1975_2015 [Accessed 5 May 2018].
O'DOHERTY, M. G. et al. 2012. A prospective cohort study of obesity and risk of oesophageal and 
gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut, 61, 1261-8.
O'NEILL, L. A. et al. 2011. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev 
Immunol, 11, 163-75.
OFFERHAUS, G. J. et al. 1988. Mortality caused by stomach cancer after remote partial gastrectomy 
for benign conditions: 40 years of follow up of an Amsterdam cohort of 2633 postgastrectomy patients. 
Gut, 29, 1588-90.
OH, H. K. et al. 2011. Genomic loss of miR-486 regulates tumour progression and the OLFM4 
antiapoptotic factor in gastric cancer. Clin Cancer Res, 17, 2657-67.
OHMIYA, N. et al. 2006. MDM2 promoter polymorphism is associated with both an increased 
susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40.
OKINES, A. et al. 2010. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow-up. Ann Oncol, 21 Suppl 5, v50-4.
OLIVEIRA, C. et al. 2015. Familial gastric cancer: genetic susceptibility, pathology, and implications 
for management. Lancet Oncol, 16, e60-70.
ONEL, K. and CORDON-CARDO, C. 2004. MDM2 and prognosis. Mol Cancer Res, 2, 1-8.
ONODERA, H. et al. 2004. Surgical outcome of 483 patients with early gastric cancer: prognosis,
postoperative morbidity and mortality, and gastric remnant cancer. Hepatogastroenterology, 51, 82-5.
ORTEGA, F. J. et al. 2014. Profiling of circulating microRNAs reveals common microRNAs linked 
to type 2 diabetes that change with insulin sensitization. Diabetes Care, 37, 1375-83.
OSAWA, S. et al. 2011. MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-
embedded samples. Oncol Lett, 2, 613-619.
240
OZATA, D. M. et al. 2017. Loss of miR-514a-3p regulation of PEG3 activates the NF-kappa B 
pathway in human testicular germ cell tumours. Cell Death Dis, 8, e2759.
PACHOLEWSKA, A. et al. 2017. Differential Expression of Serum MicroRNAs Supports CD4(+) T 
Cell Differentiation into Th2/Th17 Cells in Severe Equine Asthma. Genes (Basel), 8.
PAIS, H. et al. 2010. Analyzing mRNA expression identifies Smad3 as a microRNA-140 target 
regulated only at protein level. RNA, 16, 489-94.
PAN, H. W. et al. 2013. MicroRNA dysregulation in gastric cancer. Curr Pharm Des, 19, 1273-84.
PAN, K. F. et al. 2016. A large randomised controlled intervention trial to prevent gastric cancer by 
eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the 
eradication. Gut, 65, 9-18.
PANDO, R. et al. 2014. A serum component mediates food restriction-induced growth attenuation. 
Endocrinology, 155, 932-40.
PAPAIOANNOU, G. et al. 2013. let-7 and miR-140 microRNAs coordinately regulate skeletal 
development. Proc Natl Acad Sci U S A, 110, E3291-300.
PAPAIOANNOU, G. et al. 2015. MicroRNA-140 Provides Robustness to the Regulation of 
Hypertrophic Chondrocyte Differentiation by the PTHrP-HDAC4 Pathway. J Bone Miner Res, 30,
1044-52.
PAPP, G. et al. 2014. SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-
381, and miR-671-5p on Both mRNA and protein levels. Genes Chromosomes Cancer, 53, 168-76.
PARK, J. H. et al. 2016. p53 as guardian of the mitochondrial genome. FEBS Lett, 590, 924-34.
PARSONNET, J. et al. 1991. Helicobacter pylori infection in intestinal- and diffuse-type gastric 
adenocarcinomas. J Natl Cancer Inst, 83, 640-3.
PEEK, R. M. et al. 2010. Role of innate immunity in Helicobacter pylori-induced gastric malignancy. 
Physiol Rev, 90, 831-58.
PEGTEL, D. M. et al. 2010. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci 
U S A, 107, 6328-33.
PELETEIRO, B. et al. 2011. Salt intake and gastric cancer risk according to Helicobacter pylori 
infection, smoking, tumour site and histological type. Br J Cancer, 104, 198-207.
PENG, J. S. et al. 2016. Amelioration of Experimental Autoimmune Arthritis Through Targeting of 
Synovial Fibroblasts by Intraarticular Delivery of MicroRNAs 140-3p and 140-5p. Arthritis 
Rheumatol, 68, 370-81.
PENG, X. et al. 2013. Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 
prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21. 
PLoS One, 8, e70442.
PERIASAMY, J. et al. 2014. Stratification and delineation of gastric cancer signaling by in vitro 
transcription factor activity profiling and integrative genomics. Cell Signal, 26, 880-94.
PERRONE, F. et al. 2010. TP53 mutations and pathologic complete response to neoadjuvant cisplatin 
and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol, 28, 761-
6.
PETERSON, S. M. et al. 2014. Common features of microRNA target prediction tools. Front Genet,
5, 23.
PETRELLI, F. et al. 2017. Prognostic value of diffuse versus intestinal histotype in patients with 
gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol, 8, 148-163.
PETROCCA, F. et al. 2008. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest 
and apoptosis in gastric cancer. Cancer Cell, 13, 272-86.
241
PHILLIPS, B. 2015. Towards evidence based medicine for paediatricians. Arch Dis Child, 100, 713.
PIEPOLI, A. et al. 2012. Mirna expression profiles identify drivers in colorectal and pancreatic cancers. 
PLoS One, 7, e33663.
PLEBANI, M. et al. 1996. Helicobacter pylori serology in patients with chronic gastritis. Am J 
Gastroenterol, 91, 954-8.
PLOCIENNIKOWSKA, A. et al. 2015. Co-operation of TLR4 and raft proteins in LPS-induced pro-
inflammatory signaling. Cell Mol Life Sci, 72, 557-581.
POLLEY, E. et al. 2016. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents,
and Gene and microRNA Expression. J Natl Cancer Inst, 108.
POULSEN, A. H. et al. 2009. Proton pump inhibitors and risk of gastric cancer: a population-based 
cohort study. Br J Cancer, 100, 1503-7.
PULLARKAT, S. T. et al. 2001. Thymidylate synthase gene polymorphism determines response and 
toxicity of 5-FU chemotherapy. Pharmacogenomics J, 1, 65-70.
QIU, M. Z. et al. 2013. Clinicopathological characteristics and prognostic analysis of Lauren 
classification in gastric adenocarcinoma in China. J Transl Med, 11, 58.
QUANTE, M. et al. 2013. The rapid rise in gastroesophageal junction tumours: is inflammation of the 
gastric cardia the underwater iceberg? Gastroenterology, 145, 708-11.
RANI, S. et al. 2011. Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling. 
Methods Mol Biol, 784, 181-95.
REINHART, B. J. et al. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in 
Caenorhabditis elegans. Nature, 403, 901-6.
RENNERT, O. M. and ANKER, H. S. 1963. On the Incorporation of 5',5',5'-Trifluoroleucine into 
Proteins of E. Coli. Biochemistry, 2, 471-6.
ROBERTSON, E. V. et al. 2013. Central obesity in asymptomatic volunteers is associated with 
increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology, 145,
730-9.
ROCCO, A. et al. 2012. Cancer stem cell hypothesis and gastric carcinogenesis: Experimental 
evidence and unsolved questions. World J Gastrointest Oncol, 4, 54-9.
RODRIGUEZ, L. G. et al. 2005. Wound-healing assay. Methods Mol Biol, 294, 23-9.
ROLLAG, A. and JACOBSEN, C. D. 1984. Gastric ulcer and risk of cancer. A five-year follow-up 
study. Acta Med Scand, 216, 105-9.
RONELLENFITSCH, U. et al. 2013. Perioperative chemo(radio)therapy versus primary surgery for 
resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. 
Cochrane Database Syst Rev, CD008107.
ROTHMAN, A. M. et al. 2016. MicroRNA-140-5p and SMURF1 regulate pulmonary arterial 
hypertension. J Clin Invest, 126, 2495-508.
RUGGE, M. et al. 1994. Gastric epithelial dysplasia in the natural history of gastric cancer: a 
multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. 
Gastroenterology, 107, 1288-96.
RUGGE, M. et al. 2016. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. 
Gut, 65, 721-5.
SABROE, I. et al. 2003. Toll-like receptors in health and disease: complex questions remain. J 
Immunol, 171, 1630-5.
242
SAITO, H. et al. 2013. Clinicopathologic characteristics and prognosis of advanced gastric cancer 
simulating early gastric cancer. Yonago Acta Med, 56, 73-8.
SAITO, M. et al. 2013. Role of DNA methylation in the development of Epstein-Barr virus-associated 
gastric carcinoma. J Med Virol, 85, 121-7.
SAKAGUCHI, T. et al. 1998. Characteristics and clinical outcome of proximal-third gastric cancer. J 
Am Coll Surg, 187, 352-7.
SAKAI, T. et al. 2003. Simultaneous early adenocarcinoma and mucosa-associated lymphoid tissue 
(MALT) lymphoma of the stomach associated with Helicobacter pylori infection. Gastric Cancer, 6,
191-6.
SALEM, O. et al. 2016. The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumour-
suppressive effects of miR-140 by reducing breast cancer proliferation and migration. BMC Genomics,
17, 566.
SALIH, B. A. 2009. Helicobacter pylori infection in developing countries: the burden for how long? 
Saudi J Gastroenterol, 15, 201-7.
SALMENA, L. et al. 2011. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell,
146, 353-8.
SAND, M. et al. 2012a. Microarray analysis of microRNA expression in cutaneous squamous cell 
carcinoma. J Dermatol Sci, 68, 119-26.
SAND, M. et al. 2012b. Expression of microRNAs in basal cell carcinoma. Br J Dermatol, 167, 847-
55.
SANO, T. et al. 2004. Gastric cancer surgery: morbidity and mortality results from a prospective 
randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical 
Oncology Group study 9501. J Clin Oncol, 22, 2767-73.
SANSONE, P. et al. 2007. IL-6 triggers malignant features in mammospheres from human ductal 
breast carcinoma and normal mammary gland. J Clin Invest, 117, 3988-4002.
SASAKO, M. et al. 2006. Left thoracoabdominal approach versus abdominal-transhiatal approach for 
gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol, 7, 644-51.
SASTRE, J. et al. 2006. Chemotherapy for gastric cancer. World J Gastroenterol, 12, 204-13.
SERRANO, N. A. et al. 2012. Integrative analysis in oral squamous cell carcinoma reveals DNA copy 
number-associated miRNAs dysregulating target genes. Otolaryngol Head Neck Surg, 147, 501-8. 
SETHI, A. et al. 2013. Role of miRNAs in CD4 T cell plasticity during inflammation and tolerance. 
Front Genet, 4, 8.
SEYFRIED, T. N. and HUYSENTRUYT, L. C. 2013. On the origin of cancer metastasis. Crit Rev 
Oncog, 18, 43-73.
SHACKELFORD, D. B. and SHAW, R. J. 2009. The LKB1-AMPK pathway: metabolism and growth 
control in tumour suppression. Nat Rev Cancer, 9, 563-75.
SHAH, M. A. et al. 2011. Phase II study of modified docetaxel, cisplatin, and fluorouracil with 
bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol, 29, 868-74.
SHEN, J. et al. 2015. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler 
SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. Cancer Res, 75, 754-65.
SHERMAN, L. et al. 2002. Inhibition of serum- and calcium-induced terminal differentiation of 
human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 
transactivation, and binding to E6BP. Virology, 292, 309-20.
SHERSHER, D. D. et al. 2011. Biomarkers of the insulin-like growth factor pathway predict 
progression and outcome in lung cancer. Ann Thorac Surg, 92, 1805-11; discussion 1811.
243
SHIBUE, T. and WEINBERG, R. A. 2017. EMT, CSCs, and drug resistance: the mechanistic link and 
clinical implications. Nat Rev Clin Oncol, 14, 611-629.
SHIEH, S. Y. et al. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by 
MDM2. Cell, 91, 325-34.
SHIMOKAWA, T. et al. 1998. Hypocholesterolemic effects of the LDL receptor gene transcriptional 
upregulator CP-230821. J Biochem, 123, 596-601.
SHIN, V. Y. et al. 2015. A three-miRNA signature as promising non-invasive diagnostic marker for 
gastric cancer. Mol Cancer, 14, 202.
SHRESTHA, S. et al. 2014. A systematic review of microRNA expression profiling studies in human 
gastric cancer. Cancer Med, 3, 878-88.
SIDONI, A. et al. 1989. Changing patterns in gastric carcinoma. Tumouri, 75, 605-8.
SIEWERT, J. R. and STEIN, H. J. 1998. Classification of adenocarcinoma of the oesophagogastric 
junction. Br J Surg, 85, 1457-9.
SITARZ, R. et al. 2012. Gastroenterostoma after Billroth antrectomy as a premalignant condition. 
World J Gastroenterol, 18, 3201-6.
SITARZ, R. et al. 2018. Gastric cancer: epidemiology, prevention, classification, and treatment. 
Cancer Manag Res, 10, 239-248.
SMALLEY, S. R. et al. 2012. Updated analysis of SWOG-directed intergroup study 0116: a phase III 
trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin 
Oncol, 30, 2327-33.
SMYTH, E. C. et al. 2016. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow-up. Ann Oncol, 27, v38-v49.
SOGAARD, K. K. et al. 2016. Long-term risk of gastrointestinal cancers in persons with gastric or 
duodenal ulcers. Cancer Med, 5, 1341-51.
SOHN, B. H. et al. 2017. Clinical Significance of Four Molecular Subtypes of Gastric Cancer 
Identified by The Cancer Genome Atlas Project. Clin Cancer Res.
SOLCIA, E. et al. 2009. A combined histologic and molecular approach identifies three groups of 
gastric cancer with different prognosis. Virchows Arch, 455, 197-211.
SOMMER, H. and SANTI, D. V. 1974. Purification and amino acid analysis of an active site peptide 
from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and 
methylenetetrahydrofolate. Biochem Biophys Res Commun, 57, 689-95.
SONG, B. et al. 2009. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma 
and colon cancer cells. Oncogene, 28, 4065-74.
SONG, H. et al. 2015. Incidence of gastric cancer among patients with gastric precancerous lesions: 
observational cohort study in a low risk Western population. BMJ, 351, h3867.
SONG, J. H. et al. 2017. Risk Factors for Gastric Tumourigenesis in Underlying Gastric Mucosal 
Atrophy. Gut Liver, 11, 612-619.
SONG, J. H. and MELTZER, S. J. 2012. MicroRNAs in pathogenesis, diagnosis, and treatment of 
gastroesophageal cancers. Gastroenterology, 143, 35-47 e2.
SONG, M. Y. et al. 2012. Identification of serum microRNAs as novel non-invasive biomarkers for 
early detection of gastric cancer. PLoS One, 7, e33608.
SONGUN, I. et al. 2010. Surgical treatment of gastric cancer: 15-year follow-up results of the 
randomised nationwide Dutch D1D2 trial. Lancet Oncol, 11, 439-49.
244
SONNENBERG, A. 2011. Time trends of mortality from gastric cancer in Europe. Dig Dis Sci, 56,
1112-8.
SPICER D. 2009. FGF9 on the move. Nature genetics. 41, 272-273.
STARK, M. S. et al. 2015. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi 
sensitivity in melanoma. Oncotarget, 6, 17753-63.
STEEVENS, J. et al. 2010. Alcohol consumption, cigarette smoking and risk of subtypes of 
oesophageal and gastric cancer: a prospective cohort study. Gut, 59, 39-48.
SU, Y. et al. 2012. Aberrant expression of microRNAs in gastric cancer and biological significance of 
miR-574-3p. Int Immunopharmacol, 13, 468-75.
SU, Y. et al. 2016. MicroRNA-140-5p targets insulin like growth factor 2 mRNA binding protein 1 
(IGF2BP1) to suppress cervical cancer growth and metastasis. Oncotarget, 7, 68397-68411.
SUN, D. G. et al. 2017. miR-140-5p-mediated regulation of the proliferation and differentiation of 
human dental pulp stem cells occurs through the lipopolysaccharide/toll-like receptor 4 signaling 
pathway. Eur J Oral Sci, 125, 419-425.
SUN, M. et al. 2012. MiR-196a is upregulated in gastric cancer and promotes cell proliferation by 
downregulating p27(kip1). Mol Cancer Ther, 11, 842-52.
SUN J, et al. 2016. miR1405p regulates angiogenesis following ischemic stroke by targeting VEGFA. 
Molecular medicine reports. 13, 4499-4505.
SUZUKI, H. et al. 2016. High rate of 5-year survival among patients with early gastric cancer 
undergoing curative endoscopic submucosal dissection. Gastric Cancer, 19, 198-205.
SUZUKI, K. et al. 2006. Global DNA demethylation in gastrointestinal cancer is age dependent and 
precedes genomic damage. Cancer Cell, 9, 199-207.
SWAIN, S. M. et al. 1989. Fluorouracil and high-dose leucovorin in previously treated patients with 
metastatic breast cancer. J Clin Oncol, 7, 890-9.
SWINGLER, T. E. et al. 2012. The expression and function of microRNAs in chondrogenesis and 
osteoarthritis. Arthritis Rheum, 64, 1909-19.
SZKARADKIEWICZ, A. et al. 2006. Epstein-Barr virus (EBV) infection and p53 protein expression 
in gastric carcinoma. Virus Res, 118, 115-9.
TAKADA, K. 2000. Epstein-Barr virus and gastric carcinoma. Mol Pathol, 53, 255-61.
TAKAHASHI, K. and YAMANAKA, S. 2016. A decade of transcription factor-mediated 
reprogramming to pluripotency. Nat Rev Mol Cell Biol, 17, 183-93.
TAKATA, A. et al. 2011. MicroRNA-22 and microRNA-140 suppress NF-kappaB activity by 
regulating the expression of NF-kappaB coactivators. Biochem Biophys Res Commun, 411, 826-31.
TAKE, S. et al. 2007. Baseline gastric mucosal atrophy is a risk factor associated with the development 
of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J 
Gastroenterol, 42 Suppl 17, 21-7.
TAKE, S. et al. 2005. The effect of eradicating helicobacter pylori on the development of gastric 
cancer in patients with peptic ulcer disease. Am J Gastroenterol, 100, 1037-42.
TAMBE, M. et al. 2016. Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' 
sensitivity to paclitaxel. Oncotarget, 7, 12267-85.
TAMURA, G. et al. 1996. Inactivation of the E-cadherin gene in primary gastric carcinomas and 
gastric carcinoma cell lines. Jpn J Cancer Res, 87, 1153-9.
TAN, I. B. et al. 2011. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict 
survival and respond differently to chemotherapy. Gastroenterology, 141, 476-85, 485 e1-11.
245
TAN, X. et al. 2016. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating 
FOXM1 expression in breast cancer. Oncotarget, 7, 293-307.
TAN, X. et al. 2011. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-
miR-31 for prognosis. Clin Cancer Res, 17, 6802-11.
TANG, Y. et al. 2017. lncRNA XIST interacts with miR-140 to modulate lung cancer growth by 
targeting iASPP. Oncol Rep, 38, 941-948.
TANNER, M. et al. 2005. Amplification of HER-2 in gastric carcinoma: association with 
Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to 
trastuzumab. Ann Oncol, 16, 273-8.
TAO, S. C. et al. 2017. Exosomes derived from miR-140-5p-overexpressing human synovial 
mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in 
a rat model. Theranostics, 7, 180-195.
TARDIF, G. et al. 2009. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140
and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet Disord, 10, 148.
TARDIF, G. et al. 2013. NFAT3 and TGF-beta/SMAD3 regulate the expression of miR-140 in 
osteoarthritis. Arthritis Res Ther, 15, R197.
TATARANO, S. et al. 2011. miR-218 on the genomic loss region of chromosome 4p15.31 functions 
as a tumour suppressor in bladder cancer. Int J Oncol, 39, 13-21.
TATEMICHI, M. et al. 2008. Different etiological role of Helicobacter pylori (Hp) infection in 
carcinogenesis between differentiated and undifferentiated gastric cancers: a nested case-control study 
using IgG titer against Hp surface antigen. Acta Oncol, 47, 360-5.
TAURINO, C. et al. 2010. Gene expression profiling in whole blood of patients with coronary artery 
disease. Clin Sci (Lond), 119, 335-43.
TCHERNITSA, O. et al. 2010. Systematic evaluation of the miRNA-ome and its downstream effects 
on mRNA expression identifies gastric cancer progression. J Pathol, 222, 310-9.
TERSMETTE, A. C. et al. 1990. Meta-analysis of the risk of gastric stump cancer: detection of high 
risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer 
Res, 50, 6486-9.
TESTINO, G. 2011. The burden of cancer attributable to alcohol consumption. Maedica (Buchar), 6, 
313-20.
TEY, J. et al. 2017. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. 
Oncotarget, 8, 25797-25805.
The American Society for Gastrointestinal Endoscopy. 1988. The role of endoscopy in the surveillance 
of premalignant conditions of the upper gastrointestinal tract. Guidelines for clinical application. 
Gastrointest Endosc, 34, 18S-20S.
THORBURN, J. et al. 2014. Autophagy controls the kinetics and extent of mitochondrial apoptosis 
by regulating PUMA levels. Cell Rep, 7, 45-52.
THORPE, S. D. et al. 2010. The response of bone marrow-derived mesenchymal stem cells to dynamic 
compression following TGF-beta3 induced chondrogenic differentiation. Ann Biomed Eng, 38, 2896-
909.
TIVNAN, A. et al. 2012. Inhibition of neuroblastoma tumour growth by targeted delivery of 
microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One, 7, e38129.
TODORIC, J. et al. 2017. Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression 
in Pancreas. Cancer Cell, 32, 824-839 e8.
TORRE, L. A. et al. 2015. Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108.
246
TREECE, A. L. et al. 2016. Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma 
reveal cancer-associated and Epstein-Barr virus-related expression patterns. Lab Invest, 96, 661-71.
TSAI, K. W. et al. 2012. Aberrant expression of miR-196a in gastric cancers and correlation with 
recurrence. Genes Chromosomes Cancer, 51, 394-401.
TSAI, K. W. et al. 2011. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. 
Int J Cancer, 129, 2600-10.
TSUJIURA, M. et al. 2015. Circulating miR-18a in plasma contributes to cancer detection and 
monitoring in patients with gastric cancer. Gastric Cancer, 18, 271-9.
TU, H. et al. 2014. Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of 
histological gastritis, mucosal bacterial density, and levels of serum biomarkers. Scand J 
Gastroenterol, 49, 259-66.
UEDA, T. et al. 2010. Relation between microRNA expression and progression and prognosis of 
gastric cancer: a microRNA expression analysis. Lancet Oncol, 11, 136-46.
UEMURA, N. et al. 2001. Helicobacter pylori infection and the development of gastric cancer. N Engl 
J Med, 345, 784-9.
UNO, K. et al. 2016. Gastric cancer development after the successful eradication of Helicobacter 
pylori. World J Gastrointest Oncol, 8, 271-81.
USHIJIMA, T. and SASAKO, M. 2004. Focus on gastric cancer. Cancer Cell, 5, 121-5.
VALENZUELA-MUNOZ, V. et al. 2017. Modulation of Atlantic salmon miRNome response to sea 
louse infestation. Dev Comp Immunol, 76, 380-391.
VAN CUTSEM, E. et al. 2015. HER2 screening data from ToGA: targeting HER2 in gastric and 
gastroesophageal junction cancer. Gastric Cancer, 18, 476-84.
VAN CUTSEM, E. et al. 2011. The diagnosis and management of gastric cancer: expert discussion 
and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona,
2010. Ann Oncol, 22 Suppl 5, v1-9.
VAN CUTSEM, E. et al. 2006. Phase III study of docetaxel and cisplatin plus fluorouracil compared 
with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 
Study Group. J Clin Oncol, 24, 4991-7.
VAN CUTSEM, E. et al. 2016. Gastric cancer. Lancet, 388, 2654-2664.
VAN CUTSEM, E. et al. 2008. Expert opinion on management of gastric and gastro-oesophageal 
junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of 
Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer, 44, 182-94.
VAN LIER, M. G. et al. 2011. High cancer risk and increased mortality in patients with Peutz-Jeghers 
syndrome. Gut, 60, 141-7.
VASUDEVAN, S. et al. 2007. Switching from repression to activation: microRNAs can up-regulate 
translation. Science, 318, 1931-4.
VAZQUEZ-MARTIN, A. et al. 2013. Reprogramming of non-genomic estrogen signaling by the 
stemness factor SOX2 enhances the tumour-initiating capacity of breast cancer cells. Cell Cycle, 12,
3471-7.
VELLANKI, R. N. et al. 2010. OASIS/CREB3L1 induces expression of genes involved in 
extracellular matrix production but not classical endoplasmic reticulum stress response genes in 
pancreatic beta-cells. Endocrinology, 151, 4146-57.
VIDIGAL, J. A. and VENTURA, A. 2015. The biological functions of miRNAs: lessons from in vivo
studies. Trends Cell Biol, 25, 137-47.
247
VINCENT, A. J. et al. 2012. Cytoplasmic translocation of p21 mediates NUPR1-induced 
chemoresistance: NUPR1 and p21 in chemoresistance. FEBS Lett, 586, 3429-34.
VOLINIA, S. et al. 2006. A microRNA expression signature of human solid tumours defines cancer 
gene targets. Proc Natl Acad Sci U S A, 103, 2257-61.
WADDELL, T. et al. 2013. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab 
for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised,
open-label phase 3 trial. Lancet Oncol, 14, 481-9.
WADDELL, T. et al. 2014. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Radiother Oncol, 110, 189-94.
WADE, M. et al. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer,
13, 83-96.
WAGNER, A. D. et al. 2006. Chemotherapy in advanced gastric cancer: a systematic review and meta-
analysis based on aggregate data. J Clin Oncol, 24, 2903-9.
WAGNER, A. D. et al. 2017. Chemotherapy for advanced gastric cancer. Cochrane Database Syst 
Rev, 8, CD004064.
WANG, K. et al. 2017. Analysis of microRNA (miRNA) expression profiles reveals 11 key 
biomarkers associated with non-small cell lung cancer. World J Surg Oncol, 15, 175.
WANG, M. et al. 2013. miR-17-5p/20a are important markers for gastric cancer and murine double 
minute 2 participates in their functional regulation. Eur J Cancer, 49, 2010-21.
WANG, Q. et al. 2014. Consumption of fruit, but not vegetables, may reduce risk of gastric cancer: 
results from a meta-analysis of cohort studies. Eur J Cancer, 50, 1498-509.
WANG, S. et al. 2017. Overaccumulation of p53-mediated autophagy protects against betulinic acid-
induced apoptotic cell death in colorectal cancer cells. Cell Death Dis, 8, e3087.
WANG, W. H. et al. 2003. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a 
systematic review and meta-analysis. J Natl Cancer Inst, 95, 1784-91.
WANG, X. et al. 2018. Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse 
Chemoresistance to Cisplatin in Gastric Cancer. Mol Ther, 26, 774-783.
WANG, Y. Y. et al. 2013. Clinicopathologic significance of miR-10b expression in gastric carcinoma. 
Hum Pathol, 44, 1278-85.
WANG, Z. et al. 2014. Predictive factors for lymph node metastasis in early gastric cancer with signet 
ring cell histology and their impact on the surgical strategy: analysis of single institutional experience. 
J Surg Res, 191, 130-3.
WATANABE, M. et al. 2012. Development of gastric cancer in nonatrophic stomach with highly 
active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody 
together with endoscopic rugal hyperplastic gastritis. Int J Cancer, 131, 2632-42.
WEBLEY, S. D. et al. 2000. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the 
thymidylate synthase (TS) inhibitor ZD9331. Br J Cancer, 83, 792-9.
WEI, D. Z. et al. 2017. Ellagic acid promotes ventricular remodeling after acute myocardial infarction 
by up-regulating miR-140-3p. Biomed Pharmacother, 95, 983-989.
WEI, R. et al. 2016. miR-140-5p attenuates chemotherapeutic drug-induced cell death by regulating 
autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells. Biosci 
Rep, 36.
WEN, Y. Y. et al. 2014. Association of the IL-1B +3954 C/T polymorphism with the risk of gastric 
cancer in a population in Western China. Eur J Cancer Prev, 23, 35-42.
248
WILKE, H. et al. 2014. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with 
previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a 
double-blind, randomised phase 3 trial. Lancet Oncol, 15, 1224-35.
WILLIAMS, B. et al. 1988. Do young patients with dyspepsia need investigation? Lancet, 2, 1349-51.
WOHLHUETER, R. M. et al. 1980. Facilitated transport of uracil and 5-fluorouracil, and permeation 
of orotic acid into cultured mammalian cells. J Cell Physiol, 104, 309-19.
WOLFSON, B. et al. 2014. Roles of microRNA-140 in stem cell-associated early stage breast cancer. 
World J Stem Cells, 6, 591-7.
WONG, N. and WANG, X. 2015. miRDB: an online resource for microRNA target prediction and 
functional annotations. Nucleic Acids Res, 43, D146-52.
WONG, S. S. et al. 2014. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma 
revealed by whole-genome sequencing. Nat Commun, 5, 5477.
Wu K. et al. 2019. MicroRNA-140-5p inhibits cell proliferation, migration and promotes cell apoptosis 
in gastric cancer through the negative regulation of THY1-mediated Notch signaling. Bioscience 
reports. 39.
WU, J. et al. 2013. Up-regulation of microRNA-1290 impairs cytokinesis and affects the 
reprogramming of colon cancer cells. Cancer Lett, 329, 155-63.
XIAO, Q. et al. 2017. Overexpression of miR-140 Inhibits Proliferation of Osteosarcoma Cells via 
Suppression of Histone Deacetylase 4. Oncol Res, 25, 267-275.
XIE, M. et al. 2018. MicroRNA-1 acts as a tumour suppressor microRNA by inhibiting angiogenesis-
related growth factors in human gastric cancer. Gastric Cancer, 21, 41-54.
XIE, W. B. et al. 2018. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in 
NSCLC. Cell Physiol Biochem, 46, 654-663.
XING, Y. et al. 2018. Comprehensive analysis of differential expression profiles of mRNAs and 
lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon 
adenocarcinoma. Oncol Rep, 39, 2365-2375.
XIONG, B. H. et al. 2014. An updated meta-analysis of randomized controlled trial assessing the 
effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest, 32, 272-84.
XU, H. and EL-GEWELY, M. R. 2001. P53-responsive genes and the potential for cancer diagnostics 
and therapeutics development. Biotechnol Annu Rev, 7, 131-64.
XU, X. et al. 2013. miRNA: The nemesis of gastric cancer (Review). Oncol Lett, 6, 631-641.
XU, Y. et al. 2012. miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients 
with Gastric Cancer. Gastroenterol Res Pract, 2012, 640168.
XU, Z. Y. et al. 2015. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with 
properties of cancer stem cells. Int J Biol Sci, 11, 284-94.
YAMAGATA, H. et al. 2005. Impact of fasting plasma glucose levels on gastric cancer incidence in 
a general Japanese population: the Hisayama study. Diabetes Care, 28, 789-94.
YAMAMOTO, E. et al. 2011. Role of DNA methylation in the development of diffuse-type gastric 
cancer. Digestion, 83, 241-9.
YAMAMOTO, N. et al. 1994. Epstein-Barr virus and gastric remnant cancer. Cancer, 74, 805-9.
YAMASAKI, M. et al. 2010. p53 genotype predicts response to chemotherapy in patients with 
squamous cell carcinoma of the esophagus. Ann Surg Oncol, 17, 634-42.
YAN, C. et al. 2011. MicroRNA regulation associated chondrogenesis of mouse MSCs grown on 
polyhydroxyalkanoates. Biomaterials, 32, 6435-44.
249
YAN, H. et al. 2018. Aberrant Ki-67 expression through 3'UTR alternative polyadenylation in breast 
cancers. FEBS Open Bio, 8, 332-338.
YAN, L. X. et al. 2008. MicroRNA miR-21 overexpression in human breast cancer is associated with 
advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-60.
YANAKA, Y. et al. 2015. miR-544a induces epithelial-mesenchymal transition through the activation 
of WNT signaling pathway in gastric cancer. Carcinogenesis, 36, 1363-71.
YANG, H. et al. 2013. MicroRNA-140-5p suppresses tumour growth and metastasis by targeting 
transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. 
Hepatology, 58, 205-17.
YANG, J. et al. 2017. Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. 
Oncotarget, 8, 52403-52412.
YANG, J. et al. 2011. MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to 
target Sp1 in maintaining the chondrocyte proliferation. FEBS Lett, 585, 2992-7.
YANG, M. et al. 2011. Microvesicles secreted by macrophages shuttle invasion-potentiating 
microRNAs into breast cancer cells. Mol Cancer, 10, 117.
YANG, S. M. et al. 2013. miR-21 confers cisplatin resistance in gastric cancer cells by regulating 
PTEN. Toxicology, 306, 162-8.
YANG, Y. et al. 2015. Perioperative chemotherapy more of a benefit for overall survival than adjuvant 
chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep, 5, 12850.
YAO, Y. et al. 2009. MicroRNA profiling of human gastric cancer. Mol Med Rep, 2, 963-70.
YASUDA, K. et al. 2000. Papillary adenocarcinoma of the stomach. Gastric Cancer, 3, 33-38.
YCHOU, M. et al. 2011. Perioperative chemotherapy compared with surgery alone for resectable 
gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol,
29, 1715-21.
YEH, J. M. et al. 2016. Gastric adenocarcinoma screening and prevention in the era of new biomarker 
and endoscopic technologies: a cost-effectiveness analysis. Gut, 65, 563-74.
YEPES, S. et al. 2016. Co-expressed miRNAs in gastric adenocarcinoma. Genomics, 108, 93-101.
YIN, Y. et al. 2015. Fibroblast Growth Factor 9 Regulation by MicroRNAs Controls Lung 
Development and Links DICER1 Loss to the Pathogenesis of Pleuropulmonary Blastoma. PLoS Genet,
11, e1005242.
YOO, J. K. et al. 2014. Discovery and characterization of miRNA during cellular senescence in bone 
marrow-derived human mesenchymal stem cells. Exp Gerontol, 58, 139-45.
YOSHIDA, A. et al 2017. MicroRNA-140 mediates RB tumour suppressor function to control stem 
cell-like activity through interleukin-6. Oncotarget, 8, 13872-13885.
YOSHIDA, S. and SAITO, D. 1996. Gastric premalignancy and cancer screening in high-risk patients. 
Am J Gastroenterol, 91, 839-43.
YOSHIOKA, A. et al. 1987. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-
induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol 
Chem, 262, 8235-41.
YOU, W. C. et al. 1999. Evolution of precancerous lesions in a rural Chinese population at high risk 
of gastric cancer. Int J Cancer, 83, 615-9.
YOUN, H. G. et al. 2010. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol,
17, 448-54.
250
YOUNG, K. H. et al. 2008. Structural profiles of TP53 gene mutations predict clinical outcome in 
diffuse large B-cell lymphoma: an international collaborative study. Blood, 112, 3088-98.
YU, J. et al. 2016. Septin 2 accelerates the progression of biliary tract cancer and is negatively 
regulated by mir-140-5p. Gene, 589, 20-26.
Yu J. et al. 2019. SNHG20/miR-140-5p/NDRG3 axis contributes to 5-fluorouracil resistance in gastric 
cancer. Oncology letters. 18,1337-1343.
YU, L. et al. 2016. microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting 
ADAMTS5 and IGFBP5. Stem Cell Res Ther, 7, 180.
YUAN, Y. et al. 2013. miR-140 suppresses tumour growth and metastasis of non-small cell lung 
cancer by targeting insulin-like growth factor 1 receptor. PLoS One, 8, e73604.
ZALI, H. et al. 2011. Gastric cancer: prevention, risk factors and treatment. Gastroenterol Hepatol 
Bed Bench, 4, 175-85.
ZANGHIERI, G. et al. 1990. Familial occurrence of gastric cancer in the 2-year experience of a 
population-based registry. Cancer, 66, 2047-51.
ZARITSKY, A. et al. 2015. Seeds of Locally Aligned Motion and Stress Coordinate a Collective Cell 
Migration. Biophys J, 109, 2492-2500.
ZENG, Y. K. et al. 2012. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: 
evidence from randomized and nonrandomized clinical trials. Ann Surg, 256, 39-52.
ZERTAL-ZIDANI, S. et al. 2007. Regulation of pancreatic endocrine cell differentiation by sulphated 
proteoglycans. Diabetologia, 50, 585-95.
ZHAI, H. et al. 2015. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-
miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget, 6, 19735-46.
ZHANG, C. et al. 2017. Radioresistance of chordoma cells is associated with the ATM/ATR pathway,
in which RAD51 serves as an important downstream effector. Exp Ther Med, 14, 2171-2179.
ZHANG, J. et al. 2018. The prognostic value of age in non-metastatic gastric cancer after gastrectomy: 
a retrospective study in the U.S. and China. J Cancer, 9, 1188-1199.
ZHANG, J. et al. 2015. Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers 
to Indicate Progression of Gastric Cancer. Theranostics, 5, 733-45.
ZHANG, K. et al. 2018. SNHG16/miR-140-5p axis promotes esophagus cancer cell proliferation,
migration and EMT formation through regulating ZEB1. Oncotarget, 9, 1028-1040.
ZHANG, W. et al. 2015. MicroRNA-140-5p inhibits the progression of colorectal cancer by targeting 
VEGFA. Cell Physiol Biochem, 37, 1123-33.
ZHANG, X. et al. 2015. miR-140-5p regulates adipocyte differentiation by targeting transforming 
growth factor-beta signaling. Sci Rep, 5, 18118.
ZHANG, Y. et al. 2012. Estrogen receptor alpha signaling regulates breast tumour-initiating cells by 
down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem, 287, 41514-22.
ZHANG, Y. X. et al. 2016. Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to 
effectively suppress lung adenocarcinoma growth. Cell Death Dis, 7, e2528.
ZHAO, H. et al. 2016. The lncRNA H19 interacts with miR-140 to modulate glioma growth by 
targeting iASPP. Arch Biochem Biophys, 610, 1-7.
Zhao K, et al. 2018. Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7. 
EMBO reports. 19, 305-319.
ZHENG, H. C. et al. 2010. The pathobiological behaviors and prognosis associated with Japanese 
gastric adenocarcinomas of pure WHO histological subtypes. Histol Histopathol, 25, 445-52.
251
ZHOU, W. et al. 2015. MiR-493 suppresses the proliferation and invasion of gastric cancer cells by 
targeting RhoC. Iran J Basic Med Sci, 18, 1027-33.
ZHU, C. et al. 2014. A five-microRNA panel in plasma was identified as potential biomarker for early 
detection of gastric cancer. Br J Cancer, 110, 2291-9.
ZHU, G. et al. 2015. Identification of Gene and MicroRNA Signatures for Oral Cancer Developed 
from Oral Leukoplakia. Biomed Res Int, 2015, 841956.
ZHU, J. et al. 2016. Establishment of a miRNA-mRNA regulatory network in metastatic renal cell 
carcinoma and screening of potential therapeutic targets. Tumour Biol.
ZOMER, A. et al. 2010. Exosomes: Fit to deliver small RNA. Commun Integr Biol, 3, 447-50.
ZONG, L. et al. 2016. The challenge of screening for early gastric cancer in China. Lancet, 388, 2606.
ZOU, G. M. 2008. Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J 
Cell Physiol, 217, 598-604.
ZOU, J. and XU, Y. 2016. MicroRNA-140 Inhibits Cell Proliferation in Gastric Cancer Cell Line 
HGC-27 by Suppressing SOX4. Med Sci Monit, 22, 2243-52.
ZOU, M. X. et al. 2014. Identification of miR-140-3p as a marker associated with poor prognosis in 
spinal chordoma. Int J Clin Exp Pathol, 7, 4877-85.
ZUR HAUSEN, A. et al. 2004. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: 
a late event in gastric carcinogenesis. J Clin Pathol, 57, 487-91.
252
Appendix
Appendix 1: Peking University Cancer Hospital Patients in Consent Information
253
254
Appendix 2: General compounds used in this study and their sources.
Material/Reagent Supplier
Acetic acid Fisher Scientific, Leicestershire, UK
Acrylamide mix (30%) Sigma-Aldrich, Poole, Dorset, UK
Agarose Melford Laboratories Ltd, Suffolk, UK
Ammonium Persulphate (APS) Sigma-Aldrich, Poole, Dorset, UK 
Ampicillin Sigma-Aldrich, Poole, Dorset, UK
Bio-Rad DC™ Protein Assay Bio-Rad Laboratories, Hercules, CA, USA
Bovine serum albumin (BSA) Sigma-Aldrich, Poole, Dorset, UK
Calcium chloride (CaCl2) Sigma-Aldrich, Poole, Dorset, UK
Chloroform Sigma-Aldrich, Poole, Dorset, UK
Crystal violet Sigma-Aldrich, Poole, Dorset, UK
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Poole, Dorset, UK
Dimethylsulphoxide (DMSO) Sigma-Aldrich, Poole, Dorset, UK
Dulbecco’s Modified Eagles’ 
Medium/Nutrient mixture F12 
Sigma-Aldrich, Poole, Dorset, UK
Ethylenediaminetetraacetic acid 
(EDTA)
Duchefa Biochemie, Haarlem, Netherlands
Ethanol Fisher Scientific, Leicestershire, UK
10% Fetal calf serum (FCS) PAA Laboratories, Coelbe, Germany
Formalin Sigma-Aldrich Ltd, Dorset, UK
GoTaq® Green Master Mix Promega
G418
Hydrochloric acid (HCl) Sigma-Aldrich, Poole, Dorset, UK
Isopropyl 
alcohol/isopropanol/2-propanol
Sigma-Aldrich, Poole, Dorset, UK
Matrigel® BD Biosciences, Oxford, UK
Methanol Fisher Scientific, Leicestershire, UK
Penicillin Sigma-Aldrich, Poole, Dorset, UK
Peroxidase-conjugated goat anti-
rabbit IgG
Sigma-Aldrich, Poole, Dorset, UK
Peroxidase-conjugated rabbit 
anti-mouse IgG
Sigma-Aldrich, Poole, Dorset, UK
Phenylmethyl sulfonyl fluoride 
(PMSF)
Sigma-Aldrich, Poole, Dorset, UK
Precision qScript™ RT PCR kit Primerdesign Ltd, Southampton, UK
REDTaq® ReadyMix™ PCR 
Reaction Mix
Sigma-Aldrich, Poole, Dorset, UK
RPMI-1640 Sigma-Aldrich, Poole, Dorset, UK
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Serum bovine albumin Sigma-Aldrich, Poole, Dorset, UK
Sodium dodecyl sulphate (SDS) Melford Laboratories Ltd, Suffolk, UK
Streptomycin Sigma-Aldrich, Poole, Dorset, UK
SYBR®Safe DNA gel stain Life Technologies Ltd, Paisley, UK
Tetramethylelthylenediamine 
(TEMED)
Sigma-Aldrich, Poole, Dorset, UK
TRI Reagent Sigma-Aldrich, Poole, Dorset, UK
Tris-Cl Melford Laboratories Ltd, Suffolk, UK
Triton X-100 Sigma-Aldrich, Poole, Dorset, UK
Trypsin Sigma-Aldrich, Poole, Dorset, UK
Tween 20 Melford Laboratories Ltd, Suffolk, UK
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Appendix 3: General plastic consumables, hardware, and software used in this 
study and their sources
Hardware/Software Supplier
0.2 μm filtration unit Sigma-Aldrich Co, Poole, Dorset, UK 
25cm2 and 75cm2 culture flasks Cell Star, Germany 
Image J National Institute of Health
Lecia DM IRB microscope Lecia GmbH, Bristol, UK
R software http://www.r-project.org/
GraphPad Prism 6.0 San Diego, CA Software, La Jolla, CA
SPSS version 23.0 IBM Corporation, Armonk, NY, USA
Microsoft Excel Microsoft In., Redmond, WA, USA 
Neubauer hemocytometer counting
chamber
Reichert, Austria 
Protein spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
RNA spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
UV light chamber Germix 
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Appendix 4: Amplifluor™ Universal detection system using UniPrimer™.
Source: The Scientist: https://www.the-scientist.com/.
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Appendix 5: Amplification plot and standard curve produced using qPCR. 
A. Amplification plot showing an exponential increase in transcript copy number with cycle 
number B. Standard curve produced by plotting starting copy number against the cycle
threshold (Ct). Source: The Scientist: https://www.the-scientist.com/
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Appendix 6: Gastric Cancer Treatment Regimens.
1Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the 
intervention is appropriate. 2Category 1: Based upon the high-level evidence, there is uniform NCCN 
consensus that the intervention is appropriate. 3Category 2B: Based upon lower-level evidence, there 
is NCCN consensus that the intervention is appropriate. Source: Gastrointestinal cancer advisor 
available at https://www.cancertherapyadvisor.com/gastrointestinal-cancers/gastric-cancer-
treatment-regimens/article/218159/.
Preoperative Chemoradiation (esophagogastric junction and gastric cardia)1
Note: All recommendations are Category 2A1 unless otherwise indicated.
Preferred Regimens
REGIMEN DOSING
Paclitaxel + carboplatin
(Category 1)
Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 
2mg·min/mL IV. Repeat cycle weekly for 5 weeks.
Cisplatin + 5FU (Category 1) Days 1 and 29: Cisplatin 75–100mg/m2 IV
Days 1–4 and 29–32: 5FU 750–1000mg/m2 continuous IV 
infusion over 24 hours daily.
Or
Days 1–5: Cisplatin 15mg/m2 IV once daily + 5FU 
800mg/m2continuous IV infusion over 24 hours daily.
Repeat cycle every 21 days for 2 cycles.
Oxaliplatin + 5FU (Category 1) Day 1: Oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5FU 
400mg/m2IV push followed by
Days 1–2: 5FU 800mg/m2 24-hour continuous infusion.
Repeat cycle every 14 days for 3 cycles with radiation and 
3 cycles after radiation.
Cisplatin + capecitabine Day 1: Cisplatin 30mg/m2 IV
Days 1–5: Capecitabine 800mg/m2 orally twice daily.
Repeat cycle weekly for 5 weeks.
Oxaliplatin + capecitabine Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV
Days 1–5: Capecitabine 625mg/m2 orally twice daily for 5 
weeks.
Other Regimens
Paclitaxel + 5FU (Category
2B)
Day 1: Paclitaxel 45–50mg/m2 IV weekly
Days 1–5: 5FU 300mg/m2 IV continuous infusion.
Repeat cycle weekly for 5 weeks.
Paclitaxel + capecitabine
(Category 2B)
Day 1: Paclitaxel 45–50mg/m2 IV
Days 1–5: Capecitabine 625-825mg/m2 orally twice daily.
Repeat cycle weekly for 5 weeks.
Perioperative Chemotherapy (including esophagogastric junction)1
Epirubicin + cisplatin + 5FU
(ECF) (Category 2B)
Day 1: Epirubicin 50mg/m2 IV bolus + cisplatin 60mg/m2
IV
Days 1–21: 5FU 200mg/m2/day IV continuous infusion 
over 24 hours daily.
Repeat cycle every 21 days for 3 cycles preoperatively 
and 3 cycles postoperatively.
ECF modification: epirubicin
+ oxaliplatin + 5FU (Category
2B)
Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV
Days 1–21: 5FU 200mg/m2/day IV continuous infusion 
over 24 hours.
Repeat cycle every 21 days for 3 cycles preoperatively 
and 3 cycles postoperatively
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ECF modification: epirubicin
+ cisplatin + capecitabine
(Category 2B)
Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV
Days 1–21: Capecitabine 625mg/m2 orally twice daily.
Repeat cycle every 21 days for 3 cycles preoperatively 
and 3 cycles postoperatively.
ECF modification: epirubicin
+ oxaliplatin + capecitabine
(Category 2B)
Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV
Days 1–21: Capecitabine 625mg/m2 orally twice daily.
Repeat cycle every 21 days for 3 cycles preoperatively 
and 3 cycles postoperatively.
5FU + cisplatin (Category 1) Day 1: Cisplatin 75–80mg/m2 IV
Days 1–5: 5FU 800mg/m2 IV continuous infusion over 24 
hours daily.
Repeat cycle every 28 days for 2–3 cycles preoperatively 
and 3–4 cycles postoperatively for a total of 6 cycles.
5FU + leucovorin + oxaliplatin Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 + 
5FU 400mg/m2 IV push followed by:
Days 1–2: 5FU 1200mg/m2 continuous IV daily over 24 
hours.
Or
Day 1: Oxaliplatin 85mg/m2 + leucovorin 200mg/m2 + 5FU 
2600mg/m2 continuous IV infusion over 24 hours.
Repeat cycle every 14 days.
Capecitabine + oxaliplatin Day 1: Oxaliplatin 130mg/m2 IV
Days 1–14: Capecitabine 1000mg/m2 orally twice daily.
Repeat cycle every 21 days.
Postoperative Chemoradiation (including esophagogastric junction)1
5FU + leucovorin (Category 1) Cycles 1, 3, and 4 (before and after radiation)
Days 1–5: Leucovorin 20mg/m2 IV push + 5FU 
425mg/m2/day IV push
Repeat cycle every 28 days.
Cycle 2 (with radiation)
Days 1–4 and 31–33: Leucovorin 20mg/m2 IV push
Days 1–4: 5FU 400mg/m2/day IV push.
Repeat cycle every 35 days.
The NCCN panel acknowledges that the Intergroup 0116 
Trial formed the basis for postoperative adjuvant 
chemoradiation strategy. However, the panel does not 
recommend the above-specified doses or schedule of 
cytotoxic agents because of concerns regarding toxicity. 
The panel recommends one of the following modifications 
instead.
Capecitabine Days 1–14: Capecitabine 750–1000mg/m2 orally twice 
daily.
Repeat cycle every 28 days; 1 cycle before and 2 cycles 
after chemoradiation.
5FU + leucovorin Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV followed 
by 5FU 400mg/m2 IV push and a 24-hour infusion of 5FU 
1200mg/m2; 1 cycle before and 2 cycles after 
chemoradiation.
Repeat cycle every 28 days.
5FU with radiation Days 1–5 OR Days 1–7: 5FU 200–250mg/m2 IV 
continuous infusion over 24 hours once daily; weekly for 5 
weeks.
Capecitabine with radiation Days 1–5 OR Days 1–7: Capecitabine 625–825mg/m2
orally twice daily; weekly for 5 weeks.
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Postoperative Chemotherapy (for patients who have undergone primary D2 lymph 
node dissection)
Capecitabine + oxaliplatin
(Category 1)
Days 1–14: Capecitabine 1000mg/m2 orally twice daily
Day 1: Oxaliplatin 130mg/m2 IV.
Repeat cycle every 21 days for 8 cycles.
Unresectable Locally Advanced, Recurrent or Metastatic Disease (where local therapy 
is not indicated)1
First-line Therapy
Trastuzumab + chemotherapy
(NOTE: for HER2-neu
overexpressing
adenocarcinoma)
Day 1: Trastuzumab 8mg/kg IV loading dose (Cycle 1 
only); followed by
trastuzumab 6mg/kg IV every 3 weeks, plus 
chemotherapy
Or
Day 1 of Cycle 1: Trastuzumab 6mg/kg IV loading dose,
then 4mg/kg IV every 14 days.
Chemotherapy:
Day 1: Cisplatin 80mg/m2 IV, plus
Days 1–14: Capecitabine 1000mg/m2 orally twice daily. 
(Category 1)
Or
Days 1–5: 5FU 800mg/m2 continuous IV infusion. 
(Category 2B)
Repeat cycle every 21 days for 6 cycles.
Preferred Regimens
Fluoropyrimidine and
cisplatin (5FU + cisplatin)
(Category 1)
Day 1: Cisplatin 75−100mg/m2 IV
Days 1–4: 5FU 750−1,000mg/m2 IV continuous infusion 
over 24 hours daily.
Fluoropyrimidine and
cisplatin (5FU + cisplatin +
leucovorin) (Category 1)
Day 1: Cisplatin 50mg/m2 IV + leucovorin 200mg/m2 IV + 
5FU 2,000mg/m2 IV continuous infusion over 24 hours.
Repeat cycle every 14 days.
Fluoropyrimidine and
cisplatin (capecitabine +
cisplatin) (Category 1)
Day 1: Cisplatin 80mg/m2 IV
Day 1–14: Capecitabine 1000mg/m2 orally twice daily.
Repeat cycle every 3 weeks.
Fluoropyrimidine and
oxaliplatin (oxaliplatin +
capecitabine)
Day 1: Oxaliplatin 130mg/m2 IV
Days 1–14: Capecitabine 1000mg/m2 orally twice daily.
Repeat cycle every 21 days.
Fluoropyrimidine and
oxaliplatin (oxaliplatin +
leucovorin + 5FU)
Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV 
+ 5FU 400mg/m2 IVP
Days 1−2: 5FU 1200mg/m2 IV continuous infusion over 
24 hours daily.
Repeat cycle every 14 days.
Or
Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 200mg/m2 IV 
+ 5FU 2,600mg/m2 IV continuous infusion over 24 hours.
Repeat cycle every 14 days.
Other Regimens
Modified DCF (docetaxel +
cisplatin + leucovorin + 5FU)
Day 1: Docetaxel 40mg/m2 IV + leucovorin 400mg/m2 IV + 
5FU 400mg/m2 IV
Days 1−2: 5FU 1000mg/m2 IV continuous infusion over 
24 hours
Day 3: Cisplatin 40mg/m2 IV.
Repeat cycle every 14 days.
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Modified DCF (docetaxel +
oxaliplatin + 5FU)
Day 1: Docetaxel 50mg/m2 IV + oxaliplatin 85mg/m2 IV
Days 1−2: 5FU 1,200mg/m2 IV continuous infusion over 
24 hours.
Repeat cycle every 14 days.
Modified DCF (docetaxel +
carboplatin + 5FU) (Category
2B)
Day 1: Docetaxel 75mg/m2 IV
Day 2: Carboplatin AUC 6mg·min/mL IV
Days 1–3: 5FU 1,200mg/m2 IV continuous infusion over 
24 hours daily.
Repeat cycle every 21 days.
ECF (Category 2B) Day 1: Epirubicin 50mg/m2 IV bolus + cisplatin 60mg/m2
IV
Days 1–21: 5FU 200mg/m2 IV continuous infusion over 
24 hours daily.
Repeat cycle every 21 days.
ECF modifications (epirubicin
+ oxaliplatin + 5FU) (Category
2B)
Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV
Days 1–21: 5FU 200mg/m2 IV continuous infusion over 
24 hours.
Repeat cycle every 21 days.
ECF modifications (epirubicin
+ cisplatin + capecitabine)
(Category 2B)
Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV
Days 1–21: Capecitabine 625mg/m2 orally twice daily.
Repeat cycle every 21 days.
ECF modifications (epirubicin
+ oxaliplatin + capecitabine)
(Category 2B)
Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV
Days 1–21: Capecitabine 625mg/m2 IV orally twice daily.
Repeat cycle every 21 days.
Fluorouracil and irinotecan
(irinotecan + leucovorin +
5FU)
Day 1: Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV 
+ 5FU 400mg/m2 IV push followed by
Day 1−2: 5FU 1200mg/m2 IV continuous infusion over 24 
hours daily.
Repeat cycle every 14 days.
Paclitaxel + cisplatin or
carboplatin
Day 1: Paclitaxel 135–200mg/m2 IV
Day 2: Cisplatin 75mg/m2 IV.
Repeat cycle every 21 days.
Or
Day 1: Paclitaxel 90mg/m2 IV + cisplatin 50mg/m2 IV.
Repeat cycle every 14 days.
Or
Day 1: Paclitaxel 200mg/m2 IV + carboplatin AUC 
5mg·min/mL IV.
Repeat cycle every 21 days.
Docetaxel + cisplatin Day 1: Docetaxel 70–85mg/m2 IV + cisplatin 70–75mg/m2
IV.
Repeat cycle every 21 days.
Fluoropyridimine Day 1: Leucovorin 400mg/m2 IV + 5FU 400mg/m2 IV push
Days 1−2: 5FU 1200mg/m2 IV continuous infusion over 
24 hours daily.
Repeat cycle every 14 days.
Or
Days 1–5: 5FU 800mg/m2 IV continuous infusion over 24 
hours daily.
Repeat cycle every 28 days.
Or
Days 1–14: Capecitabine 1000–1250mg/m2 orally twice 
daily.
Repeat cycle every 21 days.
Taxane Day 1: Docetaxel 75–100mg/m2 IV.
Repeat cycle every 21 days.
Or
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Day 1: Paclitaxel 135–250mg/m2 IV.
Repeat cycle every 21 days.
Or
Days 1, 8, 15 and 22: Paclitaxel 80mg/m2 IV once 
weekly.
Repeat cycle every 28 days.
Second-line Therapy and Subsequent Therapy
Preferred Regimens
Ramucirumab (Category 12) Day 1: Ramucirumab 8mg/kg IV.
Repeat cycle every 14 days.
Ramucirumab + paclitaxel
(Category 1)
Day 1 and 15: Ramucirumab 8mg/kg IV
Day 1, 8, and 15: Paclitaxel 80mg/m2.
Repeat cycle every 28 days.
Docetaxel (Category 1) Day 1: Docetaxel 75–100mg/m2 IV.
Repeat cycle every 21 days.
Paclitaxel (Category 1) Day 1: Paclitaxel 135–250mg/m2 IV.
Repeat cycle every 21 days.
Or
Day 1: Paclitaxel 80mg/m2 IV once weekly.
Repeat cycle every 28 days.
Or
Days 1, 8, and 15: Paclitaxel 80mg/m2 IV.
Repeat cycle every 28 days.
Irinotecan (Category 1) Day 1: Irinotecan 250–350mg/m2 IV.
Repeat cycle every 21 days.
Or
Day 1: Irinotecan 150–180mg/m2 IV.
Repeat cycle every 14 days.
Or
Days 1 and 8: Irinotecan 125mg/m2 IV.
Repeat cycle every 21 days.
5FU + irinotecan (if not
previously used in first-line
therapy)
Day 1: Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV 
+ 5FU 400mg/m2 IV push followed by
Day 1 and 2: 5FU 1200mg/m2 IV continuous infusion over 
24 hours daily.
Repeat cycle every 14 days.
Other Regimens
Irinotecan + cisplatin Days 1 and 8: Irinotecan 65mg/m2 IV + cisplatin 25–
30mg/m2 IV.
Repeat cycle every 21 days.
Docetaxel + irinotecan
(Category 2B3)
Days 1 and 8: Docetaxel 35mg/m2 IV + irinotecan 
50mg/m2 IV.
Repeat cycle every 21 days.
Pembrolizumab (for second-
line or subsequent therapy for
MSI-H/dMMR tumours; for
third-line or subsequent
therapy for PD-L1-positive
adenocarcinoma)
Days 1: Pembrolizumab 200 mg IV.
Repeat cycle every 21 days.
Appendix 7: Characteristics of miRNA datasets in human gastric cancer. 
Modified from A systematic review of  microRNA expression profiling studies in human gastric cancer(Shrestha et al. 2014). miRNAs over twofold 
change provided 1 Formalin-fixed, paraffin-embedded tissues of  H. pylori-positive (n=8) or H. pylori-negative (n=8) patients with an intestinal type of  
gastric cancer. GNCA, gastric non-cardia adenocarcinoma; GCI, gastric cancer intestinal; GCD, gastric cancer diffused, NR, not reported.
Dataset Year Region Tumour 
type
No. of samples 
(cancer/normal)
Platform (manufacturer) Total 
miRNA
Differentially expressed miRNAs
Criteria Up Down Total
Wang (Y. Y. 
Wang et al. 
2013)
2013 China NR 17
Tissue specimen
miRCURY LNA Array (v.16.0; 
Exiqon, Vedbaek, Denmark)
564 FC > 2, FC < 1.5 49 39 154
Katada (Katada 
et al. 2009)
2009 Japan GCD 84 (42/42) TaqMan PCR kit protocol on an 
Applied
Biosystems 7500 real-time PCR 
System
72 FC > 2, FC < 0.5 3 3 72
Hyun (Chang et 
al. 2015)
2015 Korea GCI 16 (8/8)1
Tissue specimen
Microarray (Agilent 
Technologies, Palo Alto, CA,
USA); TaqMan miRNA assays.
3523 FC > 2, P < 0.05 18 19 219
KAZUHIRO
(Osawa et al. 
2011)
2011 Japan NR 74 (37/37) Toray 3D-Gene® miRNA oligo 
chip (Toray Industries)
885 T/N ratio >1.40,
<0.85, P < 0.05
30 11 41
Zhu (Zhu et al. 
2014)
2014 China GNCA 80 (40/40) TaqMan low density array 
(TLDA) chips (V2.0; Applied 
Biosystems, Foster city, CA,
USA) 
667 FC > 4 5 NR NR
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Carvalho
(Carvalho et al. 
2012)
2012 Netherlands GCI 47 (37/10)
Tissue specimen
miRNAChip_human_v2 
(National DNA-Microarray 
Facility, University of Aveiro,
Portugal)
703 P < 0.05, FDR < 
+0.05
5 5 70
Kim (Kim et al. 
2011)
2011 Korea GCI,
GCD
124 (90/34)
Tissue specimen
LMT miRNA microarray 
(Agilent technologies)
1667 P < 0.005 62 63 125
Li (X. Li et al. 
2011a)
2011 China GCI 12 (6/6)
Tissue specimen
miRCURY Array LNA 
microRNA Chip (v.14.0) 
(Exiqon)
904 P < 0.01
FC > 2
40 36 76
Li (X. Li et al. 
2011b)
2011 China NR 20 (10/10)
Tissue specimen
TaqMan Human miRNA Array 
v1.0 (Applied Biosystems)
365 P < 0.05 16 6 22
Oh (Oh et al. 
2011)
2011 Singapore GCI,
GCD
80 (40/40)
Tissue specimen
Agilent Human miRNA 
Microarrays (V2, Agilent)
723 FDR < 0.01 40 40 146
Tchernitsa
(Tchernitsa et 
al. 2010)
2010 Germany GCI 12 (6/6)
Tissue specimen
NCode TM MultiSpecies 
miRNA Microarray V1 
(Invitrogen)
373 Significance of class 
comparison = 0.05
20 2 22
Ding (Ding et 
al. 2010)
2010 China GCI,
GCD
12 (6/6)
Tissue specimen
μParaflo microfluidic chip (LC 
Sciences)
NR P < 0.05 8 7 15
Tsukamoto 2010 Japan GCI,
GCD
27 (22/5)
Tissue specimen
G4470A Human MiRNA 
Microarray (Agilent 
technologies)
470 P < 0.05 33 6 102
Ueda (Ueda et 
al. 2010)
2010 Japan GCI,
GCD
353 (184/169)
Tissue specimen
microRNA microarray chip 
(OSU_CCC version 3.0,
ArrayExpress)
326 P < 0.01 22 13 35
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Yao (Yao et al. 
2009)
2009 China NR 6 (3/3)
Tissue specimen
miRCURY LNA microarray 
Array (v.11.0) (Exiqon)
847 FC > 2 59 46 326
Luo (Luo et al. 
2009)
2009 China NR 27 (24/3)
Tissue specimen
NR 328 P < 0.05 7 19 26 
Liu (Liu et al. 
2009)
2009 China NR 8 (4/4)
Tissue specimen
microRNA Microarray (Packard 
Biochip Technologies 
ScanArray Express microarray)
243 P < 0.05 4 5 9
Petrocca
(Petrocca et al. 
2008)
2008 Italy GCI 40 (20/20)
Tissue specimen
second generation miRNA 
microarray chips (V2) 
(Amersham BioScience 
Codelink)
250 Significance analysis 
of microarray (SAM)
14 5 19
Volinia (Volinia 
et al. 2006)
2006 USA NR 41 (20/21)
Tissue specimen
miRNA microarray (Amersham 
BioScience Codelink)
190 FDR=0.06 22 6 28280
Appendix 8: List of overlapping differentially expressed miRNAs in gastric cancer. 
MicroRNAs in blue denote the overlapped miRNAs in current and Bowen et al. ’s analysis (Conesa et al. 2016). * denotes that the microRNAs were 
reported in Sirjana et al.’s vote ranking review as well. ^ denotes deregulated miRNA in the same trend in both Ding et al.’s analysis (Ding et al. 2017)
and Shrestha et al.’s (Shrestha et al. 2014). # denotes differentially expressed. miRNAs with an opposite change pattern between current analysis and 
Sirjana et al.’s.
DESeq2 et al. based analysis in the current study edgeRv based analysis in Bowen’s study
miRNA Base Mean log2 Fold Change P value miRNA logFC logCPM LR P value FDR
hsa-mir-490* 96.4754 -3.3 4.38E-15 hsa-mir-490* -4.8051 5.883648 227.3672 2.24E-51 3.37E-49
hsa-mir-133a-2 333.696 -3.2 1.53E-24 hsa-mir-1-2 -3.52462 8.462458 179.2811 6.96E-41 5.24E-39
hsa-mir-133a-1 365.503 -3.1 1.70E-24 hsa-mir-133a-1 -3.47009 7.686724 189.3515 4.40E-43 4.98E-41
hsa-mir-944 8.48945 -3 4.17E-15 hsa-mir-133b* -3.43591 4.882301 180.3691 4.03E-41 3.64E-39
hsa-mir-1-1 261.397 -3 1.35E-22 hsa-mir-133a-2 -3.28029 2.878416 142.2048 8.77E-33 3.60E-31
hsa-mir-1-2 277.487 -3 1.76E-22 hsa-mir-383 -2.58313 1.372154 65.92232 4.69E-16 1.18E-14
hsa-mir-5683 16.0219 -2.9 5.11E-20 hsa-mir-139* -2.56445 6.924574 144.909 2.25E-33 1.02E-31
hsa-mir-133b* 95.3475 -2.8 5.22E-19 hsa-mir-1-1 -2.5258 -0.29066 42.01943 9.04E-11 1.10E-09
hsa-mir-383 4.61665 -2.5 1.67E-12 hsa-mir-204 -2.51743 3.768183 101.6399 6.66E-24 2.32E-22
hsa-mir-205 779.212 -2.5 4.49E-05 hsa-mir-145 -2.43625 13.4502 68.19737 1.48E-16 4.18E-15
hsa-mir-145 22605.5 -2.4 1.30E-29 hsa-mir-129-1 -2.37581 3.5062 86.67324 1.28E-20 4.13E-19
hsa-mir-139* 253.038 -2.3 1.62E-42 hsa-mir-137 -2.17364 0.549852 39.20199 3.82E-10 4.11E-09
hsa-mir-143 1118321 -2.1 1.41E-22 hsa-mir-187 -2.15428 3.835279 61.5645 4.28E-15 9.22E-14
hsa-mir-551b 6.17111 -2 1.09E-16 hsa-mir-9-3 -2.10139 0.276495 41.2004 1.37E-10 1.55E-09
hsa-mir-204 27.1713 -1.9 1.75E-10 hsa-mir-129-2 -2.0211 3.623788 64.84779 8.09E-16 1.92E-14
hsa-mir-29c* 17565.9 -1.8 3.17E-23 hsa-mir-885 -1.99205 -0.00875 29.71627 5.00E-08 3.37E-07
hsa-mir-1258 4.319 -1.7 6.25E-10 hsa-mir-486 -1.98119 7.630246 78.75621 7.03E-19 2.12E-17
hsa-mir-6720 6.07512 -1.6 5.16E-12 hsa-mir-1258 -1.91162 1.044307 41.40072 1.24E-10 1.44E-09
hsa-mir-129-1 17.087 -1.6 1.10E-08 hsa-mir-9-2 -1.86005 8.839239 58.76241 1.78E-14 3.66E-13
hsa-mir-129-2 20.1071 -1.6 2.35E-08 hsa-mir-9-1 -1.84622 8.838711 57.91596 2.74E-14 5.38E-13
hsa-mir-195 167.322 -1.6 1.23E-24 hsa-mir-143 -1.8152 19.02113 26.76652 2.30E-07 1.30E-06
hsa-mir-486-2 236.69 -1.6 1.31E-15 hsa-mir-206 -1.79548 0.553828 28.00989 1.21E-07 7.18E-07
hsa-mir-486-1 241.67 -1.6 1.94E-15 hsa-mir-605 -1.70801 -0.18536 24.60363 7.04E-07 3.42E-06
hsa-mir-605 1.29341 -1.5 2.24E-11 hsa-mir-23c -1.65737 0.656976 33.62034 6.70E-09 5.41E-08
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hsa-mir-202 2.27267 -1.5 5.92E-07 hsa-mir-30a -1.65228 14.39009 35.24595 2.91E-09 2.58E-08
hsa-mir-365b 253.656 -1.5 3.01E-38 hsa-mir-144 -1.6373 7.165103 56.44918 5.77E-14 1.09E-12
hsa-mir-365a 253.876 -1.5 3.12E-38 hsa-mir-363 -1.6186 3.370372 46.60951 8.66E-12 1.22E-10
hsa-mir-203a 47749.9 -1.5 9.50E-10 hsa-mir-202 -1.60021 0.505004 26.81042 2.24E-07 1.28E-06
hsa-mir-30a 75745.6 -1.5 5.11E-19 hsa-mir-149 -1.56676 4.789035 49.14688 2.37E-12 3.70E-11
hsa-mir-149 75.7773 -1.4 9.85E-12 hsa-mir-99a -1.53989 9.092692 39.06369 4.10E-10 4.21E-09
hsa-mir-187 44.3908 -1.3 0.00051 hsa-mir-100# -1.5395 12.16728 30.5749 3.21E-08 2.30E-07
hsa-mir-218-2 65.653 -1.3 1.04E-12 hsa-mir-551b -1.50979 2.030806 29.24939 6.36E-08 4.17E-07
hsa-mir-218-1 69.2889 -1.3 1.84E-12 hsa-mir-20b^ -1.4901 4.066006 39.32045 3.60E-10 3.96E-09
hsa-mir-451a 1881.71 -1.3 6.28E-10 hsa-mir-365-1 -1.45572 4.578685 47.35135 5.93E-12 8.94E-11
hsa-let-7c 9049.56 -1.3 3.37E-08 hsa-mir-29c* -1.45217 12.17281 31.27397 2.24E-08 1.63E-07
hsa-mir-100# 20309.1 -1.3 4.07E-09 hsa-mir-218-2 -1.43116 5.544884 44.19166 2.98E-11 3.85E-10
hsa-mir-378d-2 2.39748 -1.2 2.04E-08 hsa-mir-451 -1.41848 9.482372 31.30019 2.21E-08 1.63E-07
hsa-mir-504 2.67883 -1.2 2.67E-06 hsa-mir-365-2 -1.4117 4.593021 44.94708 2.02E-11 2.69E-10
hsa-mir-6511b-2 3.468 -1.2 9.24E-13 hsa-mir-195 -1.38402 6.196652 46.34211 9.93E-12 1.36E-10
hsa-mir-144 428.623 -1.2 7.41E-08 hsa-let-7c -1.37102 11.10562 25.06968 5.53E-07 2.75E-06
hsa-mir-28 21953.9 -1.2 9.13E-25 hsa-mir-378^ -1.3524 9.977656 33.84618 5.96E-09 4.90E-08
hsa-mir-3199-2 2.55187 -1.1 2.09E-11 hsa-mir-378c -1.34841 3.995761 37.56583 8.84E-10 8.68E-09
hsa-mir-4786 3.44811 -1.1 1.19E-07 hsa-mir-504 -1.34318 0.518477 21.00924 4.57E-06 1.93E-05
hsa-mir-363 32.9539 -1.1 6.54E-07 hsa-mir-1247 -1.31901 4.444355 32.06739 1.49E-08 1.14E-07
hsa-mir-378c 48.7569 -1.1 4.40E-14 hsa-mir-802 -1.30525 2.120566 8.819754 0.00298 0.006907
hsa-mir-193a 624.346 -1.1 8.69E-21 hsa-mir-101-2 -1.238 5.831003 37.49146 9.18E-10 8.83E-09
hsa-mir-125b-1 1025.14 -1.1 7.99E-09 hsa-mir-125b-1 -1.22699 9.332394 25.33243 4.83E-07 2.49E-06
hsa-mir-125b-2 1076.54 -1.1 8.85E-09 hsa-mir-125b-2 -1.19928 4.172908 25.12644 5.37E-07 2.70E-06
hsa-mir-125a 1597.74 -1.1 1.27E-20 hsa-mir-1262 -1.19894 0.628874 18.60011 1.61E-05 6.12E-05
hsa-mir-378a 3824.24 -1.1 1.71E-15 hsa-mir-1224 -1.1755 4.110555 13.78066 0.000205 0.000611
hsa-let-7e 4583.89 -1.1 5.29E-11 hsa-mir-28 -1.16295 12.74368 20.38194 6.34E-06 2.61E-05
hsa-mir-23b 10354 -1.1 5.05E-20 hsa-mir-23b -1.14816 10.70065 23.39329 1.32E-06 6.22E-06
hsa-mir-27b 13371.1 -1.1 4.86E-26 hsa-mir-218-1 -1.13081 0.310216 12.81953 0.000343 0.001
hsa-mir-378d-1 1.80983 -1 6.40E-06 hsa-mir-125a -1.12163 8.957969 26.09095 3.26E-07 1.77E-06
hsa-mir-1262 3.89914 -1 2.39E-09 hsa-mir-328 -1.08873 4.505851 25.32157 4.85E-07 2.49E-06
hsa-mir-153-1 8.8946 -1 4.45E-05 hsa-mir-3678 -1.06929 -0.46024 9.381958 0.002191 0.005297
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hsa-mir-326 hsa-mir-193a
hsa-mir-328 23.785 -1 2.55E-09 hsa-mir-497 -1.06783 7.615196 26.51488 2.62E-07 1.46E-06
hsa-mir-497 66.3037 -1 4.19E-12 hsa-mir-381 -1.05245 4.887338 25.87917 3.63E-07 1.96E-06
hsa-mir-381 85.8655 -1 4.83E-12 hsa-mir-30c-2 -1.04833 5.898908 27.794 1.35E-07 7.92E-07
hsa-mir-30c-2 193.556 -1 7.00E-14 hsa-mir-3199-2 -1.01405 9.079368 21.95033 2.80E-06 1.22E-05
hsa-mir-99a 1442.18 -1 2.50E-20 hsa-mir-579 -1.01231 0.049924 11.01296 0.000905 0.00242
hsa-mir-140 2829.08 -1 0.00011 hsa-mir-500b 1.003594 0.173085 10.04165 0.00153 0.003864
hsa-mir-26a-1 3622.47 -1 3.36E-20 hsa-mir-1301 1.01082 2.853586 19.51406 9.99E-06 3.96E-05
hsa-mir-26a-2 3747.54 -1 2.76E-25 hsa-mir-19b-1 1.013281 2.662935 19.28604 1.13E-05 4.42E-05
hsa-mir-4640 3762.93 -1 1.58E-24 hsa-mir-3690 1.017658 2.760713 19.80815 8.56E-06 3.46E-05
hsa-mir-3664 0.93441 1 0.00215 hsa-mir-33b 1.019013 -0.45859 7.58355 0.00589 0.012157
hsa-mir-4709 1.78673 1 0.00128 hsa-mir-200c 1.06251 2.191573 17.20339 3.36E-05 0.000119
hsa-mir-219b 1.82011 1 5.84E-05 hsa-mir-181b-2 1.123707 12.62303 13.92546 0.00019 0.000573
hsa-mir-4660 1.88076 1 0.00011 hsa-mir-3682 1.131267 1.465516 18.29105 1.90E-05 7.08E-05
hsa-mir-3117 2.13797 1 0.00031 hsa-mir-1304 1.133584 0.095028 13.76865 0.000207 0.000611
hsa-mir-3922 2.54896 1 9.46E-05 hsa-mir-19a* 1.158205 0.530508 14.85341 0.000116 0.000378
hsa-mir-550a-3 2.55428 1 0.00014 hsa-mir-4326 1.169756 4.440135 29.28147 6.26E-08 4.16E-07
hsa-mir-616 5.6589 1 6.82E-07 hsa-mir-1537 1.178167 2.60476 22.28298 2.35E-06 1.03E-05
hsa-mir-323b 11.9804 1 1.58E-05 hsa-mir-335* 1.196737 -0.57095 8.840801 0.002946 0.006863
hsa-mir-421 12.6471 1 5.90E-05 hsa-mir-3127 1.200402 5.660871 34.92476 3.43E-09 2.98E-08
hsa-mir-34c 12.839 1 1.97E-10 hsa-mir-222 1.205502 1.919227 25.61662 4.16E-07 2.19E-06
hsa-mir-95 15.742 1 1.06E-08 hsa-mir-550a-1 1.229276 6.354788 34.67439 3.90E-09 3.32E-08
hsa-mir-500b 26.4724 1 1.14E-06 hsa-mir-3677 1.230369 1.765377 24.84935 6.20E-07 3.05E-06
hsa-mir-362 68.0902 1 2.29E-13 hsa-mir-3194 1.233403 2.618829 28.11401 1.14E-07 6.99E-07
hsa-mir-222 68.414 1 9.27E-12 hsa-mir-940 1.245561 -0.22182 12.65948 0.000374 0.001069
hsa-mir-106b* 386.191 1 3.26E-13 hsa-mir-142 1.252802 1.526729 23.16899 1.48E-06 6.69E-06
hsa-mir-181a-1 2069.48 1 8.98E-22 hsa-mir-147b 1.26474 11.22242 21.86826 2.92E-06 1.25E-05
hsa-mir-532 2251.98 1 4.21E-20 hsa-mir-556 1.268672 1.916673 17.66322 2.64E-05 9.53E-05
hsa-mir-200c 4282.56 1 5.06E-16 hsa-mir-1228 1.284855 0.331394 16.9532 3.83E-05 0.000134
hsa-mir-548k 33728.2 1 1.49E-09 hsa-mir-577 1.285879 0.054366 15.80262 7.03E-05 0.000237
hsa-mir-3680-1 0.90486 1.1 0.00063 hsa-mir-639 1.286575 4.265989 23.98078 9.73E-07 4.63E-06
hsa-mir-5703 0.94644 1.1 0.00098 hsa-mir-1266 1.309998 -0.29025 14.34584 0.000152 0.000477
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hsa-mir-3691 1.13193 1.1 0.00064 hsa-mir-130b 1.31746 3.625128 30.40361 3.51E-08 2.44E-07
hsa-mir-3942 1.38189 1.1 0.00063 hsa-mir-503 1.334593 4.434231 34.33792 4.63E-09 3.88E-08
hsa-mir-4797 1.49245 1.1 0.00047 hsa-mir-3944 1.339988 2.37236 28.07584 1.17E-07 7.03E-07
hsa-mir-559 1.49388 1.1 0.00031 hsa-mir-501 1.359005 -0.58497 12.04175 0.00052 0.001451
hsa-mir-548o 1.52738 1.1 0.00133 hsa-mir-1292 1.364548 4.953196 42.87447 5.84E-11 7.33E-10
hsa-mir-4766 1.54383 1.1 8.28E-05 hsa-mir-509-3 1.372709 -0.40602 14.58476 0.000134 0.000433
hsa-mir-548s 1.56175 1.1 0.00028 hsa-mir-184 1.375675 -0.11822 12.50652 0.000406 0.001153
hsa-mir-3194 1.57248 1.1 0.00061 hsa-mir-141 1.434392 3.704775 15.82452 6.95E-05 0.000236
hsa-mir-3682 1.93347 1.1 0.00058 hsa-mir-182 1.461218 10.07376 27.45664 1.61E-07 9.31E-07
hsa-mir-3652 3.23956 1.1 4.18E-07 hsa-mir-509-2 1.483654 12.73574 25.78177 3.82E-07 2.03E-06
hsa-mir-5586 3.84742 1.1 7.63E-05 hsa-mir-935 1.484827 -0.22201 13.70959 0.000213 0.000626
hsa-mir-940 7.84255 1.1 1.41E-09 hsa-mir-877 1.490044 1.558525 25.22209 5.11E-07 2.59E-06
hsa-mir-550a-2 10.075 1.1 6.07E-08 hsa-mir-200b* 1.490746 1.090363 30.53817 3.27E-08 2.31E-07
hsa-mir-3934 12.0803 1.1 1.35E-09 hsa-mir-301b 1.515505 10.36933 28.65058 8.67E-08 5.60E-07
hsa-mir-320b-1 15.2677 1.1 1.73E-10 hsa-mir-21* 1.517523 0.565191 24.26225 8.41E-07 4.04E-06
hsa-mir-4677 21.6989 1.1 2.45E-09 hsa-mir-429 1.524249 17.07657 28.22467 1.08E-07 6.78E-07
hsa-mir-3677 25.4845 1.1 3.16E-18 hsa-mir-7-3 1.550224 8.159935 35.86425 2.12E-09 1.95E-08
hsa-mir-320b-2 27.5123 1.1 2.80E-09 hsa-mir-937 1.551694 0.962984 28.57573 9.01E-08 5.74E-07
hsa-mir-130b 35.5248 1.1 5.73E-10 hsa-mir-3651 1.566361 0.824561 28.12699 1.14E-07 6.99E-07
hsa-mir-203b 113.421 1.1 8.95E-13 hsa-mir-146b 1.56792 0.552446 23.31423 1.38E-06 6.35E-06
hsa-mir-223* 386.682 1.1 1.53E-05 hsa-mir-188* 1.571159 8.577653 50.55111 1.16E-12 1.94E-11
hsa-mir-1307 1625.73 1.1 3.04E-08 hsa-mir-1254 1.584507 2.062049 41.67226 1.08E-10 1.28E-09
hsa-mir-141 5186.86 1.1 1.10E-17 hsa-mir-551a 1.594923 -0.15366 21.86838 2.92E-06 1.25E-05
hsa-mir-3684 5850.09 1.1 3.54E-09 hsa-mir-215^ 1.646534 -0.21254 18.34646 1.84E-05 6.94E-05
hsa-mir-4645 1.04176 1.2 0.0001 hsa-mir-200a 1.685801 10.59604 23.36748 1.34E-06 6.24E-06
hsa-mir-7854 1.11731 1.2 0.00019 hsa-mir-192^ 1.69807 10.43228 36.13127 1.84E-09 1.74E-08
hsa-mir-1229 1.43001 1.2 8.95E-05 hsa-mir-105-2 1.719582 14.41716 22.35297 2.27E-06 1.01E-05
hsa-mir-3150b 2.82291 1.2 8.75E-05 hsa-mir-96 1.771443 3.833691 19.13901 1.22E-05 4.74E-05
hsa-mir-3200 7.16886 1.2 0.00023 hsa-mir-18a* 1.771828 3.458154 50.32947 1.30E-12 2.10E-11
hsa-mir-217 12.7464 1.2 2.14E-06 hsa-mir-767 1.797128 4.26354 64.10104 1.18E-15 2.67E-14
hsa-mir-708 186.445 1.2 2.66E-08 hsa-mir-3648 1.813376 3.790524 23.19221 1.47E-06 6.69E-06
hsa-mir-181b-2 283.501 1.2 1.38E-11 hsa-mir-194-1 1.822511 1.564576 39.0819 4.06E-10 4.21E-09
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hsa-mir-181b-1 443.857 1.2 2.41E-18 hsa-mir-194-2 1.827376 11.98643 31.70942 1.79E-08 1.35E-07
hsa-mir-200b* 470.55 1.2 3.38E-19 hsa-mir-3662 1.858527 12.10746 32.49045 1.20E-08 9.33E-08
hsa-mir-93* 6719.84 1.2 3.80E-12 hsa-mir-183 1.887278 -0.58133 20.02632 7.64E-06 3.11E-05
hsa-mir-3174 20498.4 1.2 2.01E-16 hsa-mir-592 1.943658 11.47269 47.08264 6.81E-12 9.92E-11
hsa-mir-4461 0.89233 1.3 0.00012 hsa-mir-1911 2.046905 1.778939 55.78928 8.07E-14 1.46E-12
hsa-mir-643 2.3604 1.3 2.51E-05 hsa-mir-3176 2.127434 0.854113 20.84261 4.99E-06 2.09E-05
hsa-mir-548v 2.94041 1.3 6.55E-08 hsa-mir-105-1 2.160355 -0.58701 26.15449 3.15E-07 1.74E-06
hsa-mir-550a-1 5.93127 1.3 1.01E-06 hsa-mir-615 2.170972 3.821292 29.73005 4.97E-08 3.37E-07
hsa-mir-3127 12.2797 1.3 1.27E-13 hsa-mir-3687 2.176016 1.402284 53.00359 3.33E-13 5.79E-12
hsa-mir-1301 19.0495 1.3 1.56E-14 hsa-mir-509-1 2.324626 0.222873 38.23519 6.27E-10 6.30E-09
hsa-mir-4326 33.1328 1.3 3.47E-17 hsa-mir-549 2.430465 -0.2549 32.75796 1.04E-08 8.28E-08
hsa-mir-20a* 33.3916 1.3 3.99E-08 hsa-mir-135b* 2.68146 -0.48982 35.57181 2.46E-09 2.22E-08
hsa-mir-210 1653.88 1.3 3.90E-14 hsa-mir-552 3.186272 4.944869 171.6598 3.21E-39 2.07E-37
hsa-mir-500a 1838.62 1.3 1.85E-07 hsa-mir-196a-2 3.718047 4.015132 117.9429 1.78E-27 6.72E-26
hsa-mir-17* 2145.32 1.3 1.85E-22 hsa-mir-548f-1 3.993711 2.400791 162.9158 2.61E-37 1.47E-35
hsa-mir-194-1 5960.17 1.3 2.25E-19 hsa-mir-196b 4.040168 -0.00399 67.67345 1.93E-16 5.13E-15 
hsa-mir-5698 23296.8 1.3 7.99E-11 hsa-mir-196a-1 4.826419 7.887649 348.1235 1.09E-77 2.45E-75
hsa-mir-618 1.65549 1.4 1.37E-05 hsa-mir-1269 5.173649 6.457087 393.0208 1.82E-87 8.23E-85
hsa-mir-7702 2.06486 1.4 1.99E-05 5.24766 4.896873 153.8731 2.47E-35 1.24E-33
hsa-mir-4746 4.67635 1.4 5.00E-06
hsa-mir-7-2 9.18916 1.4 4.83E-13
hsa-mir-503 12.891 1.4 2.90E-09
hsa-mir-200a 30.0206 1.4 7.63E-14
hsa-mir-194-2 7398.47 1.4 5.51E-14
hsa-mir-6783 26030.3 1.4 4.32E-12
hsa-mir-1254-1 1.09785 1.5 1.45E-05
hsa-mir-4449 1.54109 1.5 1.96E-06
hsa-mir-3131 2.69368 1.5 4.91E-05
hsa-mir-188* 8.22796 1.5 0.00012
hsa-mir-3187 19.8367 1.5 1.06E-18
hsa-mir-1292 1.3466 1.6 4.04E-05
hsa-mir-1228 2.1785 1.6 4.04E-08
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hsa-mir-3651 3.69614 1.6 9.65E-12
hsa-mir-7-3 5.68695 1.6 3.24E-09
hsa-mir-19a* 12.5505 1.6 2.17E-10
hsa-mir-675 151.942 1.6 1.22E-23
hsa-mir-335* 153.6 1.6 1.26E-06
hsa-mir-584 387.919 1.6 3.39E-21
hsa-mir-182 462.292 1.6 1.36E-14
hsa-mir-4777 43270.4 1.6 1.07E-18
hsa-mir-2115 1.13096 1.7 8.33E-08
hsa-mir-3944 1.17655 1.7 5.05E-06
hsa-mir-3690-1 1.90094 1.7 6.73E-07
hsa-mir-1304 2.36746 1.7 8.46E-08
hsa-mir-501 6.56631 1.7 3.11E-08
hsa-mir-3176 205.564 1.7 2.85E-31
hsa-mir-514a-3 1.2533 1.8 8.32E-07
hsa-mir-6854 1.89751 1.8 3.26E-05
hsa-mir-7705 2.31974 1.8 4.53E-10
hsa-mir-96 4.21949 1.8 6.94E-12
hsa-mir-146b 63.2816 1.8 4.32E-21
hsa-mir-1254-2 2678.81 1.8 1.75E-40
hsa-mir-551a 1.55107 1.9 9.71E-09
hsa-mir-301b 2.66212 1.9 1.59E-07
hsa-mir-877 6.99953 1.9 3.63E-13
hsa-mir-21* 11.0106 1.9 8.82E-18
hsa-mir-3189 974537 1.9 1.64E-76
hsa-mir-4661 1.50429 2 1.19E-07
hsa-mir-508 18.7893 2 6.09E-16
hsa-mir-183 20.5662 2 1.01E-11
hsa-mir-514a-2 17272.3 2 1.01E-24
hsa-mir-514a-1 1.86496 2.1 1.56E-06
hsa-mir-4728 1.90098 2.1 1.11E-06
hsa-mir-18a* 10.1128 2.1 3.08E-10
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hsa-mir-592 207.313 2.1 5.96E-26
hsa-mir-509-1 20.7431 2.2 1.81E-17
hsa-mir-615 3.36674 2.3 2.98E-08
hsa-mir-184 13.2415 2.3 6.79E-16 
hsa-mir-7974 9.13882 2.4 3.47E-08
hsa-mir-937 2.95907 2.5 2.68E-11
hsa-mir-483 11.4755 2.5 7.84E-20
hsa-mir-4664 29.6098 2.5 2.88E-12
hsa-mir-934 2.76805 2.6 5.11E-14
hsa-mir-509-2 6.86696 2.6 5.89E-07
hsa-mir-509-3 3.46509 2.7 1.71E-10
hsa-mir-3662 3.79058 2.7 4.34E-11
hsa-mir-935 2.85484 2.8 1.07E-13
hsa-mir-549a 24.3065 2.9 1.47E-21
hsa-mir-135b* 2.29748 3 9.07E-14
hsa-mir-196b 214.13 3.3 1.01E-45
hsa-mir-196a-1 1928.06 4.5 3.16E-52
hsa-mir-196a-2 350.082 4.7 1.69E-67
hsa-mir-105-1 392.763 4.7 1.51E-66
hsa-mir-552 117.22 5.7 4.56E-24
hsa-mir-1269a 189.267 5.8 2.60E-40
hsa-mir-105-2 98.0023 5.9 2.86E-23
hsa-mir-767 116.387 5.9 6.40E-26
miRNA 144.592 5.9 9.33E-26
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Appendix 9: Differentially expressed miRNAs in TCGA based molecular 
classification of gastric cancer.
Appendix 10: Summary of miRNA target prediction tools.
Bold are tools used in the current study. Adopted from common features of  microRNA target prediction tools by Peterson et al. (Peterson et al. 2014)
Method Type of Method Ref Resource
Stark et. al Complementary (Stark et. al., 2003) http://www.russell.embl.de/miRNAs
miRanda Complementary (John et al., 2004) http://www.microrna.org
miRanda mirSVR Complementary (Enright et al., 2003) http://microrna.sanger.ac.uk
miRWalk - - http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html
Target Scan Seed Complementary (Lewis et al., 2005) http://www.targetscan.org
DIANA Thermodynamics (Kirakidou et al., 2004) http://diana.cslab.ece.ntua.gr/
PicTar Thermodynamics (Krek et al., 2005) http://pictar.mdc-berlin.de/
RNAHybrid Thermodynamics & Statistical model (Rehmsmeier et al., 2004) http://bibiserv.techfak.uni-bielefeld.de/rnahybrid
miRGen++ Baynesian Inference (Huang et al., 2007b) http://www.psi.toronto.edu/genmir
MiTarget Support Vector Machine (Kim et al. 2006) http://cbit.snu.ac.kr/~miTarget
MiRtaget2 Support Vector Machine (Wang and El Naqa, 2008) http://mirdb.org
TarBase Experimentally Validated Targets (Sethupathy et al., 2006) http://diana.cslab.ece.ntua.gr/tarbase/
MiRTarbase Experimentally validated (Chou CH et al., 2011) http://miRTarBase.mbc.nctu.edu.tw/
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Appendix 11: Overlapping results of targets prediction of miR-140-5p from online tools.
Gene Description Validated evidence as miR-140-5p target
SNX16 Play a role in protein transportation from endosome to lysosome (Hanson and Hong 2003) Not available
GALC The enzyme responsible for the lysosomal catabolism of galactosyl ceramide (Beier and Gorogh 2005) Barter et al. (2015)
MYO6 Motor protein of the actin cytoskeleton (Aschenbrenner et al. 2004) Not available
VEGFA Angiogenesis and tumourigenesis （Goel et al. 2013） Zhang et al. (2015), Sun et al. (2016)
FZD6 Negative regulator of the canonical Wnt/beta-catenin signalling cascade, thereby inhibiting the processes 
that trigger the oncogenic transformation, cell proliferation, and inhibition of apoptosis. (Dann and 
Mercurio 2001)
Barter et al. (2015)
FGF9 An FGF family member possessing broad mitogenic and cell survival activities (Spicer 2009) Yang et al. (2013)
HMGN5 A nucleosomal binding and transcriptional activating protein Meng et al. (2017)
PRDM1 Transcription factor that mediates a transcriptional program in various innate and adaptive immune Not available
HDAC4 Chromatin remodelling and negative regulation of transcription by RNA polymerase II (Mottet 2009) Xiao et al. (2017), Papaioannou et al. (2015), 
Song et al. (2009)
STRADB A pseudokinase, induce cell cycle arrest but protect against apoptosis. Not available
OSTM1 Osteoclast differentiation and ion transmembrane transport Liu et al. (2013), Gernapudi et al. (2015)
MRPS10 Help in protein synthesis within the mitochondrion Not available
PHACTR2 Platelet activation, signalling and aggregation Not available
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